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American skullcap (Scutellaria lateriflora) has long been an important herb in North 
American traditional medicine systems and western materia medica for anxiety and 
related disorders.  A previous clinical study assessing acute effects of S. lateriflora 
indicated it has anxiolytic actions with minimal loss of energy or cognition.  The aim of 
the present study was to extend these findings by determining the putative mood 
enhancing effects and safety of S. lateriflora following its chronic administration to 
healthy volunteers.  Based on a randomised, double-blind, placebo-controlled crossover 
design, it examined the effects of S. lateriflora on psychologic symptoms using the 
Beck Anxiety Inventory (BAI) and the Profile of Mood States (POMS) questionnaires, 
and its potential physiological effects on stress by measuring free cortisol levels in 
saliva, at baseline and following administration of S. lateriflora or placebo.  Liver 
function was assessed at the same time points by measuring levels of serum alanine 
aminotransferase (ALT).  Pre and post intervention blood pressure and pulse rate were 
also measured.  Freeze-dried S. lateriflora for use in the present study was authenticated 
by the use of high performance liquid chromatography. 
Participants (n = 43) were randomised to either freeze-dried S. lateriflora (350 mg) or 
Urtica dioica folia (300 mg) placebo three times daily for 14 days.  There was a 7 day 
washout period prior to crossover.  Analysis of results was from 31 participants 
completing the study.  Results from the BAI demonstrated no significant difference 
between S. lateriflora and placebo (p = 0.191) in anxiety scores.  The results from the 
POMS factors demonstrated there was no significant difference between S. lateriflora 
and placebo in scores for Tension-Anxiety (p = 0.473), Anger-Hostility (p = 0.070) or 
for Depression-Dejection (p = 0.067).  Overall results from subjective measures of 
global mood as measured by Total Mood Disturbance (TMD) on the POMS also 
demonstrated no significant difference between S. lateriflora and placebo (p = 0.137).  
Additionally, the POMS showed there was no reduction in energy or cognition 
following chronic administration of S. lateriflora, evidenced by there being no 
difference between S. lateriflora and placebo for Vigour-Activity (p = 0.244) and 
Confusion-Bewilderment (p = 0.838) scores respectively.  From inspection of the means 
for both BAI and the POMS factors, however, there was an enhanced effect of S. 
lateriflora compared to placebo in those who took the placebo first (n = 15) and an 
enhanced effect of placebo compared to S. lateriflora for those who took S. lateriflora 
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first (n = 16) suggesting a residual effect of S. lateriflora due to insufficient washout.  
There was no significant difference between S. lateriflora and placebo (p = 0.524) in 
salivary cortisol measurements, suggesting no attenuation of the hypothalamic-pituitary 
adrenal (HPA) axis by S. lateriflora.  The ALT measurements revealed no significant 
difference between S. lateriflora and placebo (p = 0.801), suggesting there was no acute 
toxicity from S. lateriflora.  Furthermore, there was no significant difference between S. 
lateriflora and placebo in effects on systolic (p = 0.410) or diastolic (p = 0.834) blood 
pressures or pulse rate (p = 0.144), all of which remained within the normal range for 
healthy adults.  According to the participants’ diary reports, there were no adverse 
reactions and only mild and infrequent side-effects, which may not have been 
attributable to S. lateriflora. 
 
The results suggested that S. lateriflora may have anxiolytic and mood enhancing 
effects in some individuals without notable side-effects or reduction in energy or 
cognition.  Contrary to anecdotal evidence, there was no worsening of depression 
following administration of S. lateriflora.  Further research is needed in a larger study 
population, using a sample with self-reported and/or diagnosed anxiety and mood 
disturbances, in order to further determine the effects of the herb on these paradigms.   
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Chapter 1. Introduction 
1.1 Introduction  
Traditional herbal medicines have been in use for thousands of years and are still relied 
upon for healthcare by an estimated 4 billion people in developing countries (around 
80% of the world’s population) (Lambert et al. 1997). 
Whole plant extracts were still the most common form of medicine in the western world 
until the 19
th
 century, when the advent of modern, orthodox medicine led to a decline in 
its popularity (Stuart 1979).  Recent years have seen a reversal of this trend, with use of 
herbal medicine rapidly increasing for a variety of reasons (Vickers et al. 2006):  people 
want to feel they are in control of their own health; some are dissatisfied with the 
orthodox health services (Ernst & White 2000; Vickers et al. 2006); others worry about 
the side-effects of conventional drugs (Astin 1998) or the failure of orthodox medicine 
to cure their chronic illnesses (Rawsthorne et al. 1999).  It is also a common belief that 
herbal medicines are more ‘natural’ and therefore safer (Vickers et al. 2006). 
 ‘Nervine’ herbs (those that act on the nervous system) are used traditionally for the 
alleviation of anxiety and stress and comorbidities.  Few of these herbs have been well 
researched and there is scant scientific evidence for their efficacy (Sarris et al. 2011).  
In particular, American skullcap (Scutellaria lateriflora) has long been an important 
herb in North American traditional medicine culture and western materia medica for 
anxiety and related disorders (Cole et al. 2008).  It is also used for barbiturate and 
tranquilliser withdrawal symptoms (Joshee et al. 2002).  In vitro studies of S. lateriflora 
and its phytochemicals (Liao et al. 1998; Hui et al. 2000; Gafner et al. 2003b) and a 
small clinical study (Wolfson & Hoffmann 2003) suggest a positive therapeutic benefit 
of the herb for anxiety and its comorbidities.  However, a dearth of large, high quality 
clinical studies of sufficient duration means there is insufficient scientific evidence for 
its efficacy and safety, particularly in the long-term (Gao et al. 2008; Natural Medicines 
Comprehensive Database 2011; Sarris et al. 2011).  While the results of the in vitro and 
chemical studies provide clues to the pharmacological actions of S. lateriflora, clinical 
evidence is necessary to support findings.  It is therefore appropriate and timely for 
more efforts to be made in the conduction of clinical studies in support of the 
therapeutic value of S. lateriflora.  In the short-term the results may provide evidence of 
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the potential value of this herb in reducing anxiety and stress and improving negative 
mood states and may precipitate further research into the herb.  Sarris (2007) suggested 
S. lateriflora is potentially of significant use for generalised anxiety disorder (GAD), 
proposing that urgent research is needed on the herb in this area. 
 
Using subjective test measures at baseline and during administration of placebo or S. 
lateriflora, the present study, based on a randomised, double-blind, placebo-controlled 
crossover design, examines the effects of S. lateriflora on anxiety and mood over a 
period of two weeks’ administration.  It also examines its potential physiological effects 
on stress by measuring free cortisol levels in saliva; using a non-invasive method of 
saliva sampling before and during administration of S. lateriflora and placebo.  
Measuring cortisol in participants’ saliva may determine whether or not secretory 
patterns alter following putative therapeutic interventions in those with high anxiety.  A 
crossover study was chosen to determine within subjects as well as between subjects 
comparisons.  There is less variability and more precision within a subject and fewer 
participants are needed than with a parallel study (Wang et al. 2006). 
 
The study is innovative as to date there have been no other clinical studies into the 
chronic effects of S. lateriflora on anxiety, stress or various mood states.  Furthermore, 
for the first time salivary cortisol measurements are used to determine the putative 
benefits of the herb on stress.  The results of this study may help to establish an 
evidenced-based herbal treatment for attenuation of anxiety and stress and promotion of 
wellbeing.  It also hopes to inform herbal and other health professionals and users about 
the significance of quality control of the herb.  To the author’s knowledge it is unusual 
(but not exceptional) for a herb to be authenticated prior to use in a clinical study. 
1.2 General aims  
The general aims of this study were to authenticate whole extract of S. lateriflora and to 
conduct a randomised, controlled clinical study to evaluate its effectiveness in reducing 
mood disturbance and related conditions, with particular reference to anxiety and stress.   
1.3 General methods 
In order to assess the likelihood of achieving the aims and objectives of the study a 
literature review, reported in Chapter 2, was conducted to gather information on the 
background of S. lateriflora, particularly in relation to its traditional uses and preclinical 
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and clinical research on the herb supporting psychopharmacological uses as well as 
wider therapeutic indications.  Knowledge of previous research provides a scientific 
basis for the uses of S. lateriflora and helps to inform reasons for the putative efficacy 
of the herb on anxiety, stress and positive and negative mood states as well as for 
potential anxiety and/or stress related comorbidities.  Chapter 2 also discusses the 
chemical constituents of S. lateriflora; preparations and doses used; the current safety 
profile of the herb including side-effects, contra-indications and suggested toxicity; and 
bioavailability where known.  There is also a brief botanical description and an outline 
of S. lateriflora’s historical background.  
Results of a survey amongst herbal practitioners in the UK and Ireland (Brock et al. 
2010) indicate that S. lateriflora is considered to be an effective intervention for anxiety 
and stress and is commonly prescribed for these conditions and related comorbidities.  
Chapter 3 provides the results of this survey conducted amongst herbal medicine 
practitioners on their use of S. lateriflora. 
Botanical descriptions in the literature are often from secondary sources and may not be 
accurate.  S. lateriflora is possibly the most substituted species in western materia 
medica (Wolfson & Hoffmann 2003).  Therefore, it is important, for purposes of 
identification of the true species, to have first-hand knowledge of the macroscopic 
defining characteristics of the herb.  Chapter 4 outlines methods to gain this knowledge 
- such as visits to herbariums to view authenticated voucher specimens. 
Because of frequent substitution or adulteration of S. lateriflora with other skullcaps or 
potentially harmful herbs such as Teucrium spp. (germander) (Wolfson & Hoffmann 
2003; Gorman 2008) the literature was also extensively reviewed in relation to the 
importance of quality control of the herb. The findings are in a chapter of their own 
(Chapter 5) in order to provide a background and rationale for the results of an analysis 
of the S. lateriflora material used in the clinical study, also reported in Chapter 5.  This 
chemical analysis was conducted using high performance liquid chromatography 
(HPLC).  Commercial herbal products have been found to contain significant variations 
in phytochemical profile within a species.  Although this may sometimes be the result of 
misidentification in the case of S. lateriflora, the effects of growing, harvesting, storage, 
extraction and processing methods are likely to also play a role (Ciddi 2006; Gao et al. 
2008).  Therefore, optimum conditions for production of high quality commercial 




Chapter 6 reports a randomised, placebo-controlled crossover study of the effects of S. 
lateriflora on mood, with particular reference to anxiety states.  Healthy participants, 
both males and females aged between 18 and 75 years, were recruited for the study.  
Study time for each participant was 38 days including suitability screening and a 7 day 
washout period. Participants were randomly assigned to receive either freeze-dried S. 
lateriflora test or freeze-dried Urtica dioica folia (common stinging nettle leaf) placebo 
three times daily for half of the intervention study duration (14 days) and then, 
following a washout period of 7 days, crossed over to receive the other intervention for 
comparison.  In other words, participants acted as their own controls.  Clinical reporting 
scales, participant diaries and salivary cortisol measurements were used to compare 
anxiety and mood symptoms, quality of life and physiological measurements of stress at 
the beginning, before the end of the first half prior to crossover, and at the end of the 
clinical study.  The safety profile of the herb was assessed using serum analysis of 
alanine aminotransferase (ALT), an enzyme found primarily in the liver (Kaplan 2002).  
Blood pressure and pulse were also monitored to assess any changes in either following 
administration of S. lateriflora. 
 
Chapter 7 reports the results of the clinical study, Chapter 8 provides a discussion, 
summary and conclusion of findings from the clinical study and Chapter 9 reports on 
the potential for future work. 
1.4 Statement of the problem 
1.4.1 The problem of anxiety 
In any given year, up to one in six adults in the United Kingdom may suffer from a 
medically unexplained psychological disorder, the most common being anxiety (men 
4%; women 5%), depression (men 2%; women 3%) or both experienced at the same 
time (men 7%; women 11%) (Office for National Statistics 2006).  Two recent reports 
(Halliwell 2009; McManus & Bebbington 2009) indicate anxiety disorders are on the 
increase (a 12.8% increase between 1993 and 2007).  The results of an online survey by 
the Mental Health Foundation (Halliwell 2009) of 2,246 UK adults, indicated 37% of 
the population (18 million people) are feeling more fearful (frightened, worried or 
anxious) than they used to – largely due to social and economic problems.  No timescale 
was attributed to this increase in fear.   However, a UK government report (McManus & 
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Bebbington 2009) suggests 2% more of the adult (> age 16) population in England 
experienced common mental disorders (CMD) in 2007 (17.6%) than in 1993 (15.5%).  
Of all CMDs, mixed anxiety and depression was the most prevalent (9%) followed by 
generalised anxiety disorder (4.4%).  The proportions of other categories of CMDs in 
the general adult population of England in 2007 were depression (1.9%), phobias 
(1.4%), obsessive compulsive disorder (1.1%) and panic disorder (1.1%).  There was no 
increase between 2000 and 2007 overall but CMDs significantly increased in women.  
The greatest increase was amongst women between the ages of 45-64, rising by a fifth 
(McManus & Bebbington 2009). For anxiety-related CMDs the increase amongst all 
adults in England was estimated to be 12.8%. Extrapolating to the UK population, 
800,000 more adults were experiencing an anxiety disorder in 2007 than in 1993 
(Halliwell 2009). 
 
Anxiety is ‘an unpleasant emotional state ranging from mild unease to intense fear’ 
(B.M.A. 2002).  It is a normal response to stressful situations but can become chronic as 
a result of a modern lifestyle that includes repeated daily stressors, whether through 
work, travel, family or social situations (Pavlovich 1999).  If present for no known 
reason, chronic anxiety may be a symptom of a psychiatric condition such as 
depression, phobias or generalised anxiety disorder (B.M.A. 2002).  Although anxiety is 
common it is a potentially serious disorder as it can lead to numerous health problems 
and difficulties in social and occupational functioning (Fricchione 2004).  
 
Research suggests that anxiety positively correlates to increased systemic inflammation.  
Pitsavos et al. (2006), for example, found strong evidence for a positive association 
between severity of state anxiety in both men and women and increased levels of 
plasma pro-inflammatory cytokines, coagulation factors, C-reactive protein and white 
blood cells.  In addition, studies have identified anxiety as being linked to unhealthy 
lifestyle choices such as smoking, drinking alcohol and over or under eating (Halliwell 
2009; McManus & Bebbington 2009).  For example, in 2007 6% of alcohol-dependent 
adults were in psychotherapy compared with 2% without alcohol dependence; and 24% 
of those with eating disorders had been treated for CMDs compared to 10% without an 
eating disorder (Halliwell 2009; McManus & Bebbington 2009).  The association of 
smoking and anxiety is well documented (Halliwell 2009) and some studies have 
supported the hypothesis for a causal relationship, with anxious subjects being more 
likely to start smoking than non-anxious subjects (Patton et al. 1996; Senol et al. 2006; 
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Mykletun et al. 2008).  A six year study of 93 medical students, for example, found 
those who started regular smoking had a significantly (p = < 0.05) higher mean trait 
anxiety score on the Spielberger State-Trait Anxiety Inventory (Spielberger et al. 1970) 
administered once each year (45.6 ± 6.0 points) than those who did not start during that 
time (42.2 ± 7.3 points) (Senol et al. 2006). 
Physical symptoms of anxiety include pallor, sweating, hyperventilation, diarrhoea, 
irritable bowel, flushing, dysphagia, palpitations, nausea, muscle tension and back pain 
(B.M.A. 2002).  Anxiety sufferers may also be easily fatigued and/or experience sleep 
disturbances (Fricchione 2004). Alleviation of these adverse effects on health is 
important.  Orthodox anxiolytic treatments, however, have been linked to unwanted 
side-effects (B.N.F. 2008).  
An important factor is the known comorbidity of chronic anxiety with mood disorders.  
One rarely exists without the other (Brown et al. 2001) and McNair et al. (1971) 
identified tension-anxiety as one of six mood factors.  The impact of the problems and 
prevalence of anxiety and stress, with current therapeutic strategies, and an outline of 
the necessity for their attenuation with safe, effective interventions are reviewed. 
1.4.2 Therapeutic strategies for anxiety 
Benzodiazepines, which are commonly prescribed anxiolytics, have been linked to 
muscle weakness, amnesia, headaches, vertigo, urinary retention, slurred speech and 
gastro-intestinal disturbances.  They may lead to tolerance and physical and 
psychological dependence (both manifested by withdrawal symptoms) and are 
considered by the Committee on Safety of Medicines (CSM) to be dangerous to use 
long-term. In addition to anxiety, benzodiazepines are frequently prescribed for mood 
disorders such as anger, hostility and agitation despite CSM advice to the contrary and 
the known potential paradoxical effects of increased anger and hostility during use of 
benzodiazepines (Haw & Stubbs 2007; B.N.F. 2008).  Given the known side-effects of 
benzodiazepines (B.N.F. 2008), safer therapeutic strategies for negative mood 
disturbances are also important. 
 
The side effects of antipsychotics, sometimes prescribed in the short–term for severe 
anxiety, include tremor, dystonia (abnormal face and body movements) and 
restlessness.  Beta-blockers may be prescribed for relief of physical symptoms, such as 
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tremors and palpitations, associated with anxiety.  However, side effects are similar to 
those of benzodiazepines and may additionally include bradycardia, vasoconstriction 
and heart failure.  Chronic, severe anxiety disorders such as generalised anxiety disorder 
(GAD), panic disorder and obsessive compulsive disorders are sometimes treated with 
SSRI anti-depressants such as paroxetine and fluoxetine but these may lead to 
dependency and unpleasant side effects such as gastro-intestinal disturbances, dry 
mouth, dizziness, headache, sweating and insomnia (B.N.F. 2008).  There is therefore 
an urgent need for safe alternatives to orthodox anxiolytics, without unwanted side-
effects.   
1.5 Stress 
Stress may be defined as “a state in which a strong demand is made on the nervous 
system” (Longman English Dictionary 1976).  According to Cox (1978) humans appear 
to function optimally at moderate conditions of demand and a departure from this state 
can impair performance.  When there is an imbalance between demand and capability, 
stress is experienced.  “What is important for man is his cognitive appraisal of the 
potentially stressful situation and his ability to cope” (Cox 1978).  Stimuli may be 
physical or emotional (B.M.A. 2002).  Weitz (1970) described eight types of situations 
that may elicit a stress response: perceived threat, noxious external stimuli, increased 
processing of information, abnormal physiological function, frustration, pressure from 
others, confinement and isolation, and hopelessness (Weitz 1970).  Personality type 
may influence stress response (Pavlovich 1999), particularly the more ‘driven’ type A 
personality who is generally more impatient and competitive than type B personality.  
The type A personality has been shown by research to experience more cardiovascular 
problems (Pavlovich 1999). 
 
Selye (1946) proposed three stages of response to stress, which he termed the General 
Adaptation Syndrome:  Alarm, in which the body prepares for action; Resistance, in 
which there is maximum adaptation followed by a return to equilibrium; and 
Exhaustion, in which the adaptive mechanisms cease to function (Selye 1946). 
 
During the Alarm stage, activation of sympathetic nerve fibres occurs and adrenalin and 
noradrenalin are released from the adrenal medulla to prepare the body for a fight/flight 
response.  Sympathetic responses include glycogenolysis, dilation of blood vessels in 
skeletal muscles, constriction of skin vessels, speeding up of heart rate and force, and 
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release of insulin and glucagon (Greenstein 1994).  Irritable bowel, erectile dysfunction 
and anorexia may occur through suppression of the parasympathetic nervous system 
(Marieb 2003). 
 
During the Resistance stage, stress stimuli arriving via afferent inputs activate the 
parvocellular neuroendocrine cells (PNC) in the paraventricular nucleus of the 
hypothalamus.  Increased activity of PNC cells stimulates release of corticotrophin-
releasing factor (CRF) or hormone (CRH) from nerve terminals into the hypothalamo-
hypophyseal portal system of the median eminence of the hypothalamus into the 
anterior lobe of the pituitary gland, thus stimulating pro-opiomelanocortin (POMC) 
production, a precursor to adrenocorticotrophic hormone (ACTH).  Secretion of ACTH 
in turn stimulates glucocorticoid production (principally cortisol in humans) from the 
adrenal cortex (Greenstein 1994; Wamsteeker & Bains 2010).  
 
Cortisol from the zona fasciculata (middle layer) of the adrenal cortex is released 
throughout the day in a pulsatile manner and secretion and inhibition is controlled by a 
negative feedback mechanism, believed to be responsible for its circadian rhythm and 
secretion amplitude.  Cortisol output is at its highest in the morning and lowest in the 
evening.  Only the morning peak has been shown by various studies to be relatively 
stable, regardless of external stressors (Kirschbaum & Hellhammer 1989), although in 
individuals suffering ‘burnout’ and exhaustion morning secretion may be reduced 
(Clow 2004).  
1.5.1 The HPA axis 
Stress increases the activity of the hypothalamic-pituitary-adrenal (HPA) axis, with 
stimulation of CRF and ACTH and hence plasma cortisol levels (Figure 1.1).  Feedback 
mechanisms are overridden by stressors, resulting in cortisol hypersecretion, with 
increased amplitude and at a greater frequency than the usual 15 pulses daily 
(Kirschbaum & Hellhammer 1989).  The gamma-aminobutyric acid 
(GABA)/benzodiazepine receptor system mediates the inhibition by GABA of CRF and 
consequently the HPA axis (Fries et al. 2006).  Conversely, over activity of the HPA 
axis has been postulated to be associated with anxiety states (Tallman et al. 2002).  This 
hypothesis is supported by clinical findings that patients with post traumatic stress 
disorder (PTSD), a severe anxiety disorder in which there is chronic CRF and cortisol 
output, have a smaller hippocampal volume (as a result of unrestrained cortisol receptor 
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binding to hippocampal neurones - see also 1.5.2.1) than healthy subjects (Mann et al. 
2006).  For example, in a study of post-combat patients with PTSD the right 
hippocampal volume measured a statistically significant mean 8% smaller than healthy 
comparison subjects (Bremner et al. 1996).  Furthermore, suppression of the HPA axis 
following pre-treatment with the benzodiazepine alprazolam was observed in a 
laboratory study of induction of acute stress in healthy volunteers (Fries et al. 2006).   
 
Figure 1.1  The HPA axis 
Roberto Osti art in Sternberg and Gold (2002) 
Because of the association between cortisol hypersecretion and anxiety there has been 
much interest in the development of CRF/CRH antagonists as anxiolytics (Mann et al. 
2006).  From results of pre-clinical studies the anxiogenic (and depressive) action of 
CRH is hypothesised to be by continuous activation of the CRH1 receptor subtype 
(Zobel et al. 2000), which is expressed in the hippocampus, amygdala and other areas of 
the neocortex (Refojo & Holsboer 2009) leading pharmaceutical companies to develop 
CRH1 receptor antagonists (Zobel et al. 2000).  They are still in the development stage 
(Heilig 2012) and although results of clinical studies have been encouraging, with 
significant reductions in anxiety and depression in one trial, there have nonetheless been 
some unpleasant worsening of symptoms of anxiety and depression on cessation of the 
drug in some patients (Zobel et al. 2000).   
In this research, because of the ability of certain anxiolytics to attenuate stress by 
decreasing the activity of the HPA axis, the potential of S. lateriflora to alter changes in 
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cortisol output was explored.  Changes in cortisol output due to administration of S. 
lateriflora may be indicative of decreased anxiety and stress. 
1.5.2 Negative effects of stress 
Repeated, prolonged cortisol hypersecretion promotes increased gluconeogenesis, 
resulting in protein catabolism with consequent muscle and bone atrophy and easy 
bruising; hyperglycaemia and insulin resistance (steroid diabetes); mobilisation of fat 
stores and hyperlipidaemia as cortisol is lipolytic; and production of cytokines is 
reduced, leading to lowered immunity; there may also be hippocampal atrophy, leading 
to depression (Greenspan 1991).  
1.5.2.1 Cortisol effects on the C.N.S. 
Hypercortisolism causes an initial euphoria but with prolonged exposure to cortisol (as 
exemplified by Cushing’s disease) further behavioural changes may occur.  Depression, 
insomnia, poor memory, anxiety and irritability are common (Greenspan 1991).  
Glucocorticoids enter the brain easily and central nervous system toxicity may ensue, 
particularly in the hippocampus, a part of the brain that is essential for memory 
formation (Spinella 2001) and which has a high density of corticosteroid receptors 
(Sapolsky 2000).  Cortisol hypersecretion (morning plasma level >50 nmol/L), 
diagnosed by a dexamethasone suppression test (DST) in which exogenous steroids 
suppress endogenous secretion in a healthy subject via negative feedback mechanism 
inhibiting ACTH output (Hurley & Ho 2004), may lead to dysfunction of the 
hippocampus by causing hippocampal atrophy (Brown et al. 2004).  Hippocampal 
atrophy with up to 16% loss of in volume and cognitive impairment has been seen in 
Cushing’s disease and Cushing’s syndrome and in those with major depressive disorder 
(MDD), conditions which are associated with DST non-suppression (Brown et al. 
2004).   
 
Repeated and/or sustained stress with concurrently increasing/high cortisol output and 
consequent cumulative exposure has also been associated with decreased hippocampal 
volume and cognitive impairment.  Lupien et al. (1998), for example, measured basal 
plasma cortisol levels in 51 aged volunteers annually over 5 or 6 years.  Those with high 
and increasing levels (initial 12.8 μg/dl ± 3.1) showed significant (p = < 0.001) 
cognitive impairment in memory tests and a decrease in hippocampal volume of 14% 
when compared to study volunteers with moderate or decreasing levels (initial 9.1 μg/dl 
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± 2.9).  It is clear that stress may lead to physical and mental illness. Its attenuation is 
therefore important.  
1.6 The importance of herbal psychopharmacology 
Surveys suggest that herbal medicine is used more frequently by women than by men 
(Gunther et al. 2004).  Furthermore statistics indicate that anxiety and depression are 
more prevalent in women (Office for National Statistics 2006). According to a survey in 
the United States (del Mundo et al. 2002) one of the most common conditions for which 
complementary and alternative medicine (CAM) is used (30% of users) is anxiety 
and/or stress.  Of 664 respondents (74% of whom were females), 314 were CAM users.  
Of these, only back pain was a more common reason for CAM use (31% of users).  As 
chiropractors were the most visited CAM therapists, with medical herbalists a close 
second, it may be deduced from these results that since the chiropractors are more likely 
to treat back pain (its aetiology perhaps sometimes related to anxiety (B.M.A. 2002)), 
the majority of visits to an herbal medicine practitioner were by women with anxiety 
and stress (del Mundo et al. 2002).   
1.7 Research rationale and justification  
The effectiveness of herbal remedies in psychopharmacology can be demonstrated by 
the fact that St John’s wort (Hypericum perforatum) has been shown in numerous 
randomised controlled trials (RCTs) to be effective for even major depression and is 
widely prescribed both in the herbal clinic and by orthodox physicians (Linde et al. 
2008).   
 
There have been few randomised, placebo-controlled clinical studies of herbal 
anxiolytics.  A systematic review, published in 2006, located only 7 RCTs (and one 
other systematic review) of single, oral herbal preparations being tested specifically for 
anxiety (Ernst 2006), including a study on S. lateriflora (Wolfson & Hoffmann 2003).  
The author (Ernst 2006) concluded that, other than Kava kava (Piper methysticum), for 
which there was a systematic review (Pittler & Ernst 2002), there is no evidence of 
efficacy for any of the herbs studied, mainly because of poor methodological techniques 
such as small sample sizes (18 - 40) and poor reporting methods - uncharacterised 
herbal interventions for example (Ernst 2006).  Results of a systematic review of RCTs 
of herbs for psychiatric disorders (Sarris 2007), of which 9 had been clinically studied 
for anxiety, were in agreement with those of Ernst (2006) in that only Piper 
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methysticum research provided sound evidence for the herb’s anxiolytic properties.  The 
author suggested more research is urgently needed on two of the herbs studied for 
anxiety disorders, Passiflora incarnata (passionflower) and Scutellaria lateriflora.  
Although results were promising for both herbs, methodology and reporting were poor 
(Sarris 2007).  There were only 36 participants in the Passiflora study and it was not 
equivalent, with oxazepam and Passiflora in one group and placebo and Passiflora in 
the other (Akhondzadeh et al. 2001).  The S. lateriflora study (Wolfson & Hoffmann 
2003) will be discussed in this research in Chapter 2. 
 
A recent  review of psychopharmacology found little new clinical evidence for herbs for 
anxiety (Sarris et al. 2011).  It was found that, although the evidence for efficacy and 
safety of whole herb preparations for anxiety disorders is encouraging, in many cases 
the methodology and/or reporting and good pharmaceutical manufacturing practices 
were lacking in robustness.  Sample sizes were typically small, averaging 50 
participants, and studies had not been replicated (Sarris et al. 2011).  One promising 
study was a recent 8 week double-blind, placebo-controlled RCT study (n = 57) on 
Matricaria recutita (chamomile) for anxiety, which found a significant reduction in 
anxiety scores on the Hamilton Anxiety Scale (Hamilton 1959) compared to placebo (p 
= 0.047) (Amsterdam et al. 2009). 
 
Poor quality studies of potentially anxiolytic herbs can be exemplified by systematic 
reviews of RCTs of Passiflora (Miyasaka et al. 2007) and Valeriana officinalis 
(valerian) (Miyasaka et al. 2006), which determined the studies on these herbs were too 
few in number and sample sizes in monotherapy studies of the single herbs were too 
small for conclusions to be drawn on their effectiveness for attenuation of anxiety.  In 
the only RCT of Valeriana for anxiety (Andreatini et al. 2002) that was suitable for 
review there were only 12 participants in each arm of the study, a sample size 
considered too small to yield valid results (Miyasaka et al. 2006).  One Passiflora RCT 
was reviewed by Miyasaka et al. (2007).  In this study with 36 participants, comparing 
herb with the benzodiazepine oxazepam (Akhondzadeh et al. 2001), the sample size was 
also considered too small, the randomisation process was not explained and efficacy 
data could not be re-analysed.  There was no placebo for additional comparison 




Piper methysticum on the other hand has been extensively researched for its anxiolytic 
properties in a clinical setting and a meta-analysis has shown it to be an effective 
anxiolytic when compared to placebo (Pittler & Ernst 2003).  There were, however, a 
number of reported side-effects such as drowsiness and indigestion. Following reports 
of possible hepatotoxic reactions to some preparations, P. methysticum has been 
withdrawn from sale in the UK pending further evidence (Whitton et al. 2003).  It is 
therefore timely for research to be channelled towards other herbal anxiolytics.  Perhaps 
due to it being favoured as a sedative alternative to P. methysticum, demand for S. 
lateriflora in world markets appears to be growing (Greenfield and Davis 2004).  Its 
popularity (Bergner 2002) therefore makes it an ideal candidate for this purpose (see 
also Chapter 3).  Well conducted clinical trials of S. lateriflora may prove it to be as 
effective for anxiety as P. methysticum and as H. perforatum is for depression.  
 
The current research study is innovative as it aims, for the first time, to conduct a study 
of sufficient duration to demonstrate long-term effects of S. lateriflora on anxiety, stress 
and other negative mood states as well as determining its effects on cognition and 
energy.  Furthermore, there have been very few crossover studies of herbal preparations 
used for anxiety.  Only four randomised controlled trials (RCTs) involving crossover 
studies of ‘nervine’ herbs were located by this author:  
 A study of Piper methysticum in healthy volunteers. The quality of the study 
was lacking as there was no washout period between interventions, increasing 
the risk of the  carry-over effect seen in the results (Sarris et al. 2009a). 
 A study of Trifolium pratense (red clover) for menopausal depression and 
anxiety. Either T. pratense or placebo was taken for 90 days before a 7 day 
washout and then crossover.  The results were statistically significant (Lipovac 
et al. 2010). 
 A study of a Piper methysticum/Hypericum perforatum combination for anxiety 
and depression.  Only 18 participants completed the study and there was a 
placebo run-in period phase (Sarris et al. 2009b), which may have introduced 
bias (Berger et al. 2003).  
 Wolfson and Hoffmann (2003) assessed the acute anxiolytic effects of S. 
lateriflora in healthy volunteers. The study had its limitations, which will be 




To this author’s knowledge this is the first time a crossover study of an anxiolytic herb’s 
effects on salivary cortisol has been conducted.  There was a parallel study of the effects 
of Magnolia officinalis (magnolia) and Phellodendron amurense (cork-tree) on stress, 
published in 2008, in which salivary cortisol was measured at baseline and towards the 
end of a 5 week study.  This was quite different from the current research as it was a 
study of obese women who ate in response to stressful situations (Kalman et al. 2008).  
There were no significant alterations in salivary cortisol with the intervention 
(Magnolia-Phellodendron) when compared to placebo. 
1.8 The research question 
Can American skullcap (Scutellaria lateriflora) contribute to improvement of mood? 
1.9 Aims of the research 
The study aimed to evaluate the effectiveness of S. lateriflora in enhancing mood with 
particular reference to attenuation of anxiety and stress and other negative mood states. 
1.10 Objectives of the research 
 To conduct a survey amongst UK and Ireland herbal medicine practitioners on their 
use of S. lateriflora. 
 To analyse the phytochemical and botanical profile of S. lateriflora to authenticate 
and verify quality for medicinal use. 
 To identify the macroscopic defining features of S. lateriflora to verify its 
identification at source of supply. 
 To deliver an evidence-based herbal intervention with extracts of S. lateriflora for 
promotion of wellbeing in a series of tests, using a randomised, double blind, 
placebo-controlled, crossover design with subjective measures of mood in healthy 
volunteers. 
 To measure changes in levels of cortisol in saliva samples, following administration 
of an extract of authenticated S. lateriflora to the selected group.  
 To assess the safety profile of S. lateriflora by comparing liver function tests at 




Chapter 2. Scutellaria lateriflora: 
background and literature review 
2 American skullcap (Scutellaria lateriflora L) 
2.1 Introduction 
Scutellaria lateriflora (Figure 2.1) is a perennial herb belonging to the Lamiaceae 
(mint) family (also known as Labiatae), sub-family Lamioideae, and is one of 360 
known Scutellaria species worldwide (Cole et al. 1991; Malikov & Yuldashev 2002) 
many of which are used medicinally (Joshee et al. 2002).  It grows on wetlands and is 
indigenous to North America and Canada where it is widely distributed - from Alaska to 
Florida and British Columbia to Quebec (the only places it is not found are the North-
west Territories, Alberta and Yukon in Canada and Wyoming, Nevada and Utah in the 
US) (U.S.D.A. 2012). It has also been reported to grow on riverbanks and marshes in 
northern Iran (Yaghmai 1988) and is grown commercially worldwide, particularly in the 
USA, Australia and New Zealand (Wills & Stuart 2004).   
 
Demand for S. lateriflora in world markets appears to be growing.  Harvesting and sales 
of the herb in 2001 had increased over 1997 by around 250% and amounted to 
15, 875.733 kilograms.  Between 2000 and 2001 the increase was 23%.  According to a 
market report by Greenfield and Davis (2003) there was a sharp increase (figures not 
stated) in demand in the last quarter of 2002, which suggested a continued growth in 
demand of 20-30% annually over a period of 5 years (Greenfield & Davis 2003).  This 
increased demand for S. lateriflora is believed to be attributable to it being favoured as 
a sedative alternative to Piper methysticum (kava kava), which, due to toxicity fears, is 
no longer widely prescribed by herbalists in Europe (Greenfield & Davis 2004).   
 
Although S. lateriflora is a popular herb in western herbal medicine and contained in 
many herbal formulations (Joshee et al. 2002), particularly for anxiety and stress, few 
scientific studies of this herb exist.  Therefore its safety, efficacy and pharmacology are 
not well established (Gao et al. 2008).   
 
Considering potentially increasing demand for S. lateriflora, new research on this herb 
is timely and important. Scutellaria baicalensis (Georgi) root from baical skullcap is 
extensively prescribed in traditional Chinese and Japanese (kampo) medicines, 
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particularly to treat inflammatory diseases, and has been widely researched in relation to 
its efficacy and pharmacological properties.  Some of these findings may be 
extrapolated to S. lateriflora, which is phytochemically similar (Joshee et al. 2002). 
2.2 Selected common names 
Popular names include American skullcap, Virginian skullcap, blue skullcap, dogweed, 
mad-dog, blue pimpernel, helmet flower, hoodwort, madweed and Quaker bonnet 
(Felter & Lloyd 1898; Wolfson & Hoffmann 2003; Cole et al. 2008; Hull 2010). The 
term ‘skullcap’ refers to the medieval helmet shaped calyx (Figure 2.2) and the genus 
name Scutellaria means ‘little dish’, due to the appearance of the lid of the calyx 
(Joshee et al. 2002). 
2.2.1 Synonyms 
Cassida lateriflora (L.) Moench, Scutellaria lateriflora f. albiflora Fernald, Scutellaria 
lateriflora var. albiflora Farw., Scutellaria lateriflora var. axillaris Jenn., Scutellaria 


















































Figure 2.2  Scutellaria lateriflora showing helmet-shaped calyces 
        
 
2.3 Botanical description  
S. lateriflora grows up to 30-90 cm in height and has a smooth, many branched, slender 
stem with four angles.  The stem turns brown when exposed to the sun.  Its leaves are 
ovate, smooth and with crenate-serrate margins.  They are 2-5 cm long and 1-2 cm 
wide, opposite, and are rounded at the base and acute at the apex.  The leaves are non-
sessile, the leaf stalk or petiole being around 2 cm in length. The tubular, two-lipped 
(upper hooded and lower shallow), blue to purple flowers, which appear from May to 
September, are about 2-7 mm long and are clustered in one-sided opposite racemes.  
The short, creeping roots are fibrous and yellow (Felter & Lloyd 1898; Joshee et al. 
2002; Greenfield & Davis 2004).  Scutellaria lateriflora is so called because the flowers 
are turned to one side but it is often erroneously called Scutellaria laterifolia 
(Wohlmuth 2001).  It should be noted that the above description notes of S. lateriflora 
were taken from literature and may not be entirely accurate.  A more authentic 













































2.4 Historical background 
S. lateriflora was mentioned in the first American Materia medica in 1785 but had been 
in longstanding use as a home remedy before then (Lloyd 1911).  The first European to 
record its use as a medicinal herb was German Physician Johann David Schöpff, who 
noted its use as a tonic and for fevers and as an abstergent (detergent) in 1787 (Upton et 
al. 2009).  Dr Lawrence Van Derveer (1740-1815) studied S. lateriflora extensively and 
used it as a treatment for rabies (hydrophobia); it was then used for this purpose both 
professionally and as a home remedy.  In 1819 Dr Lyman Spalding wrote ‘A history of 
the introduction and use of Scutellaria lateriflora (scullcap), as a remedy for preventing 
and curing hydrophobia, occasioned by the bite … ’ (Lloyd 1911; New Jersey 
Historical Society 2001).   
 
Medical doctor Joseph Bates wrote in 1855 in the Boston Medical Journal that Van 
Derveer was believed to have cured more than 300 people of ‘canine madness’... ...‘in 
secret’(Bates 1855). Millspaugh (1892) quoted the number being as high as 1,400.  
Bates tells how, because of these claims, S. lateriflora was eventually thoroughly tested 
as a cure for rabies.  When it was found to be utterly useless for this purpose it fell into 
disrepute and was consequently removed from pharmacopoeias.  Bates nevertheless 
described using S. lateriflora in his practice, claiming a fluid extract had great value in 
the treatment of nervousness, irritability and restlessness, particularly in children.  He 
also held it in high regard for hysteria and for relieving symptoms of inflammation in 
patients with arthritis or convalescing from fevers.  He prophesied that it would be 
found to be highly successful in treating many diseases in the future, particularly those 
for which opium was currently prescribed (Bates 1855).  In 1860 S. lateriflora was 
introduced into the official United States Pharmacopoeia as Extractum Scutellariae 
Fluidum (Millspaugh 1892; Upton et al. 2009) but was dropped in 1910.  It was in the 
US National Formulary in 1916 and removed in 1942 when interest in natural remedies 
declined.  It is not included in the European Pharmacopoeia (Upton et al. 2009). 
 
In 1869 John Shapley and AD Hutchinson applied to patent an ‘Alterative and 
invigorating cordial’ containing mainly S. lateriflora and Cimicifuga racemosa (black 
cohosh), with small amounts of eight other herbs, which were mostly carminatives 
(Shapley & Hutchinson 1869). 
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2.5  Therapeutic uses of Scutellaria lateriflora 
2.5.1 Ethnobotanical uses 
The herb has been traditionally used by Native Americans for anxiety and potentially 
related disorders such as nervous exhaustion, anxiety-related muscular tension, hysteria, 
hypertension, epilepsy, tremors and convulsions, delirium tremens, neuralgia, insomnia, 
diarrhoea and headaches (Felter & Lloyd 1898; Joshee et al. 2002; Hull 2010).  Today it 
is also smoked ceremonially and sometimes used to induce visions (Joshee et al. 2002).   
 
King’s American Dispensatory (Felter & Lloyd 1898) describes S. lateriflora as an 
antispasmodic nervine tonic that is calming in all cases of ‘nervous excitability, 
restlessness, or wakefulness...  ...When its soothing effects have ceased it does not leave 
an excitable, irritable condition of the system as is the case with some other nervines’;  
and for ‘functional cardiac disorders due to purely nervous causes’.  Jethro Kloss, who 
wrote the classic natural medicines text ‘Back to Eden’ in the 1920s and 1930s, depicted 
S. lateriflora as ‘one of the best nerve tonics we have’ (Kloss 1995).   
 
It has been used for centuries in Cherokee folk medicine for nervous disorders of the 
digestive tract, such as irritable bowel and related colic, flatulence, heartburn, 
constipation and diarrhoea.  It is believed to normalise peristalsis by the effects of its 
volatile oils, which may possess spasmolytic and carminative actions (Khosh 2000).  
However, the effects are also likely to be due to an anxiolytic action of the herb. 
 
It was also used for fever and the Iroquai tribe use the herb ‘to keep the throat clear’ 
(Joshee et al. 2002).  Additionally, Kloss (1995) advocated its use for rheumatism; and 
as an antidote to insect and snake bite venom.  These uses suggest possible direct anti-
inflammatory, antipyretic, immunomodulatory and even antimicrobial effects.  
According to Wojcikowski et al. (2007) it is traditionally used for disorders of the 
urinary tract.  It is unclear whether this  application relates to its traditional use as a 
diuretic (Greenfield & Davis 2004) or whether due to an antimicrobial or anti-
inflammatory action.  
2.5.2 The potential value of S. lateriflora in gynaecology 
Known as a woman’s herb by Native Americans, the Cherokees used it as an 
emmenagogue, thus promoting menses and aiding expulsion of the placenta following 
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childbirth.  Native American women also use it to ensure general menstrual health 
(Joshee et al. 2002; Russell et al. 2003; Hull 2010) as well as for mastalgia and 
premenstrual tension (Greenfield & Davis 2004; Hull 2010).  Some tribes still use it in 
ceremonies to induct girls into womanhood and for purification rituals (Joshee et al. 
2002).  According to Kloss (1995) S. lateriflora is useful for suppressing sexual desire.   
 
Despite its traditional use for problems relating to the menstrual cycle and for mastalgia, 
there appears to be little reference in modern herbal medicine texts to current use of S. 
lateriflora in gynaecology.   Hoffmann (2003) states that it can be safely used to ease 
premenstrual tension and Harrar and O'Donnell (1999) suggest it has healing potential 
for premenstrual syndrome and menopausal mood changes.  Due to a lack of research in 
this area, however, it is unclear whether these effects are due to direct modulation of 
hormone levels or on neurochemicals that affect mood.  Liao et al. (1995) found S. 
baicalensis root extract bound to dopamine 2 (D2) receptors in vitro.   As mouse 
striatum preparations were used it is not known whether there would be similar findings 
in the human brain in vivo.  Some future research could focus on whether S. lateriflora 
binds to D2 receptors with (if a D2 agonist) a consequent lowering of prolactin, itself a 
stress response hormone (Axelrod & Reisine 1984), with concomitant measurements of 
salivary prolactin levels (Nadeem et al. 2004).  However, it does contain vitexin (Lin et 
al. 2009), an important active constituent of Vitex agnus castus herb, commonly used 
for menstrual disturbances (Hoffmann 2003).  
 
Following its use in both folk and professional medicine for hundreds of years, the 
popularity of S. lateriflora has not waned.  It is believed to be one of the most 
commonly used medicinal herbs by western medical herbalists today (Bergner 2002). 
2.5.3 Contemporary uses of S. lateriflora 
Modern herbal medicine’s application of S. lateriflora appears to be based upon its 
traditional use as an anti-spasmodic, diuretic, anti-inflammatory, anti-pyretic and 
sedative herb.  Greenfield and Davis (2004), for example, suggest it is used most 
commonly for insomnia, nervous disorders such as anxiety, and for digestive 
disturbances.  Bergner (2002) proposes its action is primarily as a trophorestorative on 
the central nervous system (CNS), allowing relaxation following nervous exhaustion, 
whether from post-traumatic stress, organic diseases, overwork, too many stimulants, 
lack of sleep, or drug or alcohol abuse (Bergner 2002).  It is also prescribed by western 
21 
 
herbalists for epilepsy, fibromyalgia and anorexia nervosa (Hull 2010), post-stroke 
paralysis, atherosclerosis, hyperlipidaemia, allergies, skin conditions and inflammation 
(Natural Medicines Comprehensive Database 2011) and as a mild bitter and 
antispasmodic for digestive disturbances (Bergner 2002).  Other than for anxiety 
(Wolfson & Hoffmann 2003), to date no clinical trials have been conducted to provide 
evidence of efficacy for these conditions. 
2.6 The Chemical constituents of S. lateriflora 
Since 1998 a large number of compounds have been isolated from S. lateriflora (Shang 
et al. 2010), which could have far reaching implications for research into its actions and 
indications. In common with all Scutellaria species studied, S. lateriflora is rich in 
flavonoids, a group of phenolic compounds that are highly active physiologically, with 
a wide range of pharmacological actions (Malikov & Yuldashev 2002; Li et al. 2012).  
The many biological actions of flavonoids that are beneficial to the plants may also have 
therapeutic potential in herbal medicine for humans (Cody et al. 1986).  
 
Flavonoids are derived from flavone, which consists of two benzene rings connected by 
a 3 carbon chain, as methoxy or hydroxyl compounds.  These compounds are secondary 
plant metabolites and occur widely in plants (Hoffmann 2003).  They are pigments and 
provide plants with many of their natural colours, attracting pollinators.  Their diverse 
biological effects (e.g. antioxidant, antimicrobial) afford protection to plants from 
disease and predation by insects but also have numerous physiological actions in 
humans when consumed as part of the diet or as medicines.  Their actions include anti-
inflammatory, anti-allergy, antioxidant, spasmolytic, anti-hepatotoxic, antimicrobial and 
anti-carcinogenic (Gabor 1986; Glusker & Rossi 1986).  It is their phenolic properties, 
for example, which provide them with antioxidant potential (Swain 1986). 
 
An in-depth review (Malikov & Yuldashev 2002) indicated that up until the year 2000, 
of 208 phenolic compounds isolated from Scutellaria species only one (scutellarin: 
scutellarein 7-O-glucuronide) had been isolated from Scutellaria lateriflora (it had also 
been isolated in 26 other skullcap species).  However, Nishikawa et al. (1999) had also 
isolated the flavone glycoside baicalin (baicalein 7-O-glucuronide) and the aglycone 
wogonin (5,7-dihydroxy-8-methoxyflavone) (Figure 2.3) from this species.  Wogonin 
was first isolated in 1930 by Hattori (Joshee et al. 2002) from the roots of S. 
baicalensis.  Considering its history of widespread use for medicinal purposes, this lack 
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of information about the chemistry of S. lateriflora was surprising and reinforces a view 
that more research on this species was needed.   
 
More recently, a number of other flavonoids have been isolated from S. lateriflora.  In 
addition to baicalin and wogonin, baicalein (5,6,7-trihydroxyflavone) - the aglycone of 
baicalin, lateriflorin (5,6,7-trihydroxy-2'-methoxyflavone-7-O-glucuronide), 
lateriflorein (5,6,7-trihydroxy-2'-methoxyflavone) are quantitatively the major 
compounds in S. lateriflora (Gafner et al. 2000).  Perhaps due to their greater 
abundance in the herb, baicalin, baicalein and wogonin (Figure 2.3) are considered the 
most important compounds in S. lateriflora.  Of all skullcap flavonoids they have been 
most widely researched for their actions and related indications in vitro (see 2.12.1, 
p31), research that has been facilitated by their also being major flavonoids in S. 

























Figure 2.3  Three important flavonoids found in S. lateriflora 
 




Other flavonoids present are said to include apigenin; hispidulin and luteolin (Barnes et 
al. 2007) but their presence in S. lateriflora aerial parts does not appear to have been 
substantiated by laboratory methods although Parajuli et al. (2009) found 5.56 µ/mg 
apigenin in methanol root extract; both flavonoids have been chemically recovered from 
the aerial parts of some other skullcap species (Zgorka & Hajnos 2003; Shang et al. 
2010); vitexin (apigenin C8-glucoside) (Lin et al. 2009); viscidulin III-2´-O--D-
glucopyranoside (Zhang et al., 2009); viscidulin III; trans-martynoside; oroxylin A-7-
O--D glucopyranoside; wogonoside; chryin; chryin-6-C--L-arabionopyranosyl-8-C--
D-glucopyranoside; chrysin (5,7-dihydroxyflavone), dihydrochrysin (5,7-
dihydroxyflavanone); oroxylin A; ikonnoside (5,6,7,2′-tetrahydroxyflavone-7-O-
glucuronide); ikkonikoside I (7-glucuronyloxy-5,6,2´-trihydroxyflavone) and 
dihydrobaicalin (Awad et al. 2003; Bergeron et al. 2005; Li & Khan 2008; Zhang et al. 
2009); 5,7-dihydroxy-8,2´-dimethoxyflavone, dihydrooroxylin A (Li et al. 2009), 
oroxylin A-7-O-glucoronide, and dihydrowogonin-7-O-glucoronide (Li et al. 2012). 
 
Very recently (Li et al. 2012), using a sensitive method of high performance liquid 
ultraviolet photodiode array and electrospray ionization tandem mass spectromic 
detection (HPLC-DAD/ESI-MS), seven more flavonoids have been isolated from 
methanolic extracts of authenticated S. lateriflora aerial parts, none of which have been 
previously identified in this species.  The newly detected flavonoids are norwogonin-7-
O-glucoronide, wogonin-7-O-glucoronide, 5,7-dihydroxy-6,8-dimethoxy-flavone-7-O-
glucoronide, dihidrooroxylin A-7-O-glucoronide, galangin-7-O-glucuronide, and 5,6,7-
trihydroxy-flavanone-7-O-glucuronide (Li et al. 2012). 
 
According to Zhang et al. (2009) trans-verbascoside (acteoside) was also found in S. 
lateriflora.  However, the skullcap samples (n=10) used for this analysis were 
purchased from various natural product suppliers and shops (Zhang et al. 2009).  There 
is therefore no guarantee that any of the samples were authentic S. lateriflora and it is 
possible that the verbascoside content was due to contamination as this phenylethanoid 
glycoside is found in Germander (Teucrium) species but not in Scutellaria species (Lin 
et al. 2009).  In the 1970s and 1980s there were reports of liver damage from use of S. 
lateriflora (McCaleb 2004).  The cause of hepatotoxicity was subsequently attributed to 
Teucrium being used in some European commercial preparations in place of S. 




The essential oil is at low (0.01-0.02% w/w) concentrations (Wohlmuth et al. 2011). 
According to Yaghmai (1988) the essential oil is dominated by sesquiterpenes (78%), 
which are principally (in descending order of quantity) -cadinene, calamenene, -
elemene, -cubebine, -humulene and -bergamotene.  Monoterpenes (2.8%) include 
camphene and -pinene.  Other aromatic compounds exist in small quantities and 
include cinnamaldehyde and safrole (Yaghmai 1988).  It is not definite that this analysis 
(Yaghmai 1988) was conducted from authentic S. lateriflora material (Wohlmuth et al. 
2011), however, as the skullcap used in this study was collected in Northern Iran.  The 
species that is known to grow in this region is S. pinnatifida (Barceloux 2008).  The 
results differ from those arrived at by Wohlmuth et al. (2011), who analysed three 
authenticated S. lateriflora samples and found highest levels of 1-octen-3-ol (29-68%) 
and acetophenone (6-20%) (Wohlmuth et al. 2011). 
 
S. lateriflora also contains small quantities of the indoleamines melatonin and serotonin 
(Murch et al. 1997; Cole et al. 2008).  S. baicalensis contains around eight times more 
melatonin than S. lateriflora (Cole et al. 2008)*.  The amino acids -aminobutyric acid 
(GABA) (~ 0.55%) and glutamine (~ 0.34%) have also been detected in S. lateriflora 
(Awad et al. 2003; Bergeron et al. 2005) in both aqueous and ethanolic extracts, with 
markedly high levels of glutamine in aqueous extract (Awad et al. 2003) and a 70% 
ethanolic extract (Bergeron et al. 2005).   
*(see Chapter 5, Quality Control section, 5.2.2, p72 & 5.5, p79 for differentiation between skullcap 
species) 
 
Other known constituents are triterpenoids, including lupenol, ursolic acid, sitosterol 
and dauchosterol (Li & Khan 2008) and diterpenoid scutelaterins A-C, ajugapitin and 
scutecyprol A (Bruno et al. 1998); p-coumaric acid (Awad et al. 2003); a mixture of 
arachic, behenic and lignopalmitic acid (Li & Khan 2008); and wax hydrocarbons 
(Yaghmai & Benson 1979).  Barnes et al. (2007) state the iridoid glycoside catalpol as 
being present but this was not detected (by paper chromatography) in S. lateriflora; 
although found to be present in numerous (13) other species of skullcap (Cole et al. 
1991). 
 
Some of the most recent compounds to be isolated from authenticated S. lateriflora 
aerial parts (Li et al. 2009), are two previously unknown dihydropyrano coumarins, 
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named scuteflorins A and B respectively, which may be neuroprotective, cytotoxic and 
protein kinase C activating, and another coumarin, decursin (Li et al. 2009).  
 
A metabolomic analysis (the detection, identification and quantitation of all compounds 
in a sample) of S. baicalensis shoots revealed 2,400 compounds.  Of these compounds 
781 may have medicinal actions, including hyperforin; a compound found in Hypericum 
perforatum (St John’s Wort) and believed to be effective against depression (Murch et 
al. 2004).  A similar analysis of authentic S. lateriflora might be useful. Considering 
problems of substitution there is no guarantee that all of the analyses of S. lateriflora so 
far are correct. 
2.6.1 Flavonoid metabolism 
Hydrolysis of flavonoid glycosides to the corresponding aglycone is believed to be by 
micro-organisms in the intestinal walls (Hackett 1986).  This hypothesis is supported by 
studies demonstrating glycosides remained unhydrolysed in the faeces of germ-free rats 
(Griffiths & Barrow 1972).  Suppression of normal indigenous gut flora such as occurs 
following antibiotic therapy (George et al. 1977) may perhaps result in compromised 
efficacy of the herb.  It could be argued that patients using antibiotics whilst taking S. 
lateriflora (or any herbal medicines in which flavonoids are the active components) 
should be advised to take probiotic Lactobacilli and/or Bifidobacteria to modify gut 
bacteria, and prebiotics (fructo-oligoscaccharides) such as inulin to increase probiotic 
growth (Hart et al. 2002) as an adjunct therapy.  Inulin is found in Taraxacum officinale 
radix (dandelion root), for example (Hoffmann 2003). 
2.7 Preparations and dosages used 
Preparations of S. lateriflora are made from the aerial parts and are sold in the form of 
tinctures, teas and tablets; and capsules containing powders, liquids or freeze-dried 
material (Eclectic Institute Inc. 2003; Wills & Stuart 2004; Natural Medicines 
Comprehensive Database 2011).  Curiously, in Japan, medicines made from the roots of 
S. lateriflora are officially classified as pharmaceuticals, whereas products made from 
the aerial parts are considered non-pharmaceuticals (Makino et al. 2008).  Dosages vary 
according to extraction, marc: menstruum ratio, practitioner preference and preparations 
used but average at around 1 g equivalent dry weight per dose three times daily (Table 
2-1).  Preparations from fresh herb are thought to be most effective (Felter & Lloyd 
1898; Kuhn & Winston 2001; Yarnell & Abascal 2001). In 1871, Eclectic physician 
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John Scudder proposed in Specific Medication that anything other than fresh S. 
lateriflora was ‘worthless’ (Upton et al. 2009). 
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A survey of major botanical and nutritional supplies companies in Europe and the USA 
found that 22% of these companies sell S. lateriflora as a single product and 33% sell it 
both as singles and as part of a formula (Greenfield & Davis 2004).  It is often 
combined with various other anxiolytic herbs in commercial preparations for anxiety 
and stress.  ‘Serenity’ liquid-filled capsules (Gaia Herbs 2011), for example, contain 60 
mg of S. lateriflora extract per daily dose of 3 capsules combined with Passiflora 
incarnata (passion flower), Matricaria recutita (chamomile), Piper methysticum (Kava-
kava), Humulus lupulus (hops), Artemisia vulgaris (mugwort), Crataegus spp 
(hawthorn), Mentha piperata (mint) and Avena sativa (oats) (Gaia Herbs 2011). 
 
Many products contain standardised extracts.  A problem with standardisation is that the 
process is based on commercially available chemical ‘marker compounds’ so a product 
may contain irrelevant or insufficient ingredients or they may be in the wrong ratio for a 
synergistic effect.  Concomitant ingredients in an herb may not be majorly bioactive but 
they may enhance the actions of the main active phytochemicals by, for example, 
increasing their bioavailability or stability (Andrade et al. 2000; Gafner & Bergeron 
2005; Cole et al. 2008). 
2.8 Contraindications and drug interactions  
Potential side-effects of S. lateriflora were monitored during a clinical trial of its 
efficacy and none were reported.  However, those taking any kind of medication were 
excluded from the study (Wolfson & Hoffmann 2003) and effects were only monitored 
for two hours.  It is therefore important for the safety of the herb to be verified in a 
study of longer duration. 
 
It may be advisable for the use of S. lateriflora to be avoided with some conditions and 
medications where it might be contraindicated.  Awad et al. (2003) found that extracts 
of S. lateriflora equivalent to those used commercially strongly inhibited the CYP3A4 
enzyme in vitro.  As this is a drug metabolising enzyme the herb may be contraindicated 
with some orthodox medicines; for example calcium channel blockers, barbiturates, 
cimetedine, ciprofloxacin, cisapride, corticosteroids, paclitaxel and tamoxifen – to name 
a few drugs that interact with CYP3A4 (Vanin 2008).  Also, baicalein and wogonin 
inhibited diclofenac metabolism by CYP2C9 in vitro (Kim et al. 2002).  Another report 
(Kron 2004) suggests that S. lateriflora may be metabolised by the same CYP450 
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enzyme as high active anti-retroviral therapy (HAART).  It is possible that concurrent 
administration may increase serum concentration of HAART (Kron 2004).  It is 
unknown whether the evidence for effects of Scutellaria species on CYP450 enzymes 
gathered from in vitro studies, however, has clinical significance as in vitro drug 
metabolism studies have been demonstrated sometimes to be poor predictors of the 
situation in human patients (Piscitelli & Gallicano 2001). 
 
Because of its traditional use as an emmenagogue (Joshee et al. 2002) it is not possible 
to comment on the safety of using S. lateriflora during pregnancy.  
2.9 The safety profile of S. lateriflora 
There have been reports of hepatotoxicity associated with S. lateriflora.  Although 
believed to be attributed  to its adulteration with Teucrium species (McCaleb 2004), it is 
important to confirm the safety profile of S. lateriflora by ensuring that all participants 
in a clinical study of the herb undergo analysis of blood for liver function pre- and post- 
intervention (see section 6.11.3, p105). In addition, adequate quality control of the herb 
prior to clinical use in order to ensure it is not adulterated or substituted with potentially 
toxic botanicals, microbes or heavy metals is essential (de Smet 1999).  (See also 
Chapter 5: 5.2.1, p72.) 
 
Some research has suggested toxicity associated directly with S. lateriflora’s 
phytochemicals. Results of an in vitro toxicity study on rat hepatocytes, for example, 
suggested diterpenoids from S. lateriflora, including scutelaterins A-C, were 
hepatotoxic.  Hepatocytes were incubated for two hours with S. lateriflora diterpenoids.  
The diterpenoids reduced cell viability (forming membrane blebs and increasing 
apoptosis), and decreased ATP levels and protein thiols.  The apparent toxic effects 
were cytochrome P4503A (CYP 3A) dependent.  The enzyme activated the 
diterpenoids, leading to toxic effects (Haouzi et al. 2000).  The experimental results 
may not be relevant to the human situation and do not warrant the designation of S. 
lateriflora as a toxic herb.  Firstly, in vitro systems do not take first pass metabolism 
into consideration.  CYP 3A enzymes are abundant in the human small intestine and 
play a major role in xenobiotic metabolism here.  Secondly, the rat is a poor model for 
human CYP 3A enzymes, as isoforms of CYP 3A are species specific.  In humans the 
majority of drug biotransformation in the liver is by CYP 3A4 and 3A5 whereas in rats 
CYP 3A1 and CYP 3A2 predominate.  Even minor differences between species in 
29 
 
amino acid sequences in CYP enzymes can result in major differences in CYP activity 
in relation to substrate specificity and catalytic activity (Martignoni et al. 2006).  
Finally, the use of plant medicines (which the authors refer to as a ‘fad’), are seldom in 
the form of isolated constituents and there is a potential role for other phytochemicals in 
S. lateriflora acting in synergy with its diterpenoids and having a protective effect.   
 
Contrary to being hepatotoxic, the antioxidant potential of S. lateriflora (Cole et al. 
2008) may help protect hepatocytes from lethal damage.  
 
In Japan, there are also concerns regarding potential toxicity of S. lateriflora.  This is 
because the use of S. baicalensis root has been linked to a few cases of hepatotoxicity 
and interstitial pneumonia.  Baicalin, also found in S. lateriflora, is the compound 
believed to be responsible for the toxic effects.  Initial reports of toxicity were based on 
the inclusion of the root in ‘shosaikoto’ (Makino et al. 2008).  This is, ironically, an 
herbal formula popular in kampo medicine as a hepatoprotective, particularly in cases of 
hepatitis and hepatocellular carcinoma.  As it contains six other herbs: Bupleurum 
chinensis (Chinese thorowax), Pinellia spp. (green dragon), Panax ginseng, Zizyphus 
jujuba (jujube), Glycyrrhiza glabra (liquorice) and Zingiber officinale (ginger) 
(LiverSupport.com 2011), there is no evidence that baicalin is the toxic component 
linked to hepatopathy and interstitial pneumonia. 
2.10 Side-effects 
There were no reported side-effects in a clinical study of S. lateriflora (Wolfson & 
Hoffmann 2003). However, in view of purported efficacy and indications from 
experimental data (Wolfson & Hoffmann 2003) and traditional use, caution may be 
advisable in some circumstances.  For example, due to its potential sedative action 
(Greenfield & Davis 2004) it may be advisable to refrain from using S. lateriflora with 
other sedatives, including alcohol and benzodiazepines.  Although there have been no 
reported herb-drug interactions with S. lateriflora (Kuhn & Winston 2001), warnings 
could be given regarding effects on driving or operating machinery as all anxiolytics 
have the capacity to cause drowsiness in some individuals (B.N.F. 2008).  According to 
Joshee et al. (2002) overdose may result in ‘giddiness, stupor, confusion and twitching’.  
However, with normal therapeutic doses (Table 2-1, p26) there have been no reported 
side-effects (Kuhn & Winston 2001). 
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2.11 Bioavailability, biotransformation and elimination 
Very few pharmacokinetic studies of skullcap flavonoids have been conducted in 
humans. The following were based on flavonoids in S. baicalensis, also found in S. 
lateriflora. 
 
Following oral administration to 10 healthy volunteers of commercial skullcap root (S. 
baicalensis) powder, urinary excretion of conjugated metabolites of baicalein and 
wogonin was 7.2% and 11.6% of the original dose respectively.  The half-life 
eliminations for these conjugates were approximately 8 hours for baicalein and 10 hours 
for wogonin (Lai et al. 2003).  An indication of the length of time some flavonoids 
remain in the body may be a useful indicator for a washout period in a clinical study. 
 
Studies using rats have shown that very little baicalin enters the blood in its primary 
form but is first mainly hydrolysed by intestinal flora to baicalein and reconjugated to 
baicalin in plasma (Akao et al. 2000).  As baicalin is a prodrug of baicalein and because 
baicalein was shown in other studies using rats to be the main bioactive metabolite in rat 
plasma following its oral administration, baicalein was previously believed to be more 
useful than baicalin as a therapeutic for oral administration (Guo et al. 2011).  However, 
a recent study (Guo et al. 2011) investigating the metabolites of baicalein in human 
plasma 3 hours and 5 hours following its oral administration in 3 healthy volunteers 
showed the two flavonoids may be interchangeable with regard to bioactivity.  Five 
metabolites were identified by HPLC/MS.  These were glucoronides of baicalein, 
including baicalin, which was the main metabolite (Guo et al. 2011).  Although the 
results suggest the two flavonoids are interchangeable as major active compounds of S. 
lateriflora, polar glycoside flavonoids such as baicalin and wogonoside are hydrophilic 
and poorly lipophilic so are unlikely to cross the blood brain barrier; unlike their 
aglycones baicalein and wogonin respectively (Barceloux 2008).  Therefore, the 
anxiolytic properties may be due mainly to aglycones in the blood.  It is noteworthy that 
benzodiazepines are highly lipophilic and can cross the blood brain barrier (Longo & 
Johnson 2000). 
 (See also 2.6.1, p25 & 2.12.1.3, p34) 
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2.12 Research supporting anxiolytic and thymoleptic effects 
2.12.1 In vitro studies 
2.12.1.1 Benzodiazepine receptor affinity 
Benzodiazepines are allosteric ligands for the GABAA receptor (Figure 2.4), a chloride 
channel that is gated by GABA.  They bind to the benzodiazepine site of the GABAA 
receptor, thus increasing the affinity of the inhibitory neurotransmitter GABA for the 
GABA site of the GABAA receptor,  decreasing the likelihood of action potentials by 
excitatory neurotransmitters such as adrenalin and noradrenalin, implicated in anxiety 
and stress (Rabow et al. 1995; Paladini et al. 1999).   
 
A study (Liao et al. 1998), using four isolated compounds from S. baicalensis indicated 
oroxylin A, skullcapflavone II, baicalein and wogonin bound to the benzodiazepine 
(BDZ) site of GABAA receptors in tissue of neuronal origin in vitro.  Oroxylin A, 
baicalein and wogonin, which are also found in S. lateriflora (Bergeron et al. 2005), had 
weak affinities for the BDZ binding sites (Liao et al. 1998). 
 
 
Figure 2.4  The GABAA receptor complex. BDZs bind to the  and subunits  
 
(Dawson et al. 2005) 
 
In another study Hui et al. (2000) tested the binding capacity of baicalin, baicalein, 
scutellarein and wogonin, isolated from S. baicalensis, to the BDZ site of the GABAA 
receptor.  Affinity to BDZ receptors for scutellarein was moderate and weak for 
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baicalin.  Contrary to results of the study by Liao et al. (1998) they found the binding 
affinities of wogonin and baicalein were strong and wogonin, which, as with 
benzodiazepines, bound to the subunit of the GABAA receptor, had the strongest 
affinity.  The discrepancy may be due to differences in species and assay models used.  
Cerebral cortex membrane of murine origin was used in the study by Liao et al. (1998) 
and homogenised rat brain was used in the study by Hui et al. (2000).  As there are 
interspecies variations in regional distribution and binding affinity for receptors, related 
studies on species other than humans may be misleading (Dodd 1995).  In a comparison 
between rats and humans of neuroanatomical BDZ receptor binding capacity, for 
example, there were marked species differences (Duncan et al. 1998).  It would be more 
appropriate to study the potential of skullcap flavones as neurotransmitter ligands on 
human CNS tissue.  Kopp et al. (1990), for example, used homogenised human post-
mortem tissue for BDZ binding affinity studies. 
2.12.1.2 Structure-activity relationship 
BDZs have a seven membered imino ring (B or diazepine ring) with 2 nitrogen atoms 
and studies have indicated that this ring is essential for its affinity towards the BDZ 
binding site (Macdonald & Olsen 1994; Patel et al. 2009) although lipophilicity is also 
important (Wang et al. 1999).  
 
The binding sites to the BDZ receptor specifically relating to skullcap flavonoids have 
not been elucidated but studies have indicated the important BDZ binding sites of 
flavonoids are the phenyl ring (B ring), the methoxy group at C5 and position 4 of the 
carbonyl group (Wang et al. 1999).  It has been proposed that activity is via 
hydrophobic interactions and hydrogen binding causing a change in protein structure (Li 
et al. 2011).   
 
There are some similarities between flavonoid and benzodiazepine structures (Figure 
2.5) in that both have a benzene ring (A).  In benzodiazepines this is fused to a 
diazepine ring (B).  Ring C is an aryl ring.  The B ring on flavonoids is a phenyl ring 








(Jager & Saaby 2011) 
 
 
Figure 2.5  Comparison of the structures of common BDZs and flavones 
 
 
Because flavonoids, including baicalein, baicalin, wogonin and scutellarein from S. 
baicalensis bind to GABAA -BDZ receptor sites in vitro (Liao et al. 1998; Hui et al. 
2000), the presence of these flavonoids also in S. lateriflora (Zhang et al. 2009) 
indicates a possible anxiolytic action for both herbs, although relevancy for baicalin is 
doubtful as it does not cross the blood brain barrier (Barceloux 2008).  Benzodiazepines 
have a similar core structure to flavonoids (Figure 2.5), which may explain the skullcap 
flavonoid binding capacity to BDZ receptors.  The results also present the possibility of 
baicalein being more strongly implicated in having an anxiolytic effect than its 
glycoside baicalin, notwithstanding the likely inability of flavone glycosides to cross the 
blood-brain barrier (Barceloux 2008) and the hydrolysis of baicalin to baicalein at first 
pass metabolism (Hackett 1986).   
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2.12.1.3 Serotonin-7 receptor affinity 
Gafner et al. (2003b) investigated the ability of hot water and 70% ethanol extracts and 
major isolated flavonoids of dried S. lateriflora aerial parts to bind to serotonin-7 (5-
HT7) receptors in vitro.  Both the hot water and the 70% ethanol extracts as well as the 
flavonoids baicalin, scutellarin, wogonin, 5,6,7-trihydroxy-2’-methoxyflavone 
(lateriflorein), ikonnikoside I and dihydrobaicalin, were shown (by radioligand binding 
assay) to have high affinity for the 5-HT7 receptor in human 5-HT7 - transfected Chinese 
hamster ovary cell lines.  The highest affinity was for the hot water extract and for 
scutellarin (Gafner et al. 2003b).   
Although the findings by Gafner et al. (2003b) suggest that S. lateriflora may possess 
5HT7 modulating activity and may therefore assist in regulation of sleep, mood, pain 
and migraine (Gafner et al. 2003b; Agosti 2007), it is not clear which phytochemicals in 
S. lateriflora can cross the blood-brain barrier (BBB) (Gafner et al. 2003b).  Potential 
relaxant effects of S. lateriflora would be dependent on some of them being able to do 
so and there is evidence to suggest that some flavonoid aglycones and their metabolites 
can cross the BBB.  For example hispidulin, a GABAA receptor agonist found in sage, 
valerian and S. baicalensis (Johnston & Beart 2004), and reported to be present in S. 
lateriflora (Barnes et al. 2007) was found to cross the BBB in both in vitro and in vivo 
studies (Youdim et al. 2004).  It is possible, however, that the melatonin and serotonin 
contained in S. lateriflora would bind to 5HT7 receptors in vitro (Cole et al. 2008). 
It was not clear whether the binding effect of S. lateriflora flavonoids on the 5-HT7 
receptor was as agonists or antagonists.  They are likely to be 5-HT7 receptor 
antagonists or inverse agonists as, according to a patent application (Bright & Coffman 
2004), 5-HT7 receptor antagonists or inverse agonists are useful in the treatment of CNS 
and cardiovascular disorders, premenstrual syndrome, sleep disorders, appetite 
disorders, anxiety, phobias, panic, depression and for stress-related disorders such as 
irritable bowel syndrome; these are also conditions for which S. lateriflora is 
traditionally used  (Felter & Lloyd 1898; Khosh 2000; Hull 2010).   
As flavone glycosides are poorly lipid soluble it is likely that diffusion of baicalin  
across the BBB is limited (Barceloux 2008).  Furthermore, research suggests that 
scutellarin, also a flavone glycoside, is unable to cross the BBB in its primary form 




Clinical studies were conducted (Chen et al. 2006) to determine the bioavailability and 
pharmacokinetics of scutellarin, following its oral administration to 20 healthy male 
volunteers.  Each participant swallowed with 200 ml of water a ‘dripping pill’ 
containing 60 mg of scutellarin.  Blood samples were taken prior to dosing and hourly 
for 15 samples and then at 24 hours.  Urine was collected prior to dosing and at 8 and 
12 hours.  Liquid chromatography with mass spectrometry (LC/MS) was used to 
identify the scutellarin and its metabolite isoscutellarin in the plasma and urine (Chen et 
al. 2006).   
 
Scutellarin was barely detectable in plasma.  Only its isomer (isoscutellarin or 
scutellarein-6-O-glucuronide) was present as a major metabolite, at a mean of 7.85 
hours.  This indicated that bacterial hydrolysis occurred at first pass metabolism and the 
aglycone of scutellarin was absorbed from the intestines and reconjugated with 
glucuronic acid in intestinal and/or liver cells.  Four metabolites of scutellarin were 
detected in human urine and it was determined that urine analysis could be used as a 
marker for scutellarin ingestion. The results suggest the ability of scutellarin to bind to 
5-HT7 receptors in vitro (Gafner et al. 2003b) may not be implicated in its anxiolytic 
effects.  Work needs to be conducted to assess binding of isoscutellarin to 5-HT7 
receptors. 
 
The results of the study (Chen et al. 2006) conflicted with an earlier study on rats 
(Zhang et al. 2003), in which the metabolites of scutellarin appeared in the urine in 
different ratios to those detected in human urine (Chen et al. 2006).  Due to species 
specificity, more human bioavailability studies of S. lateriflora compounds are needed. 
 
Of the serotonin receptors, 5-HT7 is the most recently discovered and was first 
characterised in 1993.  Since then there has been a considerable amount of research 
conducted to investigate the effects of 5-HT7 receptor ligands (Pittala et al. 2007) but 
little is known about the function of human 5-HT7 receptors. They are known to be 
widely distributed throughout the human brain (Martin-Cora & Pazos 2004) and 
vascular system (Cifariello et al. 2008) and based in part on anatomic distribution, 
functional implications have been postulated.  It has been proposed, for example, they 
may play a role in learning and memory and that novel therapeutic interventions 
selective for 5-HT7 receptors may potentially treat psychiatric disorders and epilepsy 
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(Martin-Cora & Pazos 2004).  It is worth reiterating that S. lateriflora is traditionally 
used for the very same conditions (Hull 2010).   
 
Results of a series of in vitro studies (Cohen et al. 1999) of cultured human brain 
endothelial cells, human brain smooth muscle cells (microvascular) and human brain 
astrocytes strongly suggested the presence of functional 5-HT7 receptors on these cell 
types.  The authors hypothesised that the presence of these receptors on non-neuronal 
cells in the brain may be to help regulate cerebromicrovascular tone, BBB permeability 
and brain blood perfusion and, consequently, anti-migraine drugs accessing the brain 
parenchyma may act by stimulating these receptors (Cohen et al. 1999).  It could also be 
hypothesised that scutellarin’s affinity for 5-HT7 receptors may also increase BBB 
permeability, perhaps facilitating access of certain S. lateriflora flavonoid metabolites. 
The ability of scutellarin to bind to 5-HT7 receptors raises the possibility that this 
flavonoid, found in small amounts in S. lateriflora (Cole et al. 2008), may be partly 
implicated in the herb’s reported anti-headache and anti-hypertensive (Joshee et al. 
2002) effects (along with the anxiolytic effects of other flavonoids in the herb).  
Another compound found in S. lateriflora that does not cross the BBB in mammals, is 
the indoleamine serotonin (Polo et al. 2007; Cole et al. 2008).  It may, however, 
contribute synergistically to other physiological activity. 
2.12.1.4 Melatonin in S. lateriflora 
Melatonin, which has important physiological actions in animals, was only discovered 
in plants in 1995.  It is secreted by the mammalian pineal gland at night and plays a role 
in regulation of sleep, the circadian rhythm, immune function and mood modulation.  It 
is also an antioxidant (Arnao & Hernandez-Ruiz 2006).  According to Murch et al. 
(1997), the melatonin content of S. lateriflora has implications for treating migraine and 
insomnia.  Although melatonin is, like serotonin, an indoleamine it readily crosses the 
BBB (Jacob et al. 2002).  The melatonin content of S. lateriflora is only around 90 ng/g 
(Cole et al. 2008) and it was argued by prominent ethnobotanist Duke that the quantities 
of melatonin present in S. lateriflora are insufficient to exert any effects (Levy 2001).  
Results of a clinical trial (Zhdanova et al. 2001) suggested a single oral dose of 0.1 mg 
melatonin can improve sleep efficiency in insomniacs.  Doses lower than this do not 
appear to have been tested (no publications were located) in clinical trials.  Further, the 
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potential synergistic effect of melatonin with other phytochemicals in S. lateriflora is 
unknown and cannot be discounted.  Synergistic actions with herbs in remedies 
including S. lateriflora may be important in the therapeutic action. 
2.12.1.5 GABA and glutamine in S. lateriflora 
 
Significant amounts of the amino acids GABA, an inhibitory neurotransmitter that 
modulates anxiety, sleep, convulsions and mood (Rabow et al. 1995), and glutamine, a 
non-essential amino acid that plays an important role in immune function – particularly 
in response to stress (Griffiths 2001), occur in S. lateriflora.  They have been detected 
in both the aqueous and ethanolic extractions, with markedly high levels of glutamine 
(31mg/g) in aqueous extract (Awad et al. 2003) and 0.55% GABA expressed in dry 
weight (5.5 mg/g) of a 70% ethanolic extract (Bergeron et al. 2005).  Although GABA 
does not readily cross the blood-brain barrier (Spinella 2002), glutamine can and may 
be biosynthesised to GABA by GABA-ergic neurons.  The presence of glutamine in the 
herb may therefore add to its anxiolytic activity by increasing the availability of GABA 
in the central nervous system (Bergeron et al. 2005). 
2.12.2 Clinical trials 
To date only one clinical trial has been conducted on S. lateriflora.  Wolfson and 
Hoffmann (2003) assessed the anxiolytic properties of the herb in a double-blind, 
placebo-controlled crossover study of 19 healthy volunteers.  Participants were aged 20 
to 70 years and consisted of 15 women and 4 men.  They took either 2 placebo capsules, 
one capsule containing 100 mg of organic freeze-dried S. lateriflora extract (Phytos), 
two capsules of these, or one capsule of 350 mg organic freeze-dried S. lateriflora made 
by a different manufacturer (Eclectic Institute) than the 100 mg capsules. No mention 
was made of the composition of the placebo but one of the authors (Hoffmann 2008) 
later revealed in a personal communication it was Anthriscus cerefolium (chervil)*.   
 
Participants’ energy, cognition and anxiety were self-rated at various time points up to 2 
hours following administration of test or placebo substances, when measurements 
tended to return to baseline.  The three herb tests all had notable effects in reducing 
subjective anxiety scores when compared to placebo, the most effective being the two 
100 mg capsules.  There was only a very mild decline in cognition and energy with the 
herbs, with no adverse reactions or side-effects, suggesting that S. lateriflora could be a 
valuable anxiolytic - as many anxiolytics impair cognitive function and physical 
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performance (Wolfson & Hoffmann 2003).  It is unclear whether the results were 
statistically significant as this was not determined. 
 
Although the study results indicate an anxiolytic effect for S. lateriflora the short 
timescale of the study could not demonstrate any long-term effects, whether negative 
such as side-effects, tolerance or dependence, or positive such as prolonged well-being.  
According to the study the anxiolytic effects of the intervention wore off by 2 hours in 
most subjects but this was self-reported following instructions that the study period was 
for 2 hours and it is unclear whether the participants may have subconsciously believed 
the effects were likely to diminish in that time period.  The study also does not indicate 
whether regular doses throughout the day could have an additive effect.  More research 
needs to be conducted in order to assess this paradigm. 
 
Another confounding factor was that the tests used in the study were non-validated.  
The authors (Wolfson & Hoffmann 2003) acknowledged that the use of validated 
psychometric tests is needed to determine the herb’s clinical anxiolytic effects. 
Additionally, self-reported changes in anxiety were in healthy subjects so cannot be 
confidently extrapolated to clinically anxious subjects.  With regard to the perceived 
greater effect on anxiety with the 200 mg S. lateriflora regime over the 350 mg single 
capsule, the authors suggest this may be due to differing potencies resulting from 
variations in storage, harvesting etc.  However, it could be argued that participants 
believed they were being provided with more powerful treatment with two capsules 
than with one.   
 
*There is very little written in the literature in relation to therapeutic actions of  
Anthriscus cerefolium but there is a possibility it may be psychoactive as traditional 
uses are as a memory enhancer and anti-depressant.  It is also reported to be diuretic and 
is traditionally used as an anti-hypertensive. (Plants for a Future 2010a).  
2.13 Wider therapeutic implications 
2.13.1 Anti-inflammatory activity 
Experiments to determine the anti-inflammatory properties of S. lateriflora were 
conducted in two different in vitro systems  (Gafner et al. 2004b).  Both hot water (1:20 
w: v) and 70% (1:10 w: v) ethanol extracts inhibited cyclooxegenase 1 (COX-1) and 
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cyclooxegenase 2 (COX-2) in a cell-free medium.  Although it contained fewer 
flavonoids, the hot water extract was more potent than the ethanolic extract, which 
suggested involvement of other compounds in the anti-inflammatory process.  Hot 
water and 70% ethanol extracts of S. lateriflora assayed on human keratinocytes in 
culture for anti-inflammatory effects significantly reduced activity of PGE2 
(prostaglandin E2) (Gafner et al. 2004b) 
 
A US patent application for a polypharmacy anti-inflammatory formula (Jia et al. 2007) 
describes the anti-inflammatory activity of extracts of Scutellaria orthocalyx (root), S. 
baicalensis (root) and S. lateriflora.  Whole dried organic S. lateriflora plant 
(presumably including roots) was ground to a powder and extracted with methanol.  The 
extracts were incubated with both ovine and human COX-1 and COX-2 and the IC50 
values (the quantity of substance required to inhibit 50% of enzyme activity in 
comparison to a control) were calculated.  The extract of S. lateriflora showed greater 
inhibition of human COX-2 enzymes than of the other two species.  It also showed 
preferential inhibition of human COX-2 over ovine COX-1 and COX-2 with respective 
IC50 values of 20, 30 and 80 μg/ ml (Jia et al. 2007).  These results confirm the earlier 
findings by Gafner et al. (2004b) and suggest anti-inflammatory properties for S. 
lateriflora.  The herb may therefore have direct as well as indirect positive benefits for 
attenuation of comorbidities associated with anxiety (Pitsavos et al. 2006). 
 
Glutamine is a modulator of tissue inflammation (Coëffier et al. 2002) so it could be 
hypothesised that it may also play a role in the anti-inflammatory properties of S. 
lateriflora.  Gafner et al. (2004b) discovered that an aqueous extract of S. lateriflora 
had a more potent anti-inflammatory effect than an ethanolic extract containing more 
flavonoids and suggested that compounds other than the flavonoids contributed to this 
activity.  Furthermore, Awad et al. (2003) found high levels of glutamine in an aqueous 
extract of the herb.  A study on cultured duodenal biopsies from human volunteers 
administered enteral glutamine or amino acids indicated a strong inhibitory effect by 
glutamine on pro-inflammatory cytokines in vitro.  Inhibition of COX-2 in this 
particular study was not significant but the volunteers did not have inflammatory bowel 
disease (Coëffier et al. 2002). 
 
Li et al. (2000) investigated the effect of baicalin (isolated from S. baicalensis) on 
human chemokines (which induce leukocyte migration and contribute to inflammatory 
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reactions) in vitro.  Human leukocytes were incubated with chemokines in the presence 
of baicalin isolated from S. baicalensis.  In a dose-dependent manner, baicalin inhibited 
the binding of chemokines to human leukocytes as well as reducing the receptor binding 
capacity of chemokine receptor ligands.  There was no observed toxicity to leukocytes 
(Li et al. 2000).  The results suggest a molecular mechanism for the anti-inflammatory 
properties of baicalin in S. lateriflora as well as in S. baicalensis. 
2.13.2 Antimicrobial, larvicidal and molluscicidal activity 
Using an agar plate method, the minimum inhibitory concentration (MIC) of a 60:40 
(v/v) ethanol/water extract of S. lateriflora root against Bacillus subtilis and Escherichia 
coli was determined.  The results demonstrated 5 mg/ml MIC for B. subtilis and a 
significant MIC at 25 mg/ml for E. coli (Duffy & Power 2001).  The authors did not 
clarify why they used the root instead of aerial parts but stated that that the experiments 
were conducted on Chinese herbs.  Furthermore, as no quality controls were conducted 
it was not confirmed that the species used was in fact S. lateriflora.   
 
Bergeron et al. (1996) screened dichloromethane (DCM), methanol and water extracts 
of S. lateriflora for fungicidal, bactericidal, larvicidal and molluscicidal activities.  The 
methanol and DCM extracts quantitatively inhibited the fungi Cladosporium 
cucumerinum and Escherichia coli bacteria on a thin layer chromatography (TLC) plate 
and the methanol extract also inhibited Candida albicans.  None of the extracts had any 
inhibitory effects on Bacillus subtilis on TLC plates, or were larvicidal (Aedes aegypti) 
or molluscicidal (Biomphalaria glabrata) in solution.  A confounding factor in this 
experiment may have been the use of dried plant material, which is believed to have 
little activity (Yarnell & Abascal 2001). 
2.13.3 Antioxidant effects 
The antioxidant potential of tissues from S. lateriflora was assessed in vitro and 
compared with S. baicalensis and S. racemosa (Cole et al. 2008).  All three herbs, 
which were propagated in identical conditions, had similar antioxidant capacity 
although less tissue was required for S. lateriflora to produce a 50% reduction in 
oxygen free radicals than the other two herbs.  
 
In a controlled study of the antioxidant and antimicrobial potential of 12 different herbs, 
water, water and ethanol (60:40 v/v), and ethanol extracts were prepared from root of S. 
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lateriflora purchased from China and then ground in a blender.  The antioxidant 
properties of skullcap root were assessed by its ability to prevent formation of 
thiobarbituric acid reactive species from linoleic acid.  It had a 1.3 % antioxidant index 
for the water extract, 1.2% for the ethanol extract and 66.1% for the ethanol/water 
extract (Duffy & Power 2001). 
 
Wojcikowski et al. (2007) studied the antioxidant capacity of 55 medicinal herbs 
traditionally used to treat urinary tract disorders.  The oxygen radical absorbance 
capacity (ORAC) in vitro assay was used.  The ORAC of the 55 herbs was compared 
with that of Silybum marianum (milk thistle) and Camellia sinensis (tea), herbs known 
to have significant antioxidant properties.  S. lateriflora was among the 5 herbs with the 
most potent free radical scavenging activity, which in all 5 was higher than either of the 
control herbs (Wojcikowski et al. 2007).   
 
Further to the above study (Wojcikowski et al. 2007) an investigation of potential 
antioxidant or toxic effects of extracts of 47 herbs, including S. lateriflora, was 
conducted on kidney fibroblast and renal tubule cell lines.  Of all herbs tested, again S. 
lateriflora was amongst the top 5 herbs for antioxidant capacity (with both ethyl acetate 
and methanol extracts), suggesting it may have a protective action on renal tubular 
epithelium and may therefore be beneficial in kidney disease (Wojcikowski et al. 2009). 
 
The in vitro studies of S. lateriflora indicate its potential as an herb with strong 
antioxidant capacity.  It may therefore be of use in conditions in which a protective 
effect on tissues is required as in age-related macular degeneration, various types of 
dementias, hepatic impairment, kidney disease, and cardiovascular disorders such as 
atherosclerosis (Meydani 2001; Middleton & Yaffe 2009). It is unclear which 
compounds were responsible for its antioxidant and antimicrobial effects.   
2.13.4 Anti-neoplastic effects 
S. lateriflora leaf and root extracts (500 µg/ ml) were independently found to 
significantly inhibit proliferation of human malignant glioma cells in vitro in 
comparison to controls (100% proliferation), reducing proliferation of cancer cells by 
51% and 44% respectively.  The stems showed minimal inhibitory activity at 16% 
(Parajuli et al. 2009).  The difference in potency may have been due to the maturity of 
the plants, which were harvested before flowering.  Immature S. lateriflora has higher 
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estimated flavonoid content in the leaves (69.3 mg/g) and roots (40.4 mg/g) and 
negligible in the stems, whereas in fully mature plants the flavonoid content is 
significant in the stems (21 mg/g) although still higher in the leaves (44.4 mg/g) and 
roots (37.6 mg/g) than in the stems.  At all stages of plant growth the leaves of S. 
lateriflora contain the most flavonoids (Wills & Stuart 2004). 
 
Individual phytochemicals isolated from S. baicalensis have been studied for their anti-
cancer properties.  The studied phytochemicals are also in S. lateriflora although in 
different ratios (Cole et al. 2008).  Therefore, demonstration of their anti-cancer effects 
suggests similar actions and indications for S. lateriflora.  For example, in a controlled 
experiment wogonin was incubated at different concentrations with human leukaemia 
cell lines derived from a histiocytic lymphoma.  It inhibited cancer cell growth in a 
concentration- and time-dependent manner, reduced cell viability and nuclear to 
cytoplasmic ratio, and appeared to have the ability to induce normal cell differentiation 
(Zhang et al. 2008a).  Another study demonstrated the inhibition of proliferation and 
induction of differentiation of human promyelocytic cell lines by 55-60% (Zhang et al. 
2008b).  The results indicate a possible beneficial action for S. lateriflora in the 
treatment of haematopoietic tumours. 
 
Baicalein has also been studied for its anti-cancer properties.  Chao et al. (2007) found 
it to be cytotoxic to human bladder cancer cells in vitro.  They also compared its 
cytotoxic properties on bladder cancer cell lines with those of baicalin, rutin, catechin 
and quercetin and found it to be the most potent cytotoxic flavonoid - but without being 
cytotoxic to normal cultured human fibroblasts.  Baicalein induced cancer cell 
apoptosis, inhibited cancer cell proliferation; therefore arresting the cancer cell cycle.  It 
prevented expression of survivin (an apoptosis-inhibitory protein secreted by cancer 
cells) in bladder, breast and lung cancer cells (Chao et al. 2007).  
 
Conversely, Kumagai et al. (2007) compared the anti-cancer effects of baicalin and 
baicalein on various haemopoietic cell lines and baicalin was more potent than 
baicalein.  This suggests potential flavonoid specificity for cancer cell types. 
 
Baicalin, baicalein and wogonin induced apoptosis and reduced proliferation in human 
hepatoma cell lines, suggesting a role for these compounds in protection against human 




Heterocyclic amines (HCAs) are toxic mutagenic/carcinogenic substances, which have 
recently been in the news (Bates 2011) relating to warnings about their production by 
overcooked meats (Layton et al. 1995).  A study (Kim et al. 2002) found baicalein, 
wogonin and oroxylin A inhibited CYP1A2 activity in human liver microsomes.  As 
this enzyme is capable of catalysing HCAs with the production of toxic or carcinogenic 
intermediates S. lateriflora may have a protective effect against carcinogens produced 
from HCAs. 
 
In consideration of the results of experiments involving wogonin, baicalin and baicalein 
and oroxylin A it could be hypothesised that the flavonoids of some skullcap species 
endow the plants with inhibitory actions against a variety of human cancers.  It is 
noteworthy that in one study (Parajuli et al. 2009) extract of S. ocmulgee leaf showed 
the strongest antiproliferative activity of thirteen Scutellaria species tested.  However, 
HPLC analysis of S. ocmulgee leaf for the presence of apigenin, baicalin, baicalein, 
chrysin, scutellarein and wogonin found it contained only wogonin, which, when tested 
alone against human glioma cells, also showed strong anti-cancer activity.   Its wogonin 
content was lower than that of some of the other Scutellaria species tested, suggesting a 
synergistic effect of other flavonoids or other phytochemicals in this species or an 
antagonistic effect in others (Parajuli et al. 2009). 
 
Interestingly, scutellarein was first isolated in 1890 from the seeds of the Tree of 
Damocles (Oroxylum indicum) (Malikov & Yuldashev 2002).  They also contain 
baicalin, baicalein and chrysin (Chen et al. 2003).  These seeds are used in Bangladeshi 
folk medicine for their purported anticancer properties (Costa-Lotufo et al. 2005).  All 
these compounds are found in significant amounts in S. lateriflora (Li & Khan 2008), 
which suggests it may also have anti-cancer properties.   
 
The results of both antioxidant and anti-tumour studies indicate a role for S. lateriflora 
as a prophylactic agent for carcinogenesis, but clinical trials are needed for confirmation 
of efficacy and to determine optimal dosage.  As the western medical herbalist may not 
treat cancer, S. lateriflora may be a useful adjunct in oncology care. 
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2.13.5 Endocrine actions 
Chrysin has been demonstrated in a number of in vitro studies to be a potent inhibitor of 
human aromatase.  It is sold as an extract (of blue passion flower) for body builders as it 
is believed to increase testosterone levels (Ta & Walle 2007). 
2.13.6 Cardiovascular effects 
Scutellarin is considered a major bioactive flavonoid and is used in cardiovascular 
medicine.  It is the main constituent of the drug breviscapine, which is used in 
traditional Chinese medicine for cerebrovascular and cardiovascular disease as a platelet 
aggregation inhibitor and to reduce platelet count as well as being a vasodilator and 
benefiting microcirculation (Chen et al. 2006; Cole et al. 2008).  S. lateriflora may 
therefore also have anti-platelet activity.  Findings that scutellarin is present in much 
higher quantities (x 800) in S. baicalensis than in S. lateriflora (Cole et al. 2008), may 
be more significant for the reported cardiovascular effects of S. baicalensis (Liao et al. 
1998) than of S. lateriflora. 
There have been many more in vitro studies of the actions of individual phytochemicals 
isolated from the root of S. baicalensis, and which are also found in S. lateriflora, but 
they are too numerous to include in this review. 
2.14 Evaluation and discussion 
Results of in vitro, chemical and clinical studies of S. lateriflora and its phytochemicals 
suggest it has antineoplastic, anti-inflammatory, antioxidant, antibacterial, antifungal, 
aromatase-inhibitory and anxiolytic properties as well as potentially potent effects on 
modulation of mood, sleep, pain and blood vessel tone.  These actions support its 
traditional uses for insomnia, inflammatory conditions, urinary tract disorders, 
neurological disorders, headaches, hypertension, stress and anxiety, premenstrual 
syndrome and possibly other gynaecological complaints (due to aromatase inhibition).  
It could potentially be used by the modern western medical herbalist for inflammatory 
conditions such as arthritis, cardiovascular disorders, general debility and exhaustion 
e.g. myalgic encephalomyelitis, bacterial infections, fungal diseases such as Candida 
albicans, and oestrogen-dependent gynaecological complaints such as uterine 
leiomyomas and endometriosis as well as an adjunct for certain cancers e.g. leukaemias 




Based on the known phytochemical components it has potentially wider therapeutic 
value.  For example, as some of its major flavonoids are ligands for GABAA receptors 
(Liao et al. 1998; Hui et al. 2000) it could have benefit for tinnitus, for which GABA-
ergic compounds are reported to be of known benefit (Smith et al. 2005).  
 
Speculation on the anti-inflammatory (Li et al. 2000; Gafner et al. 2004b), anti-cancer 
(Chang et al. 2002; Chao et al. 2007; Kumagai et al. 2007; Zhang et al. 2008a) and 
BDZ-binding (Liao et al. 1998; Hui et al. 2000) properties of S. lateriflora is due, in 
part, to the similarities between S. lateriflora and S. baicalensis in phytochemical 
constitution.  These studies used isolated phytochemicals from S. baicalensis, which are 
also present in S. lateriflora.   
 
It is not known whether effects on physiological function of whole tincture or dried herb 
administered from the herbal clinic, either alone or with other herbs would be similar to 
those of isolated phytochemicals in the laboratory.  
 
While orthodox medicine tends to employ isolated phytochemicals, herbal medicine 
uses extracts of whole herbs in order to provide the synergistic benefits of multiple 
active constituents in a single herb.  S. lateriflora’s phytochemicals may act in synergy 
with each other as well as with concomitantly administered herbs.  It has also been 
suggested (Parajuli et al. 2009) that certain phytochemicals may even have an 
antagonistic action towards each other.   
 
Research shows evidence supporting the theory of synergy; medicinal effects of herbs 
are due to the actions of constituent chemicals working together (Cole et al. 2008).  
Valerian’s phytochemicals, for example, are believed to act together on multiple 
GABA-ergic systems, and the pharmacodynamic synergy of kavalactones in Piper 
methysticum increases the bioavailability of one another, resulting in a modulation of 
GABAA and amine systems in the brain (Spinella 2002).  Similarly, the numerous active 
phytochemicals in S. lateriflora may have multiple pharmacodynamic actions.   
 
While the results of the in vitro and chemical studies are interesting and provide clues to 
the pharmacological actions of S. lateriflora, clinical evidence is necessary to support 
findings.  The in vitro findings alone cannot indicate how the herb influences 
physiological, environmental, genetic and pathological characteristics inherent in a 
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human patient.  Results of in vitro studies of individual phytochemicals as an indication 
of the action of a whole herb or extract cannot be relied upon to confirm the 
pharmacology of the combined phytochemicals; nor do they indicate whether or not the 
compounds under scrutiny cross the blood-brain barrier.  More clinical research on S. 
lateriflora is therefore essential in order to assess these parameters.   
2.15 Conclusions 
The majority of findings of in vitro research have been conducted on the pharmacology 
of the individual phytochemicals of S. lateriflora, mostly due to recognition of the 
therapeutic value of S. baicalensis.  It is unlikely, however, that the potential efficacy of 
S. lateriflora is due entirely to any of these phytochemicals acting in isolation, but to its 
multiple constituents acting in synergy. This can perhaps be exemplified by the large 
number of chemical compounds that have been isolated from S. baicalensis, many with 
putative medicinal value (Murch et al. 2004).  It should be borne in mind that as similar 
metabolomics have not yet been conducted on S. lateriflora it is not certain whether 
parallels can be drawn between the two species with regard to medicinal actions.  There 
is still a need for more research into the chemistry and pharmacology of the whole aerial 
parts of the herb.    
 
The few in vitro studies on extracts of whole aerial parts of S. lateriflora and a small-
scale clinical study described above do suggest a positive therapeutic benefit of the herb 
for decreasing anxiety but a dearth of larger, high quality, controlled clinical trials of 
sufficient duration means there is insufficient scientific evidence for its efficacy and 
safety in humans, particularly in the long-term.  It is therefore appropriate and timely for 
more efforts to be made in the conduction of clinical trials in support of the therapeutic 
value of S. lateriflora for anxiety, stress and comorbidities.  In the short-term such 
studies may provide an awareness of the potential of the value of this herb as an 
anxiolytic and may precipitate further research.  In the long-term it may lead to the 
production of a useful therapeutic intervention to replace currently used anxiolytic 
pharmaceuticals available on prescription and perhaps reduce the concurrent financial 




Chapter 3. The use of S. lateriflora: A 
pilot survey amongst herbal medicine 
practitioners   
3.1  Abstract 
An email survey was conducted amongst herbal medicine practitioners in the UK and 
Ireland.  The survey aimed to gather information on the extent of, and indications for, 
current use of S. lateriflora, its perceived effectiveness and its safety.  Herbal medicine 
practitioners were selected from the membership list of the National Institute of Medical 
Herbalists (NIMH).  All members with identifiable email addresses were contacted (n = 
377) and responses were received from 62 (a 16% response rate).   
 
The results of the survey suggested that S. lateriflora is highly regarded among herbal 
medicine practitioners as an effective intervention for reducing anxiety and stress and is 
commonly prescribed for these conditions and related comorbidities.  The results were 
not conclusive as the response rate was low and respondents were only those with email 
access. 
3.2 Introduction 
American or Virginian skullcap (Scutellaria lateriflora) (Figure  3.1) is a perennial herb 
belonging to the Lamiaceae (mint) family (also known as Labiatae), sub-family 
Lamioideae, and is one of 360 known Scutellaria species worldwide (Cole et al. 1991; 
Malikov & Yuldashev 2002), many of which are used medicinally (Joshee et al. 2002).  
It grows on wetlands and is indigenous to North America and Canada where it is widely 
distributed - from Alaska to Florida and British Columbia to Quebec (the only places it 
is not found are the North-west Territories, Alberta and Yukon in Canada and 
Wyoming, Nevada and Utah in the US) (U.S.D.A. 2012). It is grown commercially 







Figure  3.1 Scutellaria lateriflora (© C. Brock) 
 
 S. lateriflora is used extensively and has been highly valued in traditional western herbal 
and ethnobotanical medicines for anxiety, hysteria, phobias, panic attacks, tension, 
depression, sleep disorders and stress (Felter & Lloyd 1898; Joshee et al. 2002).  Known 
as a woman’s herb by Native Americans, the Cherokees used it as an emmenagogue, 
thus promoting menses and aiding expulsion of the placenta following childbirth.  
Native American women also used it to ensure general menstrual health (Joshee et al. 
2002) as well as for mastalgia and premenstrual tension (Greenfield & Davis 2004).  
Some tribes still use it in ceremonies to induct girls into womanhood and for 
purification rituals (Joshee et al. 2002). 
 
The first European to record its use (in 1787) as a medicinal herb was German 
Physician Johann David Schöpff, who noted its use as a tonic, for fevers and as an 
abstergent (detergent) (Upton et al. 2009).  It was mentioned in the first American 
Materia medica in 1785 but had been in longstanding use as a home remedy before then 
(Lloyd 1911).  Dr Lawrence Van Derveer (1740-1815) studied S. lateriflora extensively 
and used it as a treatment for rabies (hydrophobia); it was then used for this purpose 
both professionally and as a home remedy.  In 1819 Dr Lyman Spalding wrote ‘A 
history of the introduction and use of Scutellaria lateriflora (scullcap), as a remedy for 
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preventing and curing hydrophobia, occasioned by the bite … ’ (Lloyd 1911; New 
Jersey Historical Society 2001).  Medical doctor Joseph Bates wrote in 1855 in the 
Boston Medical Journal (Bates 1855) that because S. lateriflora was eventually 
scientifically proved to be utterly useless for this purpose it fell into disrepute and was 
consequently removed from pharmacopoeias.  He nevertheless described using S. 
lateriflora in his practice, claiming a fluid extract had great value in the treatment of 
nervousness, irritability and restlessness, particularly in children.  He also held it in high 
regard for hysteria and for relieving symptoms of inflammation in patients with arthritis 
or convalescing from fevers.  He prophesied that it would be found to be highly 
successful in treating many diseases in the future, particularly those for which opium 
was currently prescribed (Bates 1855).  In 1860 it was introduced into the official 
United States Pharmacopoeia as Extractum Scutellariae Fluidum (Millspaugh 1892; 
Upton et al. 2009) but was dropped in 1910.  It was in the US National Formulary in 
1916 and removed in 1942 when interest in natural remedies declined.  It is not included 
in the European Pharmacopoeia (Upton et al. 2009). 
 
Modern herbal medicine’s application of S. lateriflora appears to be based upon its 
traditional uses for anxiety states.  Greenfield and Davis (2004) for example, suggest it 
is used most commonly for insomnia, nervous disorders and digestive disturbances.  
Bergner (2002) proposes its action is primarily as a trophorestorative on the central 
nervous system (CNS), allowing relaxation following nervous exhaustion (Bergner 
2002).  It is also prescribed by western herbalists for epilepsy (British Herbal Medicine 
Association 1983), post-stroke paralysis, atherosclerosis, hyperlipidaemia, allergies, 
skin conditions and inflammation (Natural Medicines Comprehensive Database 2011). 
 
A small clinical study assessing acute effects of S. lateriflora indicated it has anxiolytic 
actions with minimal loss of cognition (Wolfson & Hoffmann 2003).  The authors 
assessed the anxiolytic properties of the herb in a double-blind, placebo-controlled 
crossover study of 19 healthy volunteers.  Participants took either 2 placebo capsules, 
one capsule containing 100 mg of organic freeze-dried S. lateriflora extract, two 
capsules of these, or one capsule of 350 mg organic freeze-dried S. lateriflora.  
Participants’ energy, cognition and anxiety were self-rated at various time points up to 2 
hours following administration of test or placebo substances, when measurements 
tended to return to baseline.  The three herb tests all had notable effects in reducing 
subjective anxiety scores when compared to placebo, the most effective being the two 
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100 mg capsules.  There was only a very mild decline in cognition and energy with the 
herbs, with no adverse reactions or side-effects, suggesting that S. lateriflora could be a 
valuable anxiolytic - as many anxiolytics impair cognitive function and physical 
performance (Wolfson & Hoffmann 2003).  It is unclear whether the results were 
statistically significant as this was not determined. 
 
Commercial herbal products have been found to contain significant variations in 
phytochemical profile within a species.  Such variation may be according to geographic 
region, biodiversity, ecological variations, cultivation, seasonality, harvesting, and 
storage time affecting stability; processing method, marc to menstruum ratio and 
alcohol concentration (Ciddi 2006; Gao et al. 2008).   
Quality control and correct identification may be of particular importance in the case of 
S. lateriflora because of the large number of Scutellaria species (Malikov & Yuldashev 
2002) and frequent substitution or adulteration with other skullcaps or potentially 
harmful herbs such as germander (Teucrium) (Wolfson & Hoffmann 2003).  
Respondents to the practitioner survey said they used a variety of suppliers, mainly for 
price, convenience or habit but it is important to ensure the herb has been authenticated. 
Anxiety, stress and related disorders are problems treated most frequently in the herbal 
medicine clinic (del Mundo et al. 2002).  As S. lateriflora is reported to be one of the 
most used herbs in western materia medica (Bergner 2002) it is likely that this is the 
herb of choice by western medical herbalists for these conditions.  The purpose of the 
survey was to provide further evidence for its popularity in relation to other herbs used 
for the same conditions, to gather anecdotal evidence of its effectiveness and to gain 
information about prescribing practices such as dosage and duration of treatment, why it 
is prescribed and any reported issues in using it.  The results may help to inform 
treatment protocols in clinical studies.  A brief version of the survey was reported 
previously (Brock et al. 2010) along with a more detailed scientific basis for the use of 
S. lateriflora. 
3.3 Materials and methods 
UK and Ireland herbal medicine practitioners with an email address identifiable from 
the register of the National Institute of Medical Herbalists (NIMH) were contacted.  
NIMH members are qualified herbalists who have undergone several years’ rigorous 
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scientific training, following which they take consultations with patients with a wide 
range of conditions, using the same diagnostic skills and examination techniques as 
orthodox doctors.  This organisation was chosen as it is the largest organisation 
representing medical herbalists in the UK.  As a number of herbalists belong to more 
than one representing organisation there was a risk of some receiving a survey 
questionnaire twice if more than one register was used.  Each of the 377 practitioners 
selected received an electronic letter (Appendix I) and survey questionnaire form 
(Appendix II). 
 
A mixed methods approach was used with mainly open questions in order to gather as 
much information as possible about practitioners’ experiences with, and beliefs about, 
S. lateriflora.  Respondents were asked:  
 
 Whether they regularly prescribe S. lateriflora and, if not, reasons for not doing so;  
 what they thought were its main actions and indications;  
 what they prescribed it for and for how long;  
 the length of time in which they expect to see a response in patients and what 
responses they expected to see;  
 what patients reported from its use;  
 whether there have been any reported side-effects and what were perceived contra-
indications;  
 type of preparation used and reasons for choices;  
 dosage and strength;  
 whether used alone or in combination;  
 What was their favourite herb for anxiety?  
 They were also asked how long they had been in practice and to add any additional 
comments should they wish to do so. 
3.4 Results and discussion 
Of 377 questionnaires sent, 62 practitioners responded (16%).  Of all responders, 57 
(92%) said they regularly prescribe S. lateriflora.  Length of time in practice and 
experience varied widely but generally the responders comprised a group of highly 
experienced herbal practitioners. The average length of time in practice was 9.03 years 
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(SD = ± 7.14) and the average time spent with patients per week was 10 hours per 
practitioner. 
3.4.1 Actions and indications attributed to S. lateriflora 
The majority of respondents provided more than one indication and/or action and use of 
S. lateriflora (Table 3-1).  There was some confusion over the difference between 
actions and indications and most common conditions for which it is prescribed.  For 
example, 77% of respondents said they would prescribe it for anxiety but only 35% 
suggested it has an anxiolytic action and only 18% gave anxiety as an indication for the 
herb.  For simplicity, ‘indications’ and ‘reasons for prescribing’ have been amalgamated 
in Table 3-1. The confusion between actions and indications and reasons for prescribing 
is interesting and deserves consideration by herbalists generally; it calls into question 
how a misunderstanding of the language might potentially impose restrictions to the 
way in which herbs are used. If so, such an impediment may impact upon herbal 
practice as a whole.  Rigorous scientific research could explore this issue. 
3.4.2 The practitioners’ choice for anxiety 
Results indicate the principal use of S. lateriflora is for relief of anxiety, stress or 
associated conditions with most (77%) survey respondents stating they would prescribe 
it specifically for anxiety and all said they would prescribe it for anxiety-related 
comorbidities.  When asked what is their preferred herb for anxiety, twenty five (40%) 
chose S. lateriflora (Figure 3.2).  It is interesting to note that one respondent indicated 
their preferred anxiolytic as being S. baicalensis as,  although S. baicalensis root is most 
commonly used for inflammation (Joshee et al. 2002), it is reported to have been used 
as a sedative (Liao et al. 1998).  Conversely, S. lateriflora is reported to have been 
traditionally used for inflammation. The Iroquai tribe, for example, used it ‘to keep the 
throat clear’ (Joshee et al. 2002).  Additionally, both S. lateriflora and S. baicalensis 
have been found to inhibit cyclooxegenases in vitro (Gafner et al. 2004a; Jia et al. 
2007).   
 
Common reasons for prescribing S. lateriflora are provided in Table 3-1.  All 
respondents who regularly prescribe S. lateriflora (92%) identified use for anxiety as 
distinct from depression and whilst some reported it useful also in depression, two 
respondents reported it as unsuitable for significant depression (described as “mentally 
depressed states” and “severe depression”) as in their opinion it tended to exacerbate it.  
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Usefulness for insomnia and sleep-related disorders was reported by 33 respondents.  
Practitioners who prescribe for poor sleep invariably described it to be related to an 
overactive mind, obsessive or racing thoughts, worry and anxiety.  
 
 
Key: Avena = A. sativa (oats); Crataegus = Crataegus spp. (hawthorn); Hypericum = H. perforatum (St 
John’s wort); Lavandula = Lavandula spp. (lavender); Leonorus = L. cardiaca (motherwort); Matricaria = 
M. recutita (German chamomile); Melissa = M. officinalis (balm); None = no preference; Passiflora = P. 
incarnata (passion flower); Piper = Piper methysticum  (kava-kava); S. baicalensis (baical skullcap); S. 
lateriflora (American skullcap); Stachys = S. betonica (wood betony);  Tilia = Tilia spp (linden); 
Valeriana = Valeriana officinalis (valerian); Verbena = Verbena officinalis (vervain).   
 
NB:  Many survey respondents gave more than one choice but overall the herb of choice 
was S. lateriflora. 













Table 3-1  Actions and indications attributed to S. lateriflora 
 
Actions attributed to S. lateriflora  
(n = 62) 
N Indications/reasons for prescribing  
S. lateriflora (n= 62) 
N 
Nervine/ nerve trophorestorative 40 Anxiety 59 
Anxiolytic 22 Insomnia and other sleep-related disorders 33 
Relaxant 20 Stress 21 
Mildly sedative 14 Migraine and other types of headaches 13 
Calming  8   
Antispasmodic or spasmolytic  8 Depression 9 
Cooling  4 Drug withdrawal and addiction 8 
Tranquilising  4 Nervous and muscular tension 7 
Anti-inflammatory  3 Panic attacks 7 
Anti-stress  2 Fear and phobias  7 




Anti-allergy  2 Physical and mental exhaustion 5 
Parasympathetic  1 Excessive thought processes 5 
Anti-panic 1 Hypertension 5 
An emotional balancer 1 Palpitations 5 
Antidepressant 1 Irritability 3 
Supporting 1 Twitches and spasms of nervous 
origin/convulsions 
2 
Digestive tonic 1 Premenstrual syndrome (PMS) 2 
Sustaining 1 Allergies 2 
Anti busy brain 1 To put things into perspective 2 
Bringing focus 1 Nervousness 2 
  Chronic fatigue syndrome 2 
  Irritable bowel syndrome 2 
N = number of practitioners stating actions and/or indications/reasons for prescribing. 
 
Other anxiety-related conditions given by practitioners as reasons for prescribing 
included for: ‘those who sigh a lot’, frustration, menopausal mood swings, 
despondency, neuralgia, nerve weakness, emotional instability, shock, feelings of not 
coping, tinnitus, debility, hot flashes triggered by stress, low mood, grand mal, 
Attention Deficit Hyperactivity Disorder, Obsessive Compulsive Disorder, “liver heat 
rising” and to “relax constriction where there is heat.” 
3.4.3 Duration of treatment 
The survey respondents reported the herb as being used over a range of time periods 
from immediate short-term use to several years, with positive response expected to be 
experienced by the patient within the first two weeks and persisting throughout the 




According to 8% of respondents who did not state a timescale this is dependent on the 
health of a patient, the condition presented by a patient and its severity, how long they 
have been ill and patient compliance.  In the words of one practitioner: ‘as long as it 
takes’.  All other respondents gave a lower and/or an upper limit.  Rarely, it may be 
prescribed as a one-off but in general the minimum length of time it is prescribed is for 
1 or 2 weeks (11%).  At least 30% of user respondents consider prescribing it long-term 
(6 months or more), sometimes for years (8%), although some stated ‘long term’ 
without being explicit about the timescale.  Those who stated ‘several months’ were not 
included as long-term prescribers as it is unknown whether this could mean up to 6 
months or more than 6 months.  Of those who set an upper limit on treatment length 
31% stated they would treat for up to 4 months.  It is difficult to ascertain average 
treatment length as many replies were not explicit.  What is clear, however, is that it 
ranges from one-offs to several years. 
3.4.4 Responses looked for in patients 
Sleep quality was a major factor in assessing mental state improvement with 53% of S. 
lateriflora prescribers stating they would expect patients to sleep better; for example by 
sleeping longer, with less waking in the night, an ability to get to sleep and feeling 
refreshed in the morning.  Many (37%) felt they would be likely to notice that their 
patients were better able to cope with the stresses daily life.  A reduction in anxiety and 
feeling calmer would be looked for in patients by 33% and 32% of practitioners 
respectively.  In general, respondents expected their patients to feel happier, less 
depressed or tearful, calmer, more relaxed, less irritable, less stressed, tense or nervous 
and more in control of their emotions with elevated mood.  They also expected a 
concomitant resolution or reduction of stress- and anxiety-related physical symptoms 
such as headaches, digestive disturbances, PMS, inflammatory skin conditions, twitches 
and spasms, and cardiovascular problems such as hypertension, tachycardia and 
palpitations.   
3.4.5 Benefits reported by patients 
The benefits most often reported by patients to their practitioners were feeling calmer, 
improved sleep patterns and sleep quality, and better able to cope in stressful situations. 
Other positive effects were mood elevation, increased energy, being more focused and 
feeling generally more relaxed. Some user respondents (19%) answered that it is 
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difficult to determine what patients have reported from using S. lateriflora as they never 
prescribed it as a single herb but always mixed it with others.   
3.4.6 Effectiveness response time 
When asked: “after what length of time would you expect to see a response?” answers 
were again often implicit rather than explicit.  Most provided a range of timescales e.g. 
“one to two weeks”.  Some practitioners did not provide a minimum or maximum 
timescale, only ‘one month of treatment for every year they have been ill’ or ‘longer 
term’ and many responded to the question with ‘few days or ‘few weeks’.  One said it 
was difficult to say as they always prescribe S. lateriflora in combination with other 
herbs and therefore values for neither the average nor minimum and maximum expected 
response time could be ascertained. 
 
Most said it was dependent on the condition being treated and many said that 
improvement was time and/or dose dependent - practitioners’ own words but suggesting 
improvement over the minimum response time provided and/or with what they perceive 
as adequate doses (see Figure 3.3) - but usually noticeable within a few days; and that 
continuation of treatment for periods beyond the first signs of improvement was 
beneficial to the patient.  Responses by 12 practitioners suggest, however, that S. 
lateriflora may show an effect immediately or within hours.  Twenty practitioners 
questioned expect to see some results in one or two weeks.  Of total expected minimum 
response times provided (n = 56), only 11 practitioners did not expect S. lateriflora to 
show an effect before 3 weeks.  The maximum expected response time was 12 weeks (n 
= 2) but, as practitioners are very keen to say: “it depends on the individual”. 
3.4.7 Dosing strategies (posology) 
The weekly ethanol: water tincture dose of S. lateriflora most commonly prescribed 
(Figure 3.3) by user respondents is 20 ml (33.3 %) followed by 30 ml (19%).  As the 
average marc: menstruum ratio was 1: 3 in 25% ethanolic extract the most commonly 
prescribed weekly dose expressed as crude, dried herb was around 7g and10 g 
respectively.  The range of doses represents approximately 1.7-35 g crude, dried or fresh 
herb in 1:3 ethanol: water (w/v) per week, and the median daily dose is thus 3 ml, which 
is equivalent to 1 g at this marc to menstruum ratio. Tinctures are the preferred mode of 
administration by the majority (96%) of respondents who prescribe the herb.  The main 
reasons given were that tinctures are generally more convenient than dried herb and 
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therefore better for patient adherence.  There is also a belief that tinctures are more 
effective than dried herb.  Tinctures may be made from either fresh or dried organic and 
non-organic herb and many respondents (63%) said they prefer to use organic S. 
lateriflora and 42% prefer tinctures made from the fresh herb, believing this to be the 
most effective.   
 
All S. lateriflora users responding to the survey prescribe the herb in combination with 
other herbs.  Only 9% regularly prescribed S. lateriflora as a single herb so it is difficult 
to draw conclusions about the perceived actions of S. lateriflora used on its own.  
Nevertheless the practitioners appeared to be confident in attributing specific anxiolytic 
and related actions and responses to S. lateriflora as distinct from other herbs in a 
mixture.  Reasons are unclear but this perhaps reflects a combination of empirical, 
anecdotal and scientific knowledge relating to each of the herbs prescribed 
simultaneously. Furthermore, respondents (9% of users) prescribing it as a single herb 
reported positive feedback from their patients such as reduced anxiety, fewer and less 
intense panic attacks, feeling of well-being, feeling more positive, more able to cope.  
Significantly, a relapse of anxiety symptoms in some patients was noticed by one 
practitioner prescribing the herb in combination with other (non-anxiolytic) herbs 
whenever it was removed from the mixture.  
 




3.4.8 Contraindications and side-effects 
While the majority of respondents (81%) did not consider S. lateriflora to be 
contraindicated for any conditions, the other 19% said they would not prescribe it to 
severely depressed patients, those with bipolar disorder or other specific mental 
conditions, to those with epilepsy, thyroid conditions, in pregnancy or to children.  It 
may be possible that herbalists are unlikely to prescribe any herbs for situations where 
safety is unknown. 
The herb was reported as being well tolerated and with only minor and infrequent side 
effects (reported by 7 prescribers); including mild digestive upsets, worsening of 
depression, daytime drowsiness, light-headedness and vivid dreaming.  It is uncertain 
whether any of these side effects could definitely be attributed to S. lateriflora.  There 
were no reports of toxicity. 
3.4.9 Survey response rate 
It is not clear why there was such a low response rate to the survey questionnaire 
(despite two follow-ups, an oral presentation alert at a NIMH conference and an 
advertisement in a NIMH newsletter).  Several reasons for low feedback could be 
postulated.  One is that medical herbalists tend to receive a number of survey response 
requests during any given year, mainly from undergraduates embarking upon their 
dissertations, and may therefore be suffering from ‘survey fatigue’.  It could be that 
some didn’t feel the survey was relevant to their practice if they were non-prescribers of 
S. lateriflora.  This is difficult to assess but if this was the case then generalisability 
across herbal medicine practitioners would have been affected by non-response bias 
(Cummings et al. 2001).  Some may have been deterred by the length of the 
questionnaire and the fact that questions were in the main open-ended, requiring 
considerable time and effort on the part of already busy practitioners, many of whom 
are doing more than one job or are studying.  Studies of response rates to surveys have 
demonstrated that the more user-friendly a survey is the more likely it is to have a high 
response rate (LaGarce & Kuhn 1995).  A fair amount of typing was required to fully 
answer the questions so it could not be considered to be as user-friendly as a 





This study has added to the literature in that it has shown that S. lateriflora is prescribed 
for a range of related conditions and its widespread use for sleep disorders has 
broadened the indications in the British Herbal Pharmacopoeia.  Furthermore, the 
revelation that herbalists ascribe the action of a compound mixture to the herb has 
provided empirical evidence of its efficacy. 
 
It is recognised that the response rate (16%) for this pilot survey was low and 
respondents include only those with access to email.  It may therefore not be 
representative of all UK and Ireland herbal medicine practitioners.  An advantage of 
email surveys is that they are fast and cost-effective and provide geographical diversity 
but exclusion includes those without access to email.  Furthermore, responses may have 
been mainly from those who have had experience of the herb.  Non-responders could 
possibly be mostly non-prescribers.  Importantly, it is possible that those who do not 
prescribe S. lateriflora may not do so because they do not find the herb useful.  
Although this is speculation it could be a confounding factor.  The poor response rate 
and the propensity of respondents to administer S. lateriflora in combination with other 
herbs make it impossible to rely on evidence regarding the efficacy of the herb from the 
pilot practitioner survey alone.  A future survey could include herbal practitioners from 
other professional bodies such as the Council of Practitioners of Phytotherapy.  In 
addition, contact with herbalists internationally may provide a more useful indication of 
the benefits of this herb.  Because of the low response rate a future survey could contain 
fewer open questions and use a world-wide web electronic format so that respondents 
could have the option to simply click multiple choices with a computer mouse.  
Furthermore, it would be helpful to urge survey recipients to respond regardless of 





Chapter 4. Botanical identification: 
macroscopic differences between S. 
lateriflora and other skullcaps and 
germander  
4.1 Introduction   
Botanical descriptions in herbal text books are general and tend to be gathered from 
secondary sources.  As S. lateriflora is frequently adulterated with Teucrium 
(germander) species or substituted with other skullcap species (Gorman 2008) an 
understanding of the macroscopic characteristics of the aerial parts of the plant is 
necessary to ensure its correct identification.  In particular, for the purpose of the 
present clinical study, it is important to ensure the freeze-dried skullcap sourced from 
Oregon, USA was correctly identified by the growers/suppliers (Eclectic Institute Inc.).  
A specification sheet describing macroscopic characteristics relating to each batch of 
freeze-dried S. lateriflora was supplied by the Eclectic Institute on request.  In addition 
to botanical identification, quality control at source was with regard to organoleptics, 
bacteria, viruses, heavy metals and insects.  It was therefore necessary to confirm 
identification at the University of Westminster using HPLC (Chapter 5). 
4.2 Aims  
The aim of this study was to gain informed knowledge, using primary sources, 
regarding the botanical identification of Scutellaria lateriflora L.  
4.3 Objectives  
 To understand the identifying characteristics of Scutellaria lateriflora. 
 To compare the macroscopic identifying features of Scutellaria lateriflora with 
those of some related (skullcap) species. 
 To compare the macroscopic identifying features of Scutellaria lateriflora with 
Teucrium species. 
4.4 Method 
Email contact was made (February 2009) with the curators of both the Natural History 
Museum (John Clayton) and Linnaean Society herbariums i.e. Dr Mark Spencer and Dr 
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Charlie Jarvis respectively.  Viewing of both private collections was subsequently 
arranged for the same month.  Voucher specimens of skullcap species were viewed, 
drawings were made and notes taken.  Original botanical literature regarding skullcap 
classification was studied in the herbarium libraries. 
Contact was also made with the American Herbal Pharmacopoeia® (AHP), where a S. 
lateriflora voucher specimen is kept (Scott’s valley, California).  An image of this was 
received by email from the AHP (Appendix III).  An image of a voucher specimen was 
also supplied by the curators of the John Clayton collection at the Natural History 
Museum (Figure 4.1.). 
 
In order to recognise the defining characteristics of fresh specimens as opposed to dried 
or photographic, S. lateriflora was grown in ideal conditions of partial shade and 
frequent irrigation (Similien et al. 2008) from seed (Chiltern Seeds) planted in April 
2009 and also in April 2011 from propagations derived from division (Arne Herbs Ltd), 
originally sown in April 2005, repeatedly split and cultivated indoors down to -8 °C in 
Sinclair Alpine.  For purposes of authenticity a trail was made pertaining to the origins 
of the plants. The Chiltern seeds were originally sourced from Arne Herbs nurseries, 
whose first S. lateriflora plants were originally from Hollington Herb Garden in Berks, 
UK and expertly identified by botanists and horticulturists Judith and Simon Hopkinson  
(Lyman-Dixon 2011). 
 
Mature specimens were photographed in situ in September 2009 (Figure 4.2) and July 
2011 (Figure 4.3) when flowering and the leaves from both years were made into 1: 3 (1 
part marc: 3 parts menstruum) ethanol: water (50: 50 v/v) tinctures for possible future 
HPLC analysis.  In addition, a specimen was harvested at the end of June, 2011 when in 
full flower, and pressed (Figure 4.4).  Additionally, a wild-growing S. galericulata 
specimen was located (identified against a wildflowers handbook) on Tresco by the 
Abbey Pool in the Isles of Scilly in September 2011 and a description was noted. 
4.4.2 Voucher specimens viewed:   
American Herbal Pharmacopoeia®:  Image sent by email PDF attachment (Appendix 
III) and contained within a full report of botanical identification by the AHP. 
Natural History Museum: The following species of Scutellaria were published by 
Linnaeus in Species Plantarum (Linnaeus (1753): S. albida, S. alpina, S. altissima, S. 
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cretica, S. galericulata, S. hastifolia, S. hyssopifolia, S. indica, S. integrifolia, S. 
lateriflora, S. lupulina, S. orientalis, S. peregrina and S. supina. The voucher specimen 
of S. lateriflora in the John Clayton herbarium is attributed as being the original, 
definitive type or lectotype classified by Linnaeus (1753), who stated its habitat as 
Virginia USA and Canada.  
S. lateriflora examples in the John Clayton Herbarium collection: 
 Scutellaria palustris repens, Virginia major, flora minore – pre 1737 Clayton 
Herbarium      
 Scutellaria cassida aquatica flora minimo pallide carutro folus, veronica, autumna 
floret – Clayton number 280 ex Virginia (1753): Lectotype of Scutellaria lateriflora 
(Figure 4.1). 
Polynomials were given before Linnaeus introduced the binomial system.  
Also in the collection are S. hyssopifolia and S. integrifolia 
 
Figure 4.1  John Clayton Herbarium voucher specimen of S. lateriflora 
© The Natural History Museum, London 
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Linnaean Society collection:  Within this collection is a voucher specimen of S. 
lateriflora , cultivated and collected by Carl Linnaeus (1707-1778) in Uppsala, Sweden 
and classified by the binomial system, which he invented (genus, species) (Natural 
History Museum 2011).   Also in the collection are S. albida, S. alpina, S. cretica, S. 
galericulata, S. hastifolia, S. hyssopifolia, S. integrifolia, S. lupulina, S. minor, S. 
orientalis and S. peregrina. 
A large number of Teucrium species are also housed in the Linnaean Society 
Herbarium.  Scutellaria specimens in both collections and the Teucrium specimens were 
viewed for comparison with S. lateriflora. 
4.5  Results 
The description and artist’s impression of S. lateriflora in the Eclectic institute 
specification sheet correlated to the voucher specimens in the S. lateriflora herbariums 
visited.  The fresh herbs grown from seed (Figure 4.2) and plantlet divisions (Figure 4.3 
and Figure 4.4) could also be identified as S. lateriflora. 
 






Figure 4.3  S. lateriflora grown from a plantlet division, UK, July 2011 
 
Figure 4.4  S. lateriflora harvested in UK, July 2011 
 
A macroscopic comparison of some of the above herbarium species was made from 
observation (Table 4-1) with additional information from reputable authentication texts.  
Briefly, the main difference between S. lateriflora and other skullcaps is the distinctive 
way the flower stalks grow from the leaf axillae.  The leaves (Figure 4.6 and Figure 4.7) 
have a distinct venation and crenate dentition with longer petioles (~ 2 cm) than most 
skullcaps and the flowers are smaller (<10 mm).  According to the Eclectic Institute 
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plant specification sheet used for quality control (Nagel 2008) the size of the corolla at 
<10 mm is unique amongst skullcaps.  The most commonly confused species, S. 
galericulata (Figure 4.8) has almost sessile leaves - the petioles are up to 13 mm in 
length whereas those of S. lateriflora are up to 25 mm long - with sparse dentition.  The 
leaves are smaller (up to 5 cm) and more lanceolate than those of S. lateriflora, which 
has leaves up to 10 cm in length (Upton et al. 2009).  S. ovata (Figure 4.5), another 
commonly confused species has broad, heart-shaped leaves. The flowers of this species 
are up to 25 mm in length (Freckmann 2011a) and are therefore much larger than those 
of S. lateriflora (<10 mm).  Differences between Teucrium (Figure 4.9) and Scutellaria 
species are more pronounced. For example the flowers of Teucrium are pink, not purple 
or blue and the corolla appears to have no upper lip because it is fused with the lower 
lip (Upton et al. 2009). 
 
 Figure 4.5  S. ovata 
 
©Mark Mittelstadt, Robert Frickmann Herbarium, University of Wisconsin – Stevens Point 
 
 

















































































































































Table 4-1  Main macroscopic characteristics and differences between S. lateriflora and 2 
common skullcap and 2 Teucrium species 
 
Botanical part S. lateriflora S. galericulata S. ovata Teucrium spp 

















margins with deep 
dentition. Ovate-
lanceolate, round 
at the base with a 
pointed apex. 
Length 5-10 cm, 
width 3-5 cm. 







Rounded at the 
base. Length up to 
5 cm, width up to 
2 cm. Sub-sessile 
with petioles ~ 1 




cordate at the 
base. Long 
petioles ~5 cm. 
Coarsely serrated, 
crenate margins. 
Length 3-10 cm 
and 5-7 cm wide. 
T. canadense: 
Ovate-lanceolate, 
crenate. Up to 5 
cm long and 3 cm 
wide. Short 
petioles ~ 1 cm. 
T. chamaedrys: 
Oblanceolate.  Up 
to 3 cm long and 
Leaf margins are 
scalloped.  
Waxy cuticle. 
Very short petioles 




Less than 1 cm in 
length. 2 lipped 
with 3 lobes on 
lower lip. Exterior  
pubescent 
Blue. Up to 2 cm 
in length. 2 lipped 
with 3 lobes on 
lower lip. Exterior 
slightly pubescent. 
Purple with white 
base. 2 lipped with 
3 lobes on lower 
lip.  Length ~ 2.5 
cm (Freckmann 
2011a) 
Pink to pinkish 
purple. 2 lips. 
Length ~ 15 mm 
T. canadense: 2 
lobed upper lip, 3 
lobed lower lip  
T. chamaedrys: 5 
lobed lower lip. 
Upper lip not 
hooded 
 







Height Up to 90 cm Up to 75 cm 
(Upton et al. 2009) 
Up to 70 cm 
(Freckmann 
2011a) 








Figure 4.9  Teucrium canadense 
 
4.6 Discussion 
The number of skullcap voucher specimens housed in the two London herbariums 
visited was miniscule relative to the large number of known species, amounting to only 
3.6 % of around 360 worldwide (Malikov & Yuldashev 2002).  Although differences 
between the herbarium species were apparent it is difficult to ascertain whether, of 360 
species, there may be some in existence that appear more similar to S. lateriflora.  It is 
therefore important for identification to be confirmed by sensitive techniques such as 
HPLC, random amplified polymorphic DNA (RAPD) markers (Hosokawa et al. 2000), 
estimation of genome size (Cole et al., 2008) and/or or high-powered microscopy 
(Upton et al. 2009). 
Misidentification may occur with small scale herb farming and the possibility of those 
with an untrained eye gathering skullcap herb from the wild. Perhaps there is also a trait 
amongst herbalists and horticulturalists alike to grow the ‘wrong’ species and pass them 
on to one another.  
Of particular interest is the difference between S. lateriflora and S. galericulata as S. 








































































































































(Gorman 2008).  HPLC analysis can distinguish between the two species by the use of 
the compound 2’-methoxychrysin, which is found in S. galericulata but not S. 
lateriflora (Gafner et al. 2003c).  
A study, however, which compared flavonoid content of 13 skullcap species, found S. 
galericulata contained a considerably greater quantity (11.31 mg/g) of baicalin than S. 
baicalensis (5.07 mg/g), which is commonly believed to have particularly high baicalin 
content (Zgorka 2006).  The baicalin content of S. lateriflora was not determined in this 
study but its concentration demonstrated in S. galericulata compares well with that of 
the freeze-dried S. lateriflora (Eclectic Institute) authenticated by HPLC methods in the 
present study (see 5.5.4, p82), found to be 11.71 mg/g.  Because baicalin is considered 
to be a physiologically active flavonoid (Joshee et al. 2002) it may be useful in the 
future to conduct clinical efficacy studies of S. galericulata. 
It is also interesting to note that exacerbation of accidental substitution of S. lateriflora 
in the UK may have began in the 1930s when, it is believed, a well-known herb farmer 
misidentified the herb and consequently instigated the introduction of the wrong 
species,  thought to be S. ovata (Figure 4.5), into the UK market (Lyman-Dixon 2011).   
 
4.7 Conclusions 
S. lateriflora may be correctly identified by the trained botanist.  However, for reasons 
of quality assurance, confirmation of the identity of commercial crops with HPLC is 
advisable to ensure there is no accidental contamination with Teucrium or substitution 




Chapter 5. Quality control of               
S. lateriflora 
5.1 Introduction 
Due to the risk of contamination with potentially toxic botanicals and other hazardous 
substances, including pesticide residues, bacteria, fungi, toxic metals and radioactive 
chemicals, the importance of strict quality control of all herbal preparations cannot be 
underestimated (de Smet 1999).   
5.1.1 Identity issues surrounding S. lateriflora 
Quality control and correct identification may be of particular importance in the case of 
S. lateriflora because of the large number of Scutellaria species (around 360 species 
worldwide) (Malikov & Yuldashev 2002) and frequent substitution or adulteration with 
other skullcaps or potentially harmful herbs such as germander (Teucrium) (Wolfson & 
Hoffmann 2003; Gorman 2008).  Studies have shown wide variations in phytochemical 
profile of herb claimed to be S. lateriflora.   
Zhang et al. (2009), for example, discovered a wide variation in individual and total 
phenolic content in 10 different commercial preparations of S. lateriflora (analysed by 
HPLC and compared with S. baicalensis and whole, freeze-dried extract).  Baicalin 
content, for example, varied from 0.48% to 10.10% (compared to 18.95% for whole 
extract).  Total phenolic content for these two preparations was 1.11% (extract – type 
not described) and 20.55% (fine powder in a capsule) respectively (41% for whole 
extract) (Zhang et al. 2009). 
 
Another HPLC analysis (Gao et al. 2008), of seven commercial preparations (obtained 
from five companies), which compared baicalin, baicalein and wogonin content of S. 
lateriflora (four samples of S. baicalensis were also analysed), also found wide 
variations in individual and total content of these flavonoids.  One sample contained no 
baicalin, baicalein or wogonin.  Of all three flavonoids, µg/ml ranged from 180, 280 and 
97.5 to 12700, 629 and 152 respectively (Gao et al. 2008).   
 
Considering reports (Wills & Stuart 2004; Gorman 2008) of a high rate of substitution 
of S. lateriflora with other skullcap species, it is not certain whether the commercial 
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products tested by Gao et al. (2008) and Zhang et al. (2009) were definitely S. 
lateriflora. 
5.1.2 Authentication problems in the scientific literature 
Issues surrounding authenticity of S. lateriflora in the market have probably been a 
problem for hundreds of years.  Wohlmuth (2001)  pointed out that King’s American 
Dispensatory, published in 1898, describes S. versicolor and S. canescens as being two 
substitute species that constituted the majority of the commercial drug.  Problems of 
substitution may have been exacerbated by authentication problems in the scientific 
literature, some relating to analyses of the chemical composition of S. lateriflora.  For 
example, according to Yaghmai (1988) S. lateriflora grows on riverbanks and marshes 
in northern Iran.  However, the species known to grow in this region is S. pinnatifida 
(Barceloux 2008).  When Wohlmuth (2011) compared the composition of essential oil 
from morphologically and LC-MS authenticated S. lateriflora specimens grown in 
North America and Australia with that reported from the Iranian samples the results 
differed regarding which were the dominant oils (Wohlmuth et al. 2011).  (See 2.6, p21) 
Another study (Zhang et al. 2009), in which the chemical ingredients of S. lateriflora 
were characterised, used 10 samples of plant material purchased from herbal product 
stores and companies.  There is therefore no guarantee that any of this material, 
including the whole extract against which other samples were compared, was authentic 
S. lateriflora.  The authors even used one of the samples to test for anti-convulsant 
activity in a rat seizure model (Zhang et al. 2009) without first verifying the material 
against a voucher specimen.  In agreement with Rader and Delmonte (2007), the results 
of a study may be invalid if the botanical material tested has not been authenticated as it 
may have been misidentified or be adulterated with other species. 
Accidental substitution of S. lateriflora in the market may occur and perpetuate when 
the wrong species is cultivated by commercial growers.  For example, it is a belief 
among some growers of authentic S. lateriflora, that one UK herb farm had been 
flooding the market with a considerable amount of misidentified skullcap species, 
possibly S. ovata, since at least the 1930s (Lyman-Dixon 2011).  It is not known how 
widely spread is the use of this particular species amongst herbalists today. 
Whilst researching background information for this thesis it became apparent to this 
author that authors of both popular and academic herbal text books tend to cite from one 
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another when providing information on the chemical constituents of S. lateriflora, as do 
some authors when publishing research on the herb.  This no doubt adds to the identity 
issues surrounding the herb. 
5.2 Adulteration and substitution of S. lateriflora 
5.2.1 Reports of adulteration of S. lateriflora with 
Teucrium species 
In the 1970s and 1980s there were reports of liver damage, including hepatitis and 
fibrosis, from use of S. lateriflora (McCaleb 2004).  The cause of hepatotoxicity was 
subsequently attributed to American Germander (Teucrium canadense), which is similar 
in appearance, being used in some European commercial preparations in place of S. 
lateriflora (de Smet 1999).  T. canadense is a possible substituted species but it is now 
considered non hepatotoxic.  A European Teucrium species, T. chamaedrys, which 
contains hepatotoxic furan neoclerodane diterpenoids such as teucrin, may have been 
substituted for S. lateriflora (Bedir et al. 2003; McCaleb 2004; Lin et al. 2009).  T. 
chamaedrys was formerly thought to contain hepatotoxic pyrrolizidine alkaloids 
(McCaleb 2004).  According to researchers at Southern Cross University in Australia, 
deliberate adulteration of S. lateriflora with Teucrium species is mainly because it has a 
heavier dry weight than S. lateriflora and non-deliberate adulteration may occur through 
accidental harvesting when the different genera grow side by side (Gorman 2008).   
 
Gafner et al. (2003a) developed a method of detecting adulteration with Teucrium 
species.  This involves photomicroscopy in combination with liquid and thin layer 
chromatographic methods and UV/MS (ultraviolet/mass spectrometry), with the use of 
phenolic marker compounds e.g. teucrioside and verbascoside, found in germander 
species but not in skullcap.  The method has been further developed by Lin et al. 
(2009), who showed that chromatographic profiling can not only distinguish the two 
genera separately but also when they are mixed together (Lin et al. 2009).  A rapid and 
simple method of determining contamination with Teucrium species, flow 
injection/mass spectrometry (FI/MS) fingerprinting, has been developed recently (Sun 
& Chen 2011). 
5.2.2 Substitution with other skullcap species 
S. lateriflora crop damage may occur due to its susceptibility to a number of diseases 
such as leaf spot, stem rot and powdery mildew (Greenfield & Davis 2004); also, adult 
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species of the leaf beetle (Phyllobrotica genus) are known to attack the aerial parts and 
their larvae attack the roots (Farrell & Mitter 1990).  When such damage leads to crop 
failure, S. lateriflora is sometimes substituted with other Scutellaria species, 
particularly S. galericulata,  S. cordifolia [syn. S. ovata (U.S.D.A. 2011)] and S. 
canescens.  Substitution may also occur through misidentification (Wolfson & 
Hoffmann 2003; Gorman 2008).  Although S. galericulata is rarely used consciously in 
herbal medicine it is believed to have similar actions and indications as S. lateriflora 
(Plants for a Future 2010b).   
 
More than one species within a genus may possess exactly the same or similar 
flavonoids.  For example, in common with many other Scutellaria species, S. lateriflora 
and S. baicalensis have similar phytochemical constituents, although in different ratios 
and quantities, which may explain the differing traditional uses amongst Scutellaria 
species (Cole et al. 2008).  HPLC methods can quickly and easily distinguish between 
the species by qualitative analysis of the flavonoids contained in extracts of the plants 
(de Oliveira et al. 2001).  This is preferable to TLC as the latter lacks sensitivity and has 
poor resolution (Sun & Chen 2011).  Additionally, HPLC analysis can distinguish 
between S. galericulata  and S. lateriflora, by the use of the compound 2’-
methoxychrysin, which is found in S. galericulata but not S. lateriflora (Gafner et al. 
2003c). 
 
Using HPLC, Cole et al. (2008) quantitatively compared the content of scutellarin, 
wogonin, baicalin, baicalein, melatonin, serotonin and indole-acetic acid in stem and 
leaf tissue of S. lateriflora, S. baicalensis and S. racemosa grown in identical 
conditions.  S. lateriflora contained the highest amount of baicalein while S. baicalensis 
contained 800 times more scutellarin than the other two herbs.  Of the three herbs S. 
racemosa had the highest wogonin content.  Baicalin content was similar for the three 
herbs (Cole et al. 2008), which differs from the findings of Makino et al. (2008) who 
compared baicalin, baicalein, wogonin and wogonin-7-O-glucoronide content in roots, 
stems and leaves of S. baicalensis and S. lateriflora.  In this study, baicalin content in 
the leaves and stems of S. baicalensis was insignificant in comparison to S. lateriflora.  
There was slightly more baicalin in S. baicalensis root than in S. lateriflora leaves 
(Makino et al. 2008).  It is possible that differences between studies in flavonoid 
concentrations may have been due to differences in growing conditions.  Interestingly, 
of five skullcap species analysed (S. baicalensis, S. lateriflora, S. racemosa, S. 
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tormentosa and S. wrightii), Islam et al. (2011) found a greater baicalin content in the 
roots of S. wrightii than in root, stem or leaf of the other species and 5-fold higher than 
in S. baicalensis root.  They also demonstrated that S. wrightii and S. tormentosa, 
previously uncharacterised species, are good sources of the flavonoids scutellarin, 
baicalin, baicalein and wogonin.  As these flavonoids are also found in S. lateriflora 
there are implications that these species also have medicinal properties. 
 
When German plant extraction company Extract Chemie tested 12 samples of material 
from different sources using HPLC in 2008, none were S. lateriflora but were in fact 
other Scutellaria species.  This was apparently a surprise to the producers of these plant 
materials.  The company has now produced an HPLC ‘fingerprint’ of S. lateriflora from 
expertly identified raw plant material (Gorman 2008).   
 
In another HPLC study (Wills & Stuart 2004) a liquid commercial product, which was 
also claimed to be S. lateriflora, had the chromatographic profile of Scutellaria incana.  
Of five combination commercial preparations claimed to contain S. lateriflora, when 
tested, none had the typical profile of the herb and may therefore either have contained 
different Scutellaria species or may have lost a considerable amount of flavonoids in 
processing (Wills & Stuart 2004). 
 
Gafner et al. (2003c) have developed a flavonoid fingerprinting technique, using HPLC-
UV/MS, to distinguish between five Scutellaria species.  It is also possible to identify 
species within a genus using modern genetic techniques.  For example, Hosokawa et al. 
(2000) used random amplified polymorphic (RAPD) DNA markers of three species of 
Scutellaria, including S. lateriflora to differentiate between DNA isolated from their 
leaves; and Cole et al. (2008) distinguished between three Scutellaria species by 
estimating genome size using flow cytometry.  
5.3 Variation of phytochemical constituents dependent on 
methods of growing, harvesting, storage, extraction 
and processing  
Commercial herbal products have been found to contain significant variations in 
phytochemical profile within a species.  Such variation may be according to geographic 
region, biodiversity, ecological variations, cultivation, seasonality, harvesting, and 
storage time affecting stability; processing method, marc to menstruum ratio and 
alcohol concentration (Ciddi 2006; Gao et al. 2008).   
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5.3.1 Effects of growing and harvesting conditions  
According to Greenfield and Davis (2004) S. lateriflora grows best in fertile soil and 
with constant irrigation.  They suggest sowing the seeds indoors in shallow flats 
containing moist soil, placed in a refrigerator for a week at 4-10
o
C and then germinating 
them in a greenhouse before planting outside.  Seeds can also be planted directly outside 
in the spring.  Other methods of cultivation include root division and transplanting.  
When harvested, cut plants should be kept out of the sun or they will quickly turn brown 
(Greenfield & Davis 2004).  As cellular disruption may cause enzymatic breakdown of 
flavonoids, mechanical stress during harvesting should also be avoided to prevent their 
loss (Wills & Stuart 2004). 
 
In a controlled experiment, Similien et al. (2008) demonstrated the importance of 
growing conditions on dry matter yield (DMY) and flavonoid content of S. lateriflora.  
Seeds planted in April were harvested when in full bloom at two and four months.  The 
highest concentrations of the major flavonoid baicalin (1.8 mg/g) and its aglycone 
baicalein (0.29 mg/g) (Similien 2009) were at first harvest of fertilised, irrigated plants 
grown in full sun (32% and 50% higher respectively than at harvest 2).  Partial shade 
(40%) did not affect DMY at first harvest but increased it by 63.4% at second harvest 
(in comparison to S. lateriflora grown in full sun).  Irrigation and nutrients increased 
DMY by 23.7% and 45.7% respectively at first harvest but only nutrients increased 
DMY at second harvest, by 10.4%.  Overall, the concentration of flavonoids was greater 
in full sun but the flavonoid yield was greater in partial shade because of a higher DMY. 
There was a very low concentration of wogonin (< 0.6 mg/g) and chrysin (< 0.5 mg/g) 
at all experimental conditions (Similien et al. 2008).   
 
The findings of Similien et al. (2008), that maximum flavonoid concentration is in 
immature plants, agree with those of Wills and Stuart (2004) who assayed flavonoid 
content at four growth stages.  They found, when averaged over the different stages of 
plant growth, highest flavonoid concentration was in the leaves (50.8 mg/g) but 
particularly in immature leaves (69.3 mg/g).  The stems contained a lower flavonoid 
concentration (21.3 mg/g) than the roots (35.8 mg/g).  Due to an increase in leaf weight 
of mature plants, the third harvest, which is the usual ‘commercial harvest’ before 
fruiting, yielded the highest total S. lateriflora flavonoids per weight of whole plants.  
At full maturity as a percentage of total flavonoids the highest baicalin content is in the 
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leaves (54.5%), followed by the stems (45.2%) and roots (38.1%).  Of total flavonoid 
content of S. lateriflora, baicalin constitutes 40-50% (14-18 mg/g, calculated as 40-50% 
of a mean concentration of 36mg/g total flavonoids from whole plant at 4 different 
stages of growth). (Wills & Stuart 2004)  
 
It may be deduced that, although flavonoid concentration is higher in the young plants 
grown in full sun, as S. lateriflora’s DMY is increased over time when grown in partial 
shade the total flavonoid yield in one harvest may be higher in more mature plants. 
According to Foster and Johnson (2006) S. lateriflora plants are usually harvested when 
they are three or four years old. 
 
Differences in individual flavonoid concentrations between the leaves, stems and roots 
result in differences in their chromatographic profiles, which can be used to assist in 
identification of the plant part used for medicinal purposes.  Additionally, adulteration 
of the plant material will alter the characteristic profiles (Wills & Stuart 2004).   
5.3.2 Extraction methods affecting flavonoid 
concentration 
One commercial S. lateriflora tincture tested by Gao et al. (2008), which had the 
highest flavonoid content (12.66 mg/ml), was extracted in 45% ethanol, whereas the 
others were extracted in 25% ethanol.  When the investigators later compared extraction 
in 25% and 45% ethanol from the same batch of S. lateriflora plant material they found 
that 45% ethanol yielded around five times more flavonoids than 25% ethanol (Gao et 
al. 2008).  Similarly, Wills and Stuart (2004) found 40 - 60% ethanol extractions from 
dried powder preparations yielded the maximum flavonoid content of around 70%. 
 
An earlier study (Awad et al. 2003) using HPLC analysis also found higher alcohol 
concentrations extracted S. lateriflora flavonoids well.  Baicalin content was greater at 
50% than at 95% ethanol extraction (40.7 mg/g and 21.3 mg/g respectively) whereas 
95% ethanol was better at extracting baicalein than was 50% ethanol (32.7 mg/g and 
23.5 mg/g respectively). The analysis also indicated that an aqueous extract contained 
no baicalein and minimal baicalin (Awad et al. 2003). 
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5.3.3 Variation of Phytochemical constituents on storage  
Stability of an herbal product is important with regard to efficacy and safety and may be 
affected by various factors, such as pH, light, enzymatic degradation (for example due 
to harvesting stress, heat or insects) and temperature (Gafner & Bergeron 2005).   
 
Flavonoids in glycerite (65% glycerine: 35% water) extracts from dried S. lateriflora (1: 
12 w/v) have demonstrated extreme instability over time with 50.03% total flavonoid 
loss at 6 weeks total maceration time and up to 66.4% loss after 6 months from 
initiation of maceration.  While heat treatment destabilises the enzymes responsible for 
degradation of some flavonoids, for example hydrolysis of baicalin to baicalein by 
endogenous beta- glucoronidase, not all S. lateriflora flavonoid degradation is 
prevented in this way.  Some, such as degradation of dihydrobaicalin, can only be 
prevented by addition of antioxidants, indicating oxidation is also involved in flavonoid 
instability (Russell et al. 2003).   Wills and Stuart (2004) found total flavonoid loss 
from dried herb extracted in 40 - 60% EtOH to be considerable, at 0.17% per day at 
room temperature (this would amount to over 30% loss of flavonoids in 6 months) and 
about 50% greater than with dried herb under the same storage conditions (Wills & 
Stuart 2004).  
 
Although dry heat is believed to negatively affect the activity of herbal medicines, little 
research has been done to this affect.  However, the flavonoid profile of freeze-dried 
extracts of S. lateriflora was not affected by exposure to dry heat for 8 hours at 77
o
C 
(Gafner & Bergeron 2005).   
 
There appears to be no data available on flavonoid loss from fresh S. lateriflora 
extracted in EtOH although Russell et al. (2003) assert that fresh are more unstable than 
dried extractions.  Future studies on this aspect are important as fresh material is 
believed to be most efficacious (Felter & Lloyd 1898; Kuhn & Winston 2001; Yarnell 
& Abascal 2001). 
5.4 Discussion and conclusions 
Strict quality control must be ensured before the commencement of any in vitro or 
clinical studies.  This should include botanical identification to rule out adulteration 
with different Scutellaria species or with Teucrium spp. as has occurred in the past.  A 
problem with plants used for medicinal purposes is those that are harvested from their 
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natural habitats (wildcrafted) are not uniform in the balance of active phytochemicals. 
Successful modern herb farming needs to pay attention to this possibility and be 
selective with breeding programmes, particularly with regard to phytochemistry 
(Lambert et al. 1997). 
 
Storage, harvesting, extraction and processing methods, and marc to menstruum 
strength should be at their optimum for avoidance of flavonoid loss.  Many companies 
extract using 25% ethanol in water.  However, it is clear from HPLC studies (Awad et 
al. 2003; Wills & Stuart 2004; Gao et al. 2008) that S. lateriflora flavonoid extraction 
and stability is poor at this strength.  Gao et al. (2008) suggest that more research into 
the anxiolytic properties of S. lateriflora is needed in order to convince manufacturing 
companies to extract the herb at higher alcohol strength.   
 
To provide valid data it is important that prior to carrying out a clinical trial on 
Scutellaria lateriflora, the plant material should be selected from an identified source 
with a full botanical authentication and chemical analysis to confirm quality. The plant 
material should not be subject to deterioration during the trial period. Empirical 
evidence and research have indicated that fresh freeze-dried or fresh herb extract is 
likely to be more efficacious than the dried herb (Kuhn & Winston 2001; Yarnell & 
Abascal 2001; Gafner & Bergeron 2005), due to instability of the latter and hence fewer 
flavonoids (Wills & Stuart 2004). 
 
Freeze dried material is not widely available as it needs to be processed at harvest by 
immediately freezing freshly harvested plants, which have been washed in spring water, 
at low temperature e.g. -18
o
C.  They then undergo sublimation, a process whereby the 
frozen water is vaporised under vacuum.  The vaporised water is passed through 
condenser plates, a process which converts the water vapour back to a solid and 
removes it from the vacuum chamber.  Only the dried plant material remains and the 
separation process is complete.  Any remaining moisture is removed (around 5%) by 
gentle heat.  Active constituents remain, including flavonoids, enzymes, oils and fatty 
acids.  The colour, smell and taste of the plant material are not affected and it has a long 




5.5 An optimised HPLC method for confirming the identity, 
quality and safety of Scutellaria lateriflora aerial parts. 
5.5.1 Introduction 
S. lateriflora is believed to be safe to use but samples must be authenticated (Upton et 
al. 2009).  Evidence suggests that S. lateriflora’s flavonoids provide it with its 
therapeutic actions (Gorman 2008).  Therefore, the concentration of flavonoids in any 
commercial preparation of the herb is important in defining its quality and efficacy.  
Flavonoids in extracts from dried S. lateriflora have demonstrated extreme instability 
over time (Wills & Stuart 2004). 
As S. lateriflora’s flavonoids are unstable in both dried herb and extracts and because of 
the risk of its adulteration, some bodies of work have been devoted to developing 
reliable HPLC methods for verifying its purity and quality. A characteristic profile of 
the HPLC chromatogram or ‘fingerprint’, which is altered by adulteration, can be used 
for accurate identification of the herb.  The pattern’s relative percentage of flavonoids is 
the key point to ascertain the quality and identity of S. lateriflora (Wills & Stuart 2004). 
The purpose of conducting this present HPLC analysis was to ensure the quality, 
identity and safety of freeze-dried whole aerial parts of S. lateriflora to be used in this 
study to test its efficacy in healthy volunteers.  A freeze-dried preparation was selected 
as providing the optimum preservation of the whole plant phytochemistry (Gafner & 
Bergeron 2005; Luthria 2006).  
5.5.2 Aims and Objectives 
The main aims of this HPLC analysis were to confirm the botanical identity of the 
commercial product and to verify its quality and safety. The specific objectives were to: 
 
 Develop a characteristic chromatogram or ‘fingerprint’  from authenticated S. 
lateriflora;  
 Compare the chromatographic profile of the commercial product with the fingerprint 
of authenticated herb;  
 Qualify and quantify major flavonoids (baicalin, baicalein and wogonin: Figure 2.3, 
p22) found in the commercial product;  
 Verify the absence of germander or other adulterants. 
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The following protocol is modified from Wills and Stuart (2004), who developed a 
reliable HPLC method for the purpose of aiding the production of high quality S. 
lateriflora to be grown commercially in Australia. 
5.5.3 Materials and Methods 
5.5.3.1 Plant materials 
Dried, expertly authenticated S. lateriflora reference material was donated by the 
American Herbal Pharmacopoeia® (AHP) and freeze-dried herb was purchased from 
the Eclectic Institute Inc., Sandy, Oregon.  The herb used in the commercial product had 
been botanically identified at source and was grown on the supplier’s own farm in 
Oregon, USA (Nagel 2008). The reference S. lateriflora was grown in Colorado, USA. 
A voucher specimen for the reference sample is deposited at the herbarium of the AHP.  
5.5.3.2 Materials 
HPLC grade baicalin, wogonin and verbascoside were purchased from Extrasynthese, 
Genay, France.  Baicalein (98%) and HPLC grade methanol and phosphoric acid were 
purchased from Sigma-Aldrich, Dorset, UK.  HPLC water was obtained from a 
deioniser. 
5.5.3.3 General 
Aerial parts of Scutellaria lateriflora reference material, ground to a fine powder, and a 
freeze-dried, powdered commercial sample were extracted with methanol: water and 
their UV spectra were compared.  Qualitative and quantitative analyses of flavonoids 
were based on retention times (RTs) and peak areas (PAs) respectively of flavonoid 
biomarkers; baicalin, baicalein and wogonin. RT of verbascoside was also established. 
5.5.3.4 Extraction of S. lateriflora 
Using a coffee grinder (Braun™) the dried herb (AHP) was ground to a fine powder. 
The powdered plant material was extracted with methanol: water (80: 20 v/v) at a 
solvent/solute ratio of 100: 1 (1g plant material in 100 ml methanol/water).  Maceration 
was augmented by placing in a sonicator twice for 15 minutes.  The extract was filtered 
through Whatman™ filter paper.  The residue on the filter paper was then washed 3 
times through the filter paper with 80% methanol until the extract reached 100 ml.  The 
extract was then filtered through a Spartan® membrane filter (Sigma-Aldrich), pore size 
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0.45µ and then centrifuged for 60 minutes at 6000 r.p.m.  The procedure was repeated 
with the commercial product (Eclectic Institute) with the omission of grinding to a fine 
powder. 
5.5.3.5 HPLC analysis 
Samples were analysed using a Dionex A550 BioLC HPLC apparatus.  Mobile phase = 
linear gradient of 30% - 90% methanol/water (v/v).  A continuous gradient elution was 
used.  Methanol was acidified with 0.007M phosphoric acid, final pH 3.2; water was 
acidified with 1% 0.001M phosphoric acid, final pH 4.5. Injection volume = 20 µl.  
Stationary phase = silica C18 column (Polaris® 5 µ C18-A, 250 x 4.6 mm, Varian Ltd) 
fitted with a pre-column and a 2 µ pre-column filter (Metasaver, Varian/Agilent 
Technologies).  Flow rate = 1 ml/minute.  Optimum flavonoid peak detection was at 
wavelength = 280 nm.  Total run time = 30 minutes.  The column temperature was set at 
25
o
C.  Reference and test samples were prepared fresh daily and injected in triplicate. 
5.5.3.6 HPLC analysis of marker compounds and 
verbascoside 
Retention times (RTs) and calibration curves of the flavonoid reference standards were 
developed in order to determine their presence and concentration in the known 
(identified) S. lateriflora samples and for comparison with the freeze-dried sample 
(Eclectic Institute Inc.).  Retention time of verbascoside was also determined to ensure 
there was no adulteration of the commercial product with germander species.   
From stock solutions of 100 µg/ ml concentration, serial dilutions of (5, 10, 20, 50, 60, 
80, 100) µg/ml were made of the marker flavonoids and (40, 60, 100) µg/ml for 
verbascoside.  Each sample was injected into the column three times and an average 
peak area (PA) was taken.  The average retention time was noted for each reference 
flavonoid and for verbascoside in order to identify the major relevant peaks of S. 
lateriflora and to determine potential adulteration with germander respectively.  The 
calibration curves also enabled dry weight (mg/g) calculation of the concentration of 
major flavonoids for each of the identified S. lateriflora samples analysed by HPLC. 
5.5.3.7 HPLC analysis of plant materials 
The supernatant of the MeOH/H2O extracted S. lateriflora reference material (AHP) 
was used for obtaining a ‘fingerprint’ of the herb for comparison with the commercial 
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product.  Quantification of flavonoids was based on peak areas of the flavonoid 
glycoside baicalin and the aglycones baicalein and wogonin, all considered to be 
important flavonoid biomarkers in S. lateriflora (Gao et al. 2008), which were used as 
working flavonoid reference standards.  
5.5.4 Results 
HPLC analysis of the commercial sample showed reproducible RTs of baicalin (RT= 
14.8 min; mean ± SD = 11.71 ± 1.16 mg/g); baicalein (RT= 20.4 min; 7.67 ± 0.89 
mg/g); wogonin (RT= 23.7 min; 0.18 ± 0.01 mg/g).  The commercial sample appeared 
to be free from adulteration with germander (verbascoside was not detected; RT= 9.1 
minutes) and its phytochemical profile was consistent with that of the S. lateriflora 
reference standard Figure 5.1 (A & B).  
5.5.5 Discussion  
The concentration of baicalin in ethanol extracts of S. lateriflora aerial parts compares 
favorably with the results of other workers.  Awad et al. (2003) found 21.3 mg/g and 
40.7 mg/g in 95% and 50% ethanol respectively in powdered, dried S. lateriflora 
extract; Wills and Stuart (2004) 14-18 mg/g (calculated as 40-50% of a mean 
concentration of 36 mg/g total flavonoids from whole S. lateriflora at 4 different stages 
of growth), extracted  in 80% MeOH; Wohlmuth et al. (2009) found a mean of 1.8 ± 5.5 
mg/g (Wohlmuth et al. 2009) in a total of 27 authenticated samples extracted in 70% 
ethanol (Wohlmuth 2011) including genuine commercial S. lateriflora and herbarium 
specimens (Wohlmuth et al. 2009); Parajuli et al. (2009) found only .0098 mg/g while 
Gao et al. (2008) reported 12.6 mg/ml tincture (drug to ethanol ratio of the original 
commercial tincture was not stated) as the highest amount of baicalin in one of seven 
different products analysed.  As the samples in this latter study were not linked to a 













Figure 5.1  HPLC chromatograms demonstrating consistency between the flavonoid 
profiles of a commercial product (A) and reference material (B) 
 













































































S. lateriflora has been plagued by problems of substitution and adulteration for many 
years and must therefore be rigorously authenticated morphologically (macroscopic and 
microscopic) against a voucher specimen and/or by HPLC or other advanced laboratory 
methods (such as GC-MS, TLC or DNA analysis) before entry onto the market. 
Furthermore, it is important when carrying out a phytochemical analysis study that 
samples are compared with authenticated reference material.  
The above study represents a simple and effective method for assessing the authenticity 
of a sample of the herb and demonstrates the importance, when carrying out a 
phytochemical analysis study, of comparing samples with authenticated reference 
material. The identity and quality of a commercial product of S. lateriflora to be used in 
a clinical study have been verified through the matched patterns of investigated 
flavonoid biomarkers in the reference material and freeze-dried sample. Additionally, 
HPLC chromatograms enabled the quantification of flavonoids (baicalin; baicalein and 
wogonin) in the Eclectic Institute product, which proved to be free from adulterants 
(germander) and/or other skullcap species. The results justify the potential use of the 




Chapter 6. American skullcap 
(Scutellaria lateriflora): a randomised, 
placebo-controlled crossover study of its 
effects on mood in healthy volunteers: 
aims, objectives, materials and methods 
6.1 Introduction 
Findings from a review of the available literature on S. lateriflora, as outlined in 
Chapter 2 (see 2.5, p19) indicate this herb has been used extensively in traditional 
medicine systems for anxiety, stress and related disorders for hundreds of years.  
Furthermore, results of a survey of herbal medicine practitioners on their use of the herb 
(Brock et al. 2010) suggest it is one of the most widely prescribed herbs in western 
materia medica for these conditions (see 3.4.2, p52).  To date, only one clinical study 
(see 2.12.2, p37) has been conducted for the purpose of determining the 
psychopharmacological effects of S. lateriflora (Wolfson & Hoffmann 2003).  The 
study indicated a short-term anxiolytic effect of the herb with minimal reduction in 
energy or cognition.  In addition, chemical studies revealing CNS-active amino acid 
content of S. lateriflora, particularly glutamine (Bergeron et al. 2005) (see 2.12.1.1, 
p31) and melatonin (Murch et al. 1997) (see 2.12.1.4, p36) and in vitro studies 
demonstrating benzodiazepine binding properties (Liao et al. 1998; Hui et al. 2000) (see 
2.12.1.1, p31) and 5HT-7 binding properties (Gafner et al. 2003b) (see 2.12.1.3, p34) 
have also indicated it has anxiolytic  and mood enhancing effects.   
The purpose of the following randomised, double-blind, placebo-controlled crossover 
study was to extend the findings of Wolfson and Hoffmann (2003) (2.12.2) by 
conducting a study of longer duration and to increase the parameters of their study by 
determining its effect on mood factors and stress in addition to anxiety.   
6.2. Ethics approval and trial registration 
The clinical study was approved by the University of Westminster Research Ethics Sub-
Committee (ref: 08/09/21) and registered with the International Standard Randomised 
Controlled Trial Number Register (ISRCTN48078312) and entered onto the UK 
Current Controlled Trials database.  Ethical clearance is essential to protect the rights, 
confidentiality and welfare of study participants (Eckstein 2003). 
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6.3. Aims of the research 
The aim of the research outlined in this chapter was to determine, using a crossover 
design, the effects of S. lateriflora on anxiety, stress and other negative, as well as 
positive, mood states.  With verified self-administered scales of subjective mood and 
anxiety, and salivary cortisol measures of stress, the study assessed and compared any 
changes within and between subjects from baseline in subjective mood, anxiety and 
salivary cortisol levels following administration of skullcap test and placebo control. 
6.4. Objectives of the research 
 To deliver an evidence-based herbal intervention with extracts of American skullcap 
(S. lateriflora) for promotion of wellbeing in a series of tests, using a randomised, 
double blind, placebo-controlled, crossover design with subjective measures of 
mood and anxiety. 
 To measure changes in levels of cortisol in saliva samples as a physiological 
measure of stress, following administration of S. lateriflora extract to a test group, 
alongside a placebo control group.  
 To assess the safety profile of S. lateriflora by comparing liver function tests at 
baseline and following administration of the test herb and placebo. 
6.5. Study hypotheses  
 S. lateriflora will have a superior mood enhancing effect than placebo (when 
compared with baseline measures).  
 S. lateriflora will have a superior anxiolytic effect than placebo (when compared 
with baseline measures). 
 S. lateriflora will attenuate negative mood states without a marked diminution of 
cognition or energy.  
 S. lateriflora will alter cortisol profiles in stressed but otherwise healthy volunteers. 
 S. lateriflora will have no toxic effects on the liver. 
 
6.6 Study design (Figure  6.1) 
The study was based on a simple 2 x 2 crossover design with baseline measurement in 
which each participant was randomised to a sequence of two treatments over two 
periods with a washout period in between treatments.  This is known as an AB/BA 
design.  Participants act as their own controls and there is less variability within subjects 
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than between subjects and fewer participants are required for the study than if it were a 
parallel study (Dallal 2000).  (See 8.9, p189 for disadvantages of crossover studies).  An 
equal number of participants (a group) for each time period receives one treatment 
(either placebo or test) while the other group receives the other treatment.  In this 
research all in Group 1 (n = 22) received placebo in the first period and skullcap in the 
second period, while all in Group 2 (n = 21) received skullcap first followed by placebo.   
 
Following psychometric testing and health screening, eligible participants (see 6.8.1.2 
& 6.8.1.3, pp90-91) were randomly assigned to receive either freeze-dried Scutellaria 
lateriflora (Eclectic Institute) test, or freeze-dried Urtica dioica folia (Eclectic Institute) 
placebo, three times daily for 14 days.  In this research it was judged from empirical 
evidence of the effects of S. lateriflora, both onset and duration (see Chapter 3: 
practitioner survey 3.4.3 & 3.4.6) and evidence from a previous clinical study (Wolfson 
& Hoffmann 2003) that periods of 2 weeks administration would be sufficient for 
determination of treatment effects.  They then had a washout period of 7 days.  As a 
precautionary measure and without data from any previous study to inform the length of 
washout, it was judged that a washout period of a week would minimise potential 
physiological or psychological carry-over effects (see 8.8.1 ‘minimising carry-over’, 
p187) following repeated dosing whilst being short enough to not inconvenience 
participants and also to avoid the possibility of spontaneous resolution of negative mood 
states.  Following washout, participants crossed over to receive the other type of capsule 
for comparison. They took their first saliva samples for two days for baseline cortisol 
measurements, at the end of the first intervention prior to washout and again at the end 
of the second intervention. 
 
Each participant made three visits in all (Figure  6.1).  Psychometric tests (6.10, p96) 
and salivary cortisol measurements to compare changes in mood, anxiety symptoms and 
stress levels were re-administered before the end of the first half just prior to washout 
and at the end of the clinical study.  Blood pressure, pulse and ALT levels (6.9.3 p95) 
were also retaken.  Levels of salivary cortisol were assessed using enzyme-linked 
immunosorbent assay (ELISA) (6.12.2, p108).  
 
Subjective changes in quality of life determined by participant self-completion of a 
mood and physical effects diary were reported mostly qualitatively.  This is the 
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preferred method as in keeping a daily diary participants can note any effects that may 
or may not be as a result of the interventions, with a view to providing new information. 
 
Participants also completed a personality test, the Big 5 Mini-Marker (Saucier 1994b) to 
determine whether or not there is a typical personality trait correlating to reduction in 
anxiety scores on BAI, one of the primary outcome measures (the other is the POMS). 
6.6.1 Randomisation and blinding 
Participants were each randomised to one of two sequences.  These were either S. 
lateriflora followed by placebo or placebo followed by S. lateriflora.  Randomisation 
was drawn from a list of numbers attached to randomly generated assignation of equal 
numbers of skullcap test (T) or placebo (P), which signified which intervention each 
participant was given first.  The list was labelled ‘A’ accordingly.  An opposite list was 
produced and labelled ‘B’.  The randomisation process was carried out by a person 
independent of the study, the clinic manager in the University of Westminster 
Polyclinic, using RANDOM.ORG, a website offering high quality “real” randomization 
processes for researchers.  As capsule codes A and B did not correspond to capsule type 
it was not possible for either the participants or the researcher to know the sequence for 
each participant.  Blinding was carried out by a Polyclinic herbal medicine dispensary 
technician by placing the two different capsules into two sealed envelopes for each 
participant.  Envelopes were labelled with the participant code and capsule codes A and 
B respectively. 
6.7 Main outcome measures 
 Participants were assessed for changes in anxiety levels and mood and salivary 
cortisol measures of stress under double-blind placebo controlled conditions.  
 The primary outcome measures for assessment of effectiveness of Scutellaria 
lateriflora were changes in mean scores from baseline on Beck Anxiety 
Inventory (BAI) (Beck & Steer 1993) and the Profile of Mood States (POMS) 
(Lorr et al. 2005). 
 Secondary outcomes were mean changes from baseline in salivary cortisol 
measurements. 
 Observational outcome measures were changes in ALT levels, blood pressure 




Figure  6.1 Study design 
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6.8 Participants, Materials and Methods  
 
6.8.1 Participants 
The sample group consisted of 43 healthy volunteers; males and females, aged 18-75.  
A power calculation determined this number of participants would provide sufficient 
statistical power to yield valid results (see section 6.13.1, p109). 
6.8.1.1 Recruitment 
A recruitment drive began in May 2010 by placement of 50 advertising posters 
(Appendix IV) divided between 3 University of Westminster sites.  All University of 
Westminster staff and students were also notified of the need for volunteers by email.  
In addition, flyers (Appendix IV) were sent by email to 300 herbal and other 
complementary therapies practitioners in and around London.  Advertisements were 
placed in a national magazine (Appendix V), the University of Westminster Student 
Union website, social networking sites Twitter and Facebook and free advertising site 
Gumtree.  Although not compulsory, recruitment advertising was on the basis of 
experiencing persistent stress, anxiety, mood swings, irritability, poor sleep or difficulty 
in coping. The study inclusion criteria specified that non anxious participants were also 
included. Those expressing interest were sent an information sheet (Appendix VI) with 
a cover letter (Appendix VII).  It was ensured that a period of at least one week had 
elapsed prior to each enquirer volunteering to participate in the study.  There were 400 
enquiries in total; of these, 51 were interviewed and 43 were positively recruited to the 
study; 31 completed.   
Participants were males (n = 9) and females (n = 34); age range 19 - 66 years; mean ± 
SD age 34 ± 13; median age 31.  Of those completing the study (n = 31, males: n = 6; 
females: n = 25) the age range was 20 – 65 years; mean ± SD age was 35 ± 12; median 
age 34.  Twenty eight participants were students at the University of Westminster and 
15 were members of the general public.  Eighteen finishing participants were students at 
the University of Westminster and 13 were members of the general public. 
6.8.1.2  Inclusion criteria and rationale 
 Good general health. It was important to minimise any unnecessary risks to health 
and to ensure there are no endogenous stress chemicals that might affect levels of 
salivary cortisol, as may occur in those with severe or chronic illnesses.  Altered 
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cortisol responses have been detected in patients with chronic disease (Cooper & 
Stewart 2003; Kudielka & Kirschbaum 2003).  It would be difficult to ascertain 
whether levels at baseline are as a result of systemic stress or anxiety-related stress.  
Furthermore, those with severe or chronic illnesses are likely to be taking 
medications, which might interfere with skullcap and vice versa and be a 
confounding factor (See 2.8: Contraindications and drug interactions).  
 Participants were volunteers and had given informed consent. 
 Agree to undergo a finger prick blood test for analysis of liver health. 
 Understanding of written and spoken English. 
 
6.8.1.3 Exclusion criteria and rationale 
 Heavy alcohol (> 4 units daily), tobacco (> 20 cigarettes daily) or recreational drug 
dependence, which may otherwise interfere with salivary cortisol concentrations 
(Kirschbaum & Hellhammer 1994) or have an additive effect or other interaction 
with the test intervention.  Heavy alcohol intake increases cortisol concentrations, 
both during intoxication and withdrawal (Adinoff et al. 2003). 
 Known hypersensitivity to any herbal medicines (when taken orally). 
 Current use or use within the past month of medication affecting the CNS.  
 A history of (diagnosed) severe, psychiatric disorders.  Those with current mild 
depression were not excluded.  If there is a severe psychosis care must be taken with 
regard to the potential adverse reaction such individuals may have to skullcap.   
 Liver disease, kidney disease, cancer, endocrine disorders, severe (>150/90 mm/ 
Hg) or malignant hypertension or any other serious medical condition that might 
affect cortisol levels or require medication that might interact with S. lateriflora.  
 Moderate-high depression i.e. Hospital Anxiety and Depression Scale scores 9-21 
(Zigmond & Snaith 1983).  Depression may affect the hypothalamic-pituitary-
adrenal (HPA) axis and result in an abnormal cortisol response profile (Polk et al. 
2005).  Clinically depressed individuals have a flattened diurnal profile and 
consistently high levels of plasma cortisol (Weber et al. 2000).  Furthermore, results 
of a survey of herbal medicine practitioners (Brock et al. 2010) indicated S. 
lateriflora may exacerbate depression.  It is known that benzodiazepines worsen 
symptoms of severe depression (Vanin 2008) so, considering S. lateriflora has 
benzodiazepine receptor binding affinity in vitro (Liao et al. 1998; Hui et al. 2000), 
caution must be exercised in case it has actions similar to benzodiazepines. 
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 Initial scores of above 40 in the Beck Anxiety Inventory.  As this indicates very 
severe anxiety (Beck & Steer 1993) there is a responsibility to be aware of referral 
cases. 
 Those currently on, or with a recent history of using synthetic glucocorticoid 
hormones, including sprays or topical corticosteroid analogues.  Exogenous 
corticosteroids appear to inhibit their endogenous secretion (Masharani et al. 2005). 
 Those taking herbs or certain supplements as some may have either a direct or 
indirect effect on the HPA axis (e.g. dopaminergic, serotonergic, GABA-ergic) or 
interact with S. lateriflora. 
 Pregnancy or lactation.  S. lateriflora’s effects on the unborn or babies is unknown. 
 Those under 18 or over 75 as this raises further ethical considerations. 
 Refusal to undergo blood tests. 
 ALT level at 25OC > 22 U/L (men); > 17 U/ L women (Roche 2008). 
 Those who do not understand the spoken and written English language.  Not only 
are some questions of a sensitive nature but responses to psychometric 
questionnaires should be spontaneous.   
 Participation in another clinical study with oral intervention within the past 30 days. 
 
6.9 Materials 
6.9.1 The test and placebo interventions 
Organic freeze-dried American skullcap (Scutellaria lateriflora) (Eclectic Institute 
Inc.) in 350 mg capsules is the test herb.  A freeze-dried preparation (Eclectic Institute 
Inc.) was selected as freeze-drying at low temperatures (-18
o
C) is superior to air drying 
methods at preserving plant phytochemistry, particularly the phenolic content, because 
it is faster at removing water content, which could otherwise allow for enzymatic 
degradation and oxidation (Eclectic Institute Inc. 2003; Maisuthisakul & 
Pongsawatmanit 2004; Luthria 2006), and has superior storage time (Gafner & 
Bergeron 2005) (see 5.3.3, p77). The 350 mg capsules (Eclectic Institute Inc.) were 
found to be effective (Wolfson & Hoffmann 2003) and can deliver controlled doses, 
recommended at 1-3 capsules daily (Eclectic Institute Inc.).  
 
Freeze-dried stinging nettle leaf (Urtica dioica folia) capsules (300 mg) is the placebo 
of choice as it has no known effects on the CNS, is identical in appearance (a fine, 
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green powder in a clear capsule) and is similar in taste and smell to the skullcap 
capsules. Furthermore, capsules are better for participant adherence than tinctures or 
teas and their contents are less likely to be recognisable by appearance, taste or smell.  
The S. lateriflora used for the clinical study was proved by HPLC analysis (Chapter 5) 
to be the true herb and of suitable quality for the study. 
 
NB: Lyophilisation is carried out by immediately freezing freshly harvested plants, 
which have been washed in spring water, at low temperature e.g. -18
o
C.  They then 
undergo sublimation, a process whereby the frozen water is vaporised under vacuum.  
The vaporised water is passed through condenser plates, a process which converts the 
water vapour back to a solid and removes it from the vacuum chamber.  Only the dried 
plant material remains and the separation process is complete.  Any remaining moisture 
is removed (around 5%) by gentle heat.  Active constituents remain, including 
flavonoids, enzymes, oils and fatty acids.  The colour, smell and taste of the plant 
material are not affected and it has a long shelf life (Eclectic Institute Inc. 2003; Luthria 
2006).   
6.9.2 Saliva sampling materials 
Serum cortisol is approximately 90 – 95% bound to cortisol binding globulin 
(transcortin).  Bound cortisol is physiologically inactive whereas salivary cortisol is 
mainly the free, active form (Adinoff et al. 2003).  Measurement of free, unbound 
cortisol levels can provide an insight into the physiological activity of this 
glucocorticoid hormone.  As an alternative to analysis of blood-borne free cortisol, 
collection and measurement of unbound salivary cortisol is a viable, non-invasive and 
stress-free method, which accurately reflects serum or plasma levels of unbound 
cortisol. Urinary cortisol on the other hand does not always correctly reflect the free 
cortisol concentration in serum as it relies upon accurate 24 hour urine collection 
(Aardal & Holm 1995). Chewing on a cotton wool or synthetic swab (Figure 6.3) 
collects a sample volume 0.5-2 ml within 30-60 seconds. Samples may be stored at 
20
o
C for up to 4 weeks, but preferably frozen (Kirschbaum & Hellhammer 1994). 
 
All materials for saliva sampling and analysis were obtained from Salimetrics™ Europe 
Ltd., including storage tubes (Figure 6.2), oral swabs (Figure 6.3), boxes for storage and 
freezing (Figure 6.5), and ELISA kits (Figure 6.6).  Storage tubes consist of an inert 
polymer oral swab (10 mm x 30 mm) for saliva collection, a small inner tube for swab 
94 
 
storage and a larger outer centrifuge tube (17 mm x 100 mm) with a snap cap (Figure 
6.4).  ELISA kits contain 96 well microtitre plates, cortisol standards, cortisol controls 
(high and low), phosphate wash buffer, assay diluent, cortisol enzyme conjugate, 
3,3′,5,5′-tetramethylbenzidine (TMB) substrate solution, stop solution (containing 
sulphuric acid) and non-specific binding wells (see 6.12 Salivary cortisol assay for 
details).  Software used for data analysis of salivary cortisol was Gen5™ from Biotek®. 
 
 
Figure 6.2  Salimetrics™ swab storage tubes 
Image used with permission from www.salimetrics.com 
 
 
Figure 6.3  Salimetrics™ oral swabs 
Image used with permission from www.salimetrics.com 
 
 
Figure 6.4  Diagrammatic representations of Salimetrics™ storage tube construction 






Figure 6.5  Salimetrics™ freezer storage box 
Image used with permission from www.salimetrics.com 
 
 
Figure 6.6  Salimetrics™ salivary cortisol kit 
Image used with permission from www.salimetrics.com 
 
6.9.3 Reflotron® blood analysis 
The Reflotron® Plus (Roche) system (Figure 6.7), originally obtained from Una Health 
Ltd, Stoke-on-Trent, UK, was available for use in the University of Westminster 
Polyclinic.  Working on the principle of reflectance photometry it allows the 
quantification of 17 single parameters in whole blood using test strips (Hamer 2010).  A 
study (James & Price 1987) that compared the Reflotron (dry chemistry) analytical 
method with conventional laboratory methods found results agreed favourably.  
Reflotron ALT (GPT) test strips, glass capillary tubes (30 µ) and applicator for holding 
capillary tubes and blood dispensing were sourced from Una Health Ltd.   Accu-Chek 
sterile lancets and an Accu-Chek Softclix-Pro pen for holding them were sourced from 






Figure 6.7  The Reflotron® Plus blood analyser 
Used with permission from http://www.unahealth.co.uk 
6.10 Questionnaires 
Initially, a variety of validated anxiety instruments were evaluated from the literature to 
determine the most appropriate to use in this study (Table 6-1, p98).  Cronbach’s alpha 
coefficient ratings and main findings from validity assessments were compared and the 
advantages and disadvantages for each in relation to the proposed research were 
weighted (Table 6-1).  Instruments to differentiate anxiety from depression for 
screening purposes (in order to exclude depressed individuals) and to measure anxiety 
almost exclusively, including somatic symptoms, were desirable for this research in 
order to determine anxiolytic effects of S. lateriflora.   
Following the choice of Beck Anxiety Inventory (BAI) (Beck & Steer 1993) for a 
primary outcome measure of anxiety as a mood state and the Hospital Anxiety and 
Depression scale (HADS) (Zigmond & Snaith 1983) for screening, a pilot study on the 
use of these instruments was conducted on 12 volunteers with self-reported anxiety.  
The purpose was to determine the ease of use of the HADS and BAI and to assess the 
correlation between the two questionnaires with regard to anxiety scores - and also to 
assess their construct validity in those will self-reported anxiety.  The scores indicated a 
high correlation between the questionnaires and confirmed reported levels of anxiety. 
6.10.1 The Hospital Anxiety and Depression Scale (HADS)  
The HADS (Appendix VIII) is a 14 item scale questionnaire that differentiates between 
anxiety (A) and depression (D).  HADS-A and HADS-D are weighted equally in the 
questionnaire.  Each statement has a choice of 4 responses, scoring 0-3. The maximum 
score for anxiety or depression is 21 points.  A score of 8 for either reflects moderate 
anxiety or depression respectively, while a score of 11-21 indicates severe anxiety or 
depression (Zigmond & Snaith 1983).  Cronbach’s alpha for HADS-A and HADS-D are 
0.78 – 93 for HADS-A and 0.82 – 0.90 for HADS-D (Mykletun et al. 2001).  Two 
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month test-retest reliability for the whole scale was reported by Bjelland et al. (2002) to 
be 0.78.  Administration takes approximately 5 minutes. 
The instrument does not measure somatic symptoms of anxiety (Mykletun et al. 2001) 
so it was decided to use Beck Anxiety Inventory as an additional anxiety test measuring 
somatic symptoms  (Beck et al. 1988) for the intervention outcome.   
6.10.1 The Beck Anxiety Inventory (BAI)  
The BAI (Beck et al. 1988; Beck & Steer 1993) (Appendix IX) measures the severity of 
self-reported anxiety.  The questions are designed to measure general anxiety 
symptoms, including somatic, not to discriminate between pathological states such as 
phobias or panic disorders.  It excludes symptoms that overlap with depression so is 
specific for anxiety (Beck & Steer 1993; McDowell 2006) and was constructed for the 
purpose of minimally sharing depression symptoms as measured by the Beck 
Depression Inventory (Beck & Steer 1987). The 21-item BAI scale lists statements of 
anxiety symptoms and each response is rated on a 4-point scale: “Not at all” (0); 
“Mildly; it did not bother me much” (1); “Moderately; it was very unpleasant, but I 
could stand it” (2); and “Severely; I could barely stand it” (3) (Beck & Steer 1993).  The 
maximum score is 63 points. Below 8 = “Minimum anxiety”; 8 -15 = “Mild anxiety”; 
16 – 25 = “Moderate anxiety”; 26 – 63 = “Severe anxiety”.  The BAI has a high internal 
consistency (correlations between different items on the test), average Cronbach’s alpha 
.92, and a high external validity (can be held true for different cases, types of people) 
and high test-retest reliability (.75) (Beck & Steer 1993).  Administration takes around 5 
minutes. 
6.10.2 Profile of Mood States (POMS) 
The POMS (McNair et al. 1971; Lorr et al. 2005) standard questionnaire is regarded to 
be appropriate for monitoring responses to therapeutic interventions (Lorr et al. 2005), 
not only for psychiatric patients but for normal adults, college students and geriatrics. 
Controlled outpatient drug trials have demonstrated its construct validity (measures 
accurately what it is designed to measure) and predictive validity (scores are sensitive to 
change following intervention).  Internal consistency for items within each factor is high 
(.87 - .95) and 3 week retest reliability is between .66 and .74 (Lorr et al. 2005). 
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A) Differentiates between anxiety and 
depression. D) Physical symptoms of 
anxiety are not addressed. 





and the Anxiety 
Status Inventory 
(Zung 1974) 
Clinical assessment of 
anxiety as a psychiatric 
disorder.  Not intended to 




20 Clinical interview 
or self rating 
 
* * 
None found N/A A) Assesses anxiety severity 
specifically. D) Includes mainly physical 
symptoms and very few ‘feelings’. D) 
Appears to concentrate on severe 





& Steer 1993) 
Measures severity of self-
reported anxiety.  Survey 
or clinical screening 
(McDowell 2006). 
Discriminates between 
anxious and non-anxious 
groups (Pearson 2008). 
Past 
week 
21 Self-reporting or 




* * * 
(Wetherell et al. 
1997) 
‘High internal 
consistency and no 
significant differences by 
sex or race, suggesting 
that it is appropriate to 
use with diverse 
populations’ 
A) Excludes depression questioning so 
avoids depression as a confounding 
factor. Measures general anxiety 
symptoms, not pathological states such 
as phobias or panic disorders or social 
anxiety (McDowell 2006) 
 






Used to distinguish 
between anxiety and 
depression. Survey, clinical 
(McDowell 2006) 





* * * 
(Nieuwenhuijsen 
et al. 2003) 
High internal validity with 
high Cronbach-alpha. 
Useful for distinguishing 
between anxiety and 
depression. 
A) Useful for assessing changes over 
time following therapeutic intervention. 
D) One third loaded towards 








state (acute) and trait 
anxiety (chronic).  
Research, screening 
(McDowell 2006) 
 40 Self- administered  






A) Can be used for general population. 
Good for stressful testing conditions. 
Widely used for measures of anxiety D) 
Correlated highly with Beck depression 
scale (McDowell 2006) 
 
* * * 
Cronbach-alpha as reported by McDowell (2006) > 60 *; 60-80**; 80-90 * * *. Rating: * low; * * * high.   
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Since its introduction in 1971 the POMS has been widely used in various research 
settings, for example cancer studies e.g. (Cella et al. 1987; Blesch et al. 1991; Baker et 
al. 2002; Landsbergen et al. 2012), nicotine research e.g. (Hughes et al. 1984; Levin et 
al. 1996; Benowitz et al. 2012) , exercise and fitness and sports studies e.g. (Berlin et 
al. 2006; Chtourou et al. 2012; Kumae et al. 2012) and memory and cognition research 
e.g. (Elixhauser et al. 1999; Samuels et al. 2008; Lopez et al. 2012).  Between 1995 and 
2005 it was cited in at least 1,000 reports in 400 journals by a minimum of 3,800 
authors (Lorr et al. 2005).  Electronic searches on Google Scholar and PubMed revealed 
that from the time of its introduction up to February 2012 author citations amounted to 
6,000 with a tally of 16,400 articles. 
 
For the present study the instrument was selected not only for its popularity and 
reliability but also because it can measure multiple mood states concurrently.  
Furthermore, it has been found to be sensitive to changes in mood following 
administration of mild benzodiazepines (Lorr et al. 2005).  During early development of 
the instrument, in a double-blind placebo-controlled study of psychiatric outpatients, 
following 4 x 10 mg daily chlordiazepoxide (Librium) over five weeks there were 
significant reductions in Tension-Anxiety and an increase in Vigour-Activity compared 
to placebo and no treatment groups (p = 0.05) at one week and five weeks (Lorr et al. 
1963).  Considering that phytochemicals found in S. lateriflora bind to benzodiazepine 
receptors in vitro (Liao et al. 1998; Hui et al. 2002) these early findings are relevant to 
the present study. 
 
 On the Standard POMS (Lorr et al. 2005) there are six mood factors: Tension-Anxiety 
(T-A); Depression-Dejection (D-D); Anger-Hostility (A-H); Vigour-Activity (V-A); 
Fatigue-Inertia (F-I); and Confusion-Bewilderment (C-B).  There are 65 items 
consisting of words or statements and for each, participants circle the score that best 
describes how they are feeling right now, previously, in the past week including today 
or a time-scale of the assessors choice. For each item there are two alternative 
descriptions, which are offered by the assessor should the respondent not understand the 
meaning of the given item.  “Grouchy” for example has the alternatives “Crabby” or 
“Grumpy” (Lorr et al. 2005). “The past week, including today” was chosen for this 
study because it is long enough to assess participants’ persistent mood and short 
enough, taking potential idiosyncratic latency into consideration, to determine the 
effects of the intervention over a period of time (2 weeks) consistent with the study.  
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6.10.1.1 Scoring the POMS 
Scores are as follows: “Not at all” (0); “A little” (1); “Moderately” (2); “Quite a bit” (3); 
“Extremely” (4).  Administration: about 10 minutes (Lorr et al. 2005). 
 
Scores for each of the six mood factors, T-A, D-D, A-H, V-A, F-I and C-B are summed 
and totalled at the end of their respective columns.  For total mood disturbance (TMD) 
the factor scores are summed together with V-A being negatively weighted because it 
suggests a mood of high energy and friendliness and represents a positive mood factor 
and is negatively related to the other factors.  The TMD scores are considered highly 
reliable in clinical studies where an overall affective state is required (Lorr et al. 2005). 
 
It was expected that participants would score low on depression-dejection as moderately 
and severely depressed people were excluded from the study by HAM-D (Zigmond & 
Snaith 1983).  Also, it is possible there may be gender differences in scores for some 
factors.  For example, in a healthy, (non-psychiatric) sample women may score higher 
on fatigue than men (Lorr et al. 2005).  The main outcomes hoped for were: 
 Tension-anxiety – reduction 
 Depression-dejection - reduction 
 Anger-hostility – reduction 
 Vigour activity – increase or stable 
 Confusion bewilderment – decrease or stable (effects of skullcap on cognition) 
 Fatigue inertia – decrease or stable 
 
6.10.2 Big 5 Mini-Marker  
Following decades of research and use of a variety of personality tests without a 
common framework and which, for example, might have used anything between 2 and 
20 main characteristics, the field of personality research appears to have reached a 
general consensus of the “Big Five” factor structure being the accepted dimensions 
(John et al. 2008).  In other words, five personality traits are widely accepted as being a 
common framework, integrating multiple dimensions.  These dimensions were derived 
from the terminology used by people to describe themselves and others (John et al. 
2008) and a search for additional factors has demonstrated the Big 5 to be the only 




The Big 5 structure is now widely accepted as providing a representation of personality 
traits that are generalisable across different languages, cultures and population samples 
using variable testing methods (John et al. 2008). 
 
The Big 5 factor structure was first developed as an assessment tool by Tupes and 
Christal (1961), who termed the factor classifications as I: Surgency, II: Agreeableness, 
III: Dependability, IV: Emotional Stability and V: Culture it was further developed by 
Goldberg (1992), who simplified it by replacing sentences with adjectives; 100 unipolar  
adjectives divided into 20 for each dimension on the scale. 
 
The Big 5 Mini-Marker (Appendix X), a shortened and simplified form of Goldberg’s 
test (Goldberg 1992) was developed by Saucier (1994b) and was  used in this research 
as it is simple to administer, easier to understand than Goldberg’s model (adjectives 
such as ‘imperturbable’ have been removed) and has been shown (Saucier 1994b) to 
correlate highly (0.91 – 0.96) to the 100 adjective model and to be reliable.  Cronbach’s 
alphas were 0.86, 0.82, 0.84, 0.78 and 0.78 for each factor respectively (Mooradian & 
Nezlek 1996). This bipolar model uses 40 adjectives divided into equal numbers of 
‘desirable and undesirable attributes’ in sets of 8 for each personality dimension, which 
are termed Factors I: Extraversion, II: Agreeableness, III: Conscientiousness, IV: 
Emotional Stability and V: Intellect or Openness.  Of each set of 8 adjectives, 4 items 
each mark the positive and negative poles of each of factors I, II and III.  For Factor IV 
(Emotional Stability) there are 2 positive and 6 negative pole items and for Factor V 
(Intellect or Openness) there are 6 positive and 2 negative pole items (Saucier 1994b).  
6.10.2.1 Mini-Marker procedure and scoring 
Participants self-assessed their personalities whilst in the University of Westminster 
Polyclinic, during their first testing session, following the written instructions on the 
instrument (Saucier 1994a): “Describe yourself as you see yourself at the present time, 
not as you wish to be in the future. Describe yourself as you are generally or typically, 
as compared with other persons you know of the same sex and of roughly your same 
age. Before each trait, please write a number indicating how accurately that trait 
describes you, using the following rating scale”(Saucier 1994a). 
 
Scores were from 1-9 and participants entered the relevant number next to each 
adjective.  These were then transferred to an Excel grid (Appendix XI), which had been 
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constructed by this author for ease of interpretation of results, using reverse-scoring to 
reflect values for negatively loaded items (e.g. a score of 8 becomes 2 and a score of 2 
becomes 8).  The scores were then totalled for each factor and then each factor total was 
divided by 8 (the number of items in each factor) to obtain the mean value (Saucier 
1994a). 
 
A regression analysis was carried out to determine whether or not there is a predominant 
personality trait responding to S. lateriflora, putatively demonstrable with a correlating 
reduction in anxiety scores on BAI (Beck & Steer 1993). 
6.10.3 Participant diary  
Participants were provided with a symptom diary (Appendix XV) in which they were 
requested to list any physical or mental symptoms they experienced during the study, 
whether new or old, both negative and positive, including the disappearance of old 
symptoms.  They were also asked to write on a separate piece of paper if necessary and 
to report anything unusual they felt about their experiences whilst taking part in the 
study should they wish to do so.  They were asked to show the assessor their diaries at 
follow-up and to hand it in at the end of their participation.  In addition to qualitative 
reporting from participant statements, symptoms were grouped into categories and 
graphically illustrated. 
6.10.3.1 Adverse effects reporting 
The purpose of the diary was to provide potentially new information about the effects of 
S. lateriflora, in particular to determine: whether there are any unforeseen side-effects 
of the herb; any useful effects such as alleviation of chronic symptoms (which may or 
may not be anxiety-related); and to monitor for serious adverse reactions, which, 
although unexpected, it cannot be ruled out with any intervention that someone may 
have an idiosyncratic reaction to it.  S. lateriflora herb and the placebo Urtica dioica 
herb are both in Schedule 1 of the General Sales List (Medicines Control Agency 1984), 
which states:  
 
‘There are hereby specified classes of medicinal products which in the opinion of the 
Ministers can with reasonable safety be sold or supplied otherwise than by or under the 
supervision of a pharmacist, namely, medicinal products which are not prescription 




An electronic literature search did not reveal any reports of human toxicity or serious 
side-effects directly attributable to S. lateriflora and U. dioica is widely sold in 
supermarkets as a popular beverage.  Participants were, however, asked to contact their 
doctor immediately should they suspect a serious reaction related to either of the 
interventions and to report to the investigator also.  If such adverse reactions should 
occur the participant would be withdrawn from the study immediately. 
 
6.11 Study procedure and rationale 
 
6.11.1 General – the interview 
The contents of the information sheet (Appendix VI) were reiterated to volunteers, who 
were then asked if they had any questions.  It was made clear to volunteers that they had 
a right to refuse to participate, inclusive of a right to not respond to any questions and a 
right to withdraw at any time.  After signing a consent form (Appendix XII) they were 
screened for eligibility with a health and drug questionnaire (Appendix XIII) and the 
Hospital Anxiety and Depression Scale (Appendix VIII).  Those with moderate-high 
depression (scores > 8) were excluded.  They self-administered Beck Anxiety Inventory 
(Beck & Steer 1993) (Appendix IX) as the next step in the screening process and those 
with scores > 40 were excluded.  Exclusion was based on the premise that it was 
important to be aware of clinical cases of anxiety and depression with potential 
comorbid mood disorders with a propensity to suicide (Beck & Steer 1993) and to refer 
immediately to their general practitioner (G. P.) in the first instant for treatment if 
necessary.  Scores to specifically reflect clinical cases have not been assessed (Beck & 
Steer 1993) but it was judged that a score below median of the severe anxiety category 
(26-63) would be the cut-off point for exclusion.  It was, however, important for the 
interviewer to use judgement from experience of treating anxious patients, which was 
based on obvious signs of distress and/or very low mood.  
 
Volunteers then underwent blood pressure and ALT level measurements.  For health 
and drug exclusions, see 6.8.1.3, p91: Exclusion criteria and rationale.  Exclusion 
criteria were maintained throughout the study as participants’ blood pressure and ALT 
levels were monitored at each subsequent visit.  Predominantly somatic symptoms on 
BAI were also compared and assessed within subjects at each visit in case of previously 




Eligible volunteers then became participants and BAI scores used in the screening 
process were counted as baseline measurements.  They then self-administered the 
Profile of Mood States (standard) questionnaire (Lorr et al. 2005).  For each 
psychometric questionnaire, participants were asked how they had been feeling in the 
past week, including today.  They also self-administered the Big 5 Mini-Marker 
personality test (Saucier 1994b). 
 
 The whole procedure lasted about an hour.  On occasion it took a while longer if 
particularly anxious participants volunteered to discuss the nature of their anxiety and/or 
stress.  Medical history questioning and psychometric testing may potentially cause 
some distress to volunteers as they are asked sensitive questions about their mood, 
anxiety, feeling state, sleeping habits, medication (including contraception), pregnancy, 
lactation, alcohol intake, cigarette smoking and recreational drug use.  Confidentiality 
and participant welfare was maintained at all times during each participant visit.  This 
interviewer is an experienced practitioner of herbal medicine who sees anxious patients 
on a frequent basis and is therefore used to dealing with them in a sensitive and 
empathetic manner.  The interview room was warm, quiet and well illuminated to 
ensure optimum relaxation and concentration. 
 
Following their first interview and assessments, participants were issued with 
instruction sheets (Appendix XIV) outlining how to take their capsules, collect and store 
saliva samples, fill in the saliva sample recording sheets and participant diary and how 
to contact this researcher; a participant diary (Appendix XV); saliva sample recording 
sheets (Appendix XVI); saliva collection tubes, which were labelled according to the 
day of study and hours following waking; saliva collection swabs (in the tubes); and 
their first coded capsules.  For the majority of participants the first day of the study was 
to be the day following baseline testing (one participant wished to avoid starting at the 
weekend).  To help maximise adherence the interviewer filled in all dates on the diary 
and saliva sample recording sheets during the participants’ first visit to the Polyclinic. 
 
For avoidance of potential herb-drug interactions study participants were advised not to 
take any medications, including herbal or grapefruit juice, whilst participating in the 
study.  Grapefruit juice is known to inhibit the drug metabolising enzyme CYP34A 
(Vanin 2008). (See 2.8, p27: ‘Contraindications and drug interactions’).  On the day of 
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the first testing session and with the consent of each participant, a letter was sent to their 
G. P. informing them of their patient’s participation in the study (Appendix XVII).  This 
was considered necessary to guarantee the physical and mental health of each volunteer.  
A participant information sheet (Appendix VI) was enclosed with the letter.  In addition, 
participants were requested to fill in a data sheet (Appendix XVIII) to provide personal 
details, including contact details for their G.P.  This was also useful for some 
demographic information.  For reasons of confidentiality any personal information was 
stored separately from the study data. 
6.11.2 Blood pressure and pulse monitoring 
Volunteers’ blood pressure and radial pulse were taken to exclude those with severe 
hypertension at screening and to monitor potential changes in either as a result of the 
interventions during the study.  To avoid false high readings it was ensured that 
participants were suitably rested prior to blood pressure and pulse measurements by 
waiting until towards the end of the visit.  At each visit, for all participants, the same 
upper arm (right) was used for blood pressure measurements, using the same digital 
blood pressure monitor, and the right radial artery was used for pulse measurement each 
time for consistency.  Time-matched results (for each of the three time points) mean 
(SD) systolic and diastolic blood pressures and pulse in beats per minute (BPM) were 
recorded to see if there were any notable changes from baseline.  There is very little 
recorded evidence of S. lateriflora being useful for hypertension although Joshee et al. 
(2002) state it is traditionally used for this purpose in cases of ‘excessive heat’.  A 
recent publication, however, of a 22 year longitudinal study appears to dispel previous 
hypotheses that anxiety and stress raises blood pressure (Hildrum et al. 2011).   
6.11.3 Liver health monitoring 
To exclude those with current liver disease and to confirm the safety profile of S. 
lateriflora participants also underwent a finger-prick blood test for alanine 
aminotransferase (ALT), a transaminase enzyme found primarily in the liver (Kaplan 
2002), before testing began and again at the period end of taking both test and placebo 
herbs.  According to Pratt and Kaplan (2000) Scutellaria (species not given) is reported 
to cause elevation of liver enzyme levels - although no citation was provided.  It has not 
been revealed in the literature that there has been any hepatotoxicity related to 




ALT, which catalyses the transfer of an amino group from alanine to form glutamate 
and pyruvate, is also known as glutamate pyruvate–transaminase (GPT).  Although AST 
(aspartate aminotransferase) may indicate liver damage and both enzymes are found in 
many other organs, high levels of blood ALT (at 25
o
C > 22 U/L men; > 17 U/ L women 
(Roche 2008) are more likely to relate exclusively to liver damage as the greater 
quantities are in the liver (Kaplan 2002).  These levels relate to a 30 µ volume of blood. 
Quantities slightly above and less than twice the normal value are unlikely to be 
significant in an asymptomatic subject, however.  The test should be repeated for 
confirmation and the degree and possible reasons for the elevation should be evaluated.  
Recent alcohol consumption for example may give a higher reading (Pratt & Kaplan 
2000).  Elevation of ALT fifteen times the normal upper reference would undicate 
serious liver disease such as  cirrhosis, hepatitis or liver tumour (Hamer 2010). 
 
A drop of blood, extracted by pricking the finger with a sterile lancet, is collected on a 
Reflotron (magnetic) strip, which is placed in the chamber of a Reflotron® blood 
analyser (Figure 6.7, p96) for measurement of ALT liver enzymes.  Firstly, the depth of 
puncture was set on the lancet pen.  In order to avoid unnecessary pain the shallowest 
setting was used initially.  Participants were asked whether they had a finger preference 
and the digit pad was wiped with alcohol and dried with a sterile cotton swab.  The hand 
was rubbed to ensure warmth and an adequate blood flow and the lancet puncture was 
made 1-2 mm from the nail bed.  The first drop of blood was wiped away with a cotton 
wool swab and the finger was squeezed until a bead of blood appeared.  This was 
allowed to flow up a 30 µ capillary tube placed into an applicator until it reached an 
exact level (marked by a black line) and the blood was expelled onto the gauze of the 
ALT strip by pushing a button on the applicator.  After placing the strip in the chamber 
of the machine results were ready within 2 minutes. 
 
Results for all measured parameters were recorded on a data sheet individual to each 
participant (Appendix XIX). 
6.11.4 Saliva sampling 
Cortisol is released throughout the day in a pulsatile manner and secretion and 
inhibition is controlled by a negative feedback mechanism, believed to be responsible 
for its circadian rhythm and secretion amplitude.  Stress increases the activity of the 
hypothalamus-pituitary-adrenal (HPA) axis, with stimulation of corticotrophin-releasing 
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factor (CRF) and adrenocorticotrophic hormone (ACTH) and hence plasma cortisol 
levels (Kirschbaum & Hellhammer 1989). 
Participants were each provided with 24 tubes for saliva collection.  To reflect diurnal 
sensitivity of the HPA axis to stressors and concomitant changes in cortisol amplitude 
samples were taken at 3, 6, 9 and 12 hours following waking (Pruessner et al. 1997).  
Due to normal intra-individual variations in HPA activity samples were taken on two 
consecutive days (Kirschbaum & Hellhammer 1989) and an average nmol/L was taken 
for each time point for the two days.  Of 31 participants, 5 did not produce samples.  
One forgot to freeze them and they decayed, one forgot to take samples, one did not 
return them, one was excluded from this part of the study as he was using inhaled 
steroids and one declined due to travelling with no access to refrigeration.  
 
Participants (n = 26; 21 females, 5 males) were asked to take their first samples the 
following two days and to commence the capsules on day 3 for 14 days, collecting 
saliva samples for the last 2 days of capsules prior to a one week washout period.  
Saliva was collected again after crossover on the last two days of taking the other type 
of capsules.   
 
To avoid sample contamination, participants were requested to avoid food or drink, 
other than water, not to smoke, brush their teeth or take vigorous exercise for at least 30 
minutes prior to sampling; and to rinse their mouth with water about 10 minutes before 
sampling (Pruessner et al. 1997).  Brushing teeth may cause contamination with blood, 
although evidence that this can falsely elevate levels of cortisol in saliva is inconclusive. 
Studies (Kivlighan et al. 2004; Schwartz & Granger 2004; Granger et al. 2007) found 
the effects of mild to moderate blood leakage from minor oral micro-injury on salivary 
cortisol levels to be minimal.  The presence of relatively large amounts of blood in a 
saliva sample, however, may significantly raise salivary cortisol levels.  For example, 
10% of blood present in a sample has been demonstrated to increase levels by 37% 
(Schwartz & Granger 2004).  Exercise may have a positive effect on mood states, 
believed to be due to increased endorphin levels (Daniel et al. 1992).  Participants were 
asked to place the swab under the tongue for saliva collection as the submandibular 
glands are more likely than the parotids to secrete saliva containing quantities of cortisol 




Due to the number of samples that would be necessary, for reasons of compliance and 
as the awakening cortisol response (ACR) is relatively stable, this was not assessed in 
the healthy volunteers.  As the ACR peaks at around 30 minutes and then rapidly 
declines (Kudielka et al. 2003), a number of samples would be taken to capture the 
response before a decline occurred; for example at 0, 15, 30, 45 and 60 min (Schulz et 
al. 1998).  
 
6.12 Salivary cortisol assay 
6.12.1 Legal aspects 
On completion of saliva sampling participants returned their samples at their 
convenience.  The samples were then placed into labelled freezer storage boxes (Figure 
6.5) and stored at – 18o C.  To comply with the Control of Substances Hazardous to 
Health (COSSH) Regulations 2002 (Health & Safety Commission 2002), a COSSH 
assessment form (Appendix XX) was completed prior to commencement of the 
research.  Any tissue, bodily fluid (e.g. saliva, blood or bile) or waste product (e.g. 
sputum, faeces or urine) derived from a human body and containing human cells is 
classified as ‘relevant material’ (Human Tissue Authority 2006) and is covered by 
Human Tissue Act 2004 (C 30) (Human Tissue Authority 2004), which states that 
consent must be obtained for storage or use of any relevant material for research 
purposes.  Therefore, saliva tracking forms - for inspection by the Human Tissue 
Authority and to comply with The Human Tissue Act 2004 regulations (Human Tissue 
Authority 2006) - were completed, to include samples from each participant with regard 
to dates of appropriate consent, receipt, storage, movement, use for scheduled purposes 
and disposal of specimens. 
6.12.2 ELISA: principle and method 
 
The Salimetrics™ cortisol kit measures salivary cortisol quantitatively in vitro and is 
sensitive to levels of 0.0828 – 82nmol/L in 25 µ volume of saliva per test.  It has been 
validated to accurately reflect circulating free serum cortisol levels (Salimetrics 2008). 
 
All saliva samples are tested in duplicate to minimise error.  They are brought to room 
temperature and centrifuged for 15 minutes (this removes the saliva from the oral 




The cortisol assay works on the principle of a competitive ELISA method.  The 96 plate 
wells are pre-coated with monoclonal antibodies to cortisol (the antigen).  The cortisol 
(the analyte) in the samples of saliva competes for binding sites with cortisol conjugated 
to an enzyme, horseradish peroxidise.  After incubation the plate is washed with a 
phosphate wash buffer to remove unbound analyte and conjugate. Conjugated cortisol-
antibody binding sites turn blue when TMB substrate for the enzyme is applied. 
 
Blue colouration is inversely proportional to the amount of analyte present in the wells 
i.e. the less blue colour there is, the more cortisol there is in the saliva samples.  This is 
because the cortisol in the samples has taken up the binding sites on the antibody 
instead of the enzyme-bound cortisol. 
 
The reaction is stopped with a sulphuric acid solution and the colour changes to yellow.  
The optical density is read with a plate reader at 450 nm within 10 minutes of stopping 
the reaction.  To determine the amount of analyte in the samples a range of known 
concentrations are also analysed on each well plate and a calibration curve is established 
from the results from these standards and controls.  Standards contain cortisol 
concentrations of 82.77, 27.59, 9.19, 3.06, 1.02 and 0.33 nmol/L and the two controls 
represent high (29 ± 7.23 nmol/L) and low (2.9 ± 0.72 nmol/L) concentrations.  Results 
for the unknowns are derived from the calibration curve.  A plate reader attached to 
Gen5™ data analysis software was used.  This software generates a calibration curve 
and the results for each plate of samples, measured in nmol/L.   
6.13 Statistics 
6.13.1 Power calculation and sample size estimation 
This is based on a cut-off point of 40 at baseline on BAI and a projected mean decrease 
of 10 points during skullcap test.  Projected approximate ±SD is derived from Prasko 
(2006).  Given the mean and standard deviation for two independent samples of equal 
size, for a mean (SD) on BAI of 20.0 (5.0) at baseline and a mean of 15.0 (5.0) for the 
skullcap test, the effect size for Student’s t-test (Cohen’s d), is 1.0  Using an effect size 
for Student’s t-test (Cohen’s d), of 1.0 at 80% power to show a difference ±SD at alpha 




For a two-tailed (non-directional) hypothesis 
Minimum total required sample size: 34 
Minimum required sample size per group: 17 
 
For a paired sample t-test (for within subject differences in crossover studies) and an 
effect size of 1.0 the minimum sample size required is 17. 
 
A minimum sample size of 17 was calculated to be necessary to show a clinically 
significant minimum 25% decrease in anxiety levels at power 80% and alpha 5%.  
Considering the test-retest reliability of BAI is estimated to be 0.75 (Beck et al. 1988) it 
was determined that the planned sample size of 30 was likely to show significant results 
for the study.  A total sample size of 40 would allow for a dropout rate of 25%. 
6.13.2 Primary outcome measures 
Changes in scores as defined by the Profile of Mood States (POMS) (McNair et al. 
1971), a 65 item questionnaire that measures fluctuations in mood states in normal 
adults, and Beck Anxiety Inventory (BAI) (Beck & Steer 1993) were used to monitor 
changes in mood.  The POMS has 6 identifiable mood states: tension-anxiety, 
depression-dejection, anger-hostility, vigour-activity, fatigue-inertia and confusion-
bewilderment with a 5 point self-report scale for each item, a mean score of normal as 
indicated by the manual, of an average of 13 per mood state, each assessed individually. 
A statistically significant change is considered to be a mean of around 9 points 
(Derderian et al. 1988).  The Total Mood Disturbance score is calculated by summing 
the scores for each mood factor and subtracting the score for Vigour-Activity (Lorr et 
al. 2005).  This is negatively weighted as it is considered to be a positive mood state and 
the opposite to the other 5 mood factors on the instrument (Daniel et al. 1992). 
 
There are 40 possible scores (range = 0-40, mean = 20) in the minimal to a cut-off 
severe interval on BAI (clinical cases judged to be above this were excluded).  An 
overall response will be reflected by changes in baseline from a mean of 20 points to a 
mean decrease of 25% over time, projected to be a mean of 15 points on BAI.  A drop 
of 10 points for any participant would be clinically significant as such a decrease to a 




Based on previous studies, it was judged that following treatment with S. lateriflora, a 
mean drop in subjective anxiety scores of 10 from baseline is a realistic expectation.  A 
drop of 10 points would be clinically significant as such a decrease could indicate a 
level of mild as opposed to moderate or a change from severe to moderate anxiety.  In a 
previous study of 20 participants (Prasko et al. 2006) a mean reduction (SD) of 8-12 
points (3-5) in subjective anxiety on BAI (Beck & Steer 1993) following moclobemide 
(a monoamine oxidase inhibitor) pharmacotherapy was calculated to be statistically 
significant.  The sharpest decline was within the first month of treatment (8 points).  
Case reports of four patients who were treated for various anxiety disorders with the 
GABA transporter inhibitor tiagabine demonstrated a decrease of 17, 21, 14 and 12 
points respectively on BAI within days or weeks following treatment (Schaller et al. 
2004).   
6.13.3 Secondary outcome measures 
Saliva sampling was repeated over 2 days for each period to allow for normal intra-
individual variation and the mean (SD) of salivary cortisol in nmol/L for each diurnal 
time point following waking over each 2 day period was taken prior to use in the final 
analysis.  The means (SD) for each diurnal time point and overall was compared 
between baseline, test and placebo.  Of 26 participants who completed saliva sampling 
11 missed the occasional sampling time (totalling 20 of a potential 624 samples from all 
26 participants).  Missing variables were computed by means analysis for each time 
point for each period (3 hours, 6 hours, 9 hours and 12 hours for baseline, test and 
placebo) using the Statistical Package for Social Sciences (SPSS). 
 
The toxicity data would only be analysed in depth if it existed.  Similarly blood pressure 
and pulse rate would be analysed in depth only if there are obvious changes.  To 
determine this, the results of these tests were analysed using paired sample Student’s t-
tests followed by analysis of Group effects, using a 2 x 3 mixed ANOVA. 
6.13.4 Statistical analysis 
Differences from baseline between skullcap and placebo across primary and secondary 
measures were investigated using a mixed method 2 x 3 (sequence x treatment) analysis 




A first analysis establishes that there are no baseline shifts or order effects using the 
cross-over design.  If significant baseline shifts or order effects are present, change 
scores are calculated against each participant’s baseline score.  Change score analysis 
was selected in preference to analysis of co-variance (ANCOVA) because when there is 
a true baseline imbalance ANCOVA can produce biased treatment effects in 
observational studies (Metcalfe 2010).   
 
Subsequently, the interaction between group sequence (skullcap-placebo and placebo-
skullcap) and treatment was evaluated by a two-way ANOVA.  To determine whether 
differences in the mean scores (skullcap versus placebo) are statistically significant pair-
wise comparisons between means were carried out using paired sample t-tests.   
 
The relationship between one of the primary outcome variables, measurements from 
Beck Anxiety Inventory, and personality dimensions, was explored using regression 
analysis methods.   
 
For all statistical tests, a 5% significance level was used.  The Statistical Package for 
Social Sciences (SPSS) was used for conducting the analyses. 
 
For the purpose of description and discussion in this study the following terms are 
denoted: 
 
 Group = sequence in which participants received the treatment 
 Treatment = baseline, placebo or skullcap 




Chapter 7. RCT Results 
7.1 Participants and dropouts 
Eligible participants were adults aged over 18 years meeting the criteria of good 
physical and mental health.  Participants were males (n = 9) and females (n = 34); age 
range 19 - 66 years; mean ± SD age 34 ± 13; median age 31.  Of those completing the 
study (n = 31, males: n = 6; females: n = 25) the age range was 20 – 65 years; mean ± 
SD age was 35 ± 12; median age 34. Twenty eight participants were students at the 
University of Westminster and 15 were members of the general public.  Eighteen 
finishing participants were students at the University of Westminster and 13 were 
members of the general public. 
Of 51 screened (see Table 7-1and Figure 7.1) seven potential volunteers were excluded 
because they were did not meet the eligibility criteria: 5 were using prescribed anti-
depressant medication; 1 was on thyroid medication (thyroxin); one was pregnant and 
one was excluded following initial testing due to severe hypertension (> 180/100 
mm/Hg).  The latter was referred to his G. P. for medical investigations. This participant 
was followed up and he informed this author that his hypertension was being treated. 





Screened and evaluated 
 
51 
Did not meet inclusion criteria 
 
7 
Refused study at the beginning 
 
1 
Commenced the study 
 
43 
Dropped out during the study 
 
12 
Adverse effects of medication 
 
0 
Completed the study 
 
31 





Only participants who completed the trial (n = 31) were included in the analysis. 
Because the trial was comparatively small participants were approached to ask if they 
wished to volunteer the reason/s for withdrawal and reasons were recorded.   
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Figure 7.1  Consort trial profile for recruitment, randomisation and dropouts 
  
Assessed for eligibility (n = 51) 
Excluded (n = 8) 
   Not meeting inclusion criteria  
(n = 7) 
   Declined to participate (n = 1) 
   Other reasons (n = 0) 
Analysed (n = 15)  
 
 Excluded from saliva analysis 
(see 7.1 for reasons) (n = 1) 
 
Saliva analysis (n = 14) 
 
Lost to follow-up (n= 7) 
 
Discontinued intervention (see 
Table 7-2 for reasons) (n= 7) 
 
Other reasons (n = 0) 
 
Allocated to first intervention  
(n = 22) 
 
 Received placebo intervention 
= Group 1 
 
Lost to follow-up (n= 5) 
 
Discontinued intervention (see 
Table 7-2 for reasons) (n= 5) 
 
Other reasons (n = 0) 
 
Allocated to first intervention  
(n = 21) 
 
 Received test intervention  
= Group 2 
 
Analysed (n = 16)  
 
 Excluded from saliva analysis 
(see 7.1 for reasons) (n = 4) 
 









There was a 28% dropout rate (n = 12). Withdrawals were for a variety of reasons 
(Table 7-2).  There was no particular order in relation to intervention with the dropout 
rate; 7 left during placebo and 5 left during the test treatment period.  Of the 12 
dropouts, 10 of whom left during the first treatment period, there were two non-adherent 
participants.  One of these stopped after a couple of days because she forgot to take the 
capsules and the other said ‘they were not doing him any good’.  One participant with 
high anxiety levels and one with mild depression decided they wanted to commence 
orthodox treatment for their conditions so were no longer able to take part in the study. 
Of 31 participants completing the study for primary outcome measures (the effects of S. 
lateriflora on mood as measured by BAI and POMS), 5 did not produce saliva samples.  
One forgot to freeze them and they decayed, one forgot to take samples, one did not 
return them, one was excluded from this part of the study as he was occasionally using 
inhaled steroids and one declined due to travelling with no access to refrigeration. 







Reason for dropout (Treatment period) 
 
P.03 P-T Bereavement  (2) 
P.06 P-T Non-adherence (1) 
P.07 P-T DNA for second test session no reason offered (1) 
P.09 T-P Prescribed antidepressants; relationship breakup (1) 
P.12 P-T Time issues (1) 
P.22 T-P DNA for second test session; no reason offered (1) 
P.26 T-P Commenced orthodox anxiolytic medication (1) 
P.27 T-P Illness not related to intervention – influenza (1) 
P.31 P-T Non-adherence (1) 
P.33 P-T Personal circumstances (2) 
P.34 T-P Time issues (1) 
P.42 P-T  Felt 'weird', difficulty in concentrating (1) 
   
Key: DNA = did not arrive; P = placebo; T = test 
7.2 Blinding 
No participants reported noticing any difference between test and placebo capsules with 
regard to taste, smell or appearance. 
7.3 Beck Anxiety Inventory 
According to the BAI (Beck & Steer 1993), of the 31 participants who completed the 
study, 11 were initially experiencing minimal anxiety (BAI scores 0 -7), 14 were mildly 
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anxious (BAI scores 8-15), 3 were moderately anxious (BAI scores 16-25) and 3 had 
severe anxiety (≥ 26).   
The mean (SD) score for all participants before test intervention was 12.16 (8.59).  This 
decreased to 6.29 (4.79), a mean decrease of 48% in anxiety scores following 2 weeks 
of S. lateriflora (350 mg) three times daily.  This would appear to imply a significant 
decrease in anxiety due to S. lateriflora; paired t (df 30) = 5.537 (p < 0.001).  However, 
for placebo the mean (SD) scores decreased from baseline to 7.19 (5.99), a 42.6 % 
decrease in anxiety scores over a period of 2 weeks on placebo; paired t (df 30) = 4.343 
(p < 0.001). There was no significant difference between test and placebo; mean diff = 
0.90; paired t (df 30) = -1.145 (p = 0.261). 
However, this analysis is misleading in that it does not take into account the possibility 
of order effects and baseline shifts in anxiety scores.  It can be seen in Figure 7.2 that 1 
and 2 relate to the sequence (group) in which the intervention was taken.  Group1 (n = 
15) = placebo-test; group 2 (n = 16) = test-placebo.  The two variables showed 
differences between baseline measurements, with those in group 1 showing higher 
initial mean (SD) anxiety scores of 15.73 (10.71) than those in Group 2  at 8.81 (3.99).   
 
Figure 7.2  Mean scores on Beck Anxiety inventory showing differences between groups 
according to the order in which the interventions (test herb and placebo) were taken.  
A 2 x 3 mixed ANOVA revealed that there was a significant order effect (F1, 29 = 4.614; 
p = 0.040) as well as a significant effect of treatment (F 2, 58 = 22.8; p < 0.001) and a 
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significant group x treatment interaction (F 2, 58 = 5.03; p = 0.010) and indicated an 
enhanced effect of placebo over skullcap in Group 2 (Figure 7.2).  
Because of the shifts in baseline between the 2 groups as described above, change 
scores were calculated (by subtracting pre-scores from post-scores) and analysed using 
a 2 x 2 mixed ANOVA.  This showed that, within subjects, there was no significant 
effect of treatment (F 1, 29 = 1.791; p = 0.191).  There was however a significant 
between subjects group effect (p = 0.049) and a significant group x treatment interaction 
(F 1, 29 = 6.96; p = 0.013).  Mean changes from baseline (Table 7-3) demonstrated an 
enhanced anxiolytic effect for skullcap compared to placebo for Group 1 (placebo-test) 
and no significant change for Group 2 (test-placebo).  Independent sample t-tests 
showed differences between groups in change scores from baseline for skullcap to be 
significant (t (df 29) = -3.108; p = 0.003) but not for placebo (t (df 29 = -.928; p = 
0.361).  Paired sample t-tests showed a significant difference between skullcap and 
placebo for Group 1 (t (df 14) = -2.323, p = 0.036 (SE 1.23) but not for Group 2 (t (df 
15) = 1.198, p = 0.249 (SE 0.782) confirming an enhanced effect overall for skullcap for 
Group 1 compared with placebo. 
 
 
Figure 7.3   Mean differences in change scores between test and placebo according to 









Table 7-3  Mean baseline scores and change scores on Beck Anxiety Inventory following 
skullcap and placebo, showing an enhanced effect of skullcap compared to placebo for 
Group 1 
  Mean change scores (SD)  
 Mean initial 
scores (SD) 
Skullcap Placebo Skullcap-placebo 
(mean diff) 
   SE  SE P value 
       
Group 1 
(n = 15) 
15.73 (10.71) -8.93 (6.13)  1.58 -6.07 (7.87) 2.03 0.036 
 
       
Group 2 
(n = 16) 
 
8.81 (3.99) -3.0 (4.05) 1.01 -3.94 (4.58) 1.15 0.249 
SD = standard deviation; SE = standard error of the mean 
 
A 2 x 2 ANOVA demonstrated that although there was a significant group x treatment 
interaction (F 1, 29 = 6.96; p = 0.013), there was no significant overall difference (F 1, 29 
= 1.791, p = 0.191) between skullcap, mean (SD) = 6.29 (4.79) and placebo, mean (SD) 
= 7.19 (5.99)  
 
7.4 Profile of Mood States 
In addition to mean scores for the 5 mood factors Tension-anxiety (T-A), Depression-
dejection (D-D), Anger-hostility (A-H), Vigour-activity (V-A), Fatigue-inertia (F-I) and 
Confusion-bewilderment (C-B) the means ± SD of the Total Mood Disturbance (TMD) 
score for the same periods were calculated for assessment of an overall effect of S. 
lateriflora on negative mood.  This was obtained for each individual participant by 
summing the scores of each factor and subtracting the score for Vigour-Activity (Table 
7-4), which was negatively scored because it is a positive rather than a negative mood 
state (Lorr et al. 2005).   
 
Table 7-4  Differences in mean (M) scores (SD) with the POMS according to skullcap 
(test) or placebo treatment (n = 31).  
Mood factor Baseline M (SD) Test M (SD) %Change  Placebo M (SD) % Change 
 
      
T-A 
 
12.61 (6.76) 8.74 (5.85) - 31% 9.74 (6.98) - 23% 
D-D 
 
11.74 (11.33) 5.83 (6.84) - 50% 8.03 (8.85) -  32% 
A-H 
 
13.13 (10.16) 7.13 (5.83) - 46% 9.97 (8.63) - 24% 
V-A 
 
16.26 (5.8) 17.42 (5.51) 7% 15.90 (5.80) - 2% 
F-I 
 
8.03 (4.84) 6.16 (4.52) - 23% 7.45 (6.39) - 7% 
C-B 
 
8.67 (4.56) 6.41 (3.63) - 26% 6.54 (5.14) - 24% 
TMD 
 
37.94 (31.54) 16.54 (23.21) - 56% 25.80 (36.21) - 32% 
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From inspection of the percent change scores (Table 7-4) it appears that, overall, 
skullcap had a greater effect on wellbeing than placebo within subjects (although the 
increased energy with skullcap as suggested by Vigour-activity scores appeared minor).   
 
It was important to determine whether there was a baseline shift (as discussed 
previously in relation to BAI scores) in accordance with the order in which the 
intervention was taken as otherwise these POMS results could be misleading.  To 
determine whether these effects were present a mixed method 2 x 3 ANOVA for each 
mood state and also for TMD was conducted.  As a further step towards ascertaining the 
relevance of the results for test and placebo, paired samples t-tests and independent 




To see whether there were significant differences between groups a mixed method 2 x 3 
ANOVA (Figure 7.4) was carried out.  This revealed that there was no significant order 
effect according to group (F 1, 29 = 2.070; p = 0.161).  It also confirmed that there was a 
significant treatment effect (F 2, 58 = 4.925; p = 0.011) but there was no significant group 
x treatment interaction (F 2, 58 = 2.548; p = 0.087).   
 
 
Figure 7.4   Mean scores per group for the Tension-Anxiety factor on POMS in 




Paired sample t-tests indicated there was a significant effect of treatment from baseline 
for both skullcap, (t (df 30) = 3.345; p = 0.002) and placebo (t (df 30) = 2.314; p = 
0.028) and there was no significant difference in treatment effects between skullcap and 
placebo (t (df 30) = - 0.642; p = 0.526).  
 
Changes were from a mean (SD) baseline score of 14.47 (7.4) to skullcap treatment 
score of 8.33 (7.34) = 42% for Group 1 and from 10.88 (5.8) at baseline to skullcap 
treatment score of 9.13 (4.24) = 16% for Group 2.  The changes from baseline scores to 
placebo were to 12.20 (7.8) = 16% for Group 1 and 7.48 (5.38) = 31% for Group 2.   
 
Independent sample t- tests also confirmed there were no significant differences in 
baseline scores between groups (t (df 29) = 1.509; p = 0.142) and revealed a significant 
difference between groups in the effect of placebo (t (df 29) = 1.991; p = 0.056) but not 
for skullcap (t (df 29) = -0.371; p = 0.713).  Overall the results suggest no significant 
difference between skullcap and placebo in changes from baseline.  There was an 
enhanced effect of placebo over skullcap for Group 2.  
 
A 2 x 2 ANOVA conducted to determine overall treatment effects demonstrated there 
was no significant difference (F 1, 29 = 0.529; p = 0.473) between skullcap, mean (SD) = 
8.74 (5.85) and placebo, mean (SD) = 9.74 (6.97). 
 
7.4.2   Depression-dejection 
Similarly for Depression-dejection, a mixed method 2 x 3 ANOVA (Figure 7.5) showed 
there was no significant difference between groups (F1, 29 = 1.305; p = 0.263).  It also 
confirmed there was a significant effect of treatment (F2, 58 = 7.435; p = 0.001) and no 





Figure 7.5   Mean scores per group for the Depression-Dejection factor on POMS in 
accordance with the order in which skullcap test or placebo interventions were taken 
 
Paired sample t- tests revealed that although there was a significant effect of treatment 
for both skullcap (t (df 30) = 3.65; p = 0.001) and placebo (t = 2.02; p = 0.052) there 
was no significant difference in treatment effects between skullcap and placebo (t (df 
30) = - 1.706; p = 0.098).   
 
Independent sample t-tests revealed differences in mean (SD) baseline scores between 
Group 1 = 14.28 (13.15) and Group 2 = 9.38 (9.11) but these were not significant (t (df 
29) = 1.210; p = 0.236).  There was no significant difference between Group 1 = 5.53 
(8.95) and Group 2 = 6.13 (6.55) in the effect of skullcap (t (df 29) = - 0.244; p = 0.809) 
or between Group 1 = 10.6 (9.35) and Group 2 = 5.56 (7.89) in the effect of placebo (t 
(df 29) = 1.605; p = 0.119) but there was an enhanced effect of skullcap compared to 
placebo for Group 1 and an enhanced effect of placebo compared to skullcap for Group 
2.  The percent change scores from baseline following administration of skullcap were 
61% for Group 1 and 35% for Group 2 and for placebo they were 26% for Group 1 and 
40% for Group 2.  Overall the results confirmed there was no significant difference 
between the effects of skullcap and placebo on Depression-dejection. 
 
A 2 x 2 ANOVA conducted to determine overall treatment effects demonstrated, 
although there was a significant group x treatment interaction (F1, 29 = 5.364; p = 
0.028), there was no significant difference (F 1,29 = p = 0.067) between skullcap, mean 





A 2 x 3 mixed method ANOVA (Figure 7.6) showed no significant between subjects 
effects according to group (F1, 29  = 3.462; p = 0.073).  In addition there was no 
significant group x treatment interaction (F 2, 58 = 1.412; p = 0.252) and the tests 
confirmed a significant effect of treatment (F 2, 58 = 8.235; p = 0.001).  Mean (SD) 
scores at baseline for Group 1 reduced from 15.93 (11.03) to 7.93 (6.90) with skullcap 
(50%) and 13.2 (8.34) for placebo (17%).  For Group 2 mean (SD) scores reduced from 
baseline 10.5 (8.82) to 6.38 (4.72) for skullcap (39%) and to 6.94 (7.99) for placebo 
(33%).  The scores indicated an enhanced effect of skullcap for Group 1 compared to 
Group 2.   
 
Figure 7.6   Mean scores for Anger-Hostility according to the order in which the 
interventions skullcap test or placebo were taken 
 
Anger-hostility scores as assessed by paired sample t - tests revealed no significant 
difference between skullcap and placebo in treatment effects (t (df 30) = -1.793; p = 
0.083) but there was a significant effect of treatment from baseline for both skullcap (t 
(df 30) = 4.055; p < 0.001) and placebo (t (df 30) = 2.188; p = 0.037).   
 
Independent sample t-tests confirmed the differences between groups at baseline (t (df 
29) = 1.519; p = 0.139) and with skullcap treatment (t (df 29) = 0.738; p = 0.466) were 
not significant. They also showed a significant difference between groups in the effect 
of placebo, confirming an enhanced effect of placebo for Group 2 compared to Group 1 




Overall, these results suggest the reduction in anger and hostility scores from baseline 
following skullcap compared to placebo treatment was not significant. 
 
A 2 x 2 ANOVA was conducted to determine the main treatment effects.  This showed 
there was no significant difference (F 1, 29 = 3.534, p = 0.070) between skullcap, mean 
(SD) = 7.13 (5.83) and placebo, mean (SD) = 9.97 (8.63). 
 
7.4.4   Vigour-Activity 
To determine whether these treatment effects were significant according to the order in 
which skullcap and placebo were taken a 2 x 3 mixed method ANOVA was conducted 
(Figure 7.7).  This showed significant differences according to the order in which the 
interventions were taken as there was a significant between subjects effect according to 
group (F 1, 29 = 5.286; p = 0.029).  However, there was no significant treatment effect (F 
2, 58 = 0.785; p = 0.461) or group x treatment interaction (F 2, 58 = 1.615; p = 0.208).   
 
 
Figure 7.7   Group differences in the effects of skullcap test or placebo interventions on 
Vigour-Activity scores on POMS 
 
Paired sample t-tests confirmed there were no significant changes in Vigour-activity 
scores from baseline for either skullcap (t (df 30) = -1.219; p = 0.232) or placebo (t = 
0.219; p = 0.828) or differences between skullcap and placebo (t (df 30) = 0.118; p = 
0.213).  Mean (SD) changes in scores from baseline for Group 1 were from 17 (6.65) to 
20.33 (3.83) for skullcap (20%) and to 16.73 (6.29) for placebo (- 2%).  For Group 2 
they were from 15.56 (4.97) to 14.69 (5.55) for skullcap (- 6%) and to 15.13 (5.4) for 




Independent sample t-tests were conducted to analyse the group differences and these 
demonstrated a significant difference between groups in the effect of skullcap (t (df 29) 
= 3.276; p = 0.003) but not for baseline scores (t (df 29) = 0.685; p = 0.499) or for 
placebo (t (df29) = 0.788; p = 0.450).  There was an enhanced effect of skullcap in 
increasing Vigour-activity for Group 1 compared to Group 2, in which there was a 
slight decrease in Vigour-activity scores with skullcap.   
 
The results overall indicate that there was no significant difference between test and 
placebo in alteration of Vigour-activity scores but an enhanced effect of skullcap for 
Group 1 (in increasing energy levels). 
 
A 2 x 2 ANOVA was conducted to determine overall treatment effects. This confirmed 
overall there was no significant difference (F 1, 29 = 1.416, p = 0.244) between skullcap, 
mean (SD) = 17.42 (5.51) and placebo, mean (SD) = 15.90 (5.80). 
7.4.5   Fatigue-Inertia 
A 2 x 3 mixed methods ANOVA (Figure 7.8) showed there was no significant order 
effect according to group (F 1, 29 = 0.002; p = 0.969), no significant treatment effect (F 2, 
58 = 1.688; p = 0.194) and no significant group x treatment interaction (F 2, 58 = 0.956; p 
= 0.391).   
 
 
Figure 7.8  A 2 x 3 ANOVA demonstrating group differences in the effects of skullcap test 




Scores for Fatigue-inertia were demonstrated by the paired sample t-tests to show a 
significant change (decrease) from baseline scores for skullcap (t (df 30) = 2.246; p = 
0.032) but not for placebo (t (df 30) = 0.465; p = 0.645).  However, overall there was no 
significant difference in treatment effect between skullcap and placebo (t (df 30) = -
1.220; p = 0.232).   
 
A further analysis using independent sample t-tests showed there was no significant 
difference between groups in baseline (t (df 30) = 0.116; p = 0.909), skullcap test (t (df 
30) = - 0.904; p = 0.373) or placebo (t (df 30) = 0.625; p = 0.537) scores.   Mean (SD) 
change scores for Group 1 were from 8.13 (4.5) to 5.4 (4.45) for skullcap (33%) and to 
8.2 (6.36) for placebo (-1%); and for Group 2 from 7.94 (4.91) to 6.88 (4.62) for 
skullcap (13%) and to 6.75 (6.54) for placebo (14%).  Overall, although there was an 
enhanced effect of skullcap compared to placebo in decreasing fatigue and inertia, the 
results showed the difference in treatment effects between skullcap and placebo for 
Fatigue-inertia were not significant, indicating overall that skullcap does not cause 
fatigue when taken orally. 
 
To determine overall treatment effects a 2 x 2 ANOVA was conducted.  This confirmed 
there was no significant difference (F 1, 29 = 1.609, p = 0.209) between skullcap, mean 
(SD) = 6.16 (4.52) and placebo, mean (SD) = 7.45 (6.39). 
7.4.6   Confusion-Bewilderment 
For Confusion-bewilderment a 2 x 3 mixed method ANOVA (Figure 7.9) to see if there 
was a group sequence effect on results. This confirmed there was a significant overall 
treatment effect from baseline within subjects (F 2, 58 = 6.290; p = 0.003), no significant 
order effect according to group (F 1, 29 = 1.078; p = 0.308) and no significant group x 
treatment interaction (F 2, 58 = 1.055; p = 0.355), indicating no significant difference 




Figure 7.9   Group differences in the effects of skullcap test or placebo interventions on 
Confusion-bewilderment scores on POMS 
 
The results were further analysed by paired sample t-tests, which showed there were 
significant differences in scores from baseline for both skullcap test (t (df 30) = 4.116; p 
< 0.001) and placebo (t (df 30) = 2.745; p = 0.010) but there was no significant 
difference in treatment effects between skullcap and placebo (t (df 30) = - 0.162; p = 
0.873).  
 
Independent sample t-tests carried out to analyse the mean (SD) differences in scores 
between Group 1 and Group 2 confirmed the differences between groups were not 
significant.  A mean (SD) baseline score of 9.47 (5.24) for Group 1 and 7.94 (3.84) for 
Group 2 (t (df 29) = 0.930, p = 0.360) reduced to 6.6 (3.85) for Group 1 and 6.25 (3.53) 
for Group 2 (t (df 29) = 0.264; p = 0.794) with skullcap test (30% and 21% 
respectively).  Changes with placebo from baseline were to 7.8 (5.49) for Group 1 
(17.5%) and to 5.38 (4.65) for Group 2 (32%) (t (df 29) = 1.330, p = 0.194).   
 
Overall skullcap had no significant effect on Confusion-bewilderment because there 
was no significant difference between skullcap and placebo.  There was, however, an 
enhanced effect of placebo compared to skullcap for Group 2. 
 
A 2 x 2 ANOVA to analyse main treatment effects revealed no significant difference (p 




7.4.7 Total Mood Disturbance 
Mean Total Mood Disturbance (TMD) was calculated as the mean sum of all mood 
factors minus mean Vigour-Activity scores.  On inspection of the percent decrease in 
scores from baseline TMD it appeared that there might be a significantly enhanced 
effect of skullcap over placebo in positively altering negative mood states overall as the 
percent change for skullcap was a mean decrease of 56% from baseline following 
administration of skullcap and 32% for placebo.   
 
A 2 x 3 mixed method ANOVA (Figure 7.10) revealed no overall order effect for group 
(F 1, 29 = 0.963; p = 0.335).  There was a significant treatment effect (F 2, 58 = 7.117; p = 
0.002) but no significant group x treatment interaction (F 2, 58 = 2.508; p = 0.090) 
indicating the enhanced effect of placebo for those in Group 2 (Figure 7.10) was not 
significant.  Changes in mean (SD) scores for Group 1 from baseline were from 45.27 
(37.41) to 13.33 (27.99) with skullcap (70%) and to 34.93 (37.51) with placebo (23%).  
For Group 2 the scores changed from 31.06 (24.08) at baseline to 19.56 (18.06) with 
skullcap (37%) and to 17.25 (33.87) with placebo (44.5%) suggesting an enhanced 
effect for skullcap for Group 1 compared with placebo and compared with Group 2; and 
an enhanced effect of placebo for Group 2 compared with Group 1.  
 
 
Figure 7.10   Mean scores of Total Mood Disturbance on POMS for within and between 





A paired sample t-test indicated significantly decreased scores on POMS TMD with 
skullcap from baseline (t (df 30) = 4.884; p = <0.001) and the decrease in scores from 
baseline for placebo to be not significant (t (df 30) = 1.864; p = 0.072).  However, 
although there was an enhanced effect for the skullcap versus placebo, for overall 
treatment effects the difference between skullcap and placebo appeared to be not 
significant (t (df 30) = -1.408; p = 0.169). 
 
Subsequently a 2-way ANOVA (Figure 7.11) was conducted on change scores from 
baseline to further analyse the differences between groups and skullcap and placebo 
treatment periods.  This showed there was no significant difference in groups (F 1, 29 = 
0.897; p = 0.351), no significant effect of treatment (F 1, 29 = 2.335; p = 0.137) and no 
significant group x treatment interaction (F 1, 29 = 3.589; p = 0.068). 
 
Change scores (SD) with skullcap for Group 1 were – 32 (22) and -11.5 (23) for Group 
2; with placebo change scores for Group 1 were -10.3 (37) and -13.8 (36.6) for Group 2. 
Independent sample t-tests to analyse change scores from baseline showed overall the 
results for Total Mood Disturbance suggest a significant difference between groups in 
the response to skullcap (t (df 29) = -2.534; p = 0.017) but not placebo (t (df 29) = 
0.263; p = 0.794). From inspection of Figures 7.10 & 7.11 it can be seen there was an 
enhanced effect of skullcap for Group 1 compared to placebo and an enhanced effect of 
placebo for Group 2 compared to skullcap. 
 
 
Figure 7.11   Mean differences in change scores between skullcap test and placebo for 




A 2 x 2 ANOVA was conducted to analyse the main treatment effects.  This 
demonstrated that there was no significant difference (F 1, 29 = 2.335, p = 0.137) 
between skullcap, mean (SD) = 16.54 (23.21) and placebo, mean (SD) = 25.80 (36.21). 
 
7.5 Salivary cortisol measures 
In order to analyse mean changes in salivary cortisol concentration (nmol/L) in saliva at 
baseline, skullcap test and placebo, it was necessary to first replace missing variables. 
These were computed by means analysis for each time point for each period (3 hours, 6 
hours, 9 hours and 12 hours for baseline, test and placebo) using the ‘replace missing 
variables’ in the transform function in SPSS.  
 
 
Figure 7.12  Mean salivary cortisol concentration (nmol/L) within and between subjects in 
accordance with the order in which skullcap test and placebo were taken 
 
The 2 x 3 x 4 ANOVA (group x treatment x time) (Figure 7.12) showed no significant 
differences between Group 1 (placebo-test, n = 14) and Group 2 (test-placebo, n = 12) 
(F 1, 24 = 0.981; p = 0.332), no significant treatment effect (F 2, 48  = 1.870; p = 0.165) for 
either group and no significant within subjects group x treatment interaction (F 2, 48 = 
1.008; p = 0.373).   
 
It also showed that although both groups changed significantly for the 4 diurnal time 
points (F3, 72 = 29.702; p = < 0.0001) as expected (Figure 7.13), with salivary cortisol 
levels being at their highest 3 hours following waking and declining throughout the day 
(Kudielka & Kirschbaum 2003), there were no significant group x time (F3, 72 = 0.310; p 
= 0.818), treatment x time (F6, 144  = 0.164; p = 0.986) or group x time x treatment (F6, 
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144 = 1.942; p = 0.078) interactions, indicating no significant diurnal effects of skullcap 
and no significant diurnal differences between skullcap and placebo.  
 
 
Figure 7.13  Comparison of changes in salivary cortisol concentration from baseline over 
time according to treatment (skullcap test or placebo) 
 
Paired sample t tests (n = 12) for each time point (3, 6, 9 and 12 hours following 
waking) between baseline and skullcap, baseline and placebo, and skullcap and placebo, 
showed no significant differences between any pairs: (p > 0.091):  
Baseline – skullcap (3h, p = 0.769; 6h, p = 0.156; 9h, p = 0.091; 12h, p = 0.298); 
Baseline – placebo (3h, p = 0.870; 6h, p = 0.587; 9h, p = 0.099; 12h, p = 0.515); 
Skullcap – placebo (3h, p = 0.098; 6h, p = 0.545; 9h, p = 0.694; 12h, p = 0.649).  
 
To analyse the main treatment effects a 2 x 2 (x 4) (group x treatment x diurnal time 
points) ANOVA was conducted.  The results demonstrated that skullcap had no 
significant effect on salivary cortisol measurements. There was no significant difference 
(F 1, 24 = 0.418; p = 0.524) between skullcap, mean (SD) = 4.74 (3.68) and placebo, 
mean (SD) = 4.98 (3.89). 
 
7.6 Safety and tolerability 
 
7.6.1 ALT levels 
A 2 x 3 mixed ANOVA (Figure 7.14), showed there was no significant effect of group 
(F 1, 29 = 0.166; p = 0.687). There were no overall significant changes within subjects in 
131 
 
ALT levels according to treatment (F 2, 58 = 2.192; p = 0.121) and no significant group x 
treatment interaction (F2, 58 = 0.426; p = 0.655).   
 
Mean values (SD) in U/L at baseline = 9.72 (4.61), following skullcap = 11.74 (5.32) 
and following placebo = 12.14 (9.11).  Paired sample t-tests revealed the ALT changes 
from baseline with skullcap were significant (t (df 30) = – 2.513; p = 0.018) but not the 
ALT changes from baseline with placebo (t (df 30) = - 1.825; p = 0.078).  However, the 
tests also demonstrated that there was no significant difference in ALT levels between 
skullcap and placebo in treatment effects (t (df 30) = - 275, p = 0.785).   
 
 
Figure 7.14  Mean plasma ALT levels (U/L) for treatment x group with S. lateriflora test 
and Urtica dioica folia placebo 
 
Although there was a significant increase in ALT levels following administration of 
skullcap according to the results of the t-tests, levels were still well within the normal 
range of ≤ 22 U/L (men) and ≤ 17 U/ L (women) at 25oC (Roche 2008).  
 
A 2 x 2 ANOVA to analyse main treatment effects demonstrated there was no 
significant difference between skullcap and placebo (F 1, 29 = 0.065, p = 0.801). 
 
One male participant (13) had raised ALT levels to 51 U/L, a level slightly above the 
normal range, on his second visit (the final day of placebo treatment), (baseline = 12.5; 
test =11.3; placebo = 51.0 U/L) but admitted to drinking alcohol a few hours previously. 
Recent alcohol consumption may give a higher reading (Pratt & Kaplan 2000).  The test 
was repeated using a different Reflotron machine to ensure there was no error due to 
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faulty equipment or to operator error and the reading was the same.  He was advised to 
see his G. P. for follow-up. 
 
7.6.2 Blood pressure 
Changes in blood pressure were not particularly expected and blood pressure tests were 
for purposes of observation and health monitoring.  A plot demonstrating means of 
systolic and diastolic blood pressures at each treatment period (Figure 7.15) provides a 
visual representation of minimal change from baseline or difference between skullcap 
and placebo in their effects on blood pressure or pulse pressure (the difference between 
systolic and diastolic). The recommended average healthy blood pressure in adult 
humans is 120/80 mm/Hg (Beers et al. 2006) so the results indicate there were no 
alterations due to either skullcap or placebo.  Paired sample t-tests were carried out for 
confirmation.  However, to determine whether there might be significant changes in 
blood pressure within and between groups according to the order in which the 
interventions were taken a 2 x 3 mixed method ANOVA was also carried out for both 
mean systolic (Figure 7.16) and diastolic (Figure 7.17) blood pressures. 
 
 
Figure 7.15 Plots demonstrating the mean systolic and diastolic blood pressures 
(mm/Hg). Note that mean scores remained within the recommended healthy range for adults 
(Beers et al. 2006) following skullcap and placebo treatments, with no significant changes 






















A 2 x 3 mixed method ANOVA (Figure 7.16) demonstrated, although Group 2 (test-
placebo) showed a greater decrease in mean (SD) systolic blood pressure from baseline; 
difference = 117.31 (16.15) – 113.56 (13.86) with skullcap (3%) and 117.31 (16.15) - 
111.5 (13.08) with placebo (5%) than Group 1 (placebo-test), mean (SD) difference 
from baseline = 121.13 (18.43) – 122.13 (20.54) with skullcap (an increase of < 1%) 
and 121.13 (18.43) – 121.6 (17.37) with placebo (an increase of < 5%) this was not 
significant.  There was no significant order effect of group (F 1, 29 = 1.76; p = 0.195), no 
significant effect of treatment (F 2, 58 = 1.16; p = 0.320) and no significant group x 
treatment interaction (F 2, 58 = 3.06; p = 0.091).  
 
Figure 7.16  Mean systolic blood pressure (mm/Hg) showing within and between subjects 
effects to be non-significant in accordance with the order in which the interventions were 
taken 
 
A paired sample t-test confirmed there was no significant change from baseline in 
systolic blood pressure following either S. lateriflora or placebo.  Mean (SD) systolic 
pressure at baseline was 119.61 (17.1), with skullcap 117.71 (17.66) and with placebo 
116.39 (15.9).  The differences between baseline and skullcap (t (df 30) = 0 .76; p = 
0.454), baseline and placebo (t (df 30) = 1.497; p = 0.145) and skullcap and placebo (t 
(df 30) = 0.86; p = 0.395) were not significant. 
 
A 2 x 2 ANOVA to determine main treatment effects confirmed the difference between 




Similarly for diastolic blood pressure, a 2 x 3 mixed method ANOVA (Figure 7.17) 
confirmed there was no order effect between groups: Group 1 mean (SD) difference 
from baseline = 79.2 (11.01) – 79.2 (10.98) with skullcap (0%) and 79.46 (10.37) with 
placebo (< 0.5% increase); group 2 mean (SD) difference from baseline = 77.06 (10.20) 




Figure 7.17  Mean diastolic blood pressure (mm/Hg) showing within and between 
subjects effects in accordance with the order in which the intervention was taken 
 
There was no significant group effect (F 1, 29 = 0.874; p = 0.358), no significant effect of 
treatment (F 2, 58 = 0.201; p = 0.819) and no significant group x treatment interaction (F 
2, 58 = 0.253; p = 0 .778), confirming there were no significant effects on diastolic blood 
pressure for either skullcap or placebo or significant differences between skullcap and 
placebo in their effects on diastolic blood pressure. 
 
Paired sample t-tests showed there were no significant changes. Mean (SD) diastolic 
pressure was 78.1 (10.47) at baseline, 77.22 (SD 10.69) following skullcap and 77.51 
(10.51) after placebo.  Differences between baseline and skullcap (t (df 30) = 0.663; p = 
0.513), baseline and placebo (t (df 30) = 0.43; p = 0.669) and skullcap and placebo (t (df 




A 2 x 2 ANOVA, which was conducted to determine main treatment effects, confirmed 
there was no significant difference overall between skullcap and placebo (F 1, 29 = 0.045, 
p = 0.834). 
7.6.3 Pulse rate 
No irregularities or abnormalities such as bounding or rates that were too high (> 100 
BPM) or too low (< 60 BPM), except in trained athletes (normal BPM = 40 – 60) 
(Vorvick 2012) were palpated in the radial pulse of any participants during initial 
screening.  Changes from a mean (SD) of 69.65 (9.56) baseline beats per minute (BPM) 
were to 68.58 (8.09) with skullcap (1.5% decrease) and to 71.16 (9.76) with placebo 
(1.5% increase).  
 
To see if the results might be significant according to group a 2 x 3 mixed method 
ANOVA was conducted (Figure 7.18).  This revealed there was no significant effect of 
group (F 1, 29 = 0.090; p = 0.766), no significant group x treatment interaction (F 2, 58 = 
0.172; p = 0.842) and no overall effect of treatment (F 2, 58 = 1.054; p = 0.355), 
confirming neither skullcap nor placebo had any significant effects on pulse rate overall. 
 
 
Figure 7.18  Mean pulse rate (BPM) showing within and between subjects effects in 
accordance with the order in which the interventions were taken 
 
Paired sample t-tests indicated there was an insignificant mean change in pulse rate 
from baseline for either skullcap (t (df 30) = 0.594; p = 0.557) or placebo (t (df 30) = - 
0.827; p = 0.415) and suggested the difference in pulse rate between skullcap and 




A 2 x 2 ANOVA also confirmed there was no significant difference between skullcap 
and placebo in treatment effects (F 1, 29 = 2.251, p = 0.144).  
 
Results demonstrated that skullcap has no effect on pulse rate, which remained within 
the normal range (Vorvick 2012), in healthy adults. 
 
 
7.6.4 Summary of main effects 
To assess the main differences between skullcap and placebo a series of 2 x 2 ANOVAs 
was conducted on all variables.  The results (Table 7-5) demonstrated no significant 
differences overall between skullcap treatment and placebo for any variables analysed. 
Table 7-5 Main differences in treatment effects between skullcap and placebo 
Variables tested Skullcap mean (SD)  Placebo mean (SD)  Significance of 
treatment 
effect: p = 
BAI 6.29 (4.79) 7.19 (5.99) 0.191 
POMS T-A 8.74 (5.85) 9.74 (6.97) 0.473 
POMS D-D 5.84 (6.64) 8.03 (8.85) 0.067 
POMS A-H 7.13 (5.83) 9.97 (8.63) 0.070 
POMS V-A 17.42 (5.51) 15.90 (5.80) 0.244 
POMS F-I 6.16 (4.52) 7.45 (6.39) 0.209 
POMS C-B 6.41 (3.63) 6.54 (5.14) 0.838 
POMS TMD 16.54 (23.21) 25.80 (36.21) 0.137 
Salivary cortisol  4.74 (3.68) 4.98 (3.89) 0.524 
Systolic BP 117.71 (17.66) 116.38 (15.90) 0.410 
Diastolic BP 77.22 (10.69) 77.51 (10.51) 0.834 
Pulse 68.58 (8.09) 71.16 (9.76) 0.144 
ALT 11.74 (5.32) 12.14 (9.11) 0.801 
 Key: BAI = Beck Anxiety Inventory; POMS = Profile of Mood Disturbances: T-A = tension Anxiety; D-
D = Depression-Dejection; A-H = Anger-Hostility; V-A = Vigour Activity; F-I = Fatigue-Inertia; C-B = 




7.6.5  Toxicity and side – effects 
No participants experienced any serious adverse reactions during the study and only 
minor and infrequent side-effects were reported by seven participants whilst taking S. 
lateriflora.  Of these, one had vivid dreams, one felt ‘spaced out’, four reported mild 
digestive disturbances and one reported a constant taste of salt in her mouth.  For details 
see sections 7.7.5 & 7.7.6 of participant diary symptom reports.  Although it is uncertain 
whether these side-effects can be attributed to skullcap, mild digestive upset and vivid 
dreaming were symptoms also reported by two practitioners responding to a survey on 
their use of S. lateriflora, in one each of their patients (see 3.4.9). 
7.7 Participant symptom diary report: results and 
discussion notes 
Participants were given a symptom diary (Appendix XVI) in which they were requested 
to list any physical or mental symptoms they experienced during the study, whether new 
or old, both negative (Figure 7.19 & Figure 7.20) and positive (Figure 7.21 & Figure 
7.22), including the disappearance of old symptoms.  They were also asked to write on a 
separate piece of paper if necessary and to report anything unusual they felt about their 
experiences whilst taking part in the study should they wish to do so.  Participant 
statements are reported separately below (see 7.8).  All completed a diary except 
participants 14, 16, 29, 30 and 32 (n = 26). 
7.7.1 Negative mood symptoms reported by participants 
Diary reports of negative mood symptoms and low energy will only be briefly alluded 
to; stress, anxiety, anger and depression have been assessed in this clinical study by the 
use of validated instruments, Beck Anxiety Inventory (Beck & Steer 1993) and the 
Profile of Mood States (Lorr et al. 2005), and physiological measurements of stress, and 
will be discussed in the main discussion section (Chapter 8). 
7.7.1.1 Stress 
Stress was reported by 7 participants, 2 during skullcap treatment for one day each - the 
first and last day of treatment respectively and 1 of these participants reported stress 
during the skullcap period only.  Of the others 1 reported stress at baseline, 4 during 
placebo treatment for 2 days each and 2 of these were also stressed during washout.  
There was generally no correlation between the days stress was reported and the days on 




Two responders in a survey of herbal medicine practitioners (Chapter 3) said they found 
S. lateriflora worsens severe depression.  In this research seven participants reported 
feeling low in mood; described as tearful, upset, emotional, sad, despondent or 
depressed and one of these said they felt depressed (for a day) only during skullcap 
treatment and one (for a day) only during placebo.  Of 5 who experienced low mood 
during skullcap, 4 experienced symptoms during placebo treatment with one of these 
also feeling low at washout and at baseline.  At a total of 11 participant days amongst 5 
participants periods of depression whilst on skullcap were short-lived however, 
compared to a total of 16 participant days for placebo.  There is no indication from the 
above results that it was the skullcap that caused the depression in the individuals 
experiencing it during the study.  
7.7.1.3 Anxiety 
Anxiety symptoms, described by participants as feeling anxious, worried, nervous or 
apprehensive, were experienced by 5 people.  Two reported symptoms during skullcap 
treatment for one day each as opposed to 3 during placebo for a total of 10 days.  One 
person reported feeling anxious only whilst taking skullcap.  One person had a panic 
attack - on the second day of the washout period following cessation of skullcap 
treatment.  As this coincided with what she described as bad premenstrual syndrome it 
cannot be linked to cessation of skullcap treatment. 
7.7.1.4 Anger 
Anger, which can manifest during intense anxiety (Pary et al. 2003), was described as 
feeling irritable, bad tempered, grumpy, annoyed or angry by 6 participants.  This was 
mostly during the placebo treatment - by 5 participants for a total of 18 participant days 
and during a 7 day washout – by 2 participants for a total of 7 participant days.  The two 
who felt anger during washout had taken the interventions in reverse order to one 
another so there was no relevance regarding whether there was a residual effect of either 
skullcap or placebo.  Only 2 felt angry whilst on skullcap (for 1 day and 2 days 
respectively) but felt angry for longer periods during placebo (4 days each) and washout 
(4 days and 3 days respectively). Overall there was less anger experienced by 
participants whilst on skullcap. 
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7.7.1.5 Other negative mood symptoms reported 
Other negative mood symptoms reported by participants were poor concentration and 
feeling unmotivated.  Poor concentration was reported by 2 participants, one for one day 
of taking skullcap.  However, this same person reported improved concentration whilst 
on skullcap for another 4 days during the remainder of the skullcap period.  The other 
participant reported poor concentration during the washout period for 2 days.   
 
Feeling ‘foggy-headed’ (unable to think clearly) was reported by 2 participants, one 
during skullcap for one day.  The other reported foggy-headedness for 3 days during 
skullcap and 4 days during placebo treatment, she also felt ‘spaced out’ on 2 separate 
days during skullcap treatment.  Foggy-headedness cannot be attributed to skullcap as it 
was experienced also with placebo for an equal number of days.  Although “feeling 
spaced out” is a possible idiosyncratic reaction to skullcap by one participant, it cannot 
be definitively attributed to the herb. 
 
Feeling unmotivated was reported only during placebo treatment (2 participants for 9 
days) and during washout (1 participant for 1 day).  There is therefore no evidence from 
the diary alone that skullcap affects concentration or motivation.  
7.7.2 Low energy 
Of 8 participants who reported states of low energy such as feeling tiredness, fatigue, 
lethargy or excessive yawning, 6 of these experienced the symptoms whilst on skullcap, 
2 reported at baseline, 5 whilst on placebo and 5 during washout.  Only 1 participant 
reported extreme tiredness only whilst on skullcap but this participant also reported 
disturbed sleep whilst taking skullcap, which could account for the tiredness.  Those 
reporting these symptoms experienced them for an equal number of days in total (44) 
for both skullcap and placebo and for 4 days at baseline and 11 days during the washout 
period.  High energy was reported by 3 whilst on skullcap, 5 on placebo and 1 during 
washout.  It appears there was no difference between skullcap and placebo in relation to 
energy levels but the effects of skullcap on energy were measured by the Vigour-
Activity and Fatigue-Inertia factors on the POMS and will be discussed in Chapter 8. 
7.7.3 Headaches  
Headaches or migraines were reported by 12 participants (11 headache, 1 migraine), 
with 5 experiencing the symptoms whilst taking skullcap for a total of 14 participant 
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days.  Nine had headaches during placebo for a total of 18 participant days; 1 at baseline 
(both days) and 1 during washout (4 days).  Of those reporting headaches whilst on 
skullcap, 2 had them only during this period and one of these had a migraine on two 
separate days.  All who had headaches during the skullcap period reported them during 
the first 5 days, with none thereafter for the remaining 9 days.  Those with headaches 
during placebo reported them scattered throughout the placebo treatment period. 
 
 
Figure 7.19  No. participants reporting negative symptoms in their diaries during the 




Figure 7.20  No. participant days on which negative symptoms were reported in the 























































































































































































































































































































7.7.4 Positive mood symptoms reported in participant 
diaries 
Symptoms reported by participants in their diaries were grouped together by closest 
match, using their own words.  None reported any positive mood symptoms during the 
first 2 days (no treatment).  Feeling “calm” or “relaxed”, “chilled” or  “no anxiety” were 
grouped as calm/relaxed and reported by a total of 11 participants; 7 whilst taking 
skullcap for a total of 45 participant days, 6 on placebo for a total of 36 days and 1 
during washout for 1 day.  Although there was little difference between skullcap and 
placebo in the number of participants with these states of low anxiety as reported in 
their diaries, it lasted for longer periods during skullcap treatment.  It is notable that 
during skullcap treatment calm feelings were reported for 45 participant days in contrast 
to feelings of anxiety reported for 2 days (net 43 participant days calm).  During placebo 
treatment feelings of calm were reported for 36 days in the diaries in contrast to feelings 
of anxiety reported for 10 days (net 26 participant days calm). 
 
The main positive symptom reported during skullcap treatment was an enhanced mood, 
reported as feeling happy, in a good mood or contented, reported by 8 participants for a 
total of 54 participant days (compared with a total of 49 participant days by 11 people 
for placebo and washout periods together).  Furthermore, positive or hopeful feelings 
whilst taking skullcap were reported by 4 participants - for a total of 14 participant days. 
This was not reported during placebo, washout or baseline periods. 
 
 
Figure 7.21  No. participants reporting positive mood symptoms in their diaries during 






























Figure 7.22  No. participant days on which positive mood symptoms were reported by 
participants in their diaries during the randomised controlled trial 
 
7.7.5 Sleep experiences 
Disturbed sleep was experienced by 6 participants; for a total of 16 participant days by 3 
participants during skullcap treatment, 9 days by 4 participants during placebo treatment 
and for 2 days by 2 participants during both baseline and washout. Two of the 
participants who experienced sleep disturbances during skullcap experienced it during 
placebo too and had taken the skullcap first and placebo second so it is unclear whether 
the restlessness was due to a carryover effect of the skullcap.  One of these also reported 
2 days good night’s sleep whilst on skullcap and these same two participants also 
reported sleep disturbances prior to commencement of any treatment (baseline).  Only 
one participant reported sleep disturbance whilst on skullcap alone – waking after only 




 night inclusively before 
sleep patterns normalised.  Interestingly, poor sleep latency during skullcap treatment 
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skullcap. 
 
Insomnia is a common symptom of anxiety (Pary et al. 2003) so it was hypothesised 
that overall there would be an improvement in sleep patterns amongst the study 
participants whilst on skullcap. However, better sleep whilst taking skullcap was 
reported by only 4 participants for a total of 28 days.  They also reported feeling 
refreshed in the morning. Two reported improved sleep whilst on placebo for a total of 
12 days and also during washout for a total of 7 days.  Of the 5 participants who 
reported better sleep, only one reported this only whilst on placebo and also during 
washout.  Of the 4 reporting improved sleep whilst on skullcap, the first day of 
improvement was on days 3, 3, 5 and 7 respectively.  One participant said she felt she 
needed no more than 5 hours sleep as she has so much energy (whilst on skullcap).  
 
Although the sleep data is subjective and reported in a number too small to have any 
statistical significance, overall it might be that it may take up to a week for skullcap to 
begin to improve sleep quality or, in certain individuals, to begin to cause restlessness 
during the second week.  It is not known however, how many participants were 
previously poor sleepers so it is possible that those reporting improved sleep whilst 
taking skullcap were unique amongst the sample in suffering from chronic poor sleep.  
A future study could assess the effectiveness of S. lateriflora on insomnia. 
 
Only one participant reported extreme tiredness only whilst on skullcap but this 
participant also reported disturbed sleep whilst taking skullcap, which could account for 
the tiredness.  Of interest regarding the wakefulness during skullcap treatment is that it 
is known that Valeriana officinalis, another herbal anxiolytic, extracts of which interact 
with GABAA receptors in vitro (Cavadas et al. 1995), can also cause a similar problem 
in certain individuals, who find it stimulating (Mills & Bone 1999). 
7.7.6 Miscellaneous symptoms reported 
Various other symptoms reported in the diaries include 4 participants with attacks of 
diarrhoea for one day each; 2 during skullcap, one during placebo and one during 
washout.  Nausea was reported by another 2 participants.  One had the symptoms only 
whilst on skullcap (one day) while the other experienced episodes of nausea throughout 
the study but particularly during skullcap treatment (8 days) and both baseline days.  It 
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is not certain whether the symptoms were as a result of either of the interventions as 
nausea is a known potential comorbidity of anxiety (Pary et al. 2003). 
 
One participant had a constant taste of salt in her mouth for 10 days during skullcap 
treatment.  The reason for this is unclear.  A large number of medications (> 75 types 
including CNS drugs such as anti-epileptics, antidepressants and antipsychotics) can 
cause taste disorders or dysgeusiae in some individuals, amounting to around 32% of 
cases.  Some diseases, for example gastro-oesophageal reflux disease, diabetes, 
endocrine disease and Bell’s palsy are known to be a cause of dysgeusia, which may 
manifest as a persistent salty taste in the mouth (Collet et al. 2007).  However, the 
participant was otherwise well and not taking any other medications. 
7.7.7 Disappearance, or reduced severity of, old 
symptoms 
Five participants reported a resolution or improvement in non serious but chronic 
conditions.  One reported her irritable bowel syndrome had cleared up from the 10
th
 day 
of skullcap treatment (first intervention) and it did not return for the remainder of the 
study.  Another reported that she normally experiences intense premenstrual mastalgia 
and dysmenorrhoea, yet this did not occur for the usual few days prior to menstruation; 
only for 10 minutes at onset of menstruation, which was at 2 days following skullcap 
treatment (during the washout period).  This same participant reported her hay fever 
symptoms, described as runny nose and sneezing, as being milder than usual during 
skullcap treatment. 
 
Another participant reported itching eczema throughout placebo treatment (first 
intervention) followed by an improvement for 5 days from the fifth day of skullcap 
treatment.  The itching did, however, return for the remaining 5 days of the study. 
 
Two participants reported a disappearance of muscular aches and pains.  One 
experienced muscle aches throughout the 2 days of no treatment at baseline with a 
disappearance of the pain from day 3 of skullcap treatment.  The pains did not return 
during the 7 day washout period but reappeared intermittently during the placebo 
period. The other participant reported a return of muscle pains on day 11 of placebo 




The above conditions are some of those for which S. lateriflora is commonly 
prescribed.  It is used for allergies, skin conditions and inflammation (Natural 
Medicines Comprehensive Database 2011), which may account for reported 
improvements in eczema and hay fever symptoms.  It is also believed to relieve muscle 
spasm in irritable bowel syndrome directly by the action of volatile oils on the smooth 
muscles of the colon (Khosh 2000) as well as due to an anxiolytic action of the herb. 
Physical symptoms of anxiety include irritable bowel (B.M.A. 2002) and  S. lateriflora 
is traditionally prescribed for anxiety-related digestive disturbances (Bergner 2002).  
Muscle tension and back pain are also manifest symptoms of anxiety and the herb is 
also commonly prescribed for these conditions (Joshee et al. 2002; Hull 2010).  It is 
also used for mastalgia and premenstrual tension (Greenfield & Davis 2004; Hull 2010) 
which may explain the alleviation of these symptoms reported by one participant.  S. 
lateriflora’s antispasmodic actions (Felter & Lloyd 1898) are as likely as its anti-
inflammatory and anxiolytic effects (Greenfield & Davis 2004) to have contributed 
towards the attenuation of her dysmenorrhoea. 
 
Relief of hay fever and eczema symptoms reported by two participants during skullcap 
treatment is potentially explained by the well known phenomenon that onset or 
exacerbation of symptoms of allergies are often preceded by emotional or physical 
stress (Jefferies 1994).  S. lateriflora is traditionally used to alleviate emotional stress 
(Bergner 2002; Gao et al. 2008). 
7.8 Participant comments: with discussion notes on 
unexpected responses to interventions 
According to the BAI (Beck & Steer 1993), of the 31 participants who completed the 
study, 11 were initially experiencing minimal anxiety (BAI scores 0 -7), 14 were mildly 
anxious (BAI scores 8-15), 3 were moderately anxious (BAI scores 16-25) and 3 had 
severe anxiety (≥ 26).   
The following comments are reported exactly the way in which they were written by 
participants.  No comments have been omitted from the sample of 13 participants who 
wrote down their experiences in the form of a commentary. In addition to comments 
from participants, any unusual responses, in particular when there was a likely placebo 
response, are noted in this section.  A full discussion on placebo effects is in the main 
discussion section in Chapter 8.   
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7.8.1 Possible placebo responders 
All participants completed a personality test, the Big 5 Minimarker (Saucier 1994b) and 
for interest the predominant personality traits will be noted for each participant 
mentioned in this section in order to determine whether there is a particular personality 
type that responds to placebo.  
The following 2 participants, for whom there were notable alterations in scores whilst 
taking placebo as the first intervention, intimated satisfaction with the corresponding 
change in their mood.  
One participant (P.05) said that after 5 days of taking capsules (first intervention): 
 
She also reported that she was sleeping better and did not take a long time to fall asleep 
as she would normally.   
In her diary she marked the second day of taking the placebo with a large, black ‘X’ and 
“last strong feeling of anxiety”. 
On later revelation of the code it was evident that this participant was taking placebo 
first.  Her score on BAI had reduced by 19 points with the placebo from 32 (severe 
anxiety) to 13 (mild anxiety), which is considered to be a statistically significant 
change. In a previous study of 20 participants (Prasko et al. 2006) a mean reduction 
(SD) of 8-12 points (3-5) in subjective anxiety on BAI (Beck & Steer 1993) following 
moclobemide (a monoamine oxidase inhibitor) pharmacotherapy was calculated to be 
statistically significant.   
Her BAI score increased slightly to 14 on skullcap.  Furthermore, whilst taking skullcap 
she reported difficulty in falling asleep.  Her Tension-Anxiety (T-A) scores on POMS 
also decreased significantly, from 27 points at baseline to 11 with placebo, increasing to 
24 whilst on skullcap.  Depression-Dejection (D-D) scores decreased with placebo from 
a score of 25 at baseline to 9 and increased to 18 whilst on skullcap.  Anger-Hostility 
“I felt more sociable, not anxious - not worried about 
anything.  I had no panic attacks.  I felt good even though I 
was ill with a cold, I had problems at work and my boyfriend 





(A-H) scores were 25 at baseline, decreasing to 12 with placebo and increasing to 22 
with skullcap.  This participant’s placebo response requires special attention.  Her Total 
Mood Disturbance (TMD) score on POMS was 84 at baseline, 26 with placebo and 74 
with skullcap.  A statistically significant change is considered to be 9 points (Derderian 
et al. 1988).  At 84, her baseline TMD score was outside the normal range, the cut-off 
TMD commonly being 68, which is based on normative data of a mean of 18 with 67% 
falling between -16 and 52 and only 7% of scores being above 68 (Lorr et al. 2005).  
Her response with the placebo (26 points) amounted to her score being within the 
normal range, returning with skullcap to being outside the normal range at 74. 
Personality (P.05): Her personality score range on the Big 5 Minimarker (Saucier 
1994a) was highest for Intellect/Openness (8.0; normative = 6.55) and lowest for 
Emotional Stability (3.0; normative = 5.79) (Saucier 1994c). 
There appeared to be a placebo response in a number of other participants who took the 
placebo capsules first:  
P.01 also thought (as reported to assessor) she was taking skullcap first when she was in 
fact taking the placebo and her scores reduced from 31 (severe anxiety) to 14 (mild 
anxiety).  They reduced by 1 more point to 13 on skullcap.  She said she was sleeping 
better and “not bothering too much about anything” whilst taking the placebo.   
P.01 showed little change in Tension-Anxiety on POMS during skullcap or placebo (15 
at baseline, 16 on placebo and 15 on skullcap) as her changes on BAI were due to a 
reduction in somatic symptoms.  Her Total Mood Disturbance score on POMS remained 
constant with placebo at 36 (36 at baseline) but decreased to 23 with skullcap, mainly 
because of a reduction in Anger scores from 10 at baseline and placebo to 4 with 
skullcap and an increase in Vigour from 14 at baseline and placebo to 18 with skullcap. 
Personality (P.01): Her personality score range on the Big 5 Minimarker (Saucier 
1994a) were highest on Conscientiousness (7.88; normative = 6.74) and lowest on 
Extraversion (4.5; normative = 5.7) (Saucier 1994c). 
Both of these participants (P.05 and P.01) disclosed at initial interview they were 
usually anxious so although remission may have been spontaneous it is unlikely that this 
was the reason for reduced anxiety scores on BAI during placebo treatment.   
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P.08: Scores on BAI also dropped considerably for this participant who took the 
placebo first – from 17 (moderate anxiety) at baseline to 8 (mild anxiety) at follow-up 
(reducing slightly to 7 points with skullcap).  Her initial TMD score on POMS was 80, 
which was outside the normal range, reducing to 22 with placebo and increasing a little 
to 28 with skullcap. The most notable changes with placebo were a decrease in D-D 
scores from 36 at baseline to 4 with placebo, further decreasing to 2 with skullcap; a 
reduction in T-A scores from 20 at baseline to 10, increasing to 12 with skullcap and a 
reduction in A-H scores from 18 at baseline to 10, increasing to 14 with skullcap.  
She wrote whilst taking placebo:  
 
Whilst on skullcap she wrote: 
 
Personality (P.08): Her range of scores on the Big 5 Minimarker (Saucier 1994a) were 
highest for Agreeableness (7.87; normative = 7.32) and lowest for Emotional stability 
(3.6; normative = 5.79) (Saucier 1994c). 
Other possible placebo responders were: 
 P.20: BAI score reduced from 19 (moderately anxious) to 9 (mildly anxious) whilst on 
placebo as the first intervention and increased to 12 during skullcap treatment.  
However, the POMS scores of this participant show a different story, albeit not for T-A, 
which showed little change (baseline = 17, placebo = 20, skullcap = 18). Her TMD 
decreased from 50 at baseline to 40 with placebo and to 28 with skullcap. The reduction 
in POMS scores was mostly related to a fall in D-D (baseline = 14, placebo = 13, 
skullcap = 4), A-H (baseline = 15, placebo = 13, skullcap = 9) and F-I (baseline = 10, 
placebo = 8, skullcap = 5) scores. No comments were made by this participant, other 
than being wakeful until 3 a.m. whilst on placebo. 
“I had a surprise visit from the Department of X (name provided 
by participant but anonymised here).  Very calm and not as 
stressed as I thought I would be.  However I was very tearful 
afterwards.” (P.08) 
 
“Paid council tax and was told that my rebate hadn’t been paid. 
Instead of getting angry and upset I felt clam and laughed about 




Personality (P.20): Score range on the Big 5 Minimarker (Saucier 1994a) was highest 
for Intellect/Openness (8.38; normative = 6.55) and lowest for Emotional Stability 
(4.38; normative = 6.55) (Saucier 1994c). 
P.21: BAI score reduced by 8 points from 14 (mildly anxious) to 6 (minimally anxious) 
on placebo as the first intervention - but further reducing to 4 on skullcap. His POMS 
scores, however reduced considerably whilst on both placebo and skullcap when 
compared to baseline for TMD (baseline = 41, placebo = 10, skullcap = 12), the major 
decrease being for A-H (baseline = 26, placebo = 10, skullcap = 6).  There was little 
change for T-A (9, 5 and 9 respectively).  
Personality (P.21): His score range on the Big 5 Minimarker (Saucier 1994a) was 
highest for Extraversion (7.63; normative = 5.7) and lowest for Conscientiousness 
(4.38; normative = 6.74) (Saucier 1994c). 
P.25:  BAI scores reduced from 15 to 4 on placebo (first intervention) and remained at 4 
whilst on skullcap. Her baseline POMS TMD scores of 3 were low, reducing to -1 with 
placebo and -13 with skullcap. 
Personality: P.25’s score range on the Big 5 Minimarker (Saucier 1994a) personality 
test was highest for Agreeableness (8.25; normative = 7.32) and lowest for Extraversion 
(5.5; normative = 5.7). 
As the baseline scores for both P.21 and P.25 were in the mild anxiety category, it is 
quite possible that anxiety in these participants would have resolved regardless of 
intervention (Vickers & Altman 2001). 
P.35, who also took placebo first, was initially in the severe anxiety category at baseline 
with a BAI score of 37.  His score reduced to 27 whilst on placebo but he was still in the 
severe category.  It was not until he took skullcap that his scores reduced to 20 and were 
in the moderately anxious category.  He said he felt ‘nothing new’ whilst on placebo but 
reported whilst on skullcap: 
 
 
“From the beginning of June [3rd day of skullcap] I was acting 
careless.  I didn’t care too much about my exams and even about 




P.35 had a very high TMD score on POMS at 130, the highest possible score on the 
scale, reducing to 90 with placebo and to 63 whilst taking the skullcap. The reduction 
was particularly prevalent with D-D, which was 44 at baseline, 32 with placebo (both 
outside the normal range) and 22 with skullcap (within the normal range).  Contrary to 
beliefs that skullcap may worsen depression (see practitioner survey, Chapter 3), it 
appears to reduce it in some in individuals. However, this is uncertain as although this 
participant was not excluded for high depression by the HADS (Zigmond & Snaith 
1983), the POMS scale includes feelings of dejection concomitant with depression (Lorr 
et al. 2005), unlike the HADS (Zigmond & Snaith 1983) so may not be comparable for 
true depression.  His T-A scores of 24 at baseline (above the normal range) reduced to 
17 with placebo and 14 with skullcap (both within the normal range).  His A-H score 
was also outside the normal range at baseline at 39, reducing to 24 with placebo 
(outside normal) and 19 with skullcap (within normal).  
 
Personality (P.35): His range of scores on the Big 5 Minimarker (Saucier 1994a) was 
highest for Intellect/Openness (7.63; normative = 6.55) and lowest for Extraversion 
(3.89; normative = 5.7). 
P.40: This participant, who took placebo first, was initially moderately anxious, scoring 
21 points on BAI at baseline.  He said he did not like to sit opposite people on the train 
as it made him nervous.  He also said he spits a lot when he talks if he feels anxious at 
the time.   
Although he appeared to experience a strong placebo effect with the first capsules (BAI 
score reduced to 7), his TMD scores on POMS demonstrated an enhanced mood whilst 
taking skullcap, reducing from 44 points at both baseline and placebo to 21 whilst on 
skullcap, mainly attributable to T-A scores reducing from 17 at baseline to 10 with 
skullcap (16 on placebo) and an increase in V-A scores (energy) from 8 at baseline to 21 
with skullcap (19 with placebo).  It appears his placebo response related to BAI only 
and not the POMS.  The difference could be because those with anxiety may have a 
heightened awareness of somatic symptoms (Geers et al. 2006), which are measured by 
BAI (Beck & Steer 1993) in contrast to the POMS, which does not specifically do so 
(Lorr et al. 2005). 
P.40 kept a diary only during test (skullcap) herb (BAI score reduced to 5). 






Personality: P.40’s score range on the Big 5 Minimarker (Saucier 1994a) were highest 
for Agreeableness (8.25; normative = 7.32) and lowest for Extraversion (4.0; normative 
= 5.7) (Saucier 1994c). 
It is possible that P.35 and P.40 may have had an initial (BAI) placebo response to the 
placebo intervention but noticed the difference when they took skullcap. 
It can be seen in Table 7-6 and Figure 7.23 (p152) that of possible placebo responders 
the dominant personality traits are Agreeableness and Intellect/Openness with a low 
emotional stability.  However, this compares closely with normative data derived from 
1125 residents of Eugene-Springfield, Oregon tested in 1993 (Saucier 1994c).   
Table 7-6  Mean scores on the Big 5 Minimarker personality test of placebo responders in 
comparison normative data 




Normative ± SD 
     
I Extraversion 5.41 ±1.27 5.7 ±1.31 
2 Agreeableness 7.19 ±1.11 7.32 ± 0.86 
3  Conscientiousness 6.47 ±1.28 6.74 ±1.12 
4 Emotional 
stability 
5.09 ±1.45 5.79 ±1.18 
5 Intellect/openness 7.12 ±0.91 6.55 ±1.09 
     
 
Day 3 on skullcap: “In the train sitting in front of people, no 
anxiety and very happy about it”. 
 
Day 4 on skullcap: “Starting to believe I am on the real herbal!  
Feeling good about myself.” 
 
Day 8 on skullcap: “I am doing street fundraising for a charity, 
speaking to people and no anxiety.  Later in the evening I am 
dining with friends. No anxiety.  A little spitting but under 
control!!!” 
 
Day 10 on skullcap: “I am thinking that there are things which are 
not great in my life such as my finance and my love life but I am 





Table 7-7 and Figure 7.24 (p157), which show means for the factors of the Big 5 
Minimarker scores for all study participants, were close to normative values. The results 
of this research did not yield a demonstrable personality type for placebo response (see 
also 7.9).  See main discussion section (Chapter 8:8.6, p181) for full discussion on 
placebo responders and personality. 
In general, when participants were convinced they were taking skullcap first it is likely 
they would have been equally convinced that they were taking placebo after crossover.  
Of course this is not withstanding the possibility that some may also have had a placebo 
response to skullcap. 
 
Figure 7.23   Mean scores of Big 5 Minimarker personality factors of placebo capsule 
responders 
 
7.8.2 Other comments from participants during the study 
 
P.04 (Sequence = test-placebo): 
 
It is notable that this participant showed no significant changes on BAI, reducing from a 











Day 10 (skullcap):  “Felt snappy and irritable.  Flew off the handle 
3 times”. 
Day 12 (skullcap):  “Felt relaxed and at ease. An easygoing, 
pleasant day.” 
Day 24 (placebo):  “Tetchy, tetchy, tetchy.  Woke up at 5 a.m. and 




therefore remaining within the mild anxiety category.  There was a significant 
difference in her TMD score on POMS with skullcap, however, from a score of 70 at 
baseline to 39 with skullcap, mainly due to a marked decrease in Anger-Hostility scores 
from 32 to 14 with skullcap.  Her TMD scores on placebo were 64 points, which can be 
accounted for by decreased energy (Vigour score of 9 from 19 at baseline and 18 on 
skullcap) and return of depression to 23 points in the D-D factor on POMS (24 at 
baseline, 16 with skullcap).  Her A-H score remained stable at 19. 
 
P.19 (Sequence = placebo-test): 
 
 
Her initial scores on BAI were 15, increasing to 19 with placebo and reducing to 11 
with skullcap.  Her POMS scores changed considerably with skullcap, reducing from a 
TMD score of 94 at baseline to 19 (90 with placebo).  T-A reduced from 22 at baseline 
to 7 with skullcap (18 with placebo); D-D reduced from 27 at baseline to 10 with 
skullcap (22 with placebo); A-H reduced from 34 at baseline to 7 with skullcap (27 with 
placebo). 
 
P.23 (Sequence = placebo-test): 
 
 
Day 10 (placebo): “Woke up feeling hot and bothered, anxious and fearful 
about the commitments and issues in my life”  
Day 16 (placebo): “All week lacking motivation and generally feeling low 
emotionally, negative and angry.” 
Day 27 (skullcap): “Slept amazingly well, couldn’t remember when last 
slept so well.  Woke up relaxed and not angry. Warm, fuzzy feeling.”  
Day 36 (skullcap): “Continue to be happy and relaxed and calm and not 
getting stressed in spite of so much to do”. 
Day 37(skullcap): “I have really enjoyed doing this study and got so much 
benefit from it, especially in terms of the disappearance of my stress and 
anxiety, which previously dominated my life.”  (P.23) 
 
Day 25 (skullcap): “More hopeful, not as bad feelings as before”. 
Day 32 (skullcap):“Definitely feeling more positive about most 
things – dealing with problems more efficiently, so coping better.”  
 
“With the first capsules [placebo] I felt no different.  I was just as 




P.23’s initial BAI score was 10, rising to 17 on placebo and reducing to 1 with skullcap. 
This participant had an unusual response to placebo (in comparison with the other study 
participants) in that her scores considerably increased on the POMS from a TMD of 18 
at baseline to 115, reducing to -24 with skullcap.  Her POMS T-A score on skullcap, for 
example, was 0 (16 at baseline and 30 with placebo).  Her A-H score with skullcap was 
also 0 (17 baseline; 32 placebo) as was her F-I score (3 baseline; 21 placebo). 
 
The following two participants appeared to have a more favourable response to the 
second intervention even though it was placebo: 
 








P.37 was in the mild anxiety (< 15) category as measured by BAI, scoring 9 at baseline, 
reducing to 7 whilst taking skullcap and further to 2 with the placebo.  Similarly, her 
scores for all factors on POMS were low at baseline, with a TMD of 43 (within the 
normal range; 67% of scores for adult norms fall between -16 and 52), reducing to 4 
with skullcap and -9 with placebo. P.39 was also within the mild anxiety category at 
baseline according to BAI; initial score was 14, reducing to 4 with skullcap and to 3 
with placebo.  Her POMS TMD scores were 17 at baseline, reducing to 12 with skullcap 
and -8 with the placebo.  Those with mild anxiety are more likely to undergo a 





“Felt a distinct difference between the capsules.  Felt more alert, 
slightly more energetic [and] able to focus and remain calm during 
a ‘tasking’ week (Placebo).” (P.39) 
“Days 27-37 should have been stressed due to exams however felt 





P.41 (Sequence = test-placebo): 
 
 
This participant also wrote (not relating to any particular days): 
 
 
P.41 scored 2 points on BAI at baseline, minimal anxiety (< 8), reducing to 0 with 
skullcap and remaining at 0 with placebo.  Her TMD scores on POMS were also very 
low at -9 at baseline, reducing to -7 and -3 with skullcap and placebo respectively.  It 
appears that, although P.41 was not particularly anxious or experiencing any negative 
mood at the beginning of the study, she nevertheless experienced some benefit from S. 
lateriflora. 
 
7.8.3 Participant symptom diary summary and 
conclusions 
According to the results of the participants’ diaries there was no toxicity and only mild 
side-effects in a few individuals, such as mild digestive disturbances and vivid dreams.  
There appeared to be a placebo response in 8 participants, which is likely to have 
affected the overall results of the study.  There was no particular personality trait linked 
to placebo responders. 
 
Fewer participants reported negative mood symptoms such as stress, depression and 
anger whilst on skullcap than whilst on placebo or at baseline or during the washout 
period.  Negative mood during skullcap treatment was relatively less frequent than 
during placebo treatment or washout. A predominant feature of taking skullcap was 
“I feel my head buzz one hour after taking tablet [skullcap].  It 
disappears after about half an hour.  I could stand it.”   
“My vocabulary usage has improved 10 fold!” (skullcap) 
“Felt fine throughout taking second batch of capsules [placebo].  
Did not notice any changes in my mood.” (P.41) 
 
Day 3: (skullcap): “I felt so calm about 1 hr after taking my 2nd 
tablet and went to supermarket and just completed my tasks very 
smoothly.  I felt very friendly towards other people too.”  
Day 14: (skullcap): “Generally feel calmer and go about my duties 
without issues. When issues arise I deal with them swiftly and 




prolonged feelings of happiness, contentment and feeling hopeful.  There was no 
difference between skullcap and placebo in effects on energy and no negative effects of 
skullcap on either concentration or motivation.  On the other hand, there were more 
reports of poor motivation during the placebo period.   
 
Headaches were also more prevalent during placebo treatment than with skullcap and it 
is notable that following a latency period of 5 days skullcap appeared to decrease the 
likelihood of headaches occurring. 
 
There was also apparent latency in effects on sleep patterns in some individuals whilst 
taking skullcap; those reporting sleep disturbances experienced the symptoms when 
they had been taking skullcap for over a week and those who reported improved sleep 
did so from a minimum of 3 days.  As the diary is entirely subjective reporting however, 
that is not to say those who did not report sleep experiences (n = 25) did not sleep well. 
There was little difference in sleep patterns between skullcap and placebo reported by 
participants but it should be emphasised that as insomnia is a feature of anxiety (Pary et 
al. 2003) only results from an anxious population would likely yield relevant results. 
 
Perhaps the most important finding from the participant diary results is the revelation of 
attenuation or resolution of chronic symptoms of longstanding conditions such as 
allergies, IBS, muscle pain and premenstrual symptoms.  These findings correspond 
with those in the literature review (see 2.5, p19) and practitioner survey (see Table 3-1, 
p54). Future clinical studies on S. lateriflora could assess these paradigms. 
 
 
7.9 Personality tests 
 
All participants completed a personality test, the Big 5 Mini-Marker (Saucier 1994b) to 
determine whether or not there is a typical personality trait correlating to reduction in 
anxiety scores on BAI (Beck & Steer 1993), one of the primary outcome measures (the 
other is the POMS (Lorr et al. 2005)).  It can be seen from Table 7-7 and Figure 7.24 
that participants’ scores on the five Big 5 Mini-Marker dimensions were within the 




Table 7-7  Comparison of normative values of the Big 5 Mini-Marker (Saucier 1994b) and 
mean values from participants who completed the skullcap study. 
 





Mean participant score 














7.32 (0.86) 6.87 (1.08) 0.193 
III: Conscientiousness  
 
6.74 (1.12) 6.43 (1.20) 0.22 
IV: Emotional stability  
 
5.79 (1.18) 5.44 (1.21) 0.22 
V: Intellect/openness 
 






Figure 7.24  Mean values of scores for participants from the Big 5 Minimarker personality 
tests compared with normative values 




In order to determine which personality Factor correlated most highly with anxiolytic 
response to S. lateriflora, as determined by change scores, Pearson correlations were 
carried out against change scores from baseline following skullcap and placebo on 
Beck’s Anxiety Inventory (Beck & Steer 1993).   
 
An initial correlation analysis was conducted by entering all relevant variables (Factors 
I-V and sequence group: group 1 placebo-test, group 2 test-placebo) with BAI change 
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scores. This demonstrated a significant correlation with Factor I only (r = .318, n = 31, p 
= 0.041) and the order in which the intervention was taken (r = .511, n = 31, p = 0.002).  
Because the order in which the intervention was taken was highly significant it was 
decided to analyse the 2 order (sequence) groups independently. 
 
It can be seen from the slope in Figure 7.25 there is a high correlation between low 
scores on Factor I and change scores on BAI following skullcap for the placebo-test 
Group 1 (R2=0.399, n = 16, p = 0.006).  
 
 
Figure 7.25   Linear relationships between Factor 1 (Extraversion) and BAI change scores 
with skullcap according to group  
 
A linear regression confirmed lower scores on Factor 1 as a significant predictor of high 
change scores on BAI (F1, 13 = 8.645, p = 0.011) with 40% of change scores being 
explained by lower scores on Factor I for Group I (t = 2.94, p = 0.011). 
 
For Group 2 (test-placebo) there was no significant correlation between Factor 1 and 
BAI change scores (r = .150, n = 16, p = 0.289).   
 
As with skullcap, a correlation matrix was conducted to see which Factor could predict 
high change scores on BAI following placebo by entering all relevant variables (Factors 
I-V and sequence group: group 1 placebo-test, group 2 test-placebo). This demonstrated 
a significant correlation with Factor I (r = .323, n = 31, p = 0.038) in comparison with 
Factors II-V (p = > 0.15). There was no significance for the order (group 1 or group 2) 
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in which the placebo was taken for change scores with placebo (p = 0.181).  However, a 
regression analysis demonstrated no significant predictor of change scores on BAI for 
Factor I for placebo (F1, 30 = 3.378, p = 0.076, t = 1.838, p = 0.076). 
 
Overall, the results of the regression analyses demonstrate there is more likelihood of 
those with low  scores on personality Factor I (Extraversion) on the Big 5 Mini-Marker 
responding to skullcap but not to placebo for anxiety, shown by a reduction in scores on 
BAI following oral administration of skullcap. The response was only apparent in those 




Chapter 8. Discussion of the RCT results 
This research represents the first randomised, double-blind placebo-controlled repeated 
measures crossover study of the putative efficacy of Scutellaria lateriflora on multiple 
mood states and physiological measures of stress.  Although the results did not 
universally support the study hypotheses, nevertheless the findings make substantial 
contributions to the scientific and general herbal literature.  The positive results 
achieved in the study were from doses as recommended by the manufacturers (Eclectic 
Institute Inc.) of the freeze-dried S. lateriflora as well as those found to be effective in a 
previous clinical trial assessing the anxiolytic properties of the herb (Wolfson & 
Hoffmann 2003).  This chapter discusses major findings from the results of this clinical 
study of S. lateriflora. 
Participants were assessed for changes in anxiety levels and mood and salivary cortisol 
measures of stress following administration of S. lateriflora or placebo. Of 43 
participants commencing the study, results were obtained from those (n = 31) who 
completed it.  The primary outcome measures for assessment of effectiveness of S. 
lateriflora were changes in mean scores from baseline on Beck Anxiety Inventory 
(Beck & Steer 1993) (Appendix IX) and the Profile of Mood States (POMS) (Lorr et al. 
2005).  Secondary outcomes were mean changes from baseline in salivary cortisol 
measurements and observational outcome measures were changes in ALT levels, blood 
pressure and pulse as well as symptom reports from the participants’ diaries. 
8.1 Beck Anxiety Inventory: does S. lateriflora reduce 
anxiety? 
In any given year, up to one in six adults in the United Kingdom may suffer from a 
medically unexplained psychological disorder, the most common being anxiety (men 
4%; women 5%), depression (men 2%; women 3%) or both experienced at the same 
time (men 7%; women 11%) (Office for National Statistics 2006). Anxiety is ‘an 
unpleasant emotional state ranging from mild unease to intense fear’ (B.M.A. 2002).   
Physical symptoms of anxiety can include pallor, sweating, hyperventilation, diarrhoea, 
irritable bowel, flushing, dysphagia, palpitations, nausea, muscle tension and back pain 
(B.M.A. 2002).  Alleviation of these adverse effects on health is important.  Orthodox 
anxiolytic treatments, however, have been linked to unwanted side-effects and may lead 
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to tolerance and physical and psychological dependence (B.N.F. 2008).  There is a need 
therefore for safe, effective alternatives.  
American skullcap (Scutellaria lateriflora) has long been an important herb in North 
American traditional medicine systems and western materia medica for anxiety and 
related disorders (Cole et al. 2008). In vitro studies of S. lateriflora and its 
phytochemicals (Liao et al. 1998; Hui et al. 2000; Gafner et al. 2003b) and a small 
clinical study (Wolfson & Hoffmann 2003) suggest a positive therapeutic benefit of the 
herb for anxiety and its comorbidities.  To support and extend these findings, primary 
outcome measures for assessment of the effectiveness of S. lateriflora for anxiety were 
changes in scores from baseline on Beck Anxiety Inventory (Beck & Steer 1993).  The 
instrument was used to measure and compare subjective anxiety at baseline and during 
administration of placebo or S. lateriflora.  The hypothesis was that S. lateriflora would 
have a superior anxiolytic effect than placebo (when compared with baseline measures). 
 
Mean change scores from baseline (Table 7-3, p118) demonstrated an enhanced 
anxiolytic effect for S. lateriflora compared to placebo for Group 1 (placebo-test) and 
no significant mean change for Group 2 (test-placebo).  There was an enhanced effect of 
placebo compared to S. lateriflora for Group 2 (Figure 7.2, p116) suggesting an 
insufficient washout period for S. lateriflora, causing a sustained effect of treatment for 
those who took S. lateriflora first.  Overall, there was no significant difference between 
S. lateriflora and placebo (p = 0.191) but the results suggest that S. lateriflora may 
attenuate anxiety in some individuals. 
An important point to note, however, is the fact that very few participants could be 
considered to be in the anxious category.  On the other hand, by random chance, all of 
those in the severe anxious category (BAI scores >26) were in Group 1, which could 
account in part for the efficacy of S. lateriflora in this group, with those in Group 1 
showing higher initial mean (SD) anxiety scores of 15.73 (10.71) than those in Group 2  
at 8.81 (3.99).  Of the 31 participants who completed the study, 11 were initially 
experiencing minimal anxiety (BAI scores 0-7), 14 were mildly anxious (BAI scores 8-
15), 3 were moderately anxious (BAI scores 16-25) and 3 had severe anxiety (≥ 26).  
Altered scores following intervention in those with an initially low score could be 
explained by normal daily intra-individual fluctuations, spontaneous remission or 
regression to the mean (where the scores are likely to increase at follow-up).  
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Additionally, when there is a floor effect at baseline, as seen in Group 2, which included 
those with baseline BAI scores of below 8 and considered to have minimal anxiety, 
there is little room for the scores to go any lower (Ernst & Resch 1995; Vickers & 
Altman 2001; Twisk & Proper 2004). 
It was deemed important for the study to be of a duration that would not only prevent a 
high dropout rate but also produce less likelihood of remission of anxiety.  Although 
none of the participants had been diagnosed with any anxiety disorder, those on the 
moderate and high anxiety scales on BAI had self-reported persistent anxiety at their 
screening interview.  Generalised Anxiety Disorder (GAD) for example is a chronic 
condition characterised by excessive worrying and hypervigilance and is often 
undiagnosed.  GAD is known to have low spontaneous remission rates, even following 
an intervention, with only one third experiencing full life-time remission (Wittchen & 
Hoyer 2001).  In contrast, those with mild or minimal anxiety during initial testing 
would be more likely to experience spontaneous remission of anxiety symptoms 
(Vickers & Altman 2001).  Furthermore, those suffering from GAD often present to a 
clinician with somatic symptoms of anxiety (Wittchen & Hoyer 2001), which will be 
evident during BAI anxiety tests allowing for higher initial BAI scores than those in a 
non-anxious group (Beck & Steer 1993). 
By chance the randomisation for this current study was not very successful, as 
evidenced by differences between groups at baseline for BAI and POMS.  This chance 
pre-test difference can be attributed to the small sample size (Metcalfe 2010). 
Comparability between groups tends to be limited when a sample size is small because 
of pre-test differences occurring between groups even when there is randomisation 
(Mitte et al. 2005).  The efforts asked of participants in the present study were quite 
exacting and the mean dropout rate of 28% was higher than average for studies of 
anxiolytics.  In a meta-analysis of 48 double-blind placebo-controlled trials of 
anxiolytic drugs (including benzodiazepines, azapirones and antidepressants) in patients 
with GAD the mean dropout rate was 24.4%.  This decreased to 20% for 
benzodiazepines (BDZs) (Mitte et al. 2005).  Because the range on the BAI scale 
between subjects was wide at baseline it is unclear whether or not the results in the 
present study may have been adequately comparable between groups if the dropout rate 
had been similar to that in studies of BDZs.  It is possible an inclusively anxious 
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population may not have yielded chance differences at baseline following 
randomisation. 
 
The BAI was constructed with psychiatric outpatients in mind; so the construct validity 
assessing the severity of anxiety or detecting it in normal adults was not known at the 
time of its development (Beck and steer 1993).  McDowell (2006) states that it is not 
intended for panic or phobias but research has indicated that it is more capable of 
assessing the severity of panic disorders than of GAD.  Its superiority in assessing panic 
disorders is believed to be related to the somatic symptoms on the scale (Leyfer et al. 
2006).  Cox et al. (1996) proposed that it measures mainly panic attacks instead of 
anxiety in general, whereas evidence suggests that in the field of anxiety disorders as a 
whole, panic attacks are qualitatively distinct from anxiety symptoms (Cox et al. 1996) 
and similarly panic disorder is physiologically distinct from GAD (Graeff 2007).  Steer 
and Beck responded to Cox et al. (1996) by defending their instrument’s capability of 
measuring general anxiety symptoms, asserting that somatic symptoms such as 
pounding heart, difficulty in breathing or sweating represent anxiety generally, are 
typically found in those with GAD and are not unique to panic attacks (Steer & Beck 
1996).  Nevertheless, subjects with any anxiety disorder score significantly higher on 
BAI (p = < 0.001) than those with no anxiety (Muntingh et al. 2011).   
 
Our study sample was deliberately a non-psychiatric population and not intended for 
diagnosis of anxiety with BAI.  It was notable that somatic symptoms such as 
“wobbliness in legs” were rare in our study sample.  This may be a confounding factor, 
resulting in low scores if the scale has a tendency to be loaded towards somatic 
symptoms of GAD and panic disorder (Cox et al. 1996; Steer & Beck 1996; Leyfer et 
al. 2006; Muntingh et al. 2011).  Therefore, BAI may not be appropriate in a normal, 
non-psychiatric sample for measuring response to an intervention.  Further study is 
needed to assess its validity in non-clinical samples and it would be appropriate for 
future studies of S. lateriflora’s putative efficacy to be concentrated on clinical samples. 
8.2 Profile of Mood States: does S. lateriflora enhance 
mood? 
This 65 item validated questionnaire (Lorr et al. 2005) measuring subjective mood 
states (see 6.10.2, p97 for details) was fast and simple to administer.  It evaluated six 
mood states: tension-anxiety, depression-dejection, anger-hostility, vigour-activity, 
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fatigue-inertia and confusion-bewilderment at baseline and at the end of each 
intervention period (placebo or S. lateriflora).  In addition, it assessed participants’ 
Total Mood Disturbance as a global measure of mood. This was obtained for each 
individual participant by summing the scores of each factor and subtracting the score for 
Vigour-Activity (Table 7-4, p118), which was negatively scored because it is a positive 
rather than a negative mood state.  Participants were asked how they had been feeling 
during the past week, including today.  The POMS has been found to be sensitive to 
changes in mood following administration of benzodiazepines (Frey et al. 1998; Lorr et 
al. 2005; Uhlenhuth et al. 2008), findings considered relevant to the present study as  
flavonoids found in S. lateriflora were found to bind to benzodiazepine receptors in 
vitro (Liao et al. 1998; Hui et al. 2002) (see 2.12.1.1, p31).  
8.2.1 Tension-anxiety 
For POMS Tension-Anxiety, although there was a highly significant reduction in scores 
with S. lateriflora (p = 0.002) there was also a significant reduction in scores with 
placebo (p = 0.028); the results indicated no significant difference between S. lateriflora 
and placebo (p = 0.473) overall and no significant differences in the effects of S. 
lateriflora in T-A attenuation between groups.  There was, however, an enhanced effect 
of placebo over S. lateriflora for Group 2, suggesting an insufficient washout period 
following S. lateriflora treatment.  Because of the possibility of a continuation of the 
effects of S. lateriflora following washout for Group 2, who took S. lateriflora first, the 
overall efficacy of S. lateriflora on T-A may be underestimated by this being a 
confounding factor.  Results suggest, however, S. lateriflora attenuates tension/anxiety 
in some individuals. 
8.2.2 Depression-dejection 
The results confirmed there was no significant difference between the effects of S. 
lateriflora and placebo on Depression-dejection (p = 0.067) but there was an enhanced 
effect of S. lateriflora in reducing D-J scores compared to placebo for Group 1 (order = 
placebo-test) and an enhanced effect of placebo compared to S. lateriflora for Group 2 
(order = test-placebo), indicating an insufficient washout period and a sustained effect 
of S. lateriflora for Group 2.  As with T-A the carryover effect of S. lateriflora may be 
causing an underestimation of the ability of the herb to reduce depressive symptoms but 




An important point to note is that baseline scores for depression in this study were 
intentionally relatively low.  An exclusion criterion was significant depression i.e. > 8 
on the HADS (Zigmond & Snaith 1983) as anecdotal evidence from the practitioner 
survey (3.4.8, p58) suggested S. lateriflora might worsen severe depression.  However, 
the results demonstrated a significant reduction in D-J scores for this factor in some 
individuals.  Participant 35, for example, had a high D-J score of 44 at baseline, 32 with 
placebo (both outside the range for adult norms; mean = 8 ± 9.3 SD; cut-off > 23 
requiring special attention) and 22 with S. lateriflora (within the normal range) (Lorr et 
al. 2005).  This participant did not have an overly high HADS depression score ( = 8) 
but the POMS D-J also measures feelings of inadequacy associated with symptoms of 
depression (Lorr et al. 2005) so these feelings may have been a major factor in this 
participant.  Only 5 participants (3 of whom took S. lateriflora first) showed a mild 
increase in D-J scores following S. lateriflora (an increase of 1, 2, 3, 6 and 9 points 
respectively) and four (2 of whom took placebo first) showed an increase in D-J scores 
with placebo (an increase of 3, 8, 8 and 18 points respectively).  
 
The results from the D-J scores coupled with findings that S. lateriflora does not appear 
to worsen existing depression suggest that future work assessing its efficacy in those 
with anxiety disorders need not exclude those with comorbid depression.  This is 
important because there is a high comorbidity rate with anxiety and depression (Mitte et 
al. 2005; Greaves-Lord et al. 2007).  For example, for a lifetime diagnosis of GAD 
there is an estimated 50% rate of comorbidity with depression.  It is therefore essential 
that an effective anxiolytic does not exacerbate symptoms of depression.  A preferred 
anxiolytic would attenuate both anxiety and depression (Mitte et al. 2005).  A reduction 
in depressive symptoms comorbid with anxiety would be favourable regardless of 
whether the thymoleptic effects were as a result of S. lateriflora or to a psychological 
effect resulting from reduction in anxiety.  It would be worthwhile for future studies of 
S. lateriflora to assess the efficacy of S. lateriflora on anxiety and comorbid depression 
with the use of a validated instrument such as the Beck Depression Inventory (Beck et 
al. 1996) in addition to the Beck Anxiety Inventory (Beck & Steer 1993). 
8.2.3 Anger-hostility 
Although there was a slightly enhanced effect of S. lateriflora in reducing A-H scores (p 
< 0.001) compared with placebo (p = 0.037), overall the reduction in A-H scores from 
baseline following S. lateriflora compared to placebo treatment was not significant (p = 
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0.070).  A confounding factor, however, may be an insufficient washout period 
following S. lateriflora, demonstrated by the finding that, although there was an 
enhanced effect of S. lateriflora for Group 1, albeit insignificant, the differences, shown 
by independent sample t-tests, between Group 1 and Group 2 in the effects of S. 
lateriflora treatment were not significant (p = 0.466) but there was enhanced placebo 
effect compared to Group 1 (p = 0.041).  Overall, S. lateriflora reduced feelings of 
anger and hostility but this was not significant. The results suggest that a sufficient 
washout period may have yielded more positive results from the effect of S. lateriflora 
on T-A.  
8.2.4 Vigour-activity 
Importantly, the results showed that chronic administration of S. lateriflora does not 
cause a reduction in energy.  The results overall indicated that there was no significant 
difference between test and placebo in alteration of V-A scores (p = 0.244) but an 
enhanced effect of S. lateriflora for Group 1 (who took placebo first), for which energy 
levels were increased by a mean of 20%.  Group 2 (who took S. lateriflora first) showed 
a slight decrease in energy levels by a mean 6%.  The difference between the groups in 
the effect of S. lateriflora was significant (p = 0.003).  The reason for the difference 
between groups in the effects of S. lateriflora is unclear but could perhaps be accounted 
for by differences in anxiety levels between the groups at baseline.  Group 1 was 
generally more anxious than Group 2 with a mean anxiety score on BAI of 15.73 
(10.71), which is at the beginning of the moderate anxiety scale whereas mean scores 
for those in Group 2  at 8.81 (3.99) were just above the minimally anxious scale of < 8) 
(Beck & Steer 1993).  It is well known that anxiety sufferers, particularly those with 
GAD, may become easily fatigued and/or experience sleep disturbances such as 
frequent waking in the night or difficulty in getting to sleep (Fricchione 2004).  If 
attenuation of anxiety in the more anxious participants also led to less fatigue and better 
sleep the consequence would likely be increased daytime energy levels.  The slight 
decrease in energy following S. lateriflora for Group 2 is consistent with the earlier 
findings of Wolfson and Hoffmann (2003), who observed a mild decrease in energy in 
19 healthy volunteers following acute administration of S. lateriflora.  There was no 
mean baseline anxiety measurement provided in the Wolfson and Hoffmann (2003) 
study and no validated anxiety instrument was used so it is unknown whether or not it 
was an anxious population.  It is possible therefore that the study population was similar 




According to the British Herbal Pharmacopoeia (British Herbal Medicine Association 
1983) S. lateriflora is sedating so it could be hypothesised that a sedative effect of the 
herb may be beneficial in anxious subjects who sleep badly yet it may have a mildly 
sedating effect in the daytime in those who do not.  The difference cannot be entirely 
explained by greater anxiety and thus less energy for Group 1 at baseline, however, 
because energy levels as defined by V-A were normal at baseline for both groups. 
Normal adult populations have been estimated (from a sample of 400) to have a mean 
V-A of 19.3 ± 6.7 at baseline (Lorr et al. 2005) and in the present study, V-A was 17 ± 
6.65 for Group 1 and 15.56 ± 4.97 for Group 2.  A post-hoc correlation analysis 
confirmed there was no correlation between anxiety levels at baseline on BAI and 
change scores on V-A following S. lateriflora for either Group 1 (r = -.125, n = 15, p = 
0.328) or Group 2 (r = -.068, n = 16, p = 0 401).  There is, however, a possibility that 
the differences in alteration of V-A scores might be explained by differences between 
groups in predominant personality traits (see 8.5, p179 Personality tests). 
8.2.5 Fatigue-inertia 
Overall, although there was an enhanced effect of S. lateriflora compared to placebo in 
decreasing fatigue and inertia, the results showed the difference in treatment effects 
between S. lateriflora and placebo were not significant (p = 0.209), indicating overall 
that S. lateriflora does not cause fatigue when taken orally.  The enhanced effect of S. 
lateriflora in reduction of fatigue and inertia was only apparent in Group 1.  As 
previously discussed in relation to V-A this cannot be convincingly explained by greater 
anxiety in this group. 
8.2.6 Confusion-bewilderment 
Overall S. lateriflora had no significant effect on C-B; there was no significant 
difference between S. lateriflora and placebo (p = 0.838).  There was, however, an 
enhanced effect of placebo compared to S. lateriflora for Group 2, suggesting 
insufficient washout. Importantly the results suggest that chronic administration of S. 
lateriflora does not impair cognitive function.  One participant (P.41), for example, said 
S. lateriflora gave her increased mental clarity.  She believed her vocabulary had 
increased while she was taking the herb.  Results of the current study conflict with 
results from the study by Wolfson and Hoffmann (2003) in which there was a mild 
reduction in cognition.  The studies are not directly comparable, however as the latter 
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assessed the effects following acute administration of the herb and no validated 
instruments were used.   
8.2.7 Total Mood Disturbance 
The results for TMD suggest no significant difference between S. lateriflora and 
placebo in improvement of global mood (p = 0.137).  There was, however, a significant 
difference between groups in the effect of S. lateriflora (p = 0.017) but not of placebo (p 
= 0.794).  It can be seen from Figure 7.10 (p127) and Figure 7.11 (p128) that there was 
an enhanced effect of S. lateriflora for Group 1 (placebo-test) compared with placebo 
and there was an enhanced effect of placebo compared to S. lateriflora for Group 2 
(test-placebo).  Group 2 scores continued to decrease, suggesting an insufficient 
washout period.  Although this was not very significant it may nonetheless have caused 
an underestimation of the global effects of S. lateriflora on mood.  Despite the 
confounding factor of a potential carryover effect, the results suggest a significant effect 
of S. lateriflora on global mood in some individuals.  Mean TMD (SD) scores at 
baseline, at 45.27 (37.41) for Group 1 and 31.06 (24.08) for Group 2 were above the 
mean of 17.7 (33) for adult norms as estimated by Lorr et al. (2005) but decreased to 
13.33 (27.99) for Group 1 and 19.56 (18.06) for Group 2 (but further decreasing to 
17.25 (33.87) with placebo for Group 2). 
8.2.8 Main findings from the POMS 
The results for the POMS factors (Lorr et al. 2005) imply that chronic administration S. 
lateriflora enhances mood in healthy volunteers without a decrease in energy or 
cognition. Main findings were: 
 A significant decrease in T-A following S. lateriflora but only in those who took 
placebo first, suggesting S. lateriflora attenuates anxiety in some individuals. 
 A significant decrease in D-D following S. lateriflora but only in those who took 
placebo first, suggesting S. lateriflora has a thymoleptic or antidepressant effect 
in some individuals. 
 A slight decrease in A-H following S. lateriflora but only in those who took 
placebo first, suggesting S. lateriflora calms feelings of anger and hostility in 
some individuals. 
 No decrease in energy or cognition following chronic administration of S. 
lateriflora as evidenced by the results from V-A, F-I and C-B. 
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 For T-A, D-D, A-H and TMD an insufficient washout period following S. 
lateriflora was evident, which may account for significant results in those who 
took placebo first but may underestimate the response to S. lateriflora overall. 
 
It is difficult to extrapolate findings from the present study of the effects of S. lateriflora 
on mood as reflected by POMS (Lorr et al. 2005) results to those of orthodox 
anxiolytics, particularly considering that a comparison of dosage strength is currently 
impossible.  These findings do, however, suggest some of the effects of S. lateriflora on 
mood are comparable with certain benzodiazepines.  For example, consistent with the 
results for Group 1 (placebo-test) in the present study, during early development of the 
POMS, in a double-blind placebo-controlled study of 150 male psychiatric outpatients 
administered 4 x 10 mg daily chlordiazepoxide (Librium) over five weeks there were 
significant reductions in T-A and an increase in V-A compared to placebo and no 
treatment groups (p = 0.05) (Lorr et al. 1963).  As the study by Lorr et al. (1963) was a 
parallel study results were not complicated by a potential problem of carryover as in the 
present study (as seen in Group 2 who took S. lateriflora first). 
 
On the other hand, when Frey et al. (1998) used the POMS (Lorr et al. 2005) in a 
double-blind, placebo-controlled anxiolytic drug discrimination study in 10 healthy 
volunteers, they found buspirone and diazepam produced effects on mood differing 
from S. lateriflora and Librium (Lorr et al. 1963) and between the two anxiolytics.  In 
this study each participant randomly received ten exposures to each of 3.75, 7.5 and 15 
mg buspirone, 2.5, 5.0 and 10.0 mg diazepam, and lactose placebo and completed the 
POMS immediately before each drug administration and 2 hours following each drug 
administration.  Baseline measurements on the POMS related to how they were feeling 
‘right now’ and post-drug measurements were based on feelings during the last 2 hours. 
In comparison to placebo, the diazepam and buspirone produced dose related mean 
decreases in V-A scores; and the highest dose of buspirone but not diazepam resulted in 
significant increase in T-A scores. The high dose diazepam, but not buspirone, 
significantly increased F-I and C-B scores (Frey et al. 1998).  The results suggest that S. 
lateriflora is superior to diazepam and buspirone in its ability to produce mood 
enhancing effects without side-effects such as a reduction in energy or cognition. 
Furthermore, it has not been known for high doses of S. lateriflora to produce 
anxiogenic effects similar to those seen from a high (15 mg) dose of buspirone.  The 
results of a practitioner survey on the use of S. lateriflora did not reveal any such effects 
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(see 3.4.7, p56), even though administration was up to 105 ml or 35 g dried or fresh 
herb equivalent per week (approximately 1.7 g/dose).  Other side effects produced by 
buspirone but not diazepam included dizziness and nausea. 
 
Buspirone belongs to the azaspirodecaedione (azapirone) class of anxiolytics and is 
primarily used to treat GAD.  It is pharmacologically distinct from the benzodiazepines 
such as diazepam in that it modulates serotonin synthesis whereas BDZs act on the 
GABAA receptor, increasing availability of GABA.  Buspirone acts as a full agonist on 
the presynaptic serotonin receptor subtype 5-HT1A (decreasing neuronal firing and 
hence inhibiting serotonin synthesis) and as a partial agonist at postsynaptic serotonin 
receptors (Frey et al. 1998; Vanin 2008).   
 
In another study using the POMS as a subjective measure of mood, 26 panic disorder 
patients received escalating doses of the benzodiazepine alprazolam for 4 weeks and 
then a fixed dose for of 1 mg four times daily.  Momentary mood was measured at 
baseline and at 1, 2, 3, 4, 6 and 8 weeks (Uhlenhuth et al. 2008).  Consistent with the 
findings of Frey et al. (1998) increasing plasma levels of alprazolam was associated 
with decreasing V-A and increasing C-B scores, said to be reflecting sedation and 
dysphoria (Uhlenhuth et al. 2008).  In the current study S. lateriflora was not found to 
worsen symptoms of depression or increase confusion.  On the contrary, the results 
suggested that it may attenuate depression.  
8.3 Salivary cortisol: does S. lateriflora attenuate stress? 
Cortisol is essential to life.  It has a role in the regulation of lipid, protein and 
carbohydrate metabolism; it maintains blood glucose levels by promoting 
gluconeogenesis in times of food shortage and stress (see also 1.5, p7); maintains the 
integrity of blood vessels and modulates immune function; its immunomodulatory 
action is principally as a potent anti-inflammatory agent and prevention of over-activity 
of the immune system (Sternberg & Gold 2002).  Repeated and/or sustained stress with 
concurrently increasing/high cortisol output and consequent cumulative exposure, 
however, may result in compromised immune function, exhaustion, depression and 
behavioural changes (Greenspan 1991).  As with other hormones, it is cortisol’s 
interaction with neural pathways that causes it to have an effect on behaviour (McEwen 
2006).  Cortisol hypersecretion has also been associated with decreased hippocampal 




This is the first time measurement of salivary cortisol concentrations has been used to 
determine the putative benefits of S. lateriflora on stress.  Negative feedback 
mechanisms are overridden by stressors and during persistent stress there is increased 
activity with increased levels of circulating cortisol.  In PTSD and panic disorders, for 
example, there is chronic CRF and cortisol output (Mann et al. 2006).  Salivary cortisol 
concentrations reflect the activity of the HPA axis and over-activity of the HPA axis has 
been postulated to be associated with anxiety states (Tallman et al. 2002).  Conversely, 
the (GABA)/benzodiazepine receptor system mediates the inhibition by GABA of CRF 
and consequently the HPA axis and BDZs are thought to attenuate CRF via the effects 
of GABA-ergic neurons (Rohrer et al. 1994; Fries et al. 2006).  As S. lateriflora 
flavonoids, including baicalin, baicalein and wogonin, extracted from S. baicalensis but 
also found in S. lateriflora, had affinities for the BDZ binding site of GABAA receptors 
it was hypothesised that alterations in cortisol profile following administration of the 
herb would reflect its effectiveness in attenuation of anxiety.   
 
To this author’s knowledge, this is the first time depressed individuals have been 
excluded from a study of the relationship between anxiety, stress and diurnal salivary 
cortisol levels. Previous studies have not adjusted for overlap of anxiety with 
depression.  Depression has consistently demonstrated higher basal cortisol levels than 
in healthy adults and furthermore is strongly associated with anxiety.  If present, 
because it has this tendency to affect the HPA axis it may interfere with results desirable 
from anxiety alone (Greaves-Lord et al. 2007). 
 
The results of the salivary cortisol analysis demonstrated that there was no significant 
difference between S. lateriflora and placebo (p = 0.524) and the mean diurnal cortisol 
was within the normal range before and after treatment (see below).  The mean results 
were also consistent with findings stated in the literature that levels are at their highest 
in the morning and gradually decrease throughout the day (Greaves-Lord et al. 2007).   
 
The range in salivary cortisol concentration in normal subjects is broad but in one study 
of 20 normal adults the mean (±SEM) concentration was 15.5 ± 0.8 nmol/L (range 
10.2–27.3 nmol/L) at 0800 h and 3.9 ± 0.2 nmol/L (range 2.2−4.1 nmol/L) at 20.00 h 
(Laudat et al. 1988) and Aardal and Holm (1995) established reference ranges in 195 
healthy volunteers (121 males, 74 females) as a mean 11.9 nmol/L, range 2.6-42.8 for 
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morning values (not the awakening response values) and a mean 1.8 nmol/L, range 0.5-
9.9 nmol/L for evening values.  Participants supplied at least one morning sample and 
one evening sample over a 24 hour period (Aardal & Holm 1995). 
 
Consistent with the results of (Laudat et al. 1988) and (Aardal & Holm 1995), mean 
salivary cortisol concentrations were within the normal range at baseline and following 
S. lateriflora and placebo.  At 3 hours following waking, for example, salivary cortisol 
concentration in nmol/L for participants in the S. lateriflora study was in the range 
(mean ± SEM) 1.94-20.51(7.62 ± 5.24) at baseline, 1.95-22.77 (7.36 ± 5.21) with S. 
lateriflora and 1.24-18.44 (7.49 ± 4.67) with placebo.  At 12 hours following waking 
ranges were 0.41-10.75 (3.93 ± 2.38) at baseline, 0.95-12.51(3.37 ± 2.79) with S. 
lateriflora and 0.73-11.72 (3.58 ± 2.37) with placebo.  As secretory activity of cortisol 
declines throughout the day in relation to the awakening response (Edwards et al. 2001) 
the mean salivary cortisol concentration at 3 hours for participants in the S. lateriflora 
study therefore appears within the normal range across all treatment periods when 
compared to the above values (Laudat et al. 1988) for healthy adults.  It also compares 
well with mean salivary cortisol results of Edwards et al. (2001) at 3 and 12 hours 
following waking (in figure ~ 7.0 and 3.5 respectively  - exact figures not provided in 
text).  Furthermore, higher concentrations (> 15 nmol/L) were negatively correlated to 
those reporting stress.  For example, participant No. 24 had a mean high of 20.51 
nmol/L salivary cortisol at 3 hours of the baseline period but did not report stress in the 
diary.  As subjective reports of stress did not reflect physiological measurements of 
stress, the diary was therefore not valid in assessing this paradigm.  It is also apparent 
from the diary reports, that stress was intermittent during the study, so assessment at 
only 3 time points was insufficient.  Transitory cortisol elevations could not be 
measured.  A superior method might be to use the Perceived Stress Scale (Cohen 1994), 
taking measurements over a number of consecutive days with concomitant saliva 
sampling, for each intervention as well as at baseline and during a washout period.  
 
Because there appeared to be no correlation between subjective reporting of reduced 
anxiety levels and mean physiological cortisol measurements as demonstrated by no 
mean change in salivary cortisol measurements, a Pearson’s correlation between anxiety 
scores and salivary cortisol values was not assessed.  The association between anxiety, 
stress and basal cortisol levels in healthy adults is, however, inconclusive.  A study of 
1,768 adolescents, for example, revealed no correlation between daytime salivary 
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cortisol levels and anxiety but there was a significantly higher cortisol awakening 
response in persistently anxious individuals than in those with current or no anxiety 
(Greaves-Lord et al. 2007).  Additionally, using self-report participant diaries of 
stressors and anxiety in a naturalistic setting with concomitant saliva samples, Kurina et 
al. (2004) found no strong association between self reported anxiety and stress and 
diurnal salivary cortisol patterns.  
 
An electronic search revealed there has been much research relating to the effects of 
anxiolytic pharmacotherapy, mainly BDZs, on the HPA axis.  As it is beyond the scope 
of this chapter to outline them all a small sample of these studies is discussed here.  A 
number of studies have demonstrated the ability of BDZs to attenuate cortisol output 
following acute administration; for example, diazepam (Tormey et al. 1979; Roy-Byrne 
et al. 1991; Schuckit et al. 1992; Pomara et al. 2005), temazepam (Beary et al. 1983; 
Korbonits et al. 1995), alprazolam (Charney et al. 1986; Risby et al. 1989; Zemishlany 
et al. 1990; McIntyre et al. 1993; Osman et al. 1993; Curtis et al. 1997; Pomara et al. 
2003), oxazepam (Gram et al. 1984).  Results, however, have been conflicting.  An 
early study (Garland & Zis 1989) found no alteration in afternoon serum cortisol levels 
in comparison to placebo in nine healthy volunteers administered oxazepam. All 
participants received oxazepam, codeine and placebo orally (30 mg of each).  Each 
intervention was administered on 3 different afternoons separated by 48-72 hours. 
Neither oxazepam nor placebo attenuated afternoon serum cortisol levels whereas 
codeine caused serum cortisol levels to decline.  The effects of codeine on cortisol 
levels were hypothesised to be attributable to the inhibitory effects of opioids on the 
HPA axis (Garland & Zis 1989).  In another placebo-controlled study, 6 healthy male 
volunteers were administered 10 mg diazepam intravenously and blood samples for 
measurement of serum cortisol were taken at 0, 30, 60 and 120 minutes following 
administration at around 8 a.m.  Although there was a decline in cortisol levels over 
time for diazepam there was no difference between diazepam and placebo (Laakmann et 
al. 1984).  The study samples may have been too small, however, for the results of these 
two studies to be significant. Furthermore, studies of attenuation of cortisol by 
anxiolytics in non-stressed individuals may have little value. 
 
Few studies have assessed the acute effects of anxiolytics on the HPA axis following 
anxiogenic psychological challenge (Fries et al. 2006) but results so far have been 
promising, suggesting that certain BDZs inhibit activation of the HPA axis in stressful 
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situations.  Hellhammer et al. (1988) studied the effects of lorazepam (1 mg), 
alprazolam (0.5 mg) and placebo on the salivary cortisol stress response to harrowing 
film scenes in 60 healthy adults divided into 3 groups respectively.  Only lorazepam 
was effective in preventing a stress response.  These results conflict with those of 
Rohrer et al (1994), who found 0.5 mg alprazolam significantly attenuated serum 
ACTH and cortisol levels 15 minutes after a stressful speech by each of 10 healthy 
volunteers in comparison to placebo, which had no effect on the HPA axis (Rohrer et al. 
1994).  In another study, Benschop et al. (1996) observed 1 mg alprazolam significantly 
reduced serum cortisol and adrenalin levels in comparison to placebo in 25 males 
following a first-time parachute jump.  The study indicated alprazolam may attenuate 
the sympathetic-adrenal-medullary axis (SAM) in addition to the HPA axis.  Fries et al. 
(2006) determined the levels of blood ACTH and cortisol as well as adrenalin and 
noradrenalin and salivary cortisol in placebo-controlled study of 46 male volunteers 
administered 1 mg alprazolam prior to the Trier Social Stress Test (Kirschbaum et al. 
1993), which produces a rise in ACTH and anticipatory anxiety.  The test included 
subjective measures of mood and a free speech situation.  Participants administered 
alprazolam, but not those administered placebo, displayed a strongly blunted ACTH and 
cortisol secretion.  Inconsistent with the study by Benschop et al. (1996) the SAM axis 
was not affected by alprazolam (Fries et al. 2006).   
 
Midazolam has been shown to decrease salivary cortisol levels and thus to be of value 
in lowering anxiety and stress in patients about to undergo oral surgery.  In comparison 
to a control group (n = 18) 7.5 mg midazolam administered sublingually significantly (p 
= < 0.05) decreased salivary cortisol levels concurrently with a reduction in anxiety 
scores on the HADS (Zigmond & Snaith 1983) in otherwise healthy male patients (n = 
20) pre-medicated with the drug prior to undergoing molar extraction (Jerjes et al. 
2005). 
 
There appears to be a paucity of research relating to the chronic effects of anxiolytic 
pharmacotherapy on the HPA axis.  Consistent with findings in the present research, 
however, a study (Kalman et al. 2008) assessing chronic effects of a herbal anxiolytic 
on stress also yielded no statistically significant changes in salivary cortisol 
measurements.  A placebo-controlled parallel study of 26 obese women suffering from 
anxiety and who ate in response to stressful situations was conducted to determine the 
effects of Magnolia officinalis (magnolia) and Phellodendron amurense (cork-tree) on 
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anxiety and stress.  Saliva samples for salivary cortisol measurements were collected on 
waking, 30 minutes later and in the evening over 3 consecutive days at baseline and at 
the end of a 6 week study.  There were no significant differences in salivary cortisol 
measurements between intervention (Magnolia - Phellodendron) and placebo after 6 
weeks treatment.  The Magnolia treatment, however, significantly reduced anxiety in 
comparison with placebo when measured by the Spielberger STATE questionnaire but 
not the Spielberger TRAIT questionnaire (Spielberger et al. 1970), which may account 
for the inability of chronic administration of the active drug to significantly alter cortisol 
levels.  The authors suggested a larger study over a longer period of time may show 
efficacy with this variable (Kalman et al. 2008).  A study of the herb Rhodiola rosea 
(rosenroot), although not strictly considered an anxiolytic but is administered to stressed 
patients in the herbal clinic as an ‘adaptogen’ (a herb that modulates stress), however, 
did yield significant results when assessed for its efficacy in lowering salivary cortisol 
concentrations.  In a placebo-controlled parallel study of 60 stressed volunteers, 
Rhodiola administration significantly decreased the cortisol response to awakening in 
comparison to baseline measurements and placebo (p = < 0.05) (Olsson et al. 2009).  In 
this study, participants gave saliva samples daily, which might account for the positive 
results, unlike the present study on S. lateriflora and the study by Kalman et al. (2008), 
both of which assessed cortisol levels only at baseline and following interventions.   
 
The results of the above studies suggest that attenuation of the HPA axis is likely to be 
dependent on anxiolytic type, even within drug group as well as the test situation as 
certain BDZs appear to affect (block) cortisol secretion in some stressful situations but 
not in others.  It is unclear whether attenuation of the HPA axis is also likely to depend 
on dosage.  In a crossover study of young (n = 52, mean age 27) and elderly (n = 31, 
mean age 67) volunteers Pomara et al. (2005) found acute and chronic challenge of both 
high and low dose diazepam (2.5 mg or 10 mg) significantly decreased plasma cortisol 
levels, but only in the elderly, when compared to placebo.  Cortisol response to 
diazepam was not associated with a GAD status evident in 19 young and 16 elderly 
volunteers (Pomara et al. 2005).  Overall, the results of the above studies also suggest, 
because physiological responses to psychological (and physical) stress are reflected by a 
rise in cortisol levels (Kirschbaum & Hellhammer 1989) that the effects of S. lateriflora 
on the HPA axis could perhaps be better demonstrated during an acute stressful 




8.4 Safety and tolerability: is S. lateriflora safe to use? 
8.4.1 ALT levels 
Reports of hepatotoxicity associated with S. lateriflora have been attributed to its 
occasional adulteration with Teucrium species (McCaleb 2004).  Although the freeze-
dried S. lateriflora used in the study was found by HPLC analysis (see 5.5, p79) to be 
authentic and unadulterated it was still important to assess liver function in participants 
following administration of the herb to ensure there were no toxic effects from S. 
lateriflora.  There have been no reports of toxicity attributed to use of authentic, 
unadulterated S. lateriflora but this present clinical analysis heralded the first time this 
was demonstrated scientifically in human volunteers. 
 
According to Pratt and Kaplan (2000) Scutellaria (species not given) is reported to 
cause elevation of liver enzyme levels.  This assertion was not substantiated as no 
citation was provided by the authors.  The results of the present study showed that 
although there was a statistically significant increase in ALT levels following 
administration of S. lateriflora there was no significant difference (p = 0.801) between 
S. lateriflora and placebo in ALT elevation.  Although there was a mean elevation of 
2.01 U/L ALT levels (from a mean 9.72 U/L) following S. lateriflora, in real terms this 
was not clinically significant and the increase was very mild because ALT levels were 
still well within the normal range of ≤ 22 U/L (men) and ≤ 17 U/ L (women) at 25oC 
(Roche 2008), indicating that authenticated S. lateriflora is safe to use.  Serious liver 
disease is not indicated until elevation of ALT is fifteen times the normal upper 
reference (Hamer 2010) and elevation up to twice the normal range is considered 
unlikely to be clinically significant (Pratt & Kaplan 2000).  
8.4.2 Blood pressure 
There were no significant changes from baseline in mean systolic or diastolic blood 
pressures following treatment with either S. lateriflora (p = 0.454 systolic; p = 0.513 
diastolic) or placebo (p = 0.395 systolic; p = 0.669 diastolic) and no significant 
differences in the effects of S. lateriflora and placebo on systolic (p = 0.410) or diastolic 
(p = 0.834) blood pressure parameters.  S. lateriflora is therefore unlikely to have the 
stated traditional action as a diuretic (Greenfield & Davis 2004) as diuresis is a 
mechanism for lowering BP by elimination of salt and water and reducing blood 
volume.  Diuretics are usually the first line of treatment for hypertension; in orthodox 
177 
 
medicine thiazides are most commonly prescribed (Stone & Darlington 2004) and in 
herbal medicine Taraxacum officinale folia (dandelion leaf) is the treatment of choice 
when powerful diuresis is required (Hoffmann 2003).  It is not clear, however, whether 
or not S. lateriflora would have reduced mean blood pressure readings in a study 
population with hypertension.  For safety reasons this was a normotensive population so 
it is unclear whether a reduction in blood pressure might be observed in a hypertensive 
population. Furthermore, Urtica dioica folia is mildly diuretic so potentially reduces BP 
(Hoffmann 2003).  One of the exclusion criteria (see 6.8.1.3, p91) was severe 
hypertension (>150/90) so mean blood pressure parameters for the study were within 
the normal range at baseline.  The recommended average healthy blood pressure in adult 
humans is 120/80 mm/Hg (Beers et al. 2006) was synonymous with baseline readings 
for the study and the results demonstrated there were no alterations from this ‘text book’ 
reading in either mean systolic or diastolic BP following either S. lateriflora or placebo.   
 
According to the results of a survey of herbal medicine practitioners (Brock et al. 2010) 
a common response looked for in patients was a lowering of blood pressure concomitant 
with a reduction in anxiety (see 3.4.4, p55).  A recent publication however, of a 22 year 
longitudinal study, the Nord-Trøndelag Health Study (HUNT) in Norway (Hildrum et 
al. 2011), appears to dispel previous hypotheses dating back to the early 20th
th
 century 
(Rutledge & Hogan 2002; Hildrum et al. 2011) that anxiety and stress raise blood 
pressure.  On the contrary, data from the study by Hildrum et al. (2011) of 17,410 men 
and women aged 20 to 67 demonstrated a higher mean decrease in both systolic (-1.59 
mm/ Hg, p = 0.004) and diastolic (-0.78 mm/ Hg, p = 0.019) blood pressures in those 
with high symptom scores of anxiety or depression measured on the HADS (Snaith 
2003) at baseline, at 11 years and at 22 years, in comparison with those with a low 
anxiety or depression symptom score.  The study results, which were adjusted for health 
status, smoking and alcohol consumption, indicated overall that those with anxiety 
and/or depression are 20% less likely to suffer from hypertension (>140 mm/Hg) at year 
22 than those without anxiety and/or depression (Hildrum et al. 2011).   
 
Furthermore, a quantitative review of 15 prospective studies linking psychological 
factors such as anger, hostility, anxiety, depression and stress found only moderate 
support for a link between these psychological factors and development of 
hypertension.  This was in the main due to poor methodological quality, such as use of 
non-validated psychological questionnaires; for example non-validated anger 
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questionnaires in 12 studies (Rutledge & Hogan 2002).  There was, however a strong 
association between anger and hypertension in one study (Everson et al. 1998) using the 
Spielberger Anger questionnaire (Spielberger et al. 1985).  In this study of 537 initially 
normotensive men, at 4 year follow-up there was a 12% increase in hypertension risk 
(mm/Hg ≥ 165/95, p = 0.002) in those with high anger scores (Everson et al. 1998).  
Despite the results of the HUNT study by Hildrum et al. (2011) and the current study 
suggesting that S. lateriflora is not a useful herb for attenuation of hypertension, this 
does not obviate the possibility that that it could be a useful hypotensive by indirect 
means.  Habitual, heavy smoking and alcohol drinking are linked to anxiety (Halliwell 
2009; McManus & Bebbington 2009) (see 1.4.1, p4) and there is evidence that both 
cigarette smoking and alcohol abuse raise blood pressure (Arkwright et al. 1982; Bonita 
1986; MacMahon 1987; Etminan et al. 2005) so it could be hypothesised that  
anxiolysis by S. lateriflora might reduce hypertension proneness from these causative 
variables in anxious individuals. 
8.4.3 Pulse rate 
There was no significant mean change in pulse rate from baseline following 
administration of either S. lateriflora (p = 0.557) or placebo (p = 0.415).  The difference 
in pulse rate between S. lateriflora and placebo (p = 0.144) was also not significant.   
The results demonstrated that S. lateriflora has no effect on pulse rate, which remained 
within the normal range of 60 - 100 BPM (40-60 BPM in athletes) in healthy adults, 
indicating a favourable health status of participants.  A high pulse rate (> 100 BPM), for 
example, can indicate tachycardia and conversely, a low pulse (< 60 BPM) may indicate 
bradycardia (Vorvick 2012).  The potential causes of cardiac arrhythmias such as 
bradycardia and tachycardia are too numerous to discuss here but in relation to the 
present study, tachycardia may indicate severe anxiety or panic attacks or may result 
from excessive use of stimulants such as caffeine, alcohol or certain drugs e.g. cocaine, 
amphetamines and tricyclic antidepressants.  Bradycardia can result from use of certain 
drugs, for example antihypertensive agents, beta blockers and calcium channel blockers 
(Seller 2007).  The absence of high pulse rate in any of the study participants suggests 
that there were no episodes of severe anxiety during visits and that no participants were 
using recreational drugs during the study.  The lack of decreased pulse rate suggests that 
S. lateriflora does not cause any physiological changes such as hypotension that may 
result in bradycardia.  The evidence from the results that it does not lower blood 
pressure in healthy subjects is further reinforced by pulse rates remaining stable. 
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8.5 Personality tests 
Although much has been written about the placebo/nocebo response e.g. (Beecher 1955; 
Harrington 1997; Shapiro & Shapiro 1997; Geers et al. 2005; Link et al. 2006; Weeks 
& Newman 2011), to this author’s knowledge there is little, if anything, in the available 
literature about the association between personality type and prediction of active 
response to an active herbal treatment.  This appears to be the first time a putative link 
between responders to a herbal anxiolytic and personality trait has been assessed.  The 
Big 5 Minimarker personality test was employed in conjunction with this current 
clinical research in an attempt to address this paradigm.   
 
There was a correlation between low Extraversion (Factor I) on the Big 5 Minimarker 
and high change scores on BAI following S. lateriflora for those who took the placebo 
first (p = 0.011).  This group had a higher mean anxiety score at baseline than those in 
the group who took S. lateriflora first.  However, as only 40% of high change scores 
could be predicted by personality (low extraversion) and 60% being attributable to 
something else unknown, the relationship between personality response to the test herb 
and change scores on BAI appears weak.  It would be interesting to repeat the analysis 
with a larger study population as if a stronger or weaker relationship is found in relation 
to personality trait and prediction of response to S. lateriflora it could help to inform 
differential psychopharmacological herbal treatment. 
 
There also appears to be a dearth of current information relating to association between 
personality and active response to orthodox anxiolytics.  Eysenck (1963) hypothesized 
that response to drugs is in accordance with personality types; he conducted a series of 
experiments to prove his theory and demonstrated that introversion/extraversion is 
responsible for these individual differences.  He found that the sedation threshold is 
lower in extraverts and that the performance of more highly aroused introverts could be 
improved by administration of tranquillisers (Eysenck 1963; Netter 2000).  These 
findings are consistent with those in the current research in which participants with 
higher anxiety and hence higher change scores on BAI, and thus reflecting a greater 
response to S. lateriflora, also correlated with low extraversion.  This may also be the 
reason why those with higher anxiety scores at baseline showed a greater increase in V-
A scores and greater decrease in F-I scores in comparison to those with lower anxiety 




The findings that S. lateriflora responders generally score low on extraversion 
corresponds to earlier findings by Golding et al. (1983), Golding and Cornish (1987) 
and Ashton and Golding (1989), who found a significant correlation between use of 
tranquillisers and higher scores for neuroticism and also for low extraversion on the 
Eysenck Personality Inventory. The Eysenck Personality Inventory (Eysenck 1975) 
consists of 4 factors: Extraversion, Neuroticism, Psychoticism and Lie.  Neuroticism 
encompasses anxiety (as well as depression, guilt, tension, emotional, shyness, 
moodiness and irrationality) (Eysenck 1975; Zuckerman et al. 1988).  Although those 
with high neuroticism and low extraversion have an increased likelihood of using 
tranquillisers or hypnotics, cause and effect cannot be distinguished between these 
factors (Ashton & Golding 1989).  It could be argued, however, as indicated by results 
of the current research demonstrating a significant correlation between low extraversion 
and response to S. lateriflora, that those who score high on neuroticism and low on 
extraversion may be more anxious and more likely to respond to anxiolytics (including 
herbal) than those who score low in neuroticism and high on extraversion and are 
possibly more likely to become dependent on tranquillisers.  Although chronic 
benzodiazepine users may develop comorbid psychosomatic symptoms (Ashton & 
Golding 1989) no such adverse effects inherent in tranquilliser use have been reported 
in S. lateriflora to date. 
 
Although success in the search for a personality type as predictor of response to herbal 
anxiolytics may be of use in informing practice, other factors may need to be taken into 
consideration.  For example, a systematic review (Bagby et al. 2002) revealed certain 
personality traits, have been found to be predictors of response to antidepressants 
(passive-aggressive, high extraversion and low hostility) but variables studied 
independently as predictors of response to antidepressants - such as comorbid 
psychological conditions, personality, age, sex, religion, cultural factors, use of 
substances such as alcohol and tobacco or concomitant drug use – have not been found 
to be strong predictors of treatment response.  However, the authors suggested that these 
variables and personality variables may nonetheless interact and complicate the picture 
(Bagby et al. 2002).  It could be argued that similar interactions may confuse putative 
personality predictors of treatment response to anxiolytics. 
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8.6 Placebo responders  
Eight participants (25% of all participants) who took placebo first appeared to have a 
strong placebo response from the placebo treatment (see section 7.8.1, p146).  The 
majority of potential placebo responders were in the moderate-severe anxiety category 
(BAI scores > 16; n = 6) (Beck & Steer 1993).  Only six of all study participants were in 
the moderate to severe anxiety category on BAI so it is noteworthy that all six appeared 
to be placebo responders.  The other two likely placebo responders were borderline 
mild-moderate anxiety with scores of 14 and 15 respectively on BAI.  It is not clear why 
anxious participants had a high placebo response to the placebo capsule.  One possible 
reason is a psychological effect from the first face-to-face interview acting as subtle 
psychotherapy (Kasper et al. 2009) but in general, anxious populations are more likely 
than non-anxious populations to have high placebo response rates (Sarris et al. 2009a).   
 
 Over the past 60 years or so the literature has indicated that the positive treatment 
effects of many drugs and other treatments are as a result of placebo responses (Beecher 
1955; Harrington 1997; Shapiro & Shapiro 1997; Geers et al. 2005; Weeks & Newman 
2011).  According to Shapiro and Shapiro (1997) the placebo effect is an important 
component in drug treatment of anxiety.  Beecher (1955) found evidence, citing studies 
of anxious and stressed patients as examples, that the more severe is a disease state, the 
greater is a placebo response to a placebo - or to a purportedly active drug that has no 
more power than a placebo.  Geers et al. (2006) suggest this phenomenon is linked to 
expectation when attention is focused on somatic symptoms of anxiety.  In their study 
they found that those who were told they were taking a drug that may produce 
unpleasant somatic anxiety symptoms (such as nervousness, perspiring and trembling) 
when it was in fact a placebo, experienced more side-effects than those who were told it 
was, or might be, a placebo.  The authors speculated the response was as a result of 
unconditional expectation coupled with a heightened awareness of somatic symptoms of 
anxiety (Geers et al. 2006).   
 
In the present research, consistent with previous findings (Beecher 1955; Shapiro & 
Shapiro 1997; Geers et al. 2006) it is possible that those who took the placebo first, if 
convinced they were on active drug, were more likely to feel a response, particularly 
considering that by chance this group was more anxious at baseline than the group who 
took S. lateriflora first.  Because they were keeping a symptom diary, they would likely 
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have been paying attention to somatic symptoms on a daily basis. Placebo response is 
discussed here only in relation to the subjective responses reported from the participant 
symptom diary because inspection of the means of the BAI and the POMS may not, 
considering the size of the study population and the baseline imbalances, provide a true 
picture.  Furthermore it was unknown whether the reduction in scores was as a result of 
regression to the mean in some individuals.  A larger study population would perhaps 
have obviated the baseline imbalance in the present research.  According to 
(Hrobjartsson & Gotzsche 2004):  
“The vast majority of reports on placebos, including Beecher’s article, have 
estimated the effect of placebo as the difference from baseline in the condition of 
patients in the placebo group of a randomized trial after treatment. With this 
approach, the effect of placebo cannot be distinguished from the natural course 
of the disease, regression to the mean, and the effects of other factors. The 
reported large effects of placebo could therefore, at least in part, be artefacts of 
inadequate research methods”.  
 
The placebo responders were not significantly linked to any particular personality 
dimension on the Big 5 Minimarker (see sections 7.8.1, p146 and 7.9, p156).  Efforts to 
determine links between personality type and placebo response appear to have produced 
insignificant or weak results despite great interest in the subject and by 2005 research 
had failed to find a specific personality type for placebo responders (Geers et al. 2005).  
Acquiescence and absorption, however, are personality traits that are most reported to 
be a predictor for placebo responding (Whalley et al. 2008).  Agreeableness, which is 
synonymous with these traits, is a personality dimension (Factor 2) on the Big 5 
Minimarker (Saucier 1994b) but there was no association between this factor and 
placebo responders in the present study. 
 
In their study of 54 healthy volunteers, Geers et al. (2005) found pessimists were more 
likely than optimists to respond to placebos.  Following completion of the Revised Life 
Orientation Test, which measures optimism/pessimism (Scheier et al. 1994), optimists 
and pessimists were randomly divided into 3 intervention groups and each participant 
was provided with a placebo pill.  One group were told they were taking a pill that 
would make them feel unpleasant, a second group (conditional-expectation) were told 
the pill may or may not make them feel unpleasant and the third group was a control 
group who were told the pill they were taking was inactive.  Fifteen minutes following 
ingestion of the pills participants filled in an affect questionnaire and of those who 
believed their pill was an active drug pessimists experienced significantly more side-
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effects than optimists.  There was no difference between pessimists and optimists in 
either the conditional-expectation or the control groups. The results suggested that 
pessimism is a significant predictor of placebo responding (Geers et al. 2005).  The 
study was limited by a small sample size and the use of a subjective, non-validated brief 
affect questionnaire.  Consistent with the findings of Geers et al. (2005), Whalley et al. 
(2008) found in a study of 81 healthy volunteers that pessimists are more likely than 
optimists to believe they are taking an active drug (even reporting related negative side-
effects) if told it was so when it was in fact a placebo; although there was no difference 
between optimists and pessimists in expectation of effects when they were told they 
might be taking a placebo (Whalley et al. 2008). 
 
Only negative effect placebo responding, known as a nocebo effect (Weeks & Newman 
2011), was assessed by Geers et al. (2005) and Whalley et al. (2008) so direct 
comparisons with placebo responders in this S. lateriflora study cannot be made. 
Placebo responders in this research had a tendency to high BAI scores at baseline and 
appeared to have a positive expectation effect from the placebo (placebo effect).  It is 
known that people with chronic worry (such as those with GAD) are pessimists and 
have negative expectations (Miranda & Mennin 2007) as do those who are pessimists 
(Geers et al. 2005), which might explain the results of Geers et al. (2005) and (Whalley 
et al. 2008) but does not explain the positive placebo-proneness in certain individuals in 
the current research.  
 
It cannot be judged definitively whether or not there was a placebo response to either 
the placebo or the S. lateriflora.  As the apparent placebo responders were all 
participants who took the placebo first it is difficult to ascertain the extent to which 
positive anxiolytic effects are as a result of S. lateriflora treatment in those who took S. 
lateriflora first or in fact due to placebo response or spontaneous remission (Geers et al. 
2006; Kasper et al. 2009).  Fewer than 4% of placebo-controlled clinical studies of the 
effects of medical treatments have included a no-treatment condition in addition to 
placebo but, notwithstanding financial pressures the addition of this factor to a future 
controlled trial of S. lateriflora might provide valuable information on placebo response 
(Ernst & Resch 1995; Geers et al. 2006).  A possible way to reduce the potential 
placebo response in this study may have been to include a placebo run-in phase.  
However, it was decided not to have a run-in for the study for exclusion of placebo 




Because anxious participants in a study are likely to have a high placebo response rate 
(Geers et al. 2006; Sarris et al. 2009a); for example, approximately 50% of studies of 
GAD patients have been unable to show efficacy for putative anxiolytic interventions 
because of a high placebo response (Kasper et al. 2009), around 70% of studies of the 
effects of BDZs eliminate placebo responders during a run-in phase (Sarris et al. 
2009a).  Furthermore, it has been found that up to 50% of participants in clinical trials 
for antidepressants respond to placebos and this has, according to Eli Lily, plagued drug 
development.  It is for this reason that the company has decided to exclude placebo 
responders.  Others however, believe that this is a subtle manipulation of results that 
could lead to the marketing of ineffective drugs.  Professor Kay Dickersin, currently 
Director of the Center for Clinical Trials at John Hopkins Bloomberg Center for Public 
Health and Director of the US Cochrane Center, said “such winnowing allows bias to 
enter in" and constitutes "a subtle manipulation" of trial results (Abboud 2004).   
 
According to a report by Berger et al. (2003) “if the intention is to determine how best 
to treat a patient initially, then response run-in selection should not be used”.  Exclusion 
of placebo responders reduces internal validity of a study i.e. it introduces bias.  
Participants are no longer representative of an unselected study population and therefore 
positive results of response to the test intervention may be misleading, as the statistical 
power of the results could be falsely increased when compared to placebo.  Similarly, 
excluding active non-responders may also give “over inflated results to treatment” 
(Berger et al. 2003). On the other hand, in a meta-analysis of randomised, controlled 
trials of anxiolytics tested on anxious patients, integrating the results of 48 studies, 
Mitte et al. (2005) found there was no increase in the difference between active drug 
treatment and placebo following placebo run-ins (Mitte et al. 2005). 
 
Although the results of the current study were complicated by a high placebo response, 
to exclude placebo responders in future studies would be detrimental to the heart of the 
clinical effectiveness of any herbal medicine intervention. The placebo effect in 
complementary practice is an integral part of the practitioner-patient relationship and 
therefore the treatment (Black 2009), where talking and listening may share and 
partially relieve the ‘burden of illness’ (Paterson & Dieppe 2005).  It is true to say that 
during the face-to-face interviews in the current study some participants shared their 
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emotions and worries with this interviewer, which may therefore account in part for 
placebo responses in some individuals. 
8.6.1 The Urtica dioica folia placebo used in this study 
There was some concern when choosing the placebo for this study that it may have 
some physiological effects that might interfere with the results.  Beecher (1955) 
described a placebo as ‘...pharmacologically inert substances; i.e. lactose, saline 
solution, starch’. 
 
The Urtica dioica folia used in this study cannot be said to be pharmacologically inert.  
It is commonly used as a mild diuretic and is sometimes prescribed for anaemia or for 
the nutritional properties because of its iron and mineral content (Hoffmann 2003); but 
there are no reports in the scientific or traditional literature of it having any 
psychopharmacological effects in humans.  It was important to use a convincing 
placebo.  In other words, if it did not smell, look and taste like a herb, participants were 
likely to have been aware they were taking a placebo.  Perhaps for the same reason, 
Wolfson and Hoffmann (2003), in their RCT of S. lateriflora for anxiety, also used 
another herb (Anthriscus cerefolium) as the placebo.  One of the difficulties in 
conducting randomised, controlled trials of herbal medicines is the awareness by 
participants of particular tastes and smells of herbs, which cannot easily be disguised 
(Zick et al. 2005).  Placebos need to be not only unidentifiable but must also be 
identical to the test substance in colour, taste and smell – or both test and comparator 
need to be ‘hidden’ by being encapsulated.  Our test herb, however, had a definite 
‘herbal’ aroma and colour, which was visible through the capsule shell, so the placebo 
was chosen to look and smell similar whilst having no known effects on mood.   
8.7 Onset of efficacy 
Onset of efficacy was not determined in this study.  It appeared from the participants’ 
diary reports, however, that this was possibly anything from day 3 in some participants 
up to day 10 in others, depending on the condition reported to be alleviated; for example 
three (P.35, P.40 and P.41) noticed an attenuation of anxiety on day 3 and two others 
(P.19 and P.23) reported the same on day 4 of using S. lateriflora.  Symptoms of IBS 
disappeared in one participant after 10 days, muscle aches disappeared in another after 3 
days while eczema showed signs of improvement in another after 5 days on S. 
lateriflora.  Five participants experiencing headaches whilst on S. lateriflora noticed 
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their disappearance after 5 days.  It would be interesting if future work could assess 
onset of efficacy of different variables in order to inform herbal practice. 
8.8 Carryover effects of the test herb 
The practitioner survey respondents (Chapter 3) reported the herb as being used over a 
range of time periods from immediate short-term use to ‘several years’, with positive 
response expected to be experienced by the patient within the first two weeks and 
persisting throughout the period of use.  This perhaps indicates that people believe it to 
be effective whilst being used but does not indicate for longer. 
 
In contrast, the present study found there was a residual effect of S. lateriflora in those 
who took it first, particularly in relation to BAI and the factors T-A, D-D, A-H, F-I and 
C-B and for TMD on the POMS.  This finding is important as it signifies a previously 
unknown beneficial effect of this herb.  BDZs are commonly known to cause a rebound 
anxiolytic reaction on sudden cessation of use (B.N.F. 2008), an obviously undesirable 
effect.  BDZs may also cause a rebound stress reaction, as indicated by findings of   
Pomara et al. (2003) who assessed both acute and chronic (3 week) effects of high and 
low dose lorazepam (0.25 mg, 1.0 mg b.i.d) and alprazolam (0.25 mg. 0.5 mg b.i.d) in 
68 healthy geriatric volunteers.  Only the 0.5 mg alprazolam dose attenuated the HPA 
axis in acute treatment when compared to placebo, as demonstrated by decreased 
salivary cortisol output but there was a significant increase in pre-dose cortisol output 
during chronic alprazolam treatment.  This effect was not observed with chronic 
lorazepam treatment (Pomara et al. 2003). 
 
Prolonged anxiolysis due to a residual effect of S. lateriflora following cessation may 
be a desirable factor in its administration, which is possibly in contrast to the residual 
effects of BDZs, which manifest as unpleasant withdrawal symptoms.  The noticeable 
pharmacological effects of some BDZs with long half-lives are considerably shorter 
than their half-lives and they may leave cumulative residual effects on the body (Ashton 
2008).  King’s American Dispensatory (Felter & Lloyd 1898) describes S. lateriflora as 
an antispasmodic nervine tonic that is calming in all cases of ‘nervous excitability, 
restlessness, or wakefulness’ without any rebound excitability on cessation of use.  This 
is worth remembering as it might imply that the benefit persists after cessation – 




There is always a risk of carryover in a crossover study.  One problem is that sometimes 
the condition is actually cured by the test treatment to such an extent that placebo may 
not result in a reversal of symptoms, regardless of the length of washout period. 
Another is that it may also continue to work if the washout period is not long enough, 
producing a carryover effect (Kotler & Laster 1998). 
 
It is difficult to accurately assess carryover effects unless the condition is chronic and 
stable (EMEA 1998).  A study on patients with GAD, which is a waxing and waning 
condition with a lifetime spontaneous remission of only one third, may give more 
significant results than those from an apparently healthy population who are more likely 
to have a remission of anxiety (Wittchen & Hoyer 2001).  In this present study there 
were few chronically anxious subjects and even those who scored high on the anxiety 
scale could not be said categorically to have trait anxiety.  There is no guarantee that 
spontaneous remission did not occur in some participants.  One way to test this would 
be to have another arm of the study in which there was no treatment in order to estimate 
the extent of the placebo effects (Geers et al. 2006) and to assess the possibility of 
spontaneous remission; or to repeat the anxiety instruments following a prolonged 
washout period and prior to recommencing either S. lateriflora or placebo.   
8.8.1 Minimising carry-over 
Estimation of washout times is frequently problematic with consequent design faults 
leading to inadequate results (Wang et al. 2006).  In this research it is evident that there 
may have been an under-estimation of the half-life of S. lateriflora and perhaps a 
washout period of at least 5 x 200 hours analogous with diazepam (Ashton 2008) 
approximately 6 weeks - would be appropriate.  This would necessitate a lengthy study 
period and perhaps more dropouts so would necessitate a larger study population.  A 
way around the problem of participant adherence could be to conduct a parallel study 
(double-blind RCT) of similar duration to the current study.   
 
In a cross-over design a washout or drug-free period is important for the avoidance of 
not only carry-over effects of an intervention from one arm of the study to another but 
also to avoid a combination effect of two drugs (Smith 1992).  In the case of the Urtica 
placebo in the present study, although not known to be active for anxiety, it is unknown 
whether its phytochemicals have the potential to interact with those in the S. lateriflora.  
A washout period must also be of a duration that is sufficient to ensure there is no 
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psychological carry-over effect e.g. a ‘memory’ of treatment effects, and that all 
participants have returned to baseline (Wang et al. 2006). 
 
The washout period necessary to avoid carry-over effects in a crossover study is usually 
determined as at least five times the half-life of a study drug and should be for a 
minimum of 7 days (World Health Organisation 2006).  This assumes the half-life is 
known.  The half-life of the active metabolites of some BDZs marketed as anxiolytics, 
for example, can be as much as 200 hours even though the effects of one dose may 
appear to wear off within a few hours.  When there is repeated dosing an accumulation 
of a BDZ drug or its metabolites occurs in fatty tissues; there is a cumulative effect and 
subtle physiological effects may persist (Ashton 2008).   
 
Although subjective reporting by human volunteers in a clinical trial suggests that the 
effects of a single dose of S. lateriflora wear off after around 2 hours (Wolfson & 
Hoffmann 2003), the half-life of S. lateriflora and its possible cumulative effects in 
humans are unknown - although some of its flavonoids have been studied to this effect.  
Following oral administration to 10 healthy volunteers of commercial skullcap root (S. 
baicalensis) powder, urinary excretion of conjugated metabolites of baicalein and 
wogonin was 7.2% and 11.6% of the original dose respectively.  The half-life 
eliminations for these conjugates were approximately 8 hours for baicalein and 10 hours 
for wogonin (Lai et al. 2003).  An indication of the length of time some flavonoids 
remain in the body may be a useful indicator for a washout period in a clinical study.  
Therefore, as a precautionary measure, it was judged that a washout period of a week 
would minimise potential physiological or psychological carry-over effects following 
repeated dosing. 
 
Another reason why a week’s washout was judged to be conducive to a return to 
baseline mood and desirable prior to taking new capsules is because there is evidence to 
suggest that mood may be affected by social zeitgebers (environmental factors that 
synchronize the endogenous cycle or circadian rhythm to 24 hours) of the calendar 
week (Reid et al. 2000).  Carry-over effect of an intervention or the change itself could 
potentially disrupt this entrainment (biological clock) to the calendar week.  A week as 
a unit was judged to be preferable as a washout period than periods between 8 and 13 
days because of this influence of social zeitgebers on mood and two weeks would have 




Washout period would likely depend on whether major active substances are 
hydrophilic or lipophilic.  Baicalin is hydrophilic, whereas the aglycones, such as 
baicalein and wogonin are lipophilic (Barceloux 2008) and this lipophilicity may 
account for carry-over effects if the compounds remain in fatty tissues.  A random 
selection of 22 double-blind randomised controlled crossover trials involving 
flavonoids, whole herbs and/or anxiolytics revealed the mean (SD) washout period for 
these studies was 11 (9) days.  Where washout was included the longest period was 35 
days and the shortest for 3 days.  No reason for time choice was provided in any of the 
studies.  All studies on whole herbs (8) had a washout period of 10 days or less, usually 
7 days (5 studies); one had no washout at all.  It appears that washout period is difficult 
to judge therefore when the half life is unknown and in some cases may be arbitrary. 
Measurements of subjective anxiety and mood at an additional time point i.e. following 
washout, is paramount for assessment of carry-over and also providing information on  
placebo response in future studies. 
 
Overall, the evidence in this study of a carry-over effect of S. lateriflora seems to 
indicate a cumulative effect of the herb, which could be said to be beneficial 
considering the known rebound excitability and dependability of other anxiolytics, 
particularly BDZs (B.N.F. 2008).  Future studies could determine the duration of effects 
by repeated subjective measures of mood at regular follow-up time points following 
cessation of treatment. 
8.9 Strengths and limitations of the study  
A major strength of the study was the use of freeze-dried herb in controlled doses and 
its authentication prior to commencement of the RCT.  Another was the ability to assess 
within subjects effects as well as between subjects effects by the use of a crossover 
design.  An advantage of a crossover design is that participants act as their own controls 
and there is less variability within subjects than between subjects (Dallal 2000).  Fewer 
participants are required for the study than if it were a parallel study.  An equal number 
of participants (group) for each time period receives one treatment (either placebo or 
test) while the other group receives the other treatment.   
 
Potential disadvantages of crossover studies are that they are of longer duration than a 
bioequivalent parallel study and there is therefore more chance of dropouts because of 
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inconvenience to participants; the study might not be long enough to show effects of a 
drug as each period needs to be kept reasonably short to avoid too much inconvenience 
and/or instability in a condition. Spontaneous resolution, particularly of acute 
conditions, may be more likely during a longer period.  This situational change is 
known as a period effect (Wang et al. 2006).  In this current research, psychometric 
testing following washout would have been a useful measure of comparison between 
nothing and test and placebo, to see how much scores return to baseline or if there is a 
placebo effect. 
 
Potential carry over effect – physiological or psychological – in the group taking the test 
substance first (Shen & Lu 2006; Wang et al. 2006) is another disadvantage as evident 
in this research.  The carry-over effects in the present research indicate that a longer 
washout period was necessary.  Although it was ensured that almost equal numbers 
received the test intervention during the first and second periods of the study to help 
balance this effect and avoid bias – adequate washout is important (EMEA 2006).  The 
dropout rate of 28% in this study may have added to the chance imbalance between 
groups as demonstrated by numerous order effects.  Order effects are problems inherent 
in crossover designs, creating difficulties in the interpretation of results (Mackereth et 
al. 2009).  If there is a baseline imbalance, one approach is to abandon the results of the 
second period and to treat the study as if it were a parallel study.  This, however, wastes 
valuable time and resources as well as reducing the statistical power and the ability to 
compare within subjects effects (Sibbald & Roberts 1998).  Other approaches are to use 
either change score analysis or analysis of covariance (ANCOVA).  A problem with 
change score analysis is regression to the mean when there are low baseline scores 
(Vickers & Altman 2001).  However, when there is a true baseline imbalance as in the 
present study ANCOVA can distort treatment effects and result in bias (Metcalfe 2010). 
 
One of the major improvements for any future crossover study using healthy volunteers 
would be to recruit more participants as it was evident due to baseline shifts between 
subjects that the above study did not have enough power to eliminate this in a healthy 
sample population.  A new power calculation and sample size estimation for a future 
crossover study in a healthy population would be based on the standard deviations of 
the results of the present study instead of, as previously, an anxious population (Prasko 
et al. 2006).  Out of necessity, because of problems obtaining ethical approval for a 
study sample with self-reported anxiety, other than 3 who were moderately anxious 
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(BAI scores 16-25) and 3 who had severe anxiety the results of this study are based on 
volunteers from a mainly non-anxious population.  Baseline scores on BAI ranged from 
1-37 and 25 participants completing the study had minimal or mild anxiety at baseline.  
In this research it happened by chance that there were more non-anxious subjects in the 
Group who took the S. lateriflora first.  The two variables showed differences between 
baseline measurements, with those in group 1 showing higher initial mean (SD) anxiety 
scores of 15.73 (10.71) than those in Group 2  at 8.81 (3.99).  Spontaneous remission 
after a few weeks is more likely if they had a transient mild or minimal anxiety during 
baseline testing, for example due to upcoming examinations.  This is particularly true 
for participants with low baseline scores as they are more likely to undergo remission 
than those with high scores (Vickers & Altman 2001).  Recruiting more volunteers may 
provide inclusion of more anxious volunteers and a more equally distributed baseline 
anxiety score.  Similarly for other parameters (see POMS) an increased number of 
participants might be an advantage.  Recruitment of notably anxious volunteers may 
also help to eliminate baseline shift. 
 
Another limitation of the study is the anxiety and mood data obtained from the BAI and 
POMS respectively was retrospective and could therefore not determine the effects of 
daily stressors and psychological effects on these paradigms.  Similarly the 
physiological data from salivary cortisol samples was obtained at only three time points 
and did not reflect stressful life situations occurring during the study. 
 
This was a pilot study to determine the effects of S. lateriflora on mood states, anxiety 
and stress.  In addition to the above, another limitation was the small sample size.  
Significant delays at the start of the study due to authorisation and ethical clearance to 
conduct the study severely limited the time available and hence the number of 
participants.  Ethics and MHRA approval for recruitment of diagnosed anxiety would 
have required a major change in study design and necessitated external ethics approval, 
which were explored and were problematic for the research team to achieve.  Restricted 
resources limited the number of visits per participant.  Nevertheless the results are still 




8.10 Summary and conclusions 
Despite the problems in analysis revealed by the study design, new information has 
been obtained from this small, observational study, which can make substantial 
contributions to the literature and herbal practice as a whole.  There is an indication that 
S. lateriflora reduces symptoms of anxiety and enhances mood in some individuals as 
demonstrated respectively by a reduction in anxiety scores on BAI and T-A scores on 
the POMS in healthy volunteers.  Although the anxiolytic effects were evident only in 
the group that took placebo first, these were in the main more anxious at baseline than 
those who took S. lateriflora first and an insufficient washout period may have resulted 
in an underestimation of the effects of S. lateriflora in Group 2.  Considering the 
placebo response in the group who took the placebo first it is even more remarkable that 
there was a significantly (p = 0.036) greater response (as shown on BAI) to the S. 
lateriflora compared with placebo in this group.  Furthermore, the group that took S. 
lateriflora first experienced a carry-over effect, which precludes the apparently greater 
response to placebo compared with S. lateriflora in this group.  It is however, important 
to note that the possibility of placebo responses following S. lateriflora indicates the 
study results do not confirm a definite anxiolytic effect and emphasises the need for 
further study.  As the results were limited by a small sample size (n = 43 and 28% 
dropout rate; 31 completed) future studies may benefit from a larger sample size as well 
as recruitment of an anxious population – such as those with primary diagnosis of GAD.   
 
For the first time, personality trait as a predictor of response to S. lateriflora was 
assessed and it was found that low extraversion was a significant predictor of higher 
change scores on BAI.  Although only evident in the group that took placebo first the 
reason may be because this group was generally more anxious at baseline and therefore 
had a higher mean BAI change score. 
 
Other major findings were an overall enhancement of mood as demonstrated by TMD 
scores on the POMS and an indication that, contrary to previous beliefs and in contrast 
to some orthodox anxiolytics e.g. alprazolam, S. lateriflora does not worsen depression 
shown by D-J scores on POMS.  There was no discernible effect of S. lateriflora on 
attenuation of the HPA axis as reflected by no significant mean changes in salivary 
cortisol measurements (p = 0.524) but it was not evident that participants were 
experiencing stress during saliva sampling.  There was also no effect on blood pressure 
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but participants were normotensive and healthy at baseline so this was to be expected.  
Additionally, S. lateriflora had no effect on pulse rate.  Importantly there were no toxic 
effects from S. lateriflora as demonstrated by no clinically significant mean elevation of 
ALT levels from baseline (2.01 U/L) and no significant difference between S. 
lateriflora and placebo in mean ALT elevation (p = 0.801).  Of great importance is this 
is the first time it has been demonstrated that there were no adverse effects on energy or 
cognition (as shown by V-A, F-I and C-B on the POMS) during chronic administration 
of S. lateriflora.  Additionally, the finding, for the first time, that the effects of S. 
lateriflora persisted following cessation of use, may prove to be beneficial. 
 
In conclusion the data suggest, despite the study limitations, that S. lateriflora has 
significant anxiolytic and mood enhancing effects in some people.  Also significant is 
the lack of toxicity, adverse reactions or definite side-effects that could be attributed to 
the herb and the fact there were no rebound reactions such as tolerance, dependability or 
excitability.  This lack of harmful or unpleasant effects is central to the clinical efficacy 
of an anxiolytic.  Further studies of S. lateriflora could prove it to be a safe effective 
alternative to currently used anxiolytics. As this was an exploratory study with a 
number of design faults (e.g. carry-over effects, unmatched groups and small sample 
size) the results should be interpreted with caution.  A longer study with a larger sample 
size, either a parallel study or a crossover with a longer washout period, and using 
participants with a diagnosis of GAD may yield more significant results.  It is not clear, 
however, whether participants with GAD would yield significant results relating to 
attenuation of the HPA axis.  A sufficient number of well-matched subjects using a pre-
defined narrow range of baseline scores on a validated instrument such as BAI would be 
a parallel study of choice in order to eliminate problems of baseline shift and inadequate 
washout.  A disadvantage of a parallel study is no intra-individual comparison and more 
variation between subjects, with also a likelihood of a large number of dropouts in the 









Chapter 9. Future work 
The promising results from this study, for example an indication that S. lateriflora 
attenuates anxiety and enhances mood without a reduction in energy or cognition, could 
lead to valuable future work for which time and financial constraints of the PhD did not 
permit.  For example: 
9.1 Future clinical trials of S. lateriflora 
9.1.1 Anxiolytic and mood enhancing effects 
The regimen of the current study did not allow for longer-term effects to be assessed, 
required to determine tolerance, dependency or optimum dosage.  Tolerance, believed to 
result from sensitisation of GABAA receptors, to the anxiolytic effects of 
benzodiazepines, for example, may take several months (Ashton 2005).  A similar 
randomised, double-blind, placebo controlled crossover study could be conducted with 
varied dose regimens such as 1-4 x 350 mg capsules of freeze-dried S. lateriflora daily.  
Because it was evident from the results that there was a carryover effect of S. 
lateriflora, a longer washout period would be appropriate as would additional repetition 
of measures following washout to determine the extent of potential residual effects of  
the test herb as well as a ‘no treatment’ effect.  Furthermore, although the Urtica dioica 
placebo has no known psychopharmacological effects, it was nonetheless not an inert 
substance and its potential interactions with S. lateriflora are unknown.  It may be more 
pertinent to conduct parallel studies, given the carry-over effects seen in the current 
study and other problems inherent in the crossover design, such as order effects – on the 
proviso of course that resources allow for a large study population.  If a parallel study is 
conducted it will have three arms in order to include a no-treatment group for 
comparison with placebo and test group.  In addition, participants would have follow-up 
assessments for determination of long-term benefits or rebound effects in comparison to 
the no-treatment group. 
Assessments on those with a primary diagnosis of generalised anxiety disorder (GAD) 
are desirable as the study has revealed the difficulties inherent in the assessment of the 
efficacy of a putative anxiolytic in non-anxious subjects.  In addition, when there is a 
true baseline shift, which in the current study could be attributed to inconsistency 
between subjects in anxiety severity rather than sample size, between-subjects 
comparisons are not straightforward (Vickers & Altman 2001; Metcalfe 2010).  A 
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parallel study is likely to be ‘intention to treat’ and would benefit from having 4 arms of 
the study; skullcap treatment, a mild benzodiazepine control, placebo and no treatment.  
A mild benzodiazepine for positive control would preferably have a short half-life if a 
crossover design was used.  Oxazepam has a half-life of 5-15 hours, and Alprazolam 
has a half-life of 10-15 hours (compared to Lorazepam and Clonazepam which have a 
half-life of 10-20 and 24-56 hours respectively) (Vanin & Helsley 2008) and diazepam 
has a half-life of up to 200 hours due to the residual effect of it active metabolite 
(Ashton 2008).   
GAD is a severe, chronic anxiety disorder with a lifetime prevalence of 6% of the 
population (Kasper et al. 2009).  It is defined by the Diagnostic and Statistical Manual 
of Mental Disorders IV (American Psychiatric Association 2000) as persistent, 
excessive worry for at least 6 months and at least 3 of the symptoms of muscle tension, 
fatigue, insomnia, disturbed sleep, inability to concentrate and irritability.  The presence 
of anxiety is not due to a mood disorder or psychotic disorders and it is not as a result of 
drug or substance use or environmental factors.  The patient cannot control their anxiety 
(American Psychiatric Association 2000).  GAD is usually treated with 
benzodiazepines, buspirone, SSRIs, serotonin-norepinephrine reuptake inhibitors, 
monoamine-oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), beta-
blockers and cognitive behavioural therapy (CBT) as monotherapy or in various 
combinations (Helsley 2008).  The chronicity of the anxiety in those with GAD deems it 
to be less likely that spontaneous remission would occur during the course of the study 
in comparison to mildly anxious patients (Wittchen & Hoyer 2001) and therefore the 
efficacy of S. lateriflora could be assessed with little risk of confusion between efficacy, 
regression to the mean and spontaneous remission. 
Findings that S. lateriflora does not appear to worsen existing depression suggest that 
future work assessing its efficacy in those with anxiety disorders need not exclude those 
with comorbid depression.  This is important because there is a high comorbidity rate 
with anxiety and depression, with 7% men and 11% women experiencing both at the 
same time in any given year (Office for National Statistics 2006) and therefore a 
preferred anxiolytic would attenuate both anxiety and depression (Mitte et al. 2005; 
Greaves-Lord et al. 2007). A validated measure of subjective depression such as the 
Beck Depression Inventory (Beck et al. 1996) would be used to assess this paradigm. 
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Finally, it would be of interest to note the onset of efficacy of S. lateriflora.  In an 8 
week double-blind, placebo-controlled efficacy study of pregabalin (an anti-convulsant) 
and venlafaxine-XR (an SNRI) in GAD, Kasper et al. (2009) used investigator-rated 
HAM-A scales by telephone interview on day 4 (in advance of the first weekly visit) to 
determine efficacy onset of the drugs. There was > 20% improvement in anxiety scores 
from baseline for pregabalin compared with venlafaxine or placebo on day 4.  
Measurements were not taken on days 1, 2, or 3 but it would be useful to do so with S. 
lateriflora. 
 
As enhancement of global mood following S. lateriflora as demonstrated by the results 
of the current study in some individuals, the Profile of Mood States (Lorr et al. 2005) 
would be a useful instrument to use in conjunction with Beck’s Anxiety Inventory 
(Beck & Steer 1993) when conducting future studies on an anxious population. It would 
provide new information for general practice if it could be determined that the S. 
lateriflora also enhances mood in those suffering from chronic anxiety, particularly 
considering studies of administration of benzodiazepines have indicated that some of 
these tranquillisers have some negative effects on subjective measures of mood e.g. 
increased confusion and decreased energy, using the POMS (Frey et al. 1998). 
9.1.2 Clinical studies of S. lateriflora for premenstrual 
syndrome 
One participant in the current study reported attenuation of her premenstrual symptoms 
(see 7.7.7).  Furthermore, results of a survey of herbal medicine practitioners found it is 
commonly prescribed for this condition (see 3.4.1). Despite its traditional use for 
problems relating to the menstrual cycle and for mastalgia, there appears to be little 
reference in modern herbal medicine texts to current use of S. lateriflora in 
gynaecology. Hoffmann (2003) states that it can be safely used to ease premenstrual 
tension and Harrar and O'Donnell (1999) suggest it has healing potential for 
premenstrual syndrome. Liao et al. (1995) found S. baicalensis root extract bound to D2 
receptors in vitro.  Any resultant lowering of prolactin may modulate dysfunctional 
menstrual cycles and alleviate premenstrual mood disorders, which are implicated in 
cases of latent hyperprolactinaemia (Trickey 2003). The latter may dysregulate 
dopamine secretion, leading to a lowering of mood (Greenstein 1994). A randomised 
controlled trial to assess the efficacy of S. lateriflora for premenstrual syndrome would 
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make a valuable contribution to herbal practice.  Research into the binding capacity of 
S. lateriflora on D2 receptors could also be conducted. 
9.1.3 Antioxidant effects 
The in vitro studies of S. lateriflora indicate its potential as an herb with strong 
antioxidant capacity (Wojcikowski et al. 2007; Wojcikowski et al. 2009).  Future 
clinical studies could be conducted to determine its efficacy for conditions in which a 
protective effect on tissues is required; for example Alzheimer’s disease and non-
Alzheimer’s senile dementia (Middleton & Yaffe 2009), or liver, kidney and 
cardiovascular disorders (Meydani 2001). 
9.2 A metabolomic analysis of S. lateriflora:   
A metabolomic analysis of S. baicalensis shoots revealed 2,400 compounds. Of these 
compounds 781 may have medicinal actions, including hyperforin; a compound found 
in Hypericum perforatum and believed to be effective against depression (Murch et al. 
2004). A similar study of S. lateriflora would provide a useful contribution to the 
literature and give more insight into potential therapeutic actions and indications of the 
herb. 
9.3 Conclusions 
While there are likely to be many other studies that could be conducted on this vital 
herb, whether chemical, in vitro or clinical, it is beyond the scope of this work to ponder 
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Appendix I Letter to herbal medicine practitioners 
 
7 December 2008 
 
Dear Herbal Medicine Practitioner,     
 
I am currently a PhD student at the University of Westminster within the new 
Westminster Institute for Health and Wellbeing.  I am researching the use of skullcap 
(Scutellaria lateriflora) in the treatment of stress and anxiety.   
 
My Director of Studies is Dr Julie Whitehouse, principal lecturer in the School of 
Integrated Health.  (whitehj@wmin.ac.uk) 
 
The Institute aims to provide research-based evidence that informs policy and changes practice 
so that society reaps benefits in terms of improved understanding and promotion of health and 
well-being.  
 
I believe that high-quality research in herbal medicine is essential to provide evidence 
to support its traditional use.  Such evidence will hopefully raise the profile of the 
herbal medicine profession, engender greater acceptance by orthodox medical 
professionals and the general public, and help to provide patients with informed 
treatment choice.  
 
Although there is much anecdotal evidence of efficacy, there has been little research 
conducted on Scutellaria lateriflora.  I believe it has great potential as a candidate herb to 
provide scientific evidence in support of the traditional use of herbal medicine.   
 
No animals will be used for the purposes of this research. 
 
I am writing to you in the hope that you will be able to give a little of your time to help 
with this  research by offering your valuable practitioner experience  and answering a 
few questions (see attached) about   Scutellaria lateriflora. 
 
Please return the completed questionnaire by email attachment.  I would be most 
grateful if it could possibly be returned by 10 January 2009. 
 
All responders will remain anonymous in the use of the data collected 
 











Appendix II Practitioner survey questionnaire 
 
 
Survey amongst UK herbal practitioners on the use of Scutellaria lateriflora.   
 
Please answer the following questions as far as possible: 
 
1. Do you regularly prescribe Scutellaria lateriflora?  Y N 
 
 









































11. Please indicate the most likely dose range (min - max) and strength you would 
use, specifying either single dose, weekly dose, or both, and your preferred 
mode of administration.   Eg: 
- Tincture extracted from dried herb (marc: menstruum and % alcohol) 
- Fresh (specific tincture) (marc: menstruum and % alcohol) 
- Fluid extract 
- Dried, cut 
- Powder 
- Freeze-dried capsules 










13. Who is your supplier for the herbal preparation? 
 
 
14. Do you use it alone or in combination with other herbs? 
 
 
15. Do you have a preferred herb for anxiety (Scutellaria lateriflora or any other 
herb)? Y N 
 
 
16. If so, which one? 
 
 
17. Would you be willing to be contacted if this research plans to collect further 
information form practitioners? Y N 
 
 










Length of time in practise: 
 















































Appendix VI  Participant information sheet 
 
Researcher:  Christine Brock (PhD student) 
The researcher is a qualified medical herbalist, Member of the National Institute of Medical 
Herbalists.  She is knowledgeable in the use of herbal medicines and her training and 
experience enables her to recognise and assess a wide range of health problems.  
Principal supervisor:  Dr Julie Whitehouse 
Second supervisors:  Dr Ihab Tewfik and Professor Anthony Towell 
Address:  School of Life Sciences, Cavendish Campus, New Cavendish St, London W1W 6UW 
Email:  C.Brock@westminster.ac.uk  Tel:  020 7911 5041 (University of Westminster Polyclinic) 
Study:  American skullcap (Scutellaria lateriflora): a study of its effects on mood in healthy 
volunteers. 
Study identifier:  09/10/31/ISRCTN48078312 
Ethics: This study has been approved by the University of Westminster Research Ethics Sub-
committee  
Estimated dates of study:  April 2010 – July 2011 
Expected duration of study: 38 days 
 
Thank you for volunteering to take part in this study.  This form outlines the purposes and 
methods of the study and provides a description of your involvement and rights as a participant.  
 
PLEASE READ ALL 3 SECTIONS CAREFULLY 
 
Section 1:  The purposes of this project: 
A. To gain insight into the potential for American skullcap herb to enhance mood and 
produce feelings of wellbeing. 
B. To determine the effectiveness of American skullcap in reducing stress. 
C. The information collected from the study will add to scientific knowledge in general and 
will be used to inform practitioners of herbal medicine and other professionals of the 
effectiveness and safety of skullcap herb for reducing negative mood states.  Results 
will be published accordingly. 
D. The researcher is undertaking this study as part of the requirement for the qualification 
of PhD at the University of Westminster Institute of Health and Wellbeing. 
 
Section 2: Outline of the study and methods to be used 
This project aims to find out how safe and effective the herb skullcap is in reducing symptoms of 
stress and improving mood.  Skullcap is a medicinal plant widely prescribed over many 
centuries by medical herbalists and included in over the counter preparations to help people 
who feel stressed and anxious to relax.  It is not known to be harmful. 
 Those taking part in the study (participants) will be randomly split into two groups.  One 
group will take a skullcap capsule 3 times a day.  For comparison, the other group will take 
a placebo (dummy/harmless) capsule 3 times a day.   This is dried common nettle, often 
used as a refreshing herbal tea, which has no effects on mood. Neither you nor the 
investigator will know which type of capsule you are taking until the end of the study.  After 
2 weeks you will stop taking capsules for a week.  You will then be given the other type of 
capsule for 2 weeks.   
 To see if your feelings of wellbeing change over time you will be asked to complete 2 
questionnaires about your mood and anxiety levels (about 10 minutes each) before, in the 
middle, and at the end of the study.  We will also measure your blood pressure and pulse at 
these time points to see if there are any noticeable changes in either. 
 To determine whether personality might affect the way you respond to American skullcap 
you will be asked to complete a short personality test at the beginning of the study.  
 You will be asked to provide samples of your saliva. This is because saliva contains a 
substance (hormone) called cortisol and levels of this may change when you are stressed.  
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Measurements of the amount of cortisol in your saliva may show whether or not the skullcap 
herb is reducing your stress.  Using a convenient and comfortable method of chewing on a 
cotton wad contained in a small plastic tube you will need to provide saliva at 3, 6, 9 and 12 
hours after your natural waking time for 2 days running. I will ask you to do this at the 
beginning, in the middle, and near the end of the study.  You will not be able to eat or drink 
anything except water, smoke, clean your teeth, or do any rigorous physical exercise for at 
least 30 minutes before providing each saliva sample. 
 
 I will also take a small drop of blood from one of your fingers before, during and after the 
study so that chemicals in your blood can be tested to assess the safety of skullcap herb. 
 Throughout the study you will be asked to keep a daily diary of your mood and of any 
changes in your body you might notice. 
 
Section 3: Your rights and your involvement in the study: 
1. Your eligibility to take part in the study is not automatic and you will be invited to undergo a 
selection procedure.  This involves being asked questions about your health, having your 
blood pressure and pulse taken and filling in a brief questionnaire about your mood.   
2. If at the initial selection interview or at any later time during the study, there is any reason 
that you may not start or continue to participate in the study, you will be informed of the 
reason and offered advice by a qualified herbal practitioner in the Polyclinic.  
3. You have been invited to participate in this research because you are in good general 
health and are interested in helping to promote wellbeing with herbal medicine. 
4. Your participation in this study is voluntary. You have the right to refuse to participate and to 
withdraw at any time and for any reason without prejudice. 
5. You have the right to refuse to answer any questions if you do not wish to do so. 
6. You are encouraged to ask questions about the study.  I will endeavour to respond as soon 
as possible to any queries or concerns you may have. 
7. All questioning, blood pressure, pulse and blood checks will be performed in private at the 
University of Westminster Polyclinic, which you will be invited to attend at a mutually 
convenient time and date.  Attendance is 3 times in all, for approximately an hour followed 
by two 30 minute visits. 
8. Saliva sampling, diary keeping and capsule taking will be carried out away from the clinic. 
9. Saliva samples will be coded, frozen and then destroyed following study completion. 
10. Your participation in this study will be completely confidential and your name will never be 
revealed to anyone, either verbally or in print. Your records will be kept securely locked 
away at all times with access only by the investigator.  Your name will not be included in 
computerised data. 
11. You will have access to your own data at any time during the study, upon request. 
12. You may experience some positive effects on your mood during the study.  This may be 
immediate or may occur closer to the end of the study; or you may feel no difference at all. 
13. Although not expected, if you experience any adverse effects while taking capsules it is 
important that you report these as soon as possible to the investigator or to the Polyclinic 
and if concerned to your GP immediately. 
14. In the unlikely event that you experience any undesirable side effects as a result of the 
study you will be asked to withdraw and further advice will be offered to you.  
15. The study may be terminated early by the investigator if deemed appropriate to do so as a 
result of the investigations. 
16. You will be informed of the findings of the research on completion of the study. 
17. If there are any changes to the study design you will be informed of these and your consent 
to continue will be renewable. 


















Re: American skullcap (Scutellaria lateriflora): a study of its effects on 
mood in healthy volunteers 
 
Thank you for your interest in taking part in this study.  The enclosed form 
outlines the purposes and methods of the study and provides a description of 
your involvement and rights as a participant.  
 
If after reading the information, and giving yourself a reasonable amount of time 
to consider it, you would like to take part in this study please contact me at the 
email address above to arrange an appointment for eligibility screening.  You 
may instead telephone the university Polyclinic to leave your number and I will 
call you back.  
 
At your appointment, you will be asked to sign a consent form before screening 
commences.  If screening is successful your participation in the study will begin 
with immediate effect.  The first visit will take about an hour and the two 
subsequent visits are likely to be shorter. 
 
If you have any questions at all about the study please do not hesitate to 












School of Life sciences 
University of Westminster 
115 New Cavendish St 




Tel: 020 7911 5041  
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Appendix VIII      Hospital Anxiety and Depression Scale and scores (Zigmond & Snaith 
1983) 
 




This questionnaire is about how you feel.   For each of the following items tick the response 
that comes closest to how you have been feeling in the last week. Do not take too long to 
think about your answers - your immediate response will probably be the most accurate.  
1.  I feel tense or ‘wound up’:     MOST OF THE TIME 
  A LOT OF THE TIME 
  OCCASIONALLY 
  NEVER 
 
2.  I still enjoy the things I used to enjoy:   AS MUCH AS EVER 
  NOT QUITE AS MUCH 
  ONLY A LITTLE 
  HARDLY AT ALL 
3. I get a sort of frightened feeling as if something awful is about to happen: 
  VERY DEFINITELY AND QUITE BADLY 
  YES, BUT NOT TOO BADLY 
  A LITTLE, BUT IT DOESN’T WORRY ME 
  NEVER 
4.  I can laugh and see the funny side of things: 
  AS MUCH AS I ALWAYS COULD 
  NOT QUITE SO MUCH AS I USED TO 
  A LOT LESS THAN I USED TO 
  NEVER 
5.  Worrying thoughts go through my mind:   A GREAT DEAL OF THE TIME  
  A LOT OF THE TIME 
  FROM TIME TO TIME BUT NOT TOO OFTEN 
  ONLY OCCASIONALLY 
6.  I feel cheerful:      NEVER 
  NOT OFTEN 
  SOMETIMES 
  MOST OF THE TIME 
7.  I can sit at ease and feel relaxed:    DEFINITELY 
  USUALLY 
  NOT OFTEN 
  NOT AT ALL 
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8.  I feel as if I am slowed down:    NEARLY ALL THE TIME 
  VERY OFTEN 
  SOMETIMES 
  NOT AT ALL 
 
9.  I get a sort of frightened feeling like ‘butterflies’ in the stomach: 
  NEVER 
  OCCASIONALLY 
  QUITE OFTEN 
  VERY OFTEN 
 
10.  I have lost interest in my appearance:   COMPLETELY 
 I DON’T TAKE AS MUCH CARE AS I SHOULD 
  I MAY NOT TAKE QUITE AS MUCH CARE 
  I TAKE JUST AS MUCH CARE AS EVER 
 
11.  I feel restless as if I have to be on the move:  
  VERY MUCH INDEED 
        QUITE A LOT 
        NOT VERY MUCH 
        NOT AT ALL 
 
12.  I look forward with enjoyment to things:   AS MUCH AS EVER I DID 
  LESS THAN I USED TO  
  A LOT LESS THAN I USED TO  
  NOT AT ALL 
 
13. I get sudden feelings of panic:    VERY OFTEN 
        QUITE OFTEN 
        NOT VERY OFTEN 
        NEVER 
14.  I can enjoy a good book or radio or TV programme: 
  OFTEN 
  SOMETIMES 
  NOT OFTEN 
  VERY SELDOM 







HOSPITAL ANXIETY AND DEPRESSION SCALE: SCORES 
 
1.  I feel tense or ‘wound up’:  A 3  MOST OF THE TIME 
       2  A LOT OF THE TIME 
       1  OCCASIONALLY 
0  NEVER 
 
2.  I still enjoy the things I used to enjoy: D 0  AS MUCH AS EVER 
1  NOT QUITE AS MUCH 
2  ONLY A LITTLE 
3  HARDLY AT ALL 
 
3. I get a sort of frightened feeling as if something awful is about to happen: 
A  3  VERY DEFINITELY AND QUITE BADLY 
2  YES, BUT NOT TOO BADLY 
1  A LITTLE, BUT IT DOESN’T WORRY 
ME 
0  NEVER 
 
4.  I can laugh and see the funny side of things: 
      D 0  AS MUCH AS I ALWAYS COULD 
1  NOT QUITE SO MUCH AS I USED TO 
2  A LOT LESS THAN I USED TO 
3  NEVER 
 
5.  Worrying thoughts go through my mind:  
      A 3  A GREAT DEAL OF THE TIME  
       2  A LOT OF THE TIME 
1  FROM TIME TO TIME BUT NOT TOO 
OFTEN 
0  ONLY OCCASIONALLY 
 
6.  I feel cheerful:    D 3  NEVER 
       2  NOT OFTEN 
1 SOMETIMES 
0 MOST OF THE TIME 
 
7.  I can sit at ease and feel relaxed:        A 0  DEFINITELY 
       1  USUALLY 
2  NOT OFTEN 
3  NOT AT ALL 
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8.  I feel as if I am slowed down:  D 3  NEARLY ALL THE TIME 
2 VERY OFTEN 
1  SOMETIMES 
0  NOT AT ALL 
 
9.  I get a sort of frightened feeling like ‘butterflies’ in the stomach: 
      A 0 NEVER 
1 OCCASIONALLY 
2 QUITE OFTEN 
3 VERY OFTEN 
 
10.  I have lost interest in my appearance: D 3 COMPLETELY 
2 I DON’T TAKE AS MUCH CARE AS I 
SHOULD 
1 I MAY NOT TAKE QUITE AS MUCH 
CARE 
0 I TAKE JUST AS MUCH CARE AS 
EVER 
 
11.  I feel restless as if I have to be on the move: 3 VERY MUCH INDEED 
      A 2 QUITE A LOT 
       1 NOT VERY MUCH 
       0 NOT AT ALL 
 
12.  I look forward with enjoyment to things:  0  AS MUCH AS EVER I DID 
      D 1  LESS THAN I USED TO  
2  A LOT LESS THAN I USED TO  
3  NOT AT ALL 
 
13. I get sudden feelings of panic:   3  VERY OFTEN 
      A 2  QUITE OFTEN 
       1  NOT VERY OFTEN 
       0  NEVER 
 
14.  I can enjoy a good book or radio or TV programme: 
      D 0  OFTEN 
1  SOMETIMES 
2  NOT OFTEN 
3  VERY SELDOM 
Key: A = Anxiety  D = Depression 
 
Interpretation:  For either anxiety or depression, scores of 8-10 = possible clinical case;  
11-21 = probable clinical case (Zigmond & Snaith 1983) 
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Appendix IX  Beck Anxiety Inventory sample questions (Beck & Steer 1993) 
 


















It was very 
unpleasant, but I 
could stand it. 
 
SEVERELY 
I could barely 
stand it 
      
1. Frightened.     
      
2. Heart feels like 
it is skipping a 
beat. 
    
      




Simulated Items similar to those in the Beck Anxiety Inventory. Copyright © 1990, 1993 by 
Aaron T. Beck. Reproduced with permission of the Publisher, NCS Pearson, Inc. All rights 
reserved.  
 
“Beck Anxiety Inventory” and “BAI” are registered trademarks, in the US and/or other countries, 
of Pearson Education, Inc. or its affiliate(s). 
 
Information concerning the BAI is available from our UK office: 
Customer Services 
Tel: 0845 630 88 88 (Monday to Friday, 8am to 5pm) 




























How Accurately Can You Describe Yourself? 
 
Please use this list of common human traits to describe yourself as accurately as 
possible. Describe yourself as you see yourself at the present time, not as you wish 
to be in the future. Describe yourself as you are generally or typically, as compared 
with other persons you know of the same sex and of roughly your same age. Before 
each trait, please write a number indicating how accurately that trait describes 




____ Bashful   ____ Energetic  ____ Moody   ____ Systematic 
____ Bold   ____ Envious  ____ Organized  ____ Talkative 
____ Careless   ____ Extraverted  ____ Philosophical ____ Temperamental 
____ Cold   ____ Fretful   ____ Practical  ____ Touchy 
____ Complex  ____ Harsh   ____ Quiet   ____ Uncreative 
____ Cooperative  ____ Imaginative  ____ Relaxed  ____ Unenvious 
____ Creative  ____ Inefficient  ____ Rude   ____ Unintellectual 
____ Deep   ____ Intellectual  ____ Shy  ____ Unsympathetic 
____ Disorganized  ____ Jealous   ____ Sloppy   ____ Warm 




Scores are entered on the grid provided. Designated negative traits are reverse 
scored (e.g. a score of 8 becomes 2 and a score of 2 becomes 8).  Enter the total 














Appendix XI       Big 5 Mini-Marker scoring grid 
 
Participant code:  P. Date:   NB: Negative scores for each factor are reverse-scored  
          
I: Extraversion Score II: Agreeableness Score III: Conscientiousness Score IV: Emotional stability Score V: Intellect/openness Score 
                    
Positive scores   Positive scores   Positive scores   Positive scores   Positive scores   
Talkative   Sympathetic   Organised   Unenvious   Creative   
Extraverted   Warm   Efficient   Relaxed   Imaginative   
Bold   Kind   Systematic       Philosophical   
Energetic   Cooperative   Practical       Intellectual   
                Complex   
                Deep   
                   
Negative scores   Negative scores   Negative scores   Negative scores   Negative scores   
Shy   Cold   Disorganised   Moody   Uncreative   
Quiet   Unsympathetic   Sloppy   Jealous   Unintellectual   
Bashful   Rude   Inefficient   Temperamental      
Withdrawn   Harsh   Careless   Envious       
            Touchy       
            Fretful       
                    
Totals                   











Title of Study:  American skullcap (Scutellaria lateriflora): a study of its 
effects on mood in healthy volunteers. 
 
 
Lead researcher: Christine Brock 
--------------------------------------------------------------------------------------------------- 
 
I have read the information in the Participation Information Sheet, and I am willing 
to act as a participant in the above research study. 
 
    Name:   _______________________________ 
 
 
Signature:  __________________________ Date:  _______________ 
 
 
This consent form will be stored separately from any data you provide so that your 
responses remain anonymous. 
 
 
I have provided an appropriate explanation of the study to the participant 
 












1. Main exclusion criteria  If YES to any, do not complete Q 
 
Ever been diagnosed with:   
Depression 
Bipolar disorder 
Generalised anxiety disorder (GAD) 
Schizophrenia 
Panic disorder 
Phobias (state which) 
Any other mental condition (please state) 
 







Any other serious illness? 
Females:  Pregnancy/lactating 
_______________________________________________________________ 
2. Allergies  State how it affects participant 
Eg Foods, Drugs, Chemicals, Herbal medicines, Supplements 
 
 
Any tests and diagnosis with dates: 
 
Exclude participant: allergy to skullcap, nettle, Lamiaceae or Urticaceae allergy/ allergies to known 
constituents eg serotonin, histamine. 
_______________________________________________________________ 
3. Diagnosis of any other condition; date diagnosed and whether resolved 




CVS eg Hypertension, Hypotension, Angina, Stroke, Cardiac problem, Hypercholesterolaemia, Anaemia 
 
 























Skin   eg eczema, psoriasis 
 
______________________________________________________________ 
Endocrine Eg Thyroid, Cushing’s disease/ syndrome, Prostate 
 
_______________________________________________________________ 









Hospitalisations/ operations: reason (s), and dates 
 
  
Taken part in another study in past 30 days? Y/N 
Drug check 
In the last month (M)week (w) 6 
months (6) year (y) ever (e) 
Type/ brand/name Frequency  Quantity 
  
Alcoholic drinks w 
 
N/A   
Cigarettes 
 
N/A   
Recreational (eg cannabis, LSD, ecstasy, 
heroin, morphine, cocaine, methadone, 
amphetamines) M 
 
   
Pain killers (type, mg/day) W 
 
   
CNS drugs: antipsychotics (e) , 
antidepressants (y) sleeping tablets (m),  
tranquillisers/ sedatives (m), (type, mg/day)  
 
   
Corticosteroids eg prednisolone, nasal 
sprays, eye drops, skin creams, inhalers. (6) 
 
   
Contraception 
 
   
Herbal medicines  
Type, frequency and duration are 
important.  Use judgement but none for 
past week 
 
   
Supplements e.g. vitamins 
 
 
   
Other drug 
 
   
Other drug 
 
   
Other drug 
 





Appendix XIV  Instructions for participants 
 
American skullcap (Scutellaria lateriflora): a study of its effects 
on mood in healthy volunteers. 
 
Thank you for agreeing to take part in this study, which will involve  
 answering questionnaires about how you feel,  
 taking herbal capsules,  
 undergoing finger-prick blood tests,  
 having your blood pressure and pulse taken and  
 collecting samples of your saliva.   
 
 
Please follow these instructions carefully. If you have any questions, please do not 
hesitate to contact me:  Christine Brock:  cabrock@westminster.ac.uk or: 
020 7911 5041 to leave a message and I will ring you back. 
 






 Tick and date the checklist for capsule taking and saliva collection  






How to take your capsules: 
 
 Take one capsule three times daily with water from DAY 3 
 Take one on waking, one 6 hours later and one 12 hours later. 
 On days 15 and 16 and days 36 and 37 you will be also collecting saliva 
samples. On these days please take the capsules straight after sample 
collection (6 and 12 hours).  
 If you miss one you may take it later but no more than 3 hours before the next 
one. 
 If you miss a capsule altogether please note this on your ‘participant diary’. 
 Please refrain from using any other medication, including herbs, during the 
study. 
 It is preferable that you also avoid using alcohol during the study - or at least 









SALIVA COLLECTION and STORAGE 
 
Please record the times and dates of saliva collection on the sheets 
provided 
 
What not to do during saliva collection: 
 Do not:  
 eat 
 drink (except water) 
 smoke  
 brush your teeth 
 take strenuous exercise 
 for at least half an hour before collecting of the samples  
 
How to collect your saliva sample: 
 
 Collect samples 3, 6, 9 and 12 hours after waking. Enter times on record 
sheets. 
 Rinse mouth with water about 10 minutes before sampling. 
 Take the ridged cap off the correctly labelled tube and remove the cotton swab. 
 Place the swab under your tongue for 1-2 minutes until it is soaking wet.   
 Return the swab to the tube (with your mouth) and seal tightly with the cap. 
 
How to store your saliva samples: 
 
 Place the tube back in its original polythene bag. 
 When all 4 tubes have been replaced in the correctly labelled polythene bag 
(day 1, day 2, day 15, day 16, day 36 or day 37) place the bag in your freezer 
until all sampling has been completed (24 tubes in all). 
 
At the end of the study: 
 
 On completion of the study please bring the tubes to the Polyclinic on 
arrangement or, if necessary, place the tubes (still in their polythene bags) in 
the container and addressed envelope provided and post. 
 
When to take your saliva samples 
    
Please take your first 4 samples on day 1: _______________________    
                                                        Date       
Please take your next 4 samples on day 2: _______________________    
                                                        Date       
Please take your next 4 samples on day 15: _______________________    
                                                        Date       
Please take your next 4 samples on day 16: _______________________    
                                                        Date       
Please take your next 4 samples on day 36: _______________________    
                                                        Date       
Please take your next 4 sample on day 37: _______________________    




Appendix XV  Participant Diary 
 
 
Participant code ____________________ 
 





Starting on Day 1 and finishing on Day 37 please tick the boxes below the day on which symptoms occurred.           Page 1 (continue on page 2) 
   
Please list in this column any symptoms 
you experience - new or old, mental or 
physical - including anything positive such 
as disappearance of old symptoms. If the 
reason for a symptom is known please 









Take no capsules for 7 
days (days 17 -23) 
but continue to note 
symptoms 
                                            Day 1 2  3 4 5 6 7 8 9  10  11  12  13  14  15  16 17 18  19  20 
                                           Date                     
Please tick completed                                  
                     
Symptoms                                                 
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     
                     




              Page 2 
 
 No capsules 
(day 17-23) 
Take new (different) capsules from Day 24 to Day 37  Saliva 
samples & 
capsules 
                                            Day 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35  36  37 
                                          Date                  
Please tick completed                                 
                  
Symptoms                                                 
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Appendix XVI  Example saliva sample recording sheet (first 2 days) 
 
 
American skullcap (Scutellaria lateriflora): a study of its effects on mood in 
healthy volunteers. 
 
SALIVA SAMPLE COLLECTION RECORDING SHEET 
 
Participant code: ___________________ 
 
DAY 1        _____________________________________________    
Date:_____________________ 
What time did you wake up this morning?                             
Use your wake up time to calculate the correct sampling times and write these in the first 
column.  Record the actual time of sampling in the second column.  
  Time to take         Time sample  
 samples            is taken 
Tube 1   (3 hrs after awakening)  _______     _______ 
Tube 2   (6 hrs after awakening)  _______     _______ 
Tube 3   (9 hrs after awakening)   _______     _______ 
Tube 4   (12 hrs after awakening)  _______     _______ 
 
Do not eat, drink (except water), smoke, brush your teeth or take strenuous exercise for 
at least half an hour before collecting of the samples  
 
DAY 2 __________________________________________        
Date________________ 
What time did you wake up this morning?                             
Use your wake up time to calculate the correct sampling times and write these in the first 
column.  Record the actual time of sampling in the second column.    
Time to take         Time sample     
samples            is taken 
Tube 1   (3 hrs after awakening)  _______     _______ 
Tube 2   (6 hrs after awakening)  _______     _______ 
Tube 3   (9 hrs after awakening)   _______     _______ 
Tube 4   (12 hrs after awakening)  _______     _______ 
 
Do not eat, drink (except water), smoke, brush your teeth or take strenuous exercise for 


















Dear Dr XXX 
 
Re. NAME DOB ADDRESS 
 
The above patient has volunteered to participate in a clinical study of an herbal medicine: 
 
American skullcap (Scutellaria lateriflora): a study of its effects on mood in healthy volunteers. 
 
The study is part of a research project in the School of Life Sciences at the University of 
Westminster. 
 
The herb has been in long time use and is not reported to have any side-effects. 
 
To participate, your patient must be in good general health and not be taking steroids (e.g. 
hydrocortisone), or mind-altering drugs (including herbal) such as tranquillisers, sleeping tablets or 
anti-depressants and be between 18-75 years old. 
 
It is also important that they are not currently participating in any clinical trials and have not done so 
within the past month. 
 
If you feel that for any reason the above patient should not participate in this study I would 
appreciate it if you could inform me as soon as possible. 
 
I enclose a participant information sheet.  If you would like more information about the study please 









M: 07947 347 396 
 
School of Life Sciences 
University of Westminster  
115 New Cavendish Street  
London W1W 6UW 
T: +44 (0)020 7911 5000 
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Appendix XVIII  Participant personal data sheet 
 
 
Participant Data Sheet:  Strictly confidential 
 
Title……… Surname…………………………………………….  
 
First name(s)…………………………………………….   Sex……..M/F  














Contact name and telephone in case of emergency……………………………… 
 























Appendix XIX  Participant assessment data sheet 
 







Screening Part 2 and baseline assessment    
 
Blood pressure 1________________________  Date_______________ 
 
Pulse 1_______________________________ Date_______________ 
 
ALT 1________________________________ Date_______________ 
 




Blood pressure 2 _______________________ Date_______________ 
 
Pulse 2_______________________________ Date_______________ 
 
ALT 2________________________________ Date_______________ 
 




Blood pressure 3 _______________________ Date_______________ 
 
Pulse 3_______________________________ Date_______________ 
 
ALT 3________________________________ Date_______________ 
 




Intervention/ placebo code 
 
A Date B Date 
 
Salivary cortisol measurements 
 
 Day 1 Day 2 Day 15 Day 16 Day 36 Day 37 
3 hours  
 
     
6 hours  
 
     
9 hours  
 
     
12 hours  
 
     
Completed  Y/ N  Date_____________   
Dropout  Y/ N   Date ______________ Reason:  
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Adaptogen:  A herb with a normalising action on the mind and body, particularly with 
regard to mental and physical stress. 
Allosteric ligand:  A ligand that binds to a receptor site on a molecule and alters the shape 
of the molecule to increase its affinity for a particular substrate. 
Bleb:  An irregular protrusion on a cell membrane 
Carminative:  A herb that soothes the gut wall and promotes expulsion of gas. 
Calyx (pl. Calyces):  An outer whorl of floral leaves (sepals) forming the protective 
covering of the flower petals. 
Crenate:  Round toothed. 
Dripping pill:  A herbal extract and a matrix are blended under under warm conditions.  
The mixture is dripped into a cooling liquid in which the droplets are insoluble.  
Dysgusia:  A disorder of the sense of taste 
Dysphagia:  Difficulty in swallowing 
Dysphoria:  Negative emotions such as depression, sadness, melancholy, discontent and 
indifference. 
Enteral delivery:  Introduction directly into the stomach, duodenum or jejunum. 
Glabrous:  Smooth and hairless  
Gluconeogenesis:  Production of glucose from non-carbohydrate molecules. 
Glycogenolysis:  Conversion to glucose monomers from glycogen polymers. 
Isoform:  A protein with a similar function as another protein but which is encoded by a 
different gene and therefore has a slightly different amino acid sequence. 
Lipolysis:  Hydrolysis of triglycerides into free fatty acids 
Lyophilisation:  Freeze-drying 
Metabolomics:  Detection, identification and quantitation of all compounds in a sample 
Microsomes:  Small particles of endoplasmic reticulum containing enzymes 
Organoleptic:  The practice of recognition of herbal quality by the use of the senses, 
particularly sight e.g. colour, smell and taste. 
Pinnate:  Structural arrangement on either side of a common stalk e.g. leaf veins or leaves. 
Pubescent:  Covered in fine hairs 
Raceme:  Clusters of flowers are arranged on an unbranched stalk, with the youngest 
growing at the apex 
Radioligand binding:  A ligand e.g. drug is radioactively labelled for observation of its 
binding affinity to e.g. receptors, enzymes 
Thiols:  Sulphur-containing compounds 
Trophorestorative:  A herb with an affinity for a particular organ or system on which it 
exerts a nourishing and restorative action. 
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